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Abstract
De novo protein design permits discovery of intricate folds and functions emulating natural enzymes in
simpler, yet robust model constructs. Helical bundles serve as premier scaffolds to incorporate diverse reactivities
from oxidative, reductive, to hydrolytic transformations observed in much grander O2-utilizing metalloproteins such
as radical-generating ribonucleotide reductases and catalases. One notable family of de novo proteins is the Due
Ferri or DF series of four-helix bundles providing a dinuclear site for metal incorporation and are amenable for
tailoring active site reactivity. As reactive oxygen species and radical-based intermediates are prevalent and
necessary for steering life-essential processes through reactive radicals stabilized by metals, we were curious to
understand how the nature and number of metal ions influence sequestration of such species. We investigated the
influence metal has on semiquinone stabilization in DF bundles, a minimalist model representing active sites of more
complex natural diiron and dimanganese proteins. Coordination sphere was modified in the original DF single chain
version to incorporate a 2-His-1-carboxylate facial triad, a single metal binding motif, mirroring morphology of
mononuclear non-heme enzymes. We discovered breaking symmetry of the metal coordination site leads to a stable
construct with one site exhibiting tight affinity for metal, and this single metal binding construct Uno Ferro single
chain stabilizes semiquinone radical anions equally efficient as a two-metal binding version. We envision a robust
and easy to modify DFsc and UFsc family of proteins would be versatile tools for gaining mechanistic insights of
metalloenzymes. One application of DF constructs we've pursued is to create a hydrolase bridging a heteronuclear
metallosite. Phosphoester substrates were introduced to DFsc and UFsc to characterize hydrolase features. Defining
the structural and functional properties of hydrolases in DF proteins would facilitate creation of catalysts for
bioremediation purposes.
We further apply minimalist design approaches to redesign natural proteins displaying no inherent catalytic
properties (or showing marginal activity) for a chosen chemical transformation. Calmodulin and myoglobin were
selected as model proteins to introduce enzymatic properties rationally designed using non-rigorous set of
computational tools to modify the substrate pocket for evolution. We use HSQC-NMR to guide the directed evolution
process to arrive at beneficial mutations which enhance reactivity of generated enzymes. Our minimalist design
approach also demonstrates the practical application of our calmodulin designs to reveal an acid-base promoted

catalysis in conversion of therapeutics to their metabolically active forms. Only a single precisely positioned amino
acid is needed to promote conversion of an antirheumatic prodrug leflunomide bearing an isoxazole ring for proton
abstraction to the active form teriflunomide.
Furthermore, we dissected possible defense mechanisms microorganisms utilize to survive habitats under
oxidative stress. A reported diiron catalase conserved exclusively in Mycobacterium tuberculosis (Mtb) was
characterized to determine if the protein acts as a dimanganese catalase as we observed the coordination ligands
are similar to nonheme catalases. Therefore, we sought to identify metal preference of this four-helix bundle and
establish possible mechanisms utilized by Mtb to disproportionate toxic oxygen metabolites. Conversely, a possible
defense strategy by humans to promote bacterial clearance in cases where invasive bacteria trigger human innate
immune responses was examined. Hemoglobin is found to be antimicrobial generating cytotoxic radicals to sustain
microbicidal action. We considered myoglobin involved in similar peroxidatic processes could be reactive in presence
of pathogen associated molecular patterns, specifically lipopolysaccharides (LPS), to produce radical cations. Hence,
myoglobin was characterized in a mixture of different proteases and LPS for peroxidase activation.
Lastly, design of antimicrobial hydrogels is described. Our hydrogel design is based on self-assembly of
peptides induced by silver or copper complexation and does not incorporate permanent crosslinking agents. Short
peptides of alternating polar and nonpolar amino acids affixed by an unnatural amino acid pyridyl alanine which
coordinate metal form a strong hydrogel. The hydrogel is self-healing and can be delivered in syringe format for
application in wound healing therapy.
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1 De novo design of Due Ferri protein with coordination geometries
enforcing catalytic properties
Jennifer H. Yoon and Dr. Olga V. Makhlynets
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Yoon, J. H.,* Kulesha, A. V.,* Lengyel-Zhand, Z., Volkov, A. N., Rempillo, J. J., D'Souza, A., Costeas, C., Chester, C.,
Caselle, E. R., & Makhlynets, O. V. (2019). Uno Ferro, a de novo Designed Protein, Binds Transition Metals with High
Affinity and Stabilizes Semiquinone Radical Anion. Chemistry - A European Journal, 25(67), 15252-15256. (*co-first
author)
Yoon developed protein purification methods, performed DTBC oxidation experiments, cobalt titration, CD and ICP-OES analysis
of DFsc, UFsc and 4G-UFsc. Kulesha performed ITC experiments to determine Kd of metal binding to DF series. Lengyel-Zhand
and Rempillo performed mutagenesis and preliminary characterization of DFsc and variants including redox potential
characterization. Volkov performed NMR analysis of DFsc and Joel Rempillo performed Rosetta docking modeling of DTBC into
DFsc substrate binding pocket. D’Souza contributed in DTBC oxidation and stopped-flow experiment including protein purification
with help from Costeas and Chester.

Abstract
De novo protein design is a systematic approach to solving

OH
OH

questions deeply rooted in intricacies of Nature’s
metalloproteins and reducing the levels of complexities
imposed

by

these

catalytic

macromolecules

O
M2+
O

DTBC

to

comprehend how they operate. The quintessential
elements responsible for their overall structure and
function are active sites comprising a conserved set of
amino acids coordinating metals. Often metalloenzymes utilize radicals to achieve chemical reactivity and recently
DeGrado and coworkers discovered model proteins efficiently stabilize semiquinone radical anions generated by
oxidation of 3,5-di-tert-butylcatechol (DTBC) in presence of two zinc ions. Here, we describe work on elucidating the
nature and number of metal ions influencing semiquinone stabilization in Due Ferri or the DF bundle, a minimalist
model for active sites of more complex natural diiron and dimanganese proteins. A single metal ion is sufficient for
radical stabilization and other divalent d-block elements Mn, Co, and Ni show impact on radical ion sequestration.
Moreover, the radical is stabilized by both metal ion, hydrophobic sequestration, and interactions with hydrophilic
residues in the protein interior resulting in an impressive nearly 500 mV change in the redox potential of the
SQ•¯/catechol couple as compared to bulk aqueous solution. Moreover, we created a 2-His-1-carboxylate facial triad,
a common feature of active sites in a number of mononuclear non-heme iron(II) enzymes, in the DF model system.
The new construct Uno Ferro single chain (UFsc) protein binds zinc tightly. Upon introducing four glycine

1

substitutions inside the solvent access channel to produce 4G-UFsc, this single metal ion binding protein coordinates
metal even more tightly with pM affinity for zinc. This affinity is higher than any other reported model systems and
is on par with many natural zinc-containing proteins. We expect that the robust, easy-to-modify DFsc and UFsc family
of proteins will become a versatile tool for mechanistic model studies of metalloenzymes.
Furthermore, we look into hydrolase properties of
O

O2N

the

O
O P O
O

DF

bundle

to

potentially

incorporate

heteronuclear occupancy of metals. Purple acid
phosphatases (PAPs) are dinuclear enzymes
NO2

binding a mixture of metals in the active site. Most
frequently Fe(III) and Zn(II) are bound and catalysis

proceeds by metals other than Zn(II) such as divalent metals copper, nickel, or manganese. Ligands comprise of
aspartates, tyrosine and histidine for Fe(III) and two histidines with an asparagine for the second metal site. These
structural components are not observed in model proteins due to challenges in creating a PAP design with distinct
binding affinity and selectivity of metals in a synergistic manner at two separate sites. Thus, we present DF bundles
as an ideal platform to create a PAP model as the construct can be recombinantly expressed, obtained in apo form,
and is amenable to NMR structure determination to facilitate modification of the two-metal binding site for tuning
metal affinity. Catalytic activity of DFsc and UFsc constructs for phosphoester hydrolysis was measured for a
nitrophenolate product by a colorimetric assay. We expect to utilize the assay as a high-throughput screening
process to generate a diverse library of de novo hydrolases through directed evolution to improve catalytic
efficiencies of DF family of proteins. Defining the structural and functional properties of these metalloproteins would
complement ongoing approaches and efforts to create inexpensive protein-based catalysts for bioremediation
applications in controlling pesticide and chemical warfare agent toxicities in our environment.

2

1.1

De novo protein design of four-helix bundle metalloproteins

1.1.1 Introduction
Pioneers in the field of small molecular assembly, coordination chemistry, and structural dynamics
spearheaded by DeGrado, Baltzer, Desjarlas & Handel, Dahiyat & Mayo introduced the idea of de novo design of a
model protein to understand basic principles governing unique folds and intricacies detailed in pharmacologically
intriguing systems.1 De novo design in essence tasks the designer to create a protein model from scratch, rather
than modifying existing natural proteins, an approach allowing one to critically characterize protein properties from
first principles.2 To acquire a blueprint for a protein model, natural protein domains were computationally
repacked and mathematical equations implemented to define backbone conformations. These conformations
would then lead to exploratory elaborations on approximate symmetries of rotation and minimal perturbations
needed to construct tertiary structures.3-5 By trimming away the complexity of elaborate proteins and
implementing a sequence-directed approach, the designer could create any structure (from a rubredoxin fold as
established by Nanda et al.,6 to triosephosphate isomerase TIM barrels,7 or even B-propellers as achieved by Voet
et al.8) imaginable within the limits of a thermodynamically reasonable parameterization. Computer graphics,
molecular mechanics and dynamics including crystallographic and nuclear magnetic resonance (NMR) techniques
improved during these formative years of de novo design fueled an immense expansion of computational design.
Such dynamic discovery of processes underlying the sequence-to-fold query is credited tremendously to early
advances in the design of helical bundles, the first structurally defined proteins designed from scratch.9

1.1.2 Helical bundles and imperatives of de novo design
Designing a protein with a predetermined structure and property had not been fully established in the
early 20th century as focus in the design of enzyme and receptor mimics was limited to synthetic-driven routes using
preexisting organic scaffolds (cyclodextrin, spherand or crown ether frameworks).10 Perhaps the major challenge
in such endeavor was selecting the most optimal conformation of a scaffold to maximize recognition and catalysis.
Unlike the rigid framework of organic systems commonly enforced by multiple iterations of cyclization or aromatic
substitution, the natural protein framework is flexible. Chains of a 100-residue protein molecule could theoretically
adopt 10100 possible backbone conformations, an immense sum of possibilities to synthesize, screen, and accurately
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divulge factors influencing enzyme function. To put this number into perspective, 10100 outnumbers the estimated
observable atoms in the Universe, portraying the astronomical complexity of protein folding and, in turn, design
issues which could not be solved simply by a random search of conformational spaces.11 To simplify the design
scheme, Ho and DeGrado focused on conformations leading to the secondary structure formation of alphahelices.10 The main premise for their focus on helix motifs was the large number of proteins classified in this
structural domain with understood spectroscopic detail. Furthermore, despite the diverse functional role and little
sequence homology among helical proteins, their folding patterns were strikingly similar. Thus, underlying the
complexities of individual amino acid sequences of proteins is a highly degenerate code allowing proteins to adopt
similar conformations. Eisenberg and co-workers designed a four-helix bundle, an idealized version of proteins
observed in Nature.9 This class of helical proteins included myohemerythrin, apoferritin, tobacco mosaic virus coat
protein, and Cytochrome C’ comprised of four helices connected by three loops. The helices are packed antiparallel
and within the arrangement is a cavity open to accommodating metals or heme moieties. The design scheme
required consideration of several aspects of protein folding and stability which included helix formation, helix
termination, helix-helix packing, and loop formation.

These features stem from a solid conception and

implementation of the sequence itself. In collaboration with Eisenberg, Ho and DeGrado arrived at the following
conclusions in their design of a four-helix bundle: (1) interhelical packing in these bundles show the structural cores
of these protein motifs to be enforced by closely packed apolar residues. (2) the macrodipole on the helices is
important to stabilize the bundle geometry. (3) the loops between helices facilitate the formation of bundles and
diminish loss in configurational entropy when all four helices assemble. Given a pseudo-222 symmetry found in
natural bundles, the idealized four-helix bundle adopts symmetry whereby four peptide fragments each sharing an
identical sequence assemble into a tetramer. An incremental design approach was taken wherein peptides of 12
to 16 amino acids cooperatively self-assembled into alpha-helical tetramers. Tetramerization proceeded favorably
via apolar interactions between isobutyl groups of leucyl amino acids, the main driving force for helix formation
and self-association. Carboxamide was also placed on the c-terminus to reduce destabilizing charges near the
terminal region of the structure, and based on computer graphics, destabilizing amino acids were replaced to
reduce unfavorable hydrophobic packing. Furthermore, turns observed in natural proteins were incorporated, and
these comprised of a hydrophilic loci (PRR linker sequence) in the peptide. Regan and DeGrado subsequently
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reported a genetically encoded four-helix bundle a4 version easily expressed in E. coli and purified as a monomeric,
stable structure in aqueous solution.2 Finally, the four-helix bundle had been successfully crafted and would serve
as an attractive structure for designing synthetic binding sites and catalysts of sophisticated scale in ongoing years.

1.1.3 Building a miniaturized diiron protein and emergent catalytic properties
Natural occurring enzymes are highly robust catalysts. They provide a substrate binding site molded by
catalytic side chains geometrically configured to increase production of chiral pharmaceuticals.12 Combined with
their general selectivity and energy-efficient operation, enzymes are deemed environmentally friendly as they are
activated under mild conditions. To fully realize the potential to design proteins with enzymatic activity, metal ions
were introduced in the design scope to tailor catalysts for a specific application. Metalloproteins catalyze a number
of useful reactions based on the metal ion to promote oxidative, reductive, and hydrolytic transformations.13 Due
Ferri (in latin for two iron; DF) family of proteins emerged as a product of inspiration to incorporate reactivity in a
de novo designed protein based on natural bimetallic proteins. Di-metal sites are used throughout biology to
catalyze hydrolytic or redox-active processes.14 The common features in these metalloproteins are a rich
abundance of glutamate or aspartate and histidine ligands, and metal ions bridged by either H2O, OH-, O2- or a
carboxylate side chain. Particular focus was given to O2-utilizing metalloproteins as these comprise a large set of
enzymes from radical-generating ribonucleotide reductases, catalases, and ferritins that steer important lifepromoting processes.15 Geared with the knowledge and tools to execute essential design principles in the
construction of proteins that fold in solution, Lombardi, DeGrado and coworkers challenged the idea of capturing
reactivity, observed in much larger di-Mn or di-Fe four-helix bundles, in a simpler model protein DF1--- the original
DF prototype successfully engineered with a catalytic diiron-oxo site.16-18
The four-helix bundle DF1, created using mathematical parameterization of the backbone, adopts an
architecture with a D2 symmetric diiron-binding site. DF1 maintains the design principles mentioned prior in 1.1.2
wherein DF1 folds into an antiparallel dimer of helix-loop-helix motifs. Each helix contains hydrophobic residues
encapsulating the diiron site found close to the center of the structure. The metal-binding site consists of four
glutamate and two histidine residues as first-shell ligands positioned in the core of the protein (Figure 1.1A).
Second-shell ligands comprise of aspartate, tyrosine and lysine residues largely preorganizing the binding site
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through a set of hydrogen bond and salt bridges to maintain the overall structural integrity (Figure 1.1B). More
compact DF1 structure emerged by introducing apolar leucyl residues to the helices (Figure 1.1C). First shell amino
acid ligands coordinate or bridge metal ions, and these metal cofactors could become saturated by water molecules
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Figure 1.1 DF1 de novo design. (A) Coordination ligands of di-Zn(II) binding site in a four-helix bundle include four Glu and
two His (B) DF1 comprises a homodimer helix-loop-helix motif and second shell ligands tyrosine (lime green) and aspartate
(cyan) residues stabilizing primary ligands through hydrogen bonding interactions and modulate reactivity of the cluster. (C)
Hydrophobic core is created by packing the metal center with apolar residues (purple spheres) and interhelical loops impose
bundle stability. [PDB: 1ec5]
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to be converted into O2-utilizing model proteins, metal coordination motifs of which are typically conserved among
radical-generating ribonucleotide reductases, catalases, and ferritins. These enzymes all house di-Mn or di-Fe sites
within an antiparallel four-helix bundle embedded in more extravagant macromolecular scaffolds. Features of the
metallocofactor assembly and ligands in the vicinity of metal sites of naturally occurring proteins were masterfully
recreated in the simple DF bundle, a testament to high-precision design execution to introduce complex reactivity
in functional miniaturized proteins. Lombardi, DeGrado and coworkers in proceeding years probed the DF1
structures based on the dimetal cofactor and examined divalent Zn, Cd, Co, Mn, and Fe ligand binding preferences.19
Different ligand-binding geometries showed small shifts of protein ligands and backbone atoms allowing systematic
interpretation of the sequence to structure and reactivity relationships. Functionality in this stably folded DF1
construct began to be surveyed in depth by expanding the active site to accommodate a diverse assortment of
substrates. Such expansion led to active site occupancy of new Due Ferri analogues with changes in both sequence
and loop conformation in a combinatorial manner. One notable change was to decrease packing of the core by
replacing buried leucine sidechains with alanine or glycine in order to create a cavity into the metal site. Lombardi
and coworkers designed DFtet consisting of single monomers assembling into a four-chain helix bundle of
unconnected helical peptides.15, 20, 21 They introduced a series of asymmetric variants, mixing and matching DFtet
H+ + H2O + O2
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Figure 1.2 Catalytic cycle proposed for 4-aminophenol oxidation by DFtet.
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peptides to produce catalysts for oxidation of 4-aminophenol. Oxidation of the diferrous site allows Fe(III) to react
with 4-aminophenol to generate the benzoquinone monoamine (Figure 1.2). Diiron(II) is regenerated for another
cycle of oxidation. A G4DFtet analogue created by mutating a pair of leucine and alanine residues each to glycines
in two peptide chains enhanced kcat for oxidase reactivity by 1000-fold relative to background oxidation. Thereafter,
a helix-loop-helix dimer or DF3 was designed with four Gly at the inner and outer access sites.22 The thermodynamic
stability of DF3 outperformed other mutants and catalytic efficiency was preserved for 50 turnovers in phenol
oxidation.23

DF3 accommodated a larger substrate 3,5-di-tert-butylcatechol (DTBC) for conversion to quinone

(Figure 1.3). Separately, a single chain version of DF1 or Due Ferri single chain (DFsc) made of a single polypeptide
chain wherein four helices are linked by three computationally designed loops was redesigned. Four glycines were
incorporated along the solvent access channel affording G4DFsc.24, 25 The larger access channel led to an active site
amenable for solvent coordination to the diiron center. More interestingly, Ulas et al. showed 3His-G2DFsc,26 an
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Figure 1.3 (A) Catalytic cycle for catechol oxidation. (B) DF proteins stabilize reactive semiquinone radical species, a 3,5-ditert-butyl semiquinone radical anion (SQ•-), one electron oxidized intermediate in the redox triad between catechol (H2Q)
and quinone (Q). Semiquinones are strongly chelated to Zn(II)-bound DF relative to weak coordinating quinone or catechol.
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evolved variant of DFsc, bound Zn(II) and stabilized a reactive semiquinone radical anion (Figure 1.4). 3,5-di-tertbutyl semiquinone radical anion, one-electron oxidized intermediate, in the redox triad between catechol and
quinone was isolated. Redox-inert di-Zn(II) and hydrophobic substituents were identified to be crucial components

O

Zn2+

O

di-Zn2+

SQ

Figure 1.4 3His-G2DFsc binds two Zn(II) ions in a single chain four-helix bundle. A redox-inert transition metal is used to
observe and stabilize the semiquinone radical anion. Fe(III) was exchanged with Zn(II) in the single-stranded DF protein or
DFsc. SQ•- is the predominant form when chelated to Zn(II) as pKa is 6 and is less prone to dissociation from Zn(II) compared
to QH2 and Q mono- and dianions in neutral pH solution (pKa of 10). [PDB: 2LFD]

to facilitate SQ•- stabilization in the active site. The ability to stabilize reactive intermediates otherwise inaccessible
in native aqueous conditions is extraordinary and small model proteins can serve this role as templates for
characterizing enzyme properties such as in Ribonucleotide Reductase (RNR) enzymes, the universal life essential
proteins important for DNA replication and repair.27 RNRs promote challenging reactions by employing highly
reactive radicals to catalytically produce deoxyribonucleotides.

Other prominent enzymes requiring

metallocofactors to generate radicals are S-Adenosylmethionine, and metals are utilized to stabilize these
radicals.28
As DeGrado and coworkers demonstrated that the stability of radical species are drastically stabilized
principally by harnessing the binding energy of semiquinone radicals to the metalloprotein, we were interested to
explore the role of metals in radical production in DF model systems. Model proteins emulate basic groups found
in enzymatic active sites with much lower overall complexity than their natural enzyme counterparts. Hence, we
seek to gain insight into factors and elucidate basic principles governing mechanisms of radical enzymes in presence
of various first-row transition metals for semiquinone production. DTBC, catechol form (QH2), was used to
benchmark DFsc, the original single chain version of the DF bundle, for catechol oxidation as the substrate
coordinates redox-inert Zn(II) to chelate SQ•-. SQ•- is naturally less stable than QH2 and Q, but in aprotic organic
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solvents, coordination of SQ•- to cations or transition metal ions shifts the one electron reduction potential by
several hundreds of millivolts to form a stable Zn(II)- SQ•- complex. Thus, properties to sequester SQ•- are guided
by binding of catechol to DFsc-Zn(II)2 as the SQ•- (pKa of 6) is the predominant form and is less likely to dissociate
than QH2 or Q with pKa of 10.29 We also looked into the binding affinity of metals to DF bundles and derivatives by
ITC and considered the specificity of t-butyl (tBu) groups of catechol substrate to designed clefts by NMR.
Moreover, we sought to understand if a single metal ion binding construct, modeling the structural motif of
mononuclear non-heme enzymes,30 could transform catechol utilizing a geometry and structural features adapted
from those of earlier spectroscopically characterized DF bundles.

1.2

Design and characterization of Due Ferri and Uno Ferro proteins

1.2.1 Role of metal coordination sites in DF bundles for semiquinone radical anion stabilization
DFsc, the original single chain version of the DF bundle binding two metal ions, was selected as our model
protein. Structural characterization of DFsc is extensive and this de novo protein is a robust scaffold easily
expressed in E. coli to high yield. Moreover, DFsc folds in either the apo or holo form (Figure 1.5A), and in presence
of dioxygen oxidizes DTBC in presence of Zn(II) to generate a spectroscopically detectable semiquinone radical
anion (SQ•-) near 760 nm. We show that DFsc-Zn2 produces the SQ•- with yield comparable to that of di-zinc(II)

A

B

Figure 1.5 (A) Circular dichroism of DFsc (apo and holo forms). (B) Oxidation of DTBC by dioxygen initiated by DFsc-Zn2 or
[3His-G2DFsc-Zn2]. UV-Vis spectra of reaction mixtures in presence of DFsc with two Zn(II) ions (green), and 3His-G2DFsc
with two Zn(II) ions (purple). Experimental Conditions: 50 μM protein, 500 μM DTBC substrate, and O2-saturated 50 mM
HEPES (pH 8). Absorption bands with the maximum near 760 nm correspond to SQ•-.
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coordinated 3His-G2DFsc (Figure 1.5B). We then examined if the metal ion is essential for stabilizing SQ•- by
evaluating radical production between apo DFsc and DFsc with different amounts of Zn(II). Figure 1.6 shows spectra
for DFsc under typical reaction conditions with apo DFsc displaying no distinct band at 760 nm for semiquinone
radical anion, indicating no intermediate formation (Figure 1.6A). DFsc with one equivalent zinc (Figure 1.6B)
produced 30% less SQ•- than the amount produced by holo-DFsc (Figure 1.6C).

A

B

C

Figure 1.6 Oxidation of DTBC by dioxygen in apo- or holo-DF protein. UV-Vis spectra of reaction mixtures containing (A)
DFsc, (B) DFsc with one Zn(II), and (C) DFsc with two Zn(II) ions. Experimental conditions: 50 μM protein, 500 μM DTBC
substrate, and O2-saturated buffer (25 mM HEPES, 100 mM NaCl, pH 7.6). Absorption bands with the maximum near 760 nm
correspond to SQ•-.

Considering metals are indeed important for radical stabilization, we sought to evaluate the contribution
of metal in a single metal-binding site by mutating the bridging glutamate ligand at position 104 to histidine, in turn
creating the resulting construct Uno Ferro single chain or UFsc (Figure 1.7A). UFsc closely depicts a 2-His-1carboxylate facial triad featured in the active sites of mononuclear non-heme iron(II) enzymes and Mn-dependent
dioxygenases.31 Endogenous ligands two histidines and one carboxylate are arranged on one face of an octahedron
and this motif anchors the metal ion to maintain a cis-oriented site to bind exogenous ligands such as substrate and
O2 (Figure 1.7B). The metal center provides flexibility to promote different mechanistic schemes for diverse
chemical transformations. Thus, we hypothesized an open face of the catalytic triad occupied by redox-inert Zn(II)
could coordinate catechol and sequester SQ•-. In addition, we increased the size of the substrate access channel
leading to the metal active site by introducing four glycine mutations to UFsc: A10G, A14G, A43G, and A47G.
Increasing the channel size has been demonstrated previously to improve substrate access and rate of substrate
oxidation.20, 32-34 We named this UFsc derivative as 4G-UFsc.
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One metal binding capacity for UFsc and 4G-UFsc was confirmed by cobalt titration, and ITC data showed
one metal occupancy in metal sites (Figure 1.8). The Uno Ferro series fold into 𝛼-helical structures as determined
using circular dichroism (Figure S1.2, Appendix I) and display picomolar affinity for zinc ions with a dissociation
constant three orders of magnitude lower compared to that of DFsc (Table 1.1 in Figure 1.8). Interestingly, zinc
affinity for UFsc constructs is orders of magnitude tighter than that for other notable de novo designed coiled-coil
peptides linked by a single disulfide bond to form four-helix bundles with a bound macrocyclic metallocofactor.35
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Glu74

B

Ligand
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M2+
O2
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Figure 1.7 Creation of a de novo model system for mononuclear coordination of metal ion. (A) Uno Ferro single chain or UFsc
adopts a single metal ion binding affinity created by mutating a bridging Glu104 ligand to His. (B) Small amino acid analogs
lining the interior of bundle are predicted to increase hydration and size of cavity for catechol uptake. [PDB code: 2HZ8]

Furthermore, binding events involved for DFsc and UFsc were entropically driven, whereas metal binding for 4GUFsc proceeded both enthalpically and entropically with 4G-UFsc displaying highest affinity for zinc (Kd of 30 ± 4
pM). Thermodynamic parameters obtained are provided in Tables S1, S2, and S3 of Appendix I. In summary, we
demonstrate modification of a single bridging ligand in the metallocentre affords a stable mononuclear
coordination sphere for strong association to metals. UFsc constructs’ stability support potential binding of these
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Com
model proteins to catechol without need for interlocking protein-protein interfaces as observed in the design
scheme reported by Tezcan, Dutton and colleagues.35, 36, 37

A

B

C

D

Figure 2. Metal binding characterization: Co2 + titration monitored by visible absorption spectroscopy for UFsc (A) and 4G-UFsc (B). UFsc
maximum concentration of 140 mm Co2 + as monitored by a change in absorbance at 561 nm; 4G-UFsc (150 mm) binds a maximum conc
Co2 + as monitored by a change in absorbance at 550 nm. Insets display absorbance spectra with increasing [Co2 + ]. Dashed spectrum c
protein mixture, where Co2 + saturates UFsc and 4G-UFsc at 140 and 180 mm, respectively. The thermogram (C) and the integrated bindi
4G-UFsc-zinc binding obtained from the competition titration with triethylenetetramine (150 mm zinc with 500 mm TETA was titrated wit
25 mm HEPES, 100 mm NaCl, pH 7.6 at 25 8C). The dissociation constant of 30 ⌃ 4 pm was derived from the non-linear least square fit of
‘one set of sites’ model.

Table 1.1
Table 1. Dissociation constants (in nm) determined by ITC for metal complexes of DF family proteins.
Ni2 +

DFsc
UFsc
4G-UFsc

Kd1
Kd2

2090 ⌃ 230
10 400 ⌃ 1400
112 ⌃ 28
220 ⌃ 37

Co2 +

Mn2 +

Zn2 +

56 ⌃ 3
133 ⌃ 10
269 ⌃ 116
67 ⌃ 4

197 ⌃ 37
228 ⌃ 37
173 ⌃ 56
9250 ⌃ 520

109 ⌃ 34
213 ⌃ 14
0.076 ⌃ 0.013[a]
0.030 ⌃ 0.004[a]

[a] Dissociation constants determined by ITC competition experiments
with triethylenetetramine (TETA).

Figure 3. Kinetics of interaction between O2 and Fe2 + and UFsc: (A) UV/Vis spectra of the reaction after 2 s, c
Figure 1.8 Metal binding characterization.
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Excitingly, formation of SQ•- was observed for both UFsc and 4G-UFsc constructs in presence of one
equivalent of metal ion as evident by the appearance of colored species at 760 nm (Figure 1.9). The findings
demonstrate only one metal ion fulfills the radical stabilization role in designed proteins as addition of the second
metal ion in case for DFsc only leads to minor (if any) increase in SQ•- yield. Production of the radical species is
moreover stable in aqueous solution for days (at least two weeks) as confirmed by EPR analysis of 4G-UFsc-Fe(II)
shown in Figure 1.9C.
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Fe(II), 50 mM HEPES (pH 8). The reaction was initiated by addition of oxygenated buffer. The samples were incubated at
room temperature overnight. Glycerol was added to 10% and EPR spectra were acquired at 20 K, 9.39 GHz frequency, 0.2
mW power, 100 kHz modulation frequency, 3G modulation amplitude. EPR spectrum of buffer containing the protein and
Fe(II), but no substrate, was subtracted from EPR spectrum for baseline correction.
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1.2.2 Diversifying metallosites using different transition metals and establishing coordination
geometry
The nature of metal ion in semiquinone stabilization was quantitatively measured for DFsc, UFsc and 4GUFsc in presence of various d-block elements Ni(II), Co(II), Mn(II), and Zn(II). Stoichiometry of binding metal (two for
DFsc and one each for UFsc and 4G-UFsc) remains constant regardless of the metal ion, and binding affinities for
metals were low (in sub micromolar concentration). Binding constants are shown in Table 1.1 of Figure 1.8 with ITC
data provided in Appendix I; Figures S1.13, S1.14, and S1.15). SQ•- formation was observed for all constructs in
presence of different metal ions and yield of the radical depended on the nature of metal ion. DFsc loaded with one
equivalent of Ni(II) showed the greatest stabilization of SQ•- species (36.8% higher than holo DFsc-Zn(II)) and
addition of one more equivalent of Ni(II) showed no difference in radical production (Figure 1.10D and Figure 1.11D).
Co(II)- and Mn(II)-bound DF and UFsc constructs, in contrast, displayed little SQ•- intensity compared to UFsc and
4G-UFsc loaded with Zn(II) or Ni(II). Lastly, Uno Ferro series of proteins produced nearly the same amounts of SQ•as DFsc in either one or two metal-loaded forms (Figure 1.12 and Figure 1.13). Therefore, Zn(II) and Ni(II) are
identified as optimal for stabilizing reactive radical intermediates.
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Figure 1.10 Oxidation of DTBC by dioxygen in presence of DFsc and one equivalent of metal. UV-Vis spectra of reaction mixtures
Figure S3. Oxidation of DTBC by dioxygen in presence of DFsc and one equivalent of metal.
containing (A) DFsc with zinc, (B) DFsc with cobalt, (C) DFsc with manganese, and (D) DFsc with nickel salts. Experimental Conditions:
UV-Vis spectra of reaction mixtures containing (A) DFsc with zinc, (B) DFsc with cobalt, (C) DFsc with
50 μM protein and one
equivalent of metal (Zn(II), Co(II), Mn(II), or Ni(II)) chloride, 500 μM DTBC substrate, and O -saturated buffer
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oxygenated buffer (orange), after 1 (green), 2 (cyan), 12 (blue), 24 (violet), and 48 hours (pink).
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Figure 1.11 Oxidation of DTBC by dioxygen in presence of DFsc and two equivalents of metal. UV-Vis spectra of reaction
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with cobalt,
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Figure(A)
S4.DFsc
Oxidation
of DTBC
by dioxygen
in presence
of with
DFscmanganese,
and two equivalents
of metal.
Experimental Conditions:
50 μM
proteinmixtures
and twocontaining
equivalents
metal
Co(II),
or Ni(II))
chloride,
UV-Vis spectra
of reaction
(A) of
DFsc
with(Zn(II),
zinc, (B)
DFscMn(II),
with cobalt,
(C) DFsc
with 500 μM DTBC
substrate, and manganese,
O2- saturatedand
buffer
mM
HEPES,
mMExperimental
NaCl, pH 7.6).
Spectra were
taken
immediately
(D) (25
DFsc
with
nickel100
salts.
Conditions:
50 μM
protein
and two after addition
of metal
Co(II),
Mn(II), 12
or (blue),
Ni(II)) 24
chloride,
500
μM
of oxygenated equivalents
buffer (orange),
after(Zn(II),
1 (green),
2 (cyan),
(violet),
and
48DTBC
(pink) substrate,
hours. and O2saturated buffer (25 mM HEPES, 100 mM NaCl, pH 7.6). Spectra were taken immediately after
addition of oxygenated buffer (orange), after 1 (green), 2 (cyan), 12 (blue), 24 (violet), and 48 hours
A
B
(pink).

C

D

Figure 1.12 Oxidation of DTBC by dioxygen in presence of UFsc and one equivalent of metal. UV-Vis spectra of reaction
mixtures containing
(A) UFsc with zinc, (B) UFsc with cobalt, (C) UFsc with manganese, and (D) UFsc with nickel salts.
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Figure 1.13 Oxidation of DTBC by dioxygen in presence of 4G-UFsc and one equivalent of metal. UV-Vis spectra of reaction
mixtures containing
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To determine the coordination environment of DFsc and one metal binding derivatives, stopped-flow
kinetics was implemented to establish the coordination geometry of these proteins. DeGrado, Solomon, and coworkers demonstrated Y51, an amino acid in the second coordination sphere of DFsc active site, coordinates Fe(III)
through a side chain phenolate when DFsc-Fe(II)2 reacts with dioxygen. The Fe(III) to phenolic charge transfer shows
a transient absorbance band with 𝜆max equal to 520 nm.38 UFsc, however, loaded with Fe(II) and bubbled with O2
did not show such spectral trace (no band at 520 nm observable), suggesting there is no iron near Y51 and that the
metal ion bound is located at the neighboring site comprising Tyr18, Glu44 and His77 (Figure 1.14)
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monitored by a change in absorbance at 561 nm; 4G-UFsc (150 mm) binds a maximum concentration of 180 mm
nce at 550 nm. Insets display absorbance spectra with increasing [Co2 + ]. Dashed spectrum corresponds to a Co–
and 4G-UFsc at 140 and 180 mm, respectively. The thermogram (C) and the integrated binding isotherm (D) of
mpetition titration with triethylenetetramine (150 mm zinc with 500 mm TETA was titrated with 1.2 mm 4G-UFsc in
). The dissociation constant of 30 ⌃ 4 pm was derived from the non-linear least square fit of the isotherm using
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The redox potential of SQ /DTBC couple was determined for DFsc in presence of nickel. The radical was

first generated by incubating DTBC with protein and titrated with dithionite in presence of indigo tetrasulfonate (ITS;
redox potential of -46 mV vs. NHE)39 as a standard (Figure S1.4, Appendix I). DFsc-Ni(II)2 and SQ•-/DTBC couple
showed a redox potential of nearly -100 mV, close to 0.5 V lower than that of free DTBC (380 mV).29 In comparison
to 3His-G2DFsc-Zn(II)2, the observed redox potential of DFsc-Ni(II)2 is even lower than that for DTBC of -21 mV bound
to 3His-G2DFsc-Zn(II)2.
To further substantiate that the protein provides the environment to promote SQ•- stabilization, we probed
the influence of hydrophobic sequestration of catechol substrate using n-dodecylphosphocholine (DPC) micelles or
bovine serum albumin (BSA). Both DPC and BSA produced very little SQ•- and formed the corresponding quinone
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Figure 4. NMR model of DFsc-DTBC interaction generated using Rosetta:
(A) Surface representation of the lowest energy model with the substrate sit-
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lowest energy state with DTBC located inside a hydrophobic pocket comprising Ala10, Ala14, Ala43, and Ala47 with
OH moieties facing the interior. 3-tBu is positioned between Ala14 and Ile40 and such positioning indicates the
importance of tBu regions on catechol including their docking orientation to interact with DFsc. A molecule with a
single tBu group, 4-tert-butylcatechol (4-TBC), in presence of DFsc did not show any semiquinone radical anion
formation (Figure S1.5, Appendix I) and only generated the quinone product.

1.3

Concluding remarks
In conclusion, we created a mononuclear coordination sphere in a de novo scaffold originating from the DF

series of four-helix bundles. The catalytic site in our Uno Ferro constructs emulate prototypical 2-His-1-carboxylate
facial triads of natural mononuclear non-heme iron enzymes and are activated by dioxygen to stably sequester a
reactive semiquinone radical anion. We show that the number and nature of metal ions influence radical
stabilization, but not as nearly as specific interactions of polar functional groups buried within the hydrophobic core
of DF proteins. Furthermore, we revealed a wider substrate access channel in UFsc confers a single metal-ion binding
protein with exceptional picomolar affinity for zinc. These robust DFsc and UFsc family of proteins are proposed to
be versatile tools for mechanistic interpretation of oxidases and extend to potentially other rigorous chemical
transformations.

1.4

Metallohydrolases as potent catalysts for bioremediation

1.4.1 Introduction
A prominent family of enzymes gaining attention in translational medicine and biotechnology are
metallohydrolases catalyzing the hydrolysis of ester and amide bonds.40 Their catalytic proficiency and impressive
functional scope depend on their metal active sites influencing reaction mechanisms. More specifically, the number
of metal ion binding sites, the binding sites occupied under normal and physiological conditions, and the number of
metals required to achieve maximal activity depending on the substrate of interest constitute the diversity of
metallohydrolases.41 Metal ions in polynuclear metalloenzymes (of two or more metal ions) in particular are closely
spaced to give several layers of functional benefits: (I) facilitate charge delocalization, (II) provide small transitionstate energies to promote catalysis, (III) allow binding of large substrates, (IV) provide electrostatic conditions to
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activate substrates, and (V) initiate catalysis involving nucleophiles. The classification of these enzymes can be
extended to mono- or binuclear metalloenzymes such as glycerophosphodiesterases which catalyze hydrolysis of a
broad class of phosphate ester substrates: mono-, di- or triesters.42 These enzymes hold amazing potential as
bioremediators yet harnessing their catalytic potential is difficult as their mechanism is tightly regulated by a
substrate-promoted activation cycling between a purely mononuclear (resting) to purely binuclear (active) forms.43
Thus, coordination spheres, metal ion binding affinities, and the active site assembly mechanisms are all important
factors in metalloenzyme regulation.
Purple acid phosphatases (PAPs) found in different kingdoms of life from plants and mammals to bacteria
catalyze the hydrolysis of a broad assortment of phosphoric acid esters and anhydride substrates. Although the
sequence identity of these enzymes among diverse organisms are less than 20% and the oligomeric structure (either
monomer or homodimer) differs, the catalytic active sites are highly conserved. Seven amino acid side chains
coordinating an Fe3+ and a divalent metal (Fe in animals or Zn, Mn in plants) are found in active sites of PAPs. PAPs
employ different mechanistic strategies for adaptation by coordination chemists to generate biocatalytic systems
for use in bioremediation and biorestoration.44 The coordination site of PAP metal ion center is moreover of deep
intrigue for medicinal purposes as PAP is used as a target for developing chemotherapeutics to treat osteoporosis
and bone-related ailments.45 Due to PAP complexity, large size and nondelineated aspects of their precise
physiological roles, simpler synthetic model versions are made to understand PAP mechanistic properties.
Our overarching focus on metallohydrolases is to design a model protein which could serve as a potent
agent for organophosphate compound elimination.

Organophosphate compounds are readily employed in

agricultural industries for use as pesticides and insecticides and are produced as chemical warfare agents.46, 47 These
compounds are considered to be neurotoxic chemicals, irreversibly inhibiting acetylcholinesterases leading to
serious damage to vital organs,48 and leach into surrounding soil and ground water releasing toxic by-products and
causing poisoning.

Techniques to dispose of organophosphates include chemical treatment, incineration or

deposition in landfills; however, such methods lead to serious environmental pollution including acid waste
accumulation, groundwater contamination and toxic atmospheric emission.49 Hence, developing eco-friendly
biocatalysts to detoxify neurotoxic agents are of paramount consideration.
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As PAPs provide distinct enzymatic coordination sites and regioselectivity in terms of metal ion binding, we
set out to characterize hydrolytic capacity of de novo four-helix bundles with mononuclear and binuclear
coordination spheres. The implications in designing a model protein for PAP would be instructional in creating
scaffolds for broad-spectrum detoxification of organophosphates.

1.4.2 Biomimetic heteronuclear purple acid phosphatase complexes
PAPs constitute the only dinuclear metallohydrolases with preference for a heterovalent active site
composed of Fe3+ and M2+, a divalent metal ion (either Fe, Zn or Mn), for catalysis. Synthesis of PAP biomimetics is
difficult as the two coordination sites each exhibit a metal preference for a trivalent and another strictly divalent
metal ion. Two metal centers are coordinated by seven ligands (one aspartate, one tyrosine and one histidine for
Fe3+ and two histidines and one asparagine for M2+) and one bridging aspartate residue. PAPs characteristic purple
color is attributed to a charge transfer transition from a tyrosine ligand to Fe3+ and the second metal is invariable
depending on the enzyme source (could be divalent metals of either Zn, Mn, Ni or Co). Red kidney bean and soybean
Fe(III)-Zn(II) PAPs are prevalent50, 51 and mammalian PAPs comprise of Fe(III)-Fe(II) centers regulated by changes in
redox potential.52 Sweet potato PAPs are distinguished from others by their increased catalytic efficiency for a broad
set of activated and non-activated phosphate esters and their strict requirement for Mn(II). The phosphate substrate
binds to the Fe(III)-Mn(II) center, the first of its kind in any biological system,53 in a unique tripodal mode with two
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Figure 1.17 Crystal structure of sweet potato PAP (homodimer) in complex with phosphate molecule (one shown in blue
sphere). Cartoon helices colored in cyan, loops colored in salmon pink, and sheets highlighted in pink. Each subunit has two
domains, an N-terminal domain with no known function and a C-terminal domain containing the active site. Coordination site
comprises of Fe3+-Mn2+ stabilized by seven residues. A phosphate occupies the active center by coordinating two metal ions
in a tripodal mode whereby one of the oxygen atoms bridges iron and manganese. [PDB code: 1XZW]
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phosphate oxygen atoms binding Fe(III) and Mn(II) and one oxygen atom bridging the two metal ions (Figure 1.17).54
The basic mechanism in ester bond hydrolysis in PAPs is substrate binding to the enzyme in a second coordination
sphere forming a pre-catalytic complex. Schenk et al. co-crystallized red kidney bean PAP with a sulfate ion providing
insight into an extensive hydrogen bonding network involved in forming the pre-catalytic state (Figure 1.18). The
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sulfate ion coordinates a bridging hydr(oxo) group, histidines and a Zn(II) ligand asparagine.55 An initial binding and
orienting of the substrate may be essential to optimize catalytic efficiency as supported by an increase in kcat/KM for
phosphomonoester hydrolysis by biomimetics modeling complexes with outer shell interactions as opposed to those
with only a first coordination sphere.56, 57
The next step in the catalytic cycle illustrated in Figure 1.19 is substrate rearrangement for coordination to
the divalent metal ion and positioning for nucleophilic addition of a solvent-derived hydroxide.

Following

nucleophilic addition of the hydroxide and esterolysis of the substrate, phosphate remains bound to the active site
and bridges the two metal ions in a tripodal geometry. Such tripodal geometries can be seen in Co(II)-substituted
organophosphate-degrading enzymes and di-Ni(II) ureases.58,
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The resting state of PAP is then regenerated
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Figure 1.19 Proposed mechanism of PAP-promoted hydrolysis of phosphate monoesters. PAP forms a pre-catalytic complex with
substrate. The substrate rearranges to coordinate directly to a zinc metal ion in the active site. Direct coordination of phosphate
group to metal ion leads to an increase in electrophilicity of the phosphorus atom. A hydroxide ion is involved in nucleophilic attack
on substrate and phosphate remains bound to the active site in a bridging tripodal geometry. Ligand exchange at the divalent
metal ion site facilitates incorporation of a water molecule. Deprotonation of the H2O molecule leads to interaction of OH with
Fe(III) and regeneration of the μ-hydroxo bridge. Formation of a μ-hydroxo bridge weakens the Fe(III)-phosphate bond, allowing
release of the phosphate group and restoration of the active site.

requiring removal of phosphate. A ligand exchange at the divalent zinc site facilitates incorporation of a water
molecule and upon deprotonation of the aqua specie, OH interacts with Fe(III) to regenerate the 𝜇-hydroxo bridge.
Reformation of the bridge weakens the Fe(III)-phosphate bond and leads to phosphate release. The active site is
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then restored to a resting state. Synthesizing and characterizing model complexes based on these metalloenzymes
(their metal ion binding and active site structural features) would better facilitate our understanding of basic
arrangements needed to replicate structure and function criteria for design of applicable phosphoesterases.
Biomimetics of dinuclear metallohydrolases are compounds mimicking structural, functional and
spectroscopic properties of an enzyme.60 Only one or two aspects for a model system is often achieved and usually
display low activity for an intended chemical reaction. Though the advantages of using model complexes are their
general stability, robustness, fit for crystallization, and ease of assessing metal ion coordination as well as kinetic
and spectroscopic interpretation. Comba et al. synthesized and characterized a dinucleating ligand referred to as
H2L2+ forming a diferric complex (Figure 1.20A). The ligand is based on a cyclam platform with two appended
tridentate coordination sites for Iron(III) (Figure 1.20B). Protonated amines of the macrocycle were predicted to
stabilize a monodentate phosphoester, a monoester p-nitrophenyl phosphate (pNPP). [(H2L2+)[FeIII2(O)](X)n]m+ is the
first PAP mimic to hydrolyze monoester substrates, a significant feat as concerted binding and hydrolysis of smaller
analogues to diester substrates are difficult due to less regions for optimal binding to active site. The glue to tight
binding of the monoester substrate is attributed to secondary coordination interactions provided by the charged
macrocycle. The monoester substrate displayed comparable catalytic efficiency (kcat/KM) to that of the diester
substrate due to improvement in KM. The reactivity of PAP modeled by this synthetic macrocycle supported the
proposed catalytic mechanism of a monodentate coordination of the phosphoester followed by nucleophilic
addition of a free or terminal hydroxide ion.61 Roberts et al. further showed a synthesized PAP biomimetic, a ligand
design with two coordination sites N2O2 and NO3 able to discriminate between a trivalent iron and a divalent metal
ion, facilitated formation of an Fe(III) and Zn(II) complex (Figure 1.20C). The ligand exhibited regioselectivity and
phosphoesterase activity with substrate bis (2,4-dinitrophenyl phosphate).
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In summary, they propose the design of a heterodinuclear metallo-complex as a mimic for PAP with a
specific binding mode for Zn(II). Incorporation of secondary coordination sphere ligands as demonstrated by Comba
et al. is recommended to enhance activity as the current systems display modest kinetic rate parameters.62 Clearly
synthetic frameworks of heterodinuclear Fe(III) and Zn(II) complexes are becoming prevalent in emulating PAPs as
shown by Gerhard Schenk, Lawrence Gahan and coworkers. Metal-promoted protein interfaces modeling PAPs for
catalyzing phosphoester hydrolysis, however, are not as established. Primitive active sites of metalloproteins in
small clefts are nonetheless shown to hydrolyze 4-nitrophenyl acetate with a rate acceleration of 105 and impressive
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catalytic performance.63 Rate accelerations by unoptimized active sites are also found to demonstrate catalytic
power afforded by protein-protein interfaces. Therefore, the evolvability of protein scaffolds and de novo design of
enzyme active sites for creation of PAP models are imaginable.

1.5

Protein design to develop biocompatible catalysts for phosphoester hydrolysis

1.5.1 Engineering reactive sites for hydrolysis of esters in helix-loop-helix motifs and helical
bundles
De novo protein design provides an even more rigorous approach to discover minimal components of
protein structure and function to shape our understanding of enzyme evolution and rational enzyme engineering.
Such design aspects to meet the caliber of natural enzyme performance lead to creation of new reactivities into
existing or de novo folds less afforded by synthetic skeletal coordination frameworks. Catalytic sites can moreover
be modified at interfaces of existing peptides and proteins to drive assembly and reactivity.64 Recent advances in
protein design yield ‘Frankenstein’ proteins with no natural analogues.65 Complete design of de novo catalysts
challenges the creator to decide on residues operating concertedly to incorporate and predictably engineer the
construct to control diverse facets of form and activity. Designing hydrolases productively includes decorating small
protein folds with histidine residues and employing Zn2+ cations as Lewis acid cofactors.66-69 Derek Woolfson and
coworkers developed an impressive artificial esterase without the aid of metallocofactors. The esterase is based on
a toroid topology observed in TIM barrels, a family of proteins known for their catalytic properties.70 The topology
supports an arrangement of functional groups and facilitates substrate access, binding, and turnover. The resulting
design adopts a homo-heptameric assembly consisting of a catalytic triad of glutamate, histidine and cysteine
introduced at each 𝛼-helix facing the hydrophobic interior (Figure 1.21). The heptamer hydrolyzes p-nitrophenyl
acetate (p-NPA) in an enzyme-like multi-turnover process whereby fast acylation of the active nucleophile is followed
by a rate-limiting hydrolysis with an overall enzymatic efficiency comparable to other esterase designs (Figure
1.21A).66, 71-73 More interesting is replacement of the cysteine nucleophile with homocysteine residue results in a
higher turnover number. Woolfson and coworkers’ findings portray the marvelous possibilities of protein design to
create catalysts by precise positioning of just a few residues. In a similar approach, we propose to utilize de novo
scaffolds which provide the folds and functional group arrangements to enhance complexity and catalytic activity of
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Figure 1.21 (A) Catalytic triad of Cys-His-Glu and a proposed mechanism for the bundle with pNPA through a thioester
intermediate. Glu forms a hydrogen bond with histidine and activates a cysteine residue for nucleophilic attack on the ester
carbonyl. (B) Design of a de novo esterase comprising a coiled-coil and a Cys-His-Glu motif within a helical bundle selfassembling into a heptamer to form a doughnut-shaped structure to hydrolyze pNPA. [PDB code: 5ezc]

four-helix bundles to hydrolyze phosphate mono- and diesters.
Lars Baltzer and coworkers in a series of seminal papers reported design of helix-loop-helix dimers tailored
for hydrolysis of phosphoester linkages found in polynucleotides.66, 74, 75 Their interest in phosphorylation reactions
toward DNA and RNA backbones stemmed from nucleic acids as being important determinants in drug development
as artificial nucleases with specific cleaving activity would be useful therapeutic tools.75 Phosphoester bonds are
extremely stable and resistant to hydrolysis and enzymes evolved to catalyze hydrolysis are known to be the most
efficient through concerted action of general acid-base catalysis, nucleophilic catalysis, transition state stabilization,
and proximity interactions76, 77 Razkin et al. showed a 42-residue peptide dimerizes to form a four-helix bundle and
catalyzes cleavage of DNA model substrates in aqueous solution at pH 7.0 with a rate enhancement in hydrolysis of
heptyl 4-nitrophenyl phosphate of three orders of magnitude over the imidazole-catalyzed reaction.75 The potential
for hydrolysis of phosphodiesters by rationally designed polypeptide inspires design of metallohydrolases able to
cleave phosphodiester bonds. Metals in proteins provide several benefits particularly their affinity for basic nitrogen
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and oxygen donor ligands, their capacity for supporting big aromatic architectures, and their presence in natural
enzymes.78, 79 Our work on characterizing hydrolase activity in Due Ferri (DF) helical bundles and Uno Ferro single
chain (UFsc) protein are provided with insight on the evolvability of this robust scaffold through directed evolution
for phosphoester hydrolysis. As we showed that DF family of proteins adopt different affinities for metal ions in two
sites,80, 81 we envision these proteins could serve as ideal scaffolds to create a heteronuclear center reminiscent of
PAPs.

1.5.2 Hydrolytic catalysis in a mononuclear and dinuclear zinc metalloprotein for
organophosphate hydrolysis
We began our characterization of hydrolytic activity by Due Ferri bundles using para-nitrophenyl acetate
(pNPA) as substrate (Figure 1.22A). Hydrolysis of this substrate often proceeds using zinc for catalysis and pNPA is
frequently employed for catalytic characterization of artificial enzymes for direct rate comparisons.

We

hypothesized the metal interfaces in DF bundles with no optimization for hydrolase properties could promote
catalytic function as the active site features zinc-binding motifs shaping a primitive active site to support hydrolysis.
Rate accelerations are observed for non-optimized active sites suggesting zinc and protein interfaces are appropriate
to create enzyme active sites as demonstrated by Brian Kuhlman and coworkers.82 Spontaneous hydrolysis of pNPA
was observed in reference samples showing fast background hydrolysis (Figure 1.22B), indicating no significant
contribution for hydrolysis of nitrophenols by DF protein. No meaningful information on DF hydrolase properties
using pNPA could thus be ascertained. We then selected two substrates 4-nitrophenyl phosphate (pNPP) and bis(4nitrophenyl) phosphate (BNPP) as representative monophenyl and diphenyl phosphate esters to probe if
dinucleating ligands could hydrolyze less activated model substrates with nitrophenyl phosphate leaving groups
representing a more realistic model substrate of organophosphates (substrates shown in Figure 1.23A). Activity was
observed for both apo and holo forms (Figure 1.24A and Figure 1.25) and small variation in kcat/KM was seen for apo
versus a one Zn(II) or 2 Zn(II) molecular system to suggest DF construct in metal-free form facilitates hydrolysis. No
nitrophenol product formed in background hydrolysis (buffer with or without zinc) in presence of substrate after 60
hours. Therefore, low background hydrolysis of pNPP (Figure 1.24B) and BNPP (in pH 8.0 buffer; Figure 1.25) reveals
observable reactivity of DF protein for nitrophenyl phosphate hydrolysis and use as a potential hydrolase model.
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Although hydrolysis is a slow process, clear distinction in product formation by 60 hours is evident. Slow hydrolysis
may be due to poor availability of open ligand sites to stably position the incoming substrate as a result of the packed
nature of the interior and non-optimized peripheral coordination spheres of DF bundles (Figure 1.23B)

A

B

Figure 1.22 (A) pNPA hydrolysis in presence of 25 µM apo DF protein or DF protein with 1 equiv of Zn(II) or 2 eq of Zn(II), 500
µM substrate in 25 mM Tris-HCl (pH 8.0), 100 mM NaCl buffer. (B) Hydrolysis of pNPA occurring in aqueous buffer in absence
or presence of zinc metals. JY2053
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Figure 1.24 (A) pNPP hydrolysis in presence of 25 µM apo DF protein or DF protein with 1 equiv of Zn(II) or 2 eq of
Zn(II), 500 µM substrate in 25 mM Tris-HCl (pH 8.0), 100 mM NaCl buffer. (B) Hydrolysis of pNPP occurring in
aqueous buffer in absence or presence of Zn(II). JY2051

Figure 1.25 Bis pNPP hydrolysis in presence of 25 µM apo DF protein or DF protein with 1 equiv of Zn(II) or 2 eq of
Zn(II), 500 µM substrate in 25 mM Tris-HCl (pH 8.0), 100 mM NaCl buffer. Hydrolysis of BNPP in buffer mixed with
0, 1, and 2 eq of Zn(II) and UV-vis spectra collected after 60 h of incubation. JY2051
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We were interested to see if breaking the symmetry model by removing donor atoms in the primary
coordination sphere of the dinuclear center would lead to vacant coordination sites for better incorporation of
phosphoesters. The mononuclear coordination sphere of our Uno Ferro model protein serves as a stable site for
tetrahedral or trigonal bipyramidal geometries (could be more instances of higher coordination number)83 and is
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of Uno Ferro single chain model protein coordinating BNPP. (B) Mono pNPP and bis pNPP hydrolysis in presence
of 25 µM apo UFsc protein or UFsc with 1 equiv of Zn(II) or 2 eq of Zn(II), 500 µM substrate in 25 mM Tris-HCl (pH
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less saturated by a bridging ligand to confer structural and catalytic benefits. Furthermore, Uno Ferro model
contains a catalytic triad of two histidines and one carboxylate to allow tight binding of metal and empty metal sites
for substrates of variable size to occupy. A nearby tyrosine ligand stabilizes a glutamate residue while zinc could
polarize the phosphate-oxygen bond along with a histidine ligand and activate a hydroxyl ion to serve as a
nucleophile (Figure 1.26A). Uno Ferro single chain protein was incubated with either pNPP or BNPP for >60 h to
compare hydrolytic activity against that of DF protein. We observe again either apo protein or a one metal bound
UFsc yields similar amounts of product and detect lower hydrolase activity in presence of the bulkier bis-nitrophenyl
phosphate (Figure 1.26B). The yield of nitrophenol product is also comparable between the bi-metallic and monometallic protein scaffolds suggesting the protein environment (specific ligand arrangements and solvent access) and
possibly the substrate channel could be important determinants for hydrolase function.
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Figure 1.27 Kinetic profiles for the initial rates of phosphoester hydrolysis and second order rate constants k2 (M-1*min-1)
for DF protein in Zn(II)-free or Zn(II)-bound forms promoting cleavage of pNPP (A) and BNPP (B). Production of 4nitrophenoxide was monitored by UV-vis spectrophotometry at 405 nm. Initial rates were determined from linear fits of
absorbance versus time data subtracted by the spontaneous hydrolysis in 25 mM Tris-HCl (pH 8.0), 100 mM NaCl buffer.
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The rates of hydrolysis of pNPP and BNPP were determined in presence of DF protein and the second order
rate constants attained from measured absorbance values at 405 nm, which corresponds to formation of the product
4-nitrophenolate, as a function of time. Rate constants were calculated from slopes of linear fits and divided by the
substrate and protein concentrations to give second-order rate constants k2 as the reactions did not show saturation
kinetics (Figure 1.27). DF bundles catalyze both substrates at comparable rate constants and such modest activity is
unsurprising as hydrolysis of phosphoesters based on histidine ligands of helix-loop-helix motifs are not substantially
active as presented by Baltzer and coworkers.75

1.6

Conclusions and Outlook
Little differences in catalytic rates among apo and holo forms of DFsc and UFsc constructs suggest a

constellation of amino acids in the active site bundles are suitable for accepting and transforming complex
phosphoesters and diester derivatives. The potential rigidity and inflexibility of the backbone, however, may hinder
rearrangements in the metallocentre, which could be reasons for slow hydrolysis behaviors. Additionally, the
asymmetry imposed by protein active sites (in which a bridging carboxylate ligand was removed to disrupt two metal
ion affinity and replaced with a histidine for one metal binding capacity) was initially thought to be favorable for
coordinating substrate and providing vacant spots for solvent accessibility. The strong Lewis acidity and coordination
flexibility of zinc, moreover, are ideal for phosphoester hydrolysis.84 We thus characterized a catalytically active
mononuclear metal site in a de novo designed construct UFsc; however, one site did not show drastic promotion of
hydrolase activity indicating a need for progressive modification of structural sites for substrate stabilization.
Furthermore, reducing bulky residues lining the channel might be imperative for optimal access of metal ions and
formation of a water channel to create hydrogen bonding networks for coordinating organic substrates efficiently.
Such endeavors are feasible with a robust and easy to modify DF family of proteins.12 The future goals are to measure
the affinity of DF constructs for Fe(III) for one site and another site incorporated with either Mn(II), Ni(II), Zn(II), or
Cu(II) by ITC in order to create a heterovalent metallohydrolase, a biomimetic of PAP, with discrete sites for metal
affinity. Identity of the mixed di-metal site would be confirmed by ICP-OES. Computational redesign of DF proteins
for organophosphate hydrolysis as done by Dan Tawfik, David Baker and coworkers in other model protein systems
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would be also instrumental to achieve an optimal organophosphate binding scaffold.84 Catalytic activity would then
be measured using a colorimetric readout of phosphoester hydrolysis followed by directed evolution to improve
catalytic efficiency. The substrate binding pocket would be redesigned using error prone PCR and randomized
primers to ensure diversity in the resulting catalyst library.

1.7

Experimental

Supplementary figures noted in 1.7 Experimental can be found in Appendix I
Cloning and mutagenesis. DNA sequence that codes for DFsc protein was synthesized by Bio Basic. The gene was
then cloned into pMCSG49 expression vector (DNASU) using ligase independent cloning (LIC).85 The resulting
sequence has a N-terminal His6-tag and tobacco etch virus (TEV) protease recognition site (ENLYFQ/S). Site-directed
mutagenesis was performed using Phusion High-Fidelity DNA Polymerase (ThermoScientific) and customized
primers (Integrated DNA Technologies, Inc.) following standard protocols.
Protein expression and purification. The plasmid containing the gene of interest was transformed into E. coli
BL21(DE3) (New England Biolabs). The starter culture grown from a single colony was diluted 1:100 in LB medium
supplemented with 100 μg/mL ampicillin (Bio Basic Inc.) and incubated at 37°C with vigorous shaking until OD600 =
0.6-0.7. Upon induction of protein expression with 0.5 mM IPTG (Bio Basic Inc.), the culture was incubated for
additional 4 hours at 30°C and pelleted by centrifugation at 4°C (20 min, 4,000 g). Cell pellet was suspended in lysis
buffer (5 mL for 1 g of cell paste) containing 25 mM Tris-HCl, 20 mM imidazole, 100 mM NaCl (pH 8) with 0.5 mM
PMSF (Amresco) and lysed by sonication on ice. Soluble protein fraction was separated by centrifugation at 4°C (30
min, 20,000 g) and filtered through 0.22 μm pore size PES filter (UltraCruz) before incubation with Ni-NTA resin
(Clontech). The protein was eluted with buffer containing 25 mM Tris-HCl, 250 mM imidazole, 100 mM NaCl (pH 8).
Fractions containing protein were exchanged into TEV cleavage buffer (50 mM Tris-HCl, 75 mM NaCl, pH 8) using a
desalting column (BioRad, Econo-Pac 10 DG). The affinity tag was cleaved with TEV protease in presence of 1 mM
DTT (Santa Cruz Technology) and 2 mM EDTA (Gibco Invitrogen). TEV protease was added to a final (A280
protein)/(A280 TEV protease) ratio of 20/1. The solution was sterilized using a 0.22 μm PES filter and incubated at
34°C for 14-16 hours. After the digest, DTT and EDTA were removed on a desalting column, and pure digested
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protein in storage buffer (25 mM HEPES, 100 mM NaCl, pH 7.6) was collected in the flow through fractions from NiNTA column. The purity (> 95%) of the final samples was checked by SDS-PAGE analysis. Protein concentration was
determined by measuring A280 using the calculated (ExPASy) extinction coefficient of 8,480 M-1 cm-1. To remove any
bound metal we used the following protocol. The protein sample was treated with five equivalents of EDTA,
incubated for 30 min at room temperature to chelate any metal, and passed through a desalting column to remove
EDTA. Due to potential of EDTA forming supramolecular aggregates in solution and association with protein, an
ultrafiltration step was performed to eliminate residual EDTA.86 The protein was applied to a centrifugal filter unit
with a 10 kDa MWCO (Corning Spin-X UF), diluted with EDTA-free buffer (25 mM HEPES, 100 mM NaCl, pH 7.6), and
centrifuged at 4°C (15 min, 3,000 g) to concentrate protein down to the original volume. Concentration/dilution
procedure was repeated three times. The concentrated protein (~2-3 mL) solution was then dialyzed against 25
mM HEPES, 100 mM NaCl (pH 7.6) for at least 2 hours at 4°C using Slide-A-Lyzer G2 dialysis cassettes (ThermoFisher
Scientific) with a molecular weight cutoff of 7 kDa. Dialysis was repeated two times followed by overnight
incubation at 4°C. Cobalt titration was employed to verify the elimination of EDTA. For this we mixed protein with
cobalt salt and recorded UV-vis spectrum of this mixture after overnight incubation (see below for cobalt titration
section); increase of cobalt-protein absorbance and the lack of lag-phase was interpreted as no EDTA in the sample.
All proteins were evaluated by ICP-OES for presence of metal. 3His-G2DFsc was expressed and purified as previously
described.26 Clustal alignment of all designs used are shown in Figure S1.1.
ICP analysis. Protein stock solutions were diluted to a final concentration of 25 μM in 3 mL using storage buffer (25
mM HEPES, 100 mM NaCl, pH 7.6) containing 2% HNO3. The concentration of Zn, Mn, Fe, Co, Ni, and Cu were
measured using ICP-OES (Perkin Elmer Optima 3300 DV) to determine elemental concentration. Several
preparations of apo DF proteins were analyzed for metal content and the highest concentration found was 0.08%
Fe, 0.15% Co, 0.23% Mn, 0.56% Cu, 1.6% Ni, and 3.2% Zn (fraction of protein bound to metal).
Cobalt titration. The stoichiometric ratio of Co(II) to protein was assessed by titration of DF proteins with 0 μM to
420 μM CoCl2. 150 μM protein in 25 mM HEPES, 100 mM NaCl (pH 7.6) was incubated with metal overnight and
centrifuged to pellet any precipitate at 15000 rpm, 15 min. Spectra of mixtures were obtained from 400-700 nm
using Agilent Cary 60 UV-Vis spectrophotometer. λmax for each Co(II)-protein complex was plotted as a function of
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added Co(II) (subtracted absorbance at 700 nm). The intersection of the linear regressions of initial and final regions
of the curves were evaluated to determine the stoichiometric ratio of Co(II) to protein.
CD spectroscopy. CD spectra were obtained on a Jasco J-715 CD spectrometer using a step scan averaging mode
over three runs using a quartz cuvette with a 0.1 cm path length. Samples contained protein (20 μM) or metalbound protein (20 μM protein and 200 μM ZnCl2) in buffer (5 mM HEPES, pH 7.6). The sample absorbance never
exceeded 1.5 at all wavelengths in order to assure reliable MRE values. CD of DF proteins including variants are
shown in Figure S1.2.
UV-Vis assay for catechol oxidation. Kinetics measurements were performed on Agilent Cary 60 UV-Vis
spectrophotometer using a 1 mL quartz cuvette with a 1 cm path length. Solution of 3,5-di-tert-butyl catechol (DTBC)
[Acros Organics] was freshly prepared in methanol at 20 mM concentration, and an appropriate amount was added
to protein in non-oxygenated buffer containing 25 mM HEPES, 100 mM NaCl, pH 7.6 (500 μL total volume). Oxygensaturated buffer (25 mM HEPES, 100 mM NaCl, pH 7.6) was prepared by bubbling pure dioxygen gas for 30 min
through buffer solution kept on ice. Oxygenated buffer (500 μL) was added to the mixture and UV-Vis spectrum
was collected immediately after 0, 1, 2, 12, 24, and 48 hours of incubation at room temperature. The final
concentrations of reagents were as follows: 50 μM protein, 500 μM substrate in 25 mM HEPES, 100 mM NaCl (pH
7.6) and ~0.65 mM O2. Solubility of pure dioxygen in water at 25°C and 760 Torr is 1.3 mM.87 An appropriate amount
of metal from 10 mM stock in water was added to protein to achieve one equivalent of metal for each UFsc and
4G-UFsc, and two equivalents of metal for DFsc. Protein in buffer with metal mixtures were incubated at room
temperature for 15 min before addition of substrate and oxygenated buffer. Oxidation of DTBC by dioxygen and
apo DF proteins was also monitored to observe contribution of metal-free systems in substrate conversion (Figure
S1.3)
Kinetics of para-nitrophenyl acetate (pNPA) and phosphoester hydrolysis. Kinetic experiments were initiated by
addition of an aliquot of pNPA (100 mM in acetonitrile) to an aqueous solution of 25 mM Tris-HCl (pH 8), 100 mM
NaCl buffer. 50 μL of pH 8 protein stock solution or working buffer (blank) was combined with 150 μL of an
appropriately diluted pNPA substrate for a final concentration of 25 μM protein, 500 μM substrate. Evolution of
the reaction was monitored on Agilent Cary 60 UV-Vis spectrophotometer in a standard 1 cm path length quartz
cuvette by observing for increase in absorbance at 405 nm for para-nitrophenol product. For solutions containing
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Zn(II), a 50 mM ZnCl2 was prepared in 1 N HCl and water. A working buffer containing 0.5 mM ZnCl2 was prepared
for kinetic assays. Disodium 4-nitrophenyl phosphate hexahydrate and Bis(4-nitrophenyl) phosphate sodium salt
(each 100 mM stocks) were prepared in MilliQ H2O and used for kinetic experiments under conditions described
above. The initial rates (v0) for hydrolysis of pNPP and BNPP were acquired from the absorbance vs. time (min)
data divided by the extinction coefficient (16,600 M-1*cm-1 for 4-nitrophenoxide at pH 8). The hydrolysis of
substrate in buffer was accounted for by subtracting the initial rate in blank sample from the initial rate of protein
or protein and metal containing samples.
Stopped flow kinetics. Oxygen reaction kinetics were conducted in a stopped-flow apparatus (SX20, Applied
Photophysics) at 25°C. The tubing of the stopped-flow instrument was made anaerobic by washing several times
with sodium dithionite (Honeywell Research Chemicals) solution (300 mM) followed by several washes with
degassed water and then buffer. Degassed pure proteins DFsc and UFsc, degassed buffer (25 mM HEPES, 100 mM
NaCl, pH 7.6) and Fe(II) salt were brought into the glovebox (MBRAUN) under anaerobic conditions. The protein
samples were incubated with 300 μM ferrous ammonium sulfate for 30 minutes prior to the experiment. One
syringe was loaded with anaerobic 100 μM protein and 300 μM Fe(II) in 25 mM HEPES, 100 mM NaCl (pH 7.6) buffer
while the second syringe was loaded with oxygenated buffer. Oxygenated buffer (25 mM HEPES, 100 mM NaCl, pH
7.6) was prepared by bubbling dioxygen gas for 30 min through a buffer solution kept on ice. The reaction was
initiated by mixing equal volume from both syringes. The absorbance was monitored at 520 nm versus time for 2
seconds collecting 500 time points in diode array mode.
EPR analysis. In order to form semiquinone radical, the protein was mixed with metal and substrate inside a glove
box (to preserve Fe(II) oxidation state, but glove box is not required for other metal salts) and incubated at room
temperature for 1 hour. The reaction was then initiated by adding oxygen-saturated buffer (100 mM HEPES, pH 8).
After overnight incubation at room temperature, UV-Vis spectra were taken and then EPR samples prepared by
mixing 240 μL of the sample solution and 60 μL of glycerol in water (50/50). This mixture was transferred into EPR
tube (Wilmad, 707-SQ, thin wall quartz tube, 4 mm inner diameter) and frozen in liquid nitrogen. Samples were
acquired at 20 K on Bruker EMX EPR spectrometer equipped with a cryostat using 0.2 mW or 2 mW power. Other
experimental conditions: frequency 9.39 GHz, modulation frequency 100 kHz, modulation amplitude 3 G. Each
spectrum is an average of at least four scans.
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Isothermal titration calorimetry. The thermodynamic parameters of the metal binding to DFsc, UFsc and 4G-UFsc
were monitored using a MicroCal PEAQ-ITC instrument (Malvern). The exact concentration of proteins dialyzed
against 25 mM HEPES, 100 mM NaCl (pH 7.6) was determined by A280 using an extinction coefficient of 8480 M-1cm1

. Stock solutions of metal salts (50 mM) were prepared in water and then diluted to the appropriate concentrations

in buffer (25 mM HEPES, 100 mM NaCl, pH 7.6). The concentrations of metal stock solutions were confirmed by
ICP-OES. The protein in the calorimeter cell was titrated with metal solutions by automatic injections at 25 °C with
750 rpm stir speed. Baseline correction and integration of the peaks corresponding to each injection were
performed using the Microcal PEAQ-ITC Analysis software provided by the manufacturer. The data were fitted to
the one set of sites model for UFsc and 4G-UFsc, and the two sets of sites model was used for DFsc to determine
the stoichiometry (n), enthalpy of complex formation (△H), and equilibrium dissociation constant (Kd) parameters.
Zinc binding to UFsc and 4G-UFsc were measured by competition titration where triethylenetetramine (TETA)
complex with Zn(II) was placed in the sample cell and titrated with protein in the syringe. Results of the competition
titration for UFsc and 4G-UFsc were fitted using competitive model; thermodynamic parameters for Zn(II)-TETA
binding were determined by ITC: number of binding sites – 0.777 ± 0.005, Kd – 0.173 ± 0.065 μM, ΔH – 3.57 ± 0.06
kcal/mol. To obtain binding enthalpies, the enthalpy values were corrected for the enthalpy of dilution observed
when the protein was saturated with metal. Thermograms and integrated binding isotherms for all proteins are
shown in Figure S1.13, Figure S1.14, and Figure S1.15. Thermodynamic parameters obtained from ITC are provided
in Tables S1, S2, and S3.
UV-Vis assay in presence of DPC or BSA. Solution of DTBC was freshly prepared in methanol at 20 mM
concentration and then added to n-dodecylphosphocholine (DPC) [Sigma] in 500 μL total volume or to bovine serum
albumin (BSA) [Sigma] in water. Oxygenated buffer (500 μL) was added to the mixture containing DPC or BSA with
substrate, and UV-Vis spectra were taken immediately after 1, 18 and 23 hours of incubation at room temperature.
The final concentrations of reagents were as follows: 20 mM DPC or 50 μM BSA, 500 μM DTBC in 50 mM HEPES (pH
8) and ~0.65 mM oxygen.
Expression of labeled proteins. The plasmid containing DFsc gene was transformed into E. coli BL21(DE3). A single
colony was inoculated into 2 mL of LB medium supplemented with 100 μg/mL ampicillin and incubated at 37°C for
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4 hours with shaking at 180 rpm. The starter culture in LB (2 mL) was diluted into M9 minimal medium (18 mL)
containing 1 g/L of 15NH4Cl (Cambridge Isotope Laboratories) as nitrogen source, 6 g/L of unlabeled D-glucose or 2
g/L of D-glucose-13C (Cambridge Isotope Laboratories) as carbon source, and 100 μg/mL ampicillin, and grown at
37°C for 2 hours. The culture was further diluted with 1 L of M9 minimal medium and incubated at 37°C until OD600
= 0.6–0.7. After induction of protein expression with 0.5 mM IPTG, the culture was incubated at 18°C overnight and
pelleted by centrifugation at 4°C (20 min, 4,000 g). Typical yield of wet cell paste was 2 g/L.

NMR studies. HSQC experiments were performed at 25°C on 800 MHz Bruker AVANCE III HD, with a Triple Resonance
Inverse (TCI) Detection CryoProbe. Spectra were processed using TopSpin (Bruker), NMRPipe88 and analyzed using
CCPN.89 All NMR experiments with [13C,15N] DFsc were recorded at 300 K. Double labelled protein [13C,15N] had 6.9%
of Ni as measured by ICP-OES. The samples contained 0.4 – 0.8 mM [13C,15N] DFsc in 25 mM MES, 100 mM NaCl (pH
6) and 10% D2O for the lock. Backbone resonance assignments were obtained from a series of 3D BEST HNCACB,
HN(CO)CACB, HNCA, HN(CO)CA, HNCO, and HN(CA)CO spectra, followed by assignment of the HA, HB and methyl
groups from 2D [1H,13C] HSQC, 3D HBHA(CO)NH, and 3D H(C)CH-TOCSY experiments. Side-chain NH2 resonances of
Asn and Gln residues and the NH indole group of Trp were assigned from a 15N-edited 3D NOESY-HSQC spectrum
(τmix = 120 ms). Partial assignments of the aromatic side-chains were obtained from 2D [1H,13C] CT-HSQC(aro), 2D
(HB)CB(CGCD)HD and 13C-edited 3D NOESY-HSQC spectra (τmix = 120 ms).

HSQC spectrum of [1H,15N] DFsc acquired immediately after addition of DTBC is identical to that of DFsc itself (Figure
S1.8), but signals shifted after 24-hour incubation of DFsc with DTBC (Figure S1.9). Having established that we can
follow substrate binding by HSQC, we performed titration of DFsc with DTBC acquiring NMR spectra after addition
of the substrate. The NMR titration (Figure S1.11) was performed by incremental addition of a freshly prepared DTBC
stock solution (51.7 mM in CD3OD) to the DFsc sample at the initial concentration of 0.4 mM. At each increment,
changes in chemical shifts of the protein resonances were monitored in 2D [1H,15N] HSQC spectra, and the titration
curve analysed with a two-parameter non-linear least squares fit using a one-site binding model corrected for
dilution effect:90
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mM in CD3OD) to the DFsc sample at the initial concentration of 0.4 mM. At each increment, changes
in chemical shifts of the protein resonances were monitored in 2D [1H,15N] HSQC spectra, and the
titration curve analysed with a two-parameter non-linear least squares fit using a one-site binding
model corrected for dilution effect:7
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nitrogen and proton, respectively, at the end of the DFsc-DTBC titration. The intermolecular NOEs between 13C,15N-

prepared 0.4 mM [13C,15N] DFsc sample containing two equivalents of DTBC.

labelled DFsc and natural-abundance DTBC were detected in 2D [13C,15N]-half-filtered NOESY and 3D [13C,15N]-

NMR data were submitted to BMRB database with entry 27481.

filtered, 13C-edited NOESY-HSQC spectra and verified in 3D 13C-edited NOESY-HSQC, all acquired with τmix = 120 ms

Redox titration. In order to form semiquinone radical with DFsc, the reaction was set up by mixing
on a freshly prepared 0.4 mM [13C,15N] DFsc sample containing two equivalents of DTBC.

apo-DFsc, 2 equiv of metal salt and a freshly prepared DTBC (20 mM in methanol) in water (750 µL
total volume). Oxygen-saturated buffer (100 mM HEPES, pH 8) (750 µL) was then added to the
NMR data were submitted to BMRB database with entry 27481.

mixture. The final concentrations of reagents are as follows: 50 µM protein, 100 µM metal, 500 µM
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Sodium dithionite solution was further diluted 10-fold in water and its concentration was measured as follows. Two
solutions were prepared: 1) 990 μL of water and 10 μL of K3Fe(CN)6 solution; 2) 980 μL of water, 10 μL of K3Fe(CN)6,
and 10 μL of dithionite (1/10 dilution). Absorbance of both solutions was measured at 420 nm and concentration of
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reducing equivalents calculated using extinction coefficient of ferricyanide (𝜀420 = 1020 M cm ).91
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The mixture of DFsc-SQ• and ITS was transferred into an anaerobic quartz cuvette (Starna) and fitted with a 50 μL
Hamilton airtight syringe containing 4 mM sodium dithionite solution (all preparations performed in the glove box).
To prevent oxidation during spectrophotometry, the cuvette with syringe were kept inside a bag constantly purged
with nitrogen gas. Sodium dithionite (in the syringe) was titrated into protein-containing solution in 2 μL aliquots
until saturation (ITS dye signal (𝜆 max = 589 nm) no longer decreased). After each injection, the solution was
equilibrated for 30 min at room temperature, and UV-Vis spectra were acquired using Agilent 8453 UV-Vis
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Computational docking of DTBC into DFsc using RosettaScripts
The ligand docking protocol was based on the approach by Lemmon et al using XML scripting
to control the parameters.9 DFsc protein (PDB 2HZ8) was prepared by stripping the water molecules
and two zinc ions using the clean_pdb.py tool42
in Rosetta. The side chain positions of the resulting
apo protein were optimized without perturbing the backbone using the fixbb protocol with -

Computational docking of DTBC into DFsc using RosettaScripts

The ligand docking protocol was based on the approach by Lemmon et al using XML scripting to control the
parameters.92 DFsc protein (PDB 2HZ8) was prepared by stripping the water molecules and two zinc ions using the
clean_pdb.py tool in Rosetta. The side chain positions of the resulting apo protein were optimized without

perturbing the backbone using the fixbb protocol with - packing:repack_only -ex1 -ex2 flags. 3D structure of
DTBC was obtained from PubChem (CID: 66099) in .sdf format. Since DTBC has only two rotatable bonds on its tertbutyl groups, generating conformers presents no significant change. Ligand.params and .pdb files were generated
using the molfile_to_params.py application. Using the .pdb format of DTBC, ligand and protein structures were
concatenated

into

a

single

file

using

the

following

Terminal

command:

$cat <protein.pdb> <ligand.pdb> > <complex.pdb>

The scoring parameters used for ligand docking was based on DeLuca et al.93 The XML script can be used to apply
constraints and guide the ligand to the known binding or active site. The algorithm begins by positioning the ligand
at a user-specified starting point with the StartFrom mover. The ligand is then sampled within a specified radius via
the Transform mover and Monte Carlo Minimization algorithm until clashing between side chains and ligand are
minimized. We used the xyz coordinates between the two water molecules originally present in the protein PDB file
as the starting point for the ligand with a box radius of 8.0 Å.

Using the data derived from the NOE, atomic distance constraints of 6.0 Å were applied between Ala14 and
Ile40 H𝛼 atoms and the tertiary carbon of 3-tBu group. The XML script was run using the following command:

$<path_to_Rosetta>/main/source/bin/rosetta_scripts.default.macosclan
grelease -database <path_to_database>

With the flags:

-s <complex.pdb>
-nstruct 2000
-in:ignore_unrecognized_res
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-run
-ignore_zero_occupancy false
-qsar
-max_grid_cache_size 1
-mistakes
-restore_pre_talaris_2013_behavior
-score:analytic_etable_evaluation true
-ex1
-ex2

The .params file and XML script were utilized by adding the flag -extra_res_fa <ligand.params> and parser:protocol <path_to_XML_script.xml>, respectively. Evaluation of the lowest energy models were solely

based on the total_score, where the lowest scoring pose represents most probable DTBC and DFsc interactions.
XML Script:
<ROSETTASCRIPTS> <SCOREFXNS>
<ScoreFunction name="ligand_soft_rep" weights="ligand_soft_rep"> <Reweight scoretype="fa_elec" weight="0.42"/>
<Reweight scoretype="hbond_bb_sc" weight="1.3"/>
<Reweight scoretype="hbond_sc" weight="1.3"/>
<Reweight scoretype="rama" weight="0.2"/> </ScoreFunction>
<ScoreFunction name="hard_rep" weights="ligand"> <Reweight scoretype="fa_intra_rep" weight="0.004"/> <Reweight scoretype="fa_elec"
weight="0.42"/> <Reweight scoretype="hbond_bb_sc" weight="1.3"/> <Reweight scoretype="hbond_sc" weight="1.3"/> <Reweight
scoretype="rama" weight="0.2"/>
</ScoreFunction> </SCOREFXNS> <LIGAND_AREAS>
<LigandArea name="docking_sidechain" chain="X" cutoff="6.0" add_nbr_radius="true" all_atom_mode="true" minimize_ligand="10"/>
<LigandArea name="final_sidechain" chain="X" cutoff="6.0" add_nbr_radius="true" all_atom_mode="true"/>
<LigandArea name="final_backbone" chain="X" cutoff="7.0" add_nbr_radius="false" all_atom_mode="true" Calpha_restraints="0.3"/>
</LIGAND_AREAS>
<INTERFACE_BUILDERS>
<InterfaceBuilder name="side_chain_for_docking" ligand_areas="docking_sidechain"/> <InterfaceBuilder name="side_chain_for_final"
ligand_areas="final_sidechain"/> <InterfaceBuilder name="backbone" ligand_areas="final_backbone" extension_window="3"/>
</INTERFACE_BUILDERS>
<MOVEMAP_BUILDERS>
<MoveMapBuilder name="docking" sc_interface="side_chain_for_docking" minimize_water="true"/> <MoveMapBuilder name="final"
sc_interface="side_chain_for_final" bb_interface="backbone" minimize_water="true"/>
</MOVEMAP_BUILDERS>
<SCORINGGRIDS ligand_chain="X" width="17.0"> <ClassicGrid grid_name="vdw" weight="1.0"/>
</SCORINGGRIDS>
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<RESIDUE_SELECTORS>
<Index name="116X" resnums="116"/> <Index name="A14" resnums="14"/> <Index name="I40" resnums="40"/>
</RESIDUE_SELECTORS>
<MOVERS>
<StartFrom name="start_from" chain="X">
<Coordinates x="3.82999992" y="0.16" z="-1.33899999"/> </StartFrom>
<AddConstraints name="add_csts" >
<DistanceConstraintGenerator name="gen_my_csts" residue_selector1="116X" residue_selector2="A14" atom_name1="C1"
atom_name2="HA" function="HARMONIC 6.0 0.5" />
<DistanceConstraintGenerator name="gen_my_csts" residue_selector1="116X" residue_selector2="I40" atom_name1="C1"
atom_name2="HA" function="HARMONIC 6.0 0.5" />
</AddConstraints>
<Transform name="transform" chain="X" box_size="8.0" move_distance="0.3" angle="5.0" cycles="500" repeats="1" temperature="5"
initial_perturb="3.0" />
<ParsedProtocol name="low_res_dock"> <Add mover_name="start_from"/>
<Add mover_name="add_csts"/> <Add mover_name="transform"/>
</ParsedProtocol>
<HighResDocker name="high_res_docker" cycles="6" repack_every_Nth="3" scorefxn="ligand_soft_rep" movemap_builder="docking"/>
<FinalMinimizer name="final" scorefxn="hard_rep" movemap_builder="final"/>
<InterfaceScoreCalculator name="add_scores" chains="X" scorefxn="hard_rep" compute_grid_scores="0"/>
<ParsedProtocol name="high_res_dock"> <Add mover_name="high_res_docker"/> <Add mover_name="final"/>
</ParsedProtocol>
<ParsedProtocol name="reporting"> <Add mover_name="add_scores"/>
</ParsedProtocol> </MOVERS>
<PROTOCOLS>
<Add mover_name="low_res_dock"/> <Add mover_name="high_res_dock"/> <Add mover_name="reporting"/>
</PROTOCOLS>
<OUTPUT scorefxn="hard_rep" /> </ROSETTASCRIPTS>

Models of protein-DTBC interaction generated using Rosetta are shown in Figure S1.12
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Streptococcus pneumoniae biofilm inhibition and dispersion directed by
synthetic saccharides binding to lectin sites
Jennifer H. Yoon, Dr. Areetha D’Souza, Dr. Olga V. Makhlynets

Yoon constructed TIGR4 ∆rrgA genome by SOE PCR, validated construct design by PCR screen, made TIGR4 competent cells for
chimeric ∆rrgA uptake, and prepared glycerol stocks of recombinant construct. Yoon performed cloning of RrgA into pET-24a
(vector provided by Hougland lab at Syracuse University Chemistry Department), expression, and purification (with help from
Magdelynn Mege and Sadie Novak) including preliminary ITC experiments using commercially available maltose and DβM (Avanti).
Docking of ligands to RrgA using UCSF Chimera server was done by Yoon. Biofilm inhibition assays on S. sanguinis pilin mutants
were done by D’Souza and Yoon using commercially available DβM. D’Souza performed compound screen and established bacteria
growth conditions using synthetic ligands provided by Luk lab at Syracuse University Chemistry Department with S. sanguinis
organism, and with Magdelynn Mege performed hemolysis experiment of RBC with DβM.

Abstract
Streptococcus pneumoniae is a commensal bacterial pathogen and carriage in host microflora is asymptomatic until
microorganisms gain capacity to initiate disease. Pneumococci comprise of unique capsular polysaccharides
contributing to pathogen virulence and the immense chemical versatility of polysaccharide capsules confers distinct
immunologic triggers detrimentally limiting the potency of existing vaccines to fully cover all serotype specific capsular
variants. Likewise, the inefficiency in vaccines to easily adapt to sequence diversity and immune evasion along with
antibiotic resistance of pneumococci potentiates a deep search for alternative therapeutic modalities to treat
pneumococcal infection. Pneumococci principally mounts invasion by colonizing host nasopharynx and produces
bacterial biofilm accompanied by an extracellular matrix to protect the bacterium from external challenges. Our vision
is to create a combination therapy of glycosylated ligands to act on invasive pneumococcal proteins involved in biofilm
formation by concerted action of antibiotics to inhibit and disperse biofilm-associated microbial colonizers.
Conformational diversity and topology of carbohydrates permit biomolecular associations of oligosaccharides (ligands)
to glycan binders (lectins) and influence adhesion and pathogen virulence properties, inflammatory responses, and
signal transducing cascades. Lectins thus highlight potential inhibitory domains to control early and late stage
attachment of pathogenic bacteria to glycosylated host tissues and serve as virulence markers to control pathogenicity
in infectious processes. Herein, the use of multivalent saccharides for inhibitory and dispersive roles in pneumococcal
biofilm established by an invasive human pathogen Streptococcus pneumoniae TIGR4 is explored. A panel of ligands
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was validated to target surface extension proteins, pili, putative lectins. Our lead compound n-Dodecyl-β-D-Maltoside
(DβM), a nontoxic alkylsaccharide surfactant, is shown to inhibit bacterial growth in Streptococcal species, such as
Streptococcus sanguinis SK36, and disperse preformed biofilm. Docking models show sugars of various sizes bind a
pocket of a major adhesin protein RrgA, a pilin protein conserved in TIGR4 we propose contributes to biofilm
formation. RrgA was recombinantly expressed and the TIGR4 genome reconstructed to characterize pili contribution
to biofilm progression. TIGR4 inhibition was furthermore validated by crystal violet screens in presence of DβM.
Altogether findings suggest pili adhesins underly the mechanism of biofilm establishment and antiadhesion-based
therapies using saccharide components could be effective in preventing and treating bacterial infections.

2.1

Streptococcus pneumoniae disease epidemiology and pharmacotherapy

2.1.1 Introduction
Streptococcus pneumoniae (pneumococcus) is a commensal organism in humans and is able to disseminate
into normally sterile areas such as the blood or lungs to promote infectivity. Pneumococcus causes a series of
infections from pneumonia (confined to lungs), meningitis (infection of brain and spinal cord covering), otitis media
(middle ear infection) to sepsis (bloodstream toxicity). 1, 2 Children younger than the age of two, adults aged 65 years
or older, and people with immunosuppressive or chronic health conditions are especially vulnerable to invasive
pneumococcal disease (IPD). 3 Pneumococcal infections furthermore contribute to a worldwide annual death toll of
one million children under the age of five. 4, 5 900,000 cases of pneumococcal pneumonia infection occur in the U.S.
alone resulting in 400,000 hospitalizations with an associated 5 to 7 % mortality rate in hospitalized patients as
reported by the U.S. Center for Disease Control. 6 Pneumococcal infections are thus the foremost cause of global
morbidity and mortality by human contact through respiratory droplets. 7
Clinical isolates are generally identified by serotype comprised of unique capsular polysaccharides (CPS)
surrounding the cell wall blocking access of antibodies and complement factors to pneumococcal surfaces. 8, 9 Over
90 different immunologically distinct CPS are identified and grouped by antigenic similarity and strains producing an
abundance of such polysaccharides cause virulence. 10 Polysaccharide capsules, moreover, not only mediate invasion
but also protect the pathogen from neutrophils (immune-mediated phagocytes) to evade the host immune clearance
system.

11, 12

Therefore, the diverse immunologic and chemical specificities of the polysaccharide capsule
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contributing to invasive pneumococcal disease continue to challenge pneumococcal vaccine development.
Correspondingly, overexhausted use of antibiotics contributing to pneumococcal resistance demands creative
treatment methods to withstand the repertoire of bacterial resistance mechanisms. 13
CPS principally undergo a phase shift along an infection process wherein the CPS density changes and
surface proteins are exposed once bacteria approach the epithelial barrier. 14 These surface proteins participate in
virulence, antibiotic resistance, oxidative stress and are essential for host colonization. Moreover, pneumococcal
surface proteins are expressed to respond and adapt to environmental signals and changing habitats. 15 Henceforth,
mechanism of pneumococcal resistance and information on existing vaccines and anti-adhesive therapy platforms
to interfere in the intrinsic binding affinity of infectious pneumococci to glycosylated host surfaces are elaborated.
Importantly glycan interactions with biofilm-associated pilins (elongated proteins projecting from pneumococci cell
wall surface) are described. Our motivation to implement synthetic saccharides to interfere in the binding capacity
of pili to host mucosa (upper respiratory system being the first entry point and nasopharynx as site of colonization)16
is proposed. The focus lies on a pilin protein RrgA conserved in Streptococcus pneumoniae TIGR4 strain. RrgA is
shown to be an essential adhesin in infectivity with potential for blocking interaction to natural sugars provided by
the host and promoting invasion through the blood-brain barrier. 17-19 Comparative inhibition and dispersion studies
are performed in a Streptococcus sanguinis model with a panel of disaccharides of various sizes and lengths to
understand the influence of structure and activity correlation. A lead compound n-Dodecyl-β-D-Maltoside (DβM) is
shown to display inhibitory and dispersive roles in streptococci and could be functionalized for tight affinity to RrgA.
Hence, ligands specific for RrgA would be beneficial to outcompete binding of RrgA to host carbohydrates and
dismantle biofilm establishment, a grave concern across medical communities.

2.1.2 Mechanism of Resistance
Mortality associated with pneumococcal pneumonia (20%), pneumococcal bacteremia (50%) and
pneumococcal meningitis (80-100%) significantly dropped to 5%, 20%, and 30%, respectively with the introduction
of penicillin. 20 Clinical isolates of Staphylococcus aureus, microorganism causing serious bloodstream infection and
pneumonia, showed an emerging resistance to ß-lactams and multidrug components such as tetracycline,
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erythromycin, chloramphenicol, clindamycin, streptomycin, and rifampin. 21, 22 The unique mechanism of antibiotic
resistance among several hundred resistant isolates from various parts of the world dramatically reduced their
binding capacity or affinity to antibiotic molecules for as many as four out of five penicillin binding proteins (PBPs)
translating to an elevated MIC for individual isolates. 23, 24 Isolates shared a protein polymorphism composed of a
unique PBP pattern or a genetically distinct lineage of pneumococcal clones. These isolates also shared properties
including serotype, resistance to antibiotics, and geographic origin. The mosaic of PBP genes were heterogenous and
nonpneumococcal in nature through recombinant integration of heterologous DNA sequences into the structural
gene composition of PBP. 25 The sequence diversity therefore alters the active site of proteins allowing spread of
antibiotic resistant bacterial strains distinguished by three distinct processes: acquisition of the resistance trait,
transfer of the resistance gene from one bacterial cell to another termed horizontal gene transfer, and subsequent
clonal expansion and spread of resistant clones.

26

Low resistance to antibiotics is associated with a progeny of

numerous ancestral cells acquiring unique heterologous DNA sequences whereas multidrug resistance traits are
accompanied by genetically homogenous traits belonging to the same serotype: 19A being the most common
serotype isolated globally; 6A, 7F, and 3 common in adults over seventeen years old; 19A, 6A, 19F, 14, 6B, 9V, and
15A likely to be drug resistant.27 Thus, due to the ongoing acquisition of multidrug-resistant traits by gram positive
pathogens such as pneumococci, MRSA, and enterococci, as well as limited understanding of these organisms
controlling bacterial disease, efforts to identify the molecular basis of colonization and functional properties are
imperative. Moreover, design of alternative drugs against a broad spectrum of multidrug resistant pathogens owing
to a resurgence of infectious disease is crucial.

2.1.3 Pneumococcal vaccines
Licensed pneumococcal vaccines comprising pneumococcal polysaccharides to generate serotype-specific
antibody responses significantly reduced rates of pediatric invasive pneumococcal disease (IPD).

28

Yet, the high

manufacturing complexity along with costs and limited serotype coverage weaken their universal vaccine impact
especially in low resource areas or developing nations. An affordable vaccine which confers a broad serotypeindependent protection from pneumococcal disease is a major global health priority. Various adjunctive options
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Vaccine

Serotype coverage

Pneumovax®23 (Merck)

Purified polysaccharides of 23
different serotypes
Seven different pneumococcal
polysaccharides conjugated to a
carrier protein (CRM197™, a
cross-reactive mutant of a
diphtheria toxin) contributing to
herd immunity by this vaccination
regimen

PCV7, Prevnar®
(originally Wyeth,
now Pfizer)

Age group

Limitations

Adults over age of 65 and
some high-risk patient
populations
Four doses administered at 2,
4, 5, and 12-15 months of age
for infants and adults over 50

Use in children is limited as
polysaccharides
are
poorly
immunogenic in infants and for
children under the age of two years.
Less pronounced in preventing
pneumonia or mucosal disease such
as acute otitis media (AOM) than
reducing bacteremic disease.

Six weeks through five years
of age and adults 18 years of
age and older

13-valent Prevnar®
(Pfizer)
10-valent with three
different
protein
carriers (Synflorix™,
GlaxoSmithKline
Biologicals)

Second generation of PCVs

V114, 15-valent
(Merck)

Pneumococcal conjugate vaccine in Phase 3 development consisting of 15 serotypes conjugated to a CRM197
carrier protein including serotypes 22F and 33F not contained in other PCV under license for use in adults 36.

PCV

PnuBiovax
(ImmunoBiology Ltd)

Six weeks through five years
of age

Does not protect against disease
caused by Streptococcus pneumoniae
serotypes not included in the vaccine
as other aforementioned PCVs.

Progressed into full Clinical Development (Phase I Clinical Trial completed). Implements chaperone proteins
to properly fold polypeptide chains of pathogen-derived products to activate dendritic cells and stimulate an
immune response. Observed subjects receiving the vaccine have >2-fold increase in antibodies against
pneumococcal proteins including RrgA 37.

Table 2.1 Pneumococcal vaccines currently available and undergoing development.38

and approaches to promote an immunogenic response are pursued that include protein-based strategies, variations
of polysaccharide-protein conjugate strategies, and inactivated whole cell pneumococcal vaccines.
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Vaccines

currently in use to treat pneumococcal infection are described in Table 2.1. Often the limitations of these vaccines

are they are all polysaccharide capsule-based and do not cover other serotypes not included in the formulations. 34
Furthermore, IgM representing the major classes of antibodies induced are not boosted by subsequent
immunization because their immune response does not induce memory B cells. Lack of memory B cells is principally
due to polysaccharides poorly promoting T-cell dependent immune responses. 35

Glycoconjugated carrier proteins relieve the strain imposed by capsular polysaccharide-based vaccine
designs (such as ill-defined T cell activation) by presenting peptides or glycopeptides associating the major
histocompatibility complex (MHCII) for CD4+ T cell recognition. 39 Avci et al. raised the possibility of peptide-glycan
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Figure 2.1 Polysaccharide antigen linked to a protein is internalized by a surface immunoglobulin on a B cell. Endolysosomes
process the glycoconjugate into a glycopeptide to bind MHCII. Sugar epitope is presented by MHCII to interact with T cell
receptors. T cells activate interleukin generation, production of plasma cells, and memory B cells.

epitopes inducing a T cell response, a proposal deflating the accepted notion that carbohydrates are unrecognizable
by T cells. 40 Kasper and coworkers proposed a mechanism by which sugars on glycoconjugates can trigger a T cell
response through the following model: (1) a glycoconjugate binds and crosslinks to a B cell receptor (2)
glycoconjugate is internalized into the B cell endosome and processed by ROS and acidic proteases at junctions
between the carrier protein and polysaccharide (3) the resulting glycopeptide is loaded into a MHC molecule and
the attached sugar is available for recognition by T cell receptors (4) T cells promote IL-4 and IL-2 cytokine activation,
inducing maturation of B cells, memory B cells and in turn carbohydrate-specific IgG antibodies (illustrated
mechanism shown in Figure 2.1). Avci et al.’s findings showed that T cells do recognize polysaccharides if covalently
linked to a peptide anchor, and the importance of understanding the immune mechanisms involving glycoconjugate
immunization for rational design of new peptide-polysaccharide conjugates. 41
Noncapsular components to elicit an antibody response for improving protection are increasingly identified
such as pneumococcal surface protein (Psp) PspA, and choline binding protein (Cbp or PspC). These antigens promote
cross-reactive humoral immune responses among diverse strains in experimental human carriage research.
Recombinant PspA has been used in phase I clinical trials and is immunogenic. 42 Other various pneumococcal surface
adhesins (Psa) PsaA, a manganese binding lipoprotein, reduces carriage and delays invasive disease in animal models,
but to be fully effective the immunogen needs to be combined with other pneumococcal proteins. Toxoid derivatives
of pneumolysin are also effective in preventing invasive disease in mice models (although such vaccines require more
than one protein to be potent). GlaxoSmithKline is investigating proteins including the pneumococcal histidine triad
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(Pht) family of proteins identified through reverse vaccinology (an approach using pneumococcal genomic scans for
ORFs with secretion signal motifs or hydrophobic leader sequences most probable to encode for cell wall attachment
sites) as potential antigens likely to interact with host immune cells and antibodies.

38

Lastly, killed whole cell

pneumococcal vaccines, whereby a greater sum of pneumococcal antigens could be presented at once, has been
studied and manufactured by Instituto Butantan to confer protection in mouse model carriage, pneumonia, and
sepsis. 43 The potential advantage of using whole cell-based vaccines to increase response to noncapsular antigens
is severalfold: (1) low cost of production, (2) serotype-independent mechanism of protection, and (3) promoting
comprehensive immunity to colonization and invasive disease. 44
Although above approaches represent certain strengths in the design of robust and long-lasting immunity
against pathogens, the reproducibility in generating such vaccines is often ill-achieved and serious side effects are
frequent. Bioconjugate methods are often limited by low conjugation yields, incompatibility with biological buffers,
variable labelling sites as a result of indiscriminate polypeptide conjugate orientations, and complex chemical and
purification steps (Scheme outlining production method shown in Figure 2.2).
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At each step considerable losses

(either antigen or carrier protein integrity) can occur, and large-scale cultivation of pathogenic bacteria is required
for polysaccharide biosynthesis, reckoning conjugate vaccines expensive for vaccination campaigns. Furthermore,
above vaccines do not formulate a coherent strategy in eliminating biofilm, the primary cause of pneumococcal

purification

polysaccharide
antigen

chemical
cleavage &
purification

lipid A

bacterial
pathogen

purification

purification

expression
vector

chemical
linkage

conjugate
vaccine

recombinant
carrier protein

Figure 2.2 Scheme for routine production of conjugate vaccines: cultivation of bacteria strains producing polysaccharide
antigens and carrier proteins, purification of LPS and carrier proteins, chemical cleavage of LPS polysaccharides from lipids
followed by subsequent purification steps. Lastly, chemical coupling of polysaccharides to carrier protein is done to obtain final
conjugate vaccine.
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infection, at different stages of pathogenicity for treatment (Figure 2.3A). These vaccines promote clearance of both
avirulent commensal microbes and virulent colonizers, resulting in changes in microflora of unknown consequences.
46

Importantly, even after successful bacterial clearance, there is risk for recolonization by more lethal serotypes

equally adept at biofilm formation, mechanical tolerance, and resistance to antibiotics (Figure 2.3B). 47-49 There is

A
ECM

Pathogenesis

Bacteria shedding & dispersion
into secondary sites to form
new colonies or incorporate into
other biofilm

Viral colonization &
budding biofilm stalks

B

C

Figure 2.3 (A) Pneumococci pathogenesis proceeds through viral colonization and budding of biofilm into mounting debris.
Invasive pneumococci shed and disperse into secondary sites to establish colonies in fresh niches. (B) Polysaccharide
conjugated vaccines (PCV) interfere in proliferation of both commensal microflora and invasive microorganisms before
complete maturation. Serotype replacement do occur concurrently in other niches and evade PCV, heightening risk of
more aberrant and lethal colonizers. (C) Generation of new vaccines directly targeting only proteins upregulated during
biofilm transition into invasive form, delivered using metalloporphyrin conjugate systems.
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also little consideration and mechanistic insight into structural motifs of surface proteins owing to specificity and
pathogenicity in Streptococcus pneumoniae species. The proceeding advances in vaccine production including metal
ion affinity-based porphyrin conjugates to direct clearance of virulent biofilm secretors (Figure 2.3C) and
antiadhesives based on protein-glycan interactions specific to biofilm eradication are described.

2.2

Perspectives of chemical biology in antigen design and maximizing multivalency of

carbohydrates to select potent inhibitors of pneumococcal biofilm
2.2.1 Directed vaccination approaches and glycan inspired mimetics as anti-infective drugs selective for
virulent pneumococcal proteins in biofilm
Anders Hakansson, Blaine Pfeifer, Charles Jones and coworkers developed a strategy to design vaccine
candidates using pneumococcal antigens capable of broad serotype coverage. They built their platform on the
fundamental principle of S. pneumoniae biofilm progressing disease once external triggers prompt pneumococci to
escape asymptomatic biofilm. S. pneumoniae serotype 19F was conditioned to become lethally infectious by
releasing cells from biofilms upon increasing temperature to mimic fever and inducing septicemia and death in mice
(a clinical surrogate model of human pneumococcal disease). Antigens upregulated in biofilm-released bacteria
were made as recombinant proteins and analyzed for direct protection in comparison to PspA, an established S.
pneumoniae surface protein antigen upregulated during virulence transition.

Two antigens GlpO ( 𝛼 -

glycerophosphate oxidase) and PncO (a bacteriocin ABC transporter transmembrane protein) with conserved
sequence homology and specific biofilm prominence were recombinantly produced with histidyl tags and mixed with
a cobalt porphyrin phospholipid (Co-PoP) liposomal carrier (Figure 2.4).

Histidyl tag binds to immobilized

metalloporphyrins. Co(II) macrocycles oxidize to Co(III) in aqueous solutions, confining Co(III) coordinated his-tag
polypeptides within a sheltered liposome bilayer. Delivery of GlpO and PncO using the Co-PoP delivery platform
offers potential to create unprecedented valency of protein antigens on surface localized liposomes.46 The delivery
technology showcases the unique multivalent surface display of proteins without the need for advanced chemical
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conjugation. The production technology significantly reduces complex, multistep processes and obviates need for
cultivation of bacteria strains producing polysaccharide antigens and carrier proteins.
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Figure 2.4 Chemical structure of metallo-PoPs composed of a cobalt porphyrin inserted into a phospholipid bilayer. Cobalt
porphyrin binds polyhistidine tag on polypeptide and buries the polyhistidine into a membrane phase of porphyrin.

Other impressive body of literature illustrates unconventional methods to mitigate bacterial pathogenesis
and colonization at early stages of infection by preventing bacterial adhesion. Adhesion blockers are impactful for
interfering a molecular fit between a microbial adhesin and a carbohydrate sequence characteristically displayed by
host mucosal cells. 50 One foreseeable benefit of using anti-adhesins is such agents can displace bacteria from cell
surfaces by free oligosaccharides, promoting bacterial suspension in secretory fluids. A combination therapy of
antibiotics can kill remaining bacteria, reducing antibiotic dose and time of exposure for therapy. A promising
strategy to arrive at multivalent compounds similar to protein antigens are high-affinity protein ligands.

51

The

approach considers structure-based information on the spatial arrangement of a target binding site seldom reflected
in other design processes. Examples of high-affinity protein ligands applicable in disease diagnosis of Vibrio cholerae
are inhibitors of multivalent carbohydrate-binding proteins namely shiga toxin (Stx), cholera toxin (CT) and choleralike heat-labile toxin family of A𝛽5 bacterial exotoxins. 52 The 𝛽 subunits assemble to form a central pore termed a
toroid-shaped pentamer and each subunit contains a carbohydrate binding site. The pentamers engage up to five
host cell carbohydrate receptor sequences. Fan et al. created a symmetric pentavalent inhibitor for cholera toxins
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using a modular design of various flexible linkers (Figure 2.5). 53 The design comprises of a central pentacyclen core
linked to five single site antagonists or starfish arms. The terminal arms bind to cholera toxin sites to antagonize
binding capacity of toxin to ganglioside GM1 found on human epithelial cell surfaces. This multivalent receptor
blocker displayed approximately 100-fold higher single site affinity of m-nitrophenyl- 𝛼 -D-galactoside (MNPG)
compared to 𝛽 -D galactose yielding a proportionate increase in affinity and IC50 measurement. Dynamic light
scattering showed 1:1 inhibitor to toxin association rather than an inhibitor mediated aggregation, supporting the
favorable single site binding interaction of MNPG. 54
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Figure 2.5 Scheme of galactose binding to Escherichia coli heat-labile enterotoxin. Arrows and dashes indicate hydrogen
bonding interactions of five identical carbohydrate binding sites recognizing ganglioside headgroups (found in
gastrointestinal lumen). The crystal structure of cholera toxin (PDB code 1LTT) directs structure-based design of a
pentavalent ligand with a semirigid core adopting a five-fold symmetric configuration. Linkers (noted as R sketched out in
chemical detail) project in direction of receptor and are referred to as “fingers” fitting snuggly into binding site.

Roland Pieters and coworkers examined the galactose-specific Pseudomonas aeruginosa lectin LecA. 55 The
pathogen is an opportunistic human pathogen causing infections especially in blood and lungs, and due to serious
antibiotic resistance alternative interventions based on adhesion and biofilm blocking tactics were explored. The
influence of multivalency on GalNAc𝛽1-4 Gal and binding specificity present on pathogen type IV pili for synthetic
glycodrugs were assessed. 56 A glycan of optimal size able to fit to the binding site with tight affinity was determined.
A monovalent reference compound 9 and a galactoside of a similar anomeric carbon and triazole moiety 8 were
tested. The triazole-glucose unit is important for the design with 12 being the most optimal length achieved.
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Compound 12 comprising two galactose units was observed to be the best fit stretching across two binding pockets
on LecA (crystallized LecA and 12 shown in Figure 2.6). This structure was the first of the kind to visibly show the
spacer involved in hydrogen bonding to protein in a multivalent carbohydrate complex. Conversion of 12 into a
dendrimer (crosslinking two divalent molecules to form a covalently dimerized tetravalent ligand) increases
dimension of the molecule to improve ligand potency. However, the bulky ligand induces aggregation, necessitating
creation of optimized inhibitors using a library-based approach to improve biofilm blocking through ligand avidity
and not simply due to supramolecular aggregates caused by mismatch of valencies of toxin and inhibitor. Jean-Louis
Reymond and coworkers further demonstrated galactosylated peptide dendrimers had strong affinity for LecA
displaying biofilm inhibition and dispersion activity.
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The anti-biofilm impact of glycopeptide dendrimers was

unprecedented suggesting a new therapeutic approach to control Pseudomonas aeruginosa infections. These
findings provide a foundation in capitalizing on unique features of glycoconjugate lectin interactions to develop
potent biofilm inhibitors.

OH
HO

OH OH
O

O

N
N N

HO

OH OH
O

8

O

OH

OH

9

IC50 : 20 uM

IC50 : 120 uM

HO
OH OH
O O
HO
OH

NHO
N N

OH
O
OH

12
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2.3

Inhibition of polymeric bacterial adhesins with receptor analogs

2.3.1 Oligosaccharides as anti-infective agents to inhibit pili adhesion in TIGR4 biofilm
Carbohydrates are abundant biomolecules on Earth with diverse energy storage and molecular recognition
properties. Avidity and selectivity of carbohydrates mediate interactions between sugars and proteins, the first step
of infection for pathogens (viruses, fungi, bacteria) that use carbohydrate binding proteins to attach to cells and
initiate disease. Thus, ligands to competitively interfere in recognition between host receptors and pathogens to
inhibit colonization or reverse formation of biofilm is of interest. 58 Erkang Fan and Roland Pieters independently
demonstrated the potency of rationally designed multivalent ligands (described in 2.2) emulating natural sugar
components found in human mucosa. An especially important component of the innate immune system is the body
fluid excreting hydrophobic molecules, sphingolipids, as defense systems against pathogens (Figure 2.7A).
Sphingolipids comprised of oligosaccharides and fatty acyl chains lower adhesion of Streptococcus mitis in buccal
mucosa (the inside lining of cheeks) and Staphylococcus aureus to nasal mucosal surfaces.
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Mucins comprising

acidic polysaccharides, glycoproteins, glycolipids and ions are also secreted by the host and are important for innate
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immunity through binding specificity to pathogens, trapping them within the mucus blanket and preventing access
to underlying epithelial cells. 60
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Figure 2.8 Oligosaccharides identified to associate RrgA. RrgA recognizes maltose, chitobiose and cellobiose saccharides
(repeating units of glucose typically produced in plants, algae, and bacteria). Blood group trisaccharides and Lewis X are
members of histo-blood group antigens originating on red blood cells as glycolipids expressed on cell types notably human
tumor cells.

Lastly, other secretors found in individuals are blood group antigens in fluids (Figure 2.7B). Blood groups
are glycoconjugated and act as receptors for bacterial adhesins. Carriage of Neisseria meningitidis in one case study
of a group outbreak of meningitis was shown to be significantly elevated in individuals void of distinct blood group
determinants. 61, 62 James Paton, Michael Jennings, and coworkers examined pilus-1 proteins of S. pneumoniae. They
showed the tip adhesin RrgA had the broadest glycan recognition, binding to maltose, cellobiose, galactose and
blood group A and H antigens by surface plasmon resonance (Figure 2.8). 63 A blood group H trisaccharide provided
the best blocking of S. pneumoniae TIGR4 adherence. The findings provided some clues as to pilus proteins adhering
to specific host glycoconjugates and foreseeable potential in designing synthetic glycosylated derivatives as
competitive inhibitors of TIGR4. Izoré et al. crystallized RrgA and indicated the pilus protein may promote
colonization through conserved structural domains to recognize a variety of carbohydrate structures of extracellular
matrix proteins and glycosylated host cell proteins.64 Considering how structure-based methods prove to be
successful in blocking interfaces of lectin binding sites, we focused on characterizing carbohydrates in anti-adhesion
therapy of Streptococcal species including TIGR4. As no glycocompound therapy has been sought out in TIGR4 S.

64

pneumoniae biofilm inhibition, and vaccines specific for this organism are just beginning to emerge, our proposal is
to inhibit the binding site of the putative lectin protein RrgA by screening a repertoire of ligands with potential tight
affinity to the macromolecule. Firstly, the origin of TIGR4 and an overview of epitope mapping to identify distinct
binding motifs on RrgA based on the crystal structure are elaborated.

2.3.2 TIGR4 microbe and host interactions
The chief contributor to pneumococcal invasion especially in TIGR4, an invasive serotype 4 strain of S.
pneumoniae, of principal focus herein, is biofilms, bacteria that adhere to surface epithelia and form a densely
packed aggregate surrounded by an extracellular matrix (ECM) of polysaccharides, bacterial debris, proteins, and
lipids (Figure 2.9).65, 66 Biofilm pneumococci are resistant to host clearance and antimicrobial therapy during
colonization as pneumococcal metabolic activity is reduced. Importantly, transcriptional changes during biofilm
growth downregulate genes encoding proteins and upregulating others in TIGR4.67 As TIGR4 pathogens persist
during colonization and outcompete planktonic growth of bacteria to deposit on host niches, adhesive molecules
are expressed to adsorb eukaryotic host surfaces. These bacterial adhesins promote interaction with host cell
receptors or soluble macromolecules and are ubiquitous antiphagocytic surface proteins referred to as pili. 68 Pili
are polymeric structures extending from the bacteria cell surface and allow initial contact with the host to initiate
colonization.

Adhesins reach beyond the capsular layer to access sources of nutrition and combine with

complementary carbohydrates. Hence, pili provides sites for potential inhibition and blocking lectin-glycan interfaces

pili
biofilm
bacteria

planktonic
bacteria

surface attachment

microcolony

Bacterial debris,
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polysaccharides,
lipids
ECM
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Figure 2.9 Pneumococcal biofilm formation. Planktonic bacteria are involved in initial attachment of biofilm on biotic
surfaces. Anchoring proteins (pili) on bacteria surface establish attachment to form microcolonies. Bacteria transform into
biofilm via a quorum sensing system and gradually mature into a biofilm with an extracellular matrix (ECM). ECM comprises
substances to protect biofilm from host challenges. Biofilm bacteria mount aggregates to eventually form stalks and
disperse to form separate colonies.
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would mediate preventive treatment methods of microbial diseases for anti-adhesion therapy.69 Saccharides are
considered to be ideal anti-adhesive agents as these are less likely to be toxic or immunogenic since sugars are
natural constituents of cell surfaces and in bodily fluids. 70 Furthermore, as anti-adhesive agents do not act by killing
the pathogen, such non-microbicidal approach would be a less aggressive regimen exerting minimal selective
pressure on pathogens and deterring generation of resistant phenotypes. 71, 72

2.3.3 Pneumococcal pilus 1 ancillary protein RrgA as a vaccine candidate to impair bacterial adhesion
Discovery of a genetic element encoding a pilus structure (pilus islet I or PI-1) in Streptococcus pneumoniae
and the role for pilus virulence in mice led to deep intrigue in use of pilus-based formulations as pneumococcal
vaccine candidates. The pilus islet is strongly associated with specific pneumococcal strains in Gram-positive
pathogens and codes for pilus proteins involved in adhesion to host cells, biofilm formation, and disruption of
mucosal barriers to facilitate subsequent invasion.73, 74 TIGR4 encodes a 14-kb rlrA pathogenicity islet for three
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Figure 2.10 (A) S. pneumoniae exists as a diplococci (outlined as blue spheres) and colonize the host mucosa. Carriage of the
pathogen in mucus leads to pneumococcal recognition of surface carbohydrates or glycans on the host epithelium. (B) A
depiction of S. pneumoniae detailing hair-like extensions on the bacteria surface. RrgA (carbohydrate-binding protein) is
responsible for adhering to host cells and can interlock other pili proteins on neighboring bacteria surfaces to create a thick
biofilm. (C) RlrA pathogenicity islet comprises of a transcriptional regulator, three structural proteins RrgA, RrgB and RrgC, and
three sortases SrtC-1, SrtC-2 and SrtC-3. The pilus stalk is composed of RrgB, adhesin tip RrgA, and RrgC at the base all linked
through rlrA encoded sortases. Structural domains D3, D2, D1 and D4 are depicted in order of assembly from crystal structure
of RrgA. D3 domain lies at edge with an integrin domain to mediate RrgA interaction with collagen, laminin and fibronectin
(components of eukaryotic ECM).
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structural proteins RrgA, RrgB and RrgC including three sortases SrtC-1, SrtC-2 and SrtC-3 covalently linking the pilus
proteins present in 30% of clinical strains.75, 76 The pilus stalk is composed of RrgB, RrgC anchoring the stalk into the
bacterial membrane, and RrgA acting as the tip adhesin site involved in eliciting host inflammatory responses.77-79
Nelson et al. showed RrgA to be a major adhesin to respiratory epithelial cells and pneumococci with RrgA deleted
were less adherent to human nasopharyngeal epithelial cells compared to wildtype bacteria. In contrast,
overexpressed RrgA enhanced bacterial adhesion and could be found in a non-polymerized form, covalently linking
to the peptidoglycan in absence of RrgB. Furthermore, only mutations in rrgA are shown to impair bacterial capacity
to form biofilm, whereas rrgB or rrgC did not influence biofilm forming capacity.80 These findings show RrgA to be
most important in biofilm formation. 81
In a separate study, Gianfaldoni et al. showed active and passive immunization with recombinant pilus
subunits in mouse models afforded protection against lethal challenge of TIGR4. Bacteremia was lower and survival
rates higher for groups vaccinated with recombinant pilus antigens. RrgA or a combination of RrgA/RrgB/RrgC
afforded protection, with one out of eight mice becoming bacteremic and seven of eight mice surviving challenge.
These results were not much different from the group vaccinated with heat-inactivated TIGR4, providing evidence
that recombinant subunits are novel protective antigens.82 A combination of these pilus antigens with other
protective antigens could therefore lead to potent multiprotein vaccines against S. pneumoniae.
Amerighi et al. further validated the important roles of type I pili components as protective antigens. AntiRrgA antibodies impaired bacterial adhesion in a dose-dependent manner (Figure 2.11A), whereas 𝛽-galactosidase
or BgaA (an unrelated surface exposed protein) incubated with anti-BgaA antibodies had no effect on bacterial
adhesion. Additionally, a panel of anti-RrgA monoclonal antibodies selected for their ability to recognize RrgA on
bacterial surface by fluorescence activated cell sorting analysis (Figure 2.11B) reduced adhesiveness. The most
pronounced anti-adhesion effect was by mAb 11B9/61 and the region identified on RrgA to be targeted by mAb
11B9/61 was analyzed by hydrogen-deuterium exchange (HDX) epitope mapping. The recombinant protein RrgA in
complex with the mAb showed a significant reduction in deuterium uptake of peptide sequence 638-666. The region
was further narrowed to 638-646 (epitope X in pink) as mAb 11B9/61 did not influence deuteration of overlapping
peptide 647-666 (Figure 2.11C). RrgA mutants with epitope X deleted or a portion of sequence (epitope Y not
covered by HDX analysis) deleted were constructed. The purified isoforms could not be recognized by the mAb (as
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observed by western blot analysis) and mAb 11B9/61 only bound to RrgA wild-type isoform. The observations
suggest epitope X + Y region is involved in mAb recognition of RrgA. 83 Overall details of the poorly capsulated TIGR4
strain (characterized by a reduced capsule thickness in comparison with other piliated strains) that allow for
exposure of elongated adhesin motifs to protrude from the pneumococcal surface unveil essential protein structural
motifs conferring adhesion-dependent interaction with mucosal epithelia.
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The capsular material and adhesive

capacity perhaps elicit pathogenesis through a mechanism yet to be revealed. Strategies to use pilus-associated
RrgA observed in mediating adherence and disease progression as a therapeutic virulence marker and validating
ligand-epitope interactions would be valuable to precisely inhibit TIGR4.
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2.11 In vitro adherence assays of TIGR4 on ME180 cervical epithelial monolayers in presence of polyclonal anti-RrgA antibodies. (A)
Polyclonal antibodies at various concentrations against RrgA and phosphate buffered saline or antisera against a surface exposed
protein BgaA test for adhesion. (B) TIGR4 treated with monoclonal antibodies against RrgA and comparison for adhesion on
epithelial cells. (C) Deuteration levels of overlapping peptides in a complex of mAb 11B9/61 with RrgA or absence of mAb. Colored
regions on protein sequence are highlighted on crystal structure of RrgA located on D2 domain. Figures A through C were
reproduced from reference 83 by permission of Oxford University Press (portions Figure 4, page 519; Figure 5, page 520).
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2.3.4 Glycocompounds as anti-pathogenic agents of TIGR4 Streptococcus pneumoniae for colony
inhibition and dispersion
As the principle agent of pneumococcal virulence is bacterial attachment to host cells, developing
techniques and approaches to obstruct ability of bacteria to adhere to or detach from tissues at early stages of
infection are chief priorities. An emerging strategy to introduce nonmicrobicidal control of biofilm formation causing
serious drug resistance and tolerance is applying synthetic saccharides to inhibit biofilm formation and biofilm
adhesion. Singh et al. functionalized various saccharides to see for impact on Pseudomonas aeruginosa activity and
discovered farnesyls tethered to disaccharide derivatives displayed inhibition of swarming motility and biofilm
formation. 85 The novelty of Yan-Yeung Luk and coworkers’ molecular drug design demonstrates structural elements
of naturally secreted quorum sensors to guide compound production through systematic variation of aliphatic
structures and saccharide stereochemistry modification. The chemicals secreted by Pseudomonas aeruginosa are
rhamnolipids, molecules of rhamnose sugars and fatty acids, which disperse bacteria from biofilm. Pseudomonas
aeruginosa produce flagella proteins similar to other pneumococcal organisms to bind sugar moieties including
galactose, fucose and disaccharide units of glycosphingolipids.
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These pilin proteins are essential in recognizing

disaccharides to mediate bacterial adhesion. 87 Synthetic rhamnolipid analogues comprised of aliphatic regions of
differing chain lengths showed to dominate bioactivity of their natural counterpart. Altogether, bulky hydrocarbons
selectively recognized Pseudomonas aeruginosa receptors, whereas saturated farnesols conjugated to hydrophilic
groups were unable to inhibit biofilm.
Considering the depth of knowledge on RrgA and observed lectin properties of the pilus protein, we set out
to establish the mechanism of biofilm disruption by our lead compound n-Dodecyl β-D-maltoside (DβM), identified
from a preliminary screen with a Streptococcus sanguinis model. Secondly, the interaction of isolated RrgA and DβM
was studied by Isothermal Titration Calorimetry (ITC) to quantitatively measure the binding affinity of the compound
to protein. Lastly, molecular modeling of DβM and RrgA interaction was performed to assess the specific binding
mode of RrgA and see if substrate pocket could accommodate different sizes of saccharides. Such information is
fruitful in optimizing design of synthetic saccharides to binding pocket of RrgA and to improve molecule's biofilm
dispersion properties. In summary, specifically targeting lectin protein RrgA by screening a synthetic compound
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library for biofilm dispersion has not been previously explored before and, thus, would be an advanced approach to
treating pneumococcal infection.

2.4

DβM disrupts streptococcal growth and biofilm formation

2.4.1 DβM pharmacological activity
DβM is a mild maltoside detergent with non-denaturing properties and has been used to characterize
anesthetic binding sites in human serum albumin, apoferritin, G-protein-coupled receptors and ligand-gated ion
channels. Xu et al. showed by competition titration experiments DβM interacts with anesthetic binding sites of
human serum albumin (Kd = 40 μM) for propofol and isoflurane. The sites were identified to be fit for assorted fatty
acids interacting with DβM through polar and hydrophobic contributions and accommodate amphipathic
compounds including sodium dodecyl sulfate (SDS).88 SDS is a commonly used anionic detergent but exerts
pharmacological activity, for instance potentiating GABA responses independent of the molecule’s surfactant
properties. Liu et al. demonstrated SDS specifically interacts at low and non-denaturing concentrations (Kd of 24 μM)
with horse spleen apoferritin, a mammalian helical bundle model for anesthetic mechanisms. X-ray crystal structure
of apoferritin and SDS complex mapped the cavity in which SDS bends its alkyl tail to localize at an interface between
two four-helix bundle protomers.89 Patrick Loll, Renyu Liu and coworkers’ findings demonstrated detergent
molecules, commonly perceived to adopt nonspecific contacts with proteins, are recognized rather by
macromolecules at clearly defined binding sites. Moreover, SDS does not adsorb onto ambiguous surfaces but rather
to a single protein cavity as shown by an unambiguous electron density for ligand in crystal structure. These
molecules are also found to suppress protein adsorption. The monolayer of nonionic surfactant shields surface
charges and reduces nonspecific protein adsorption on hydrophobic substrates.90
Collectively, detergents provide structural and biophysical characteristics that offer potential clinical
applications. One distinguishing feature of dodecylmaltoside is that the molecule reduces aggregation of a protein
drug interferon-β in vitro and immunogenicity in vivo for prolonged effectiveness in multiple sclerosis treatment. 91
Rifken et al. thus demonstrates maltosides are robust and beneficial therapeutic drug adjuvants for medicines
minimizing immunogenicity of biopharmaceuticals.
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Considering sugar-based nonionic surfactant DβM demonstrates safety and efficacy features with no known
biological effects 92, the molecule could be used in humans. We envision DβM and its derivatives would be used in
combination with antibiotics in a spray formulation to eradicate biofilm, inhibiting tissue colonization of invasive
pneumococci and treat pneumonia.

2.4.2 DβM competes with binding of pneumococcal pili receptors to host surface sugars
A set of ligands shown to bind pili of Pseudomonas aeruginosa was screened for binding of pilin protein
RrgA from S. pneumoniae. We hypothesized synthetic disaccharides effective against Pseudomonas aeruginosa, an
opportunistic bacterium compromising health of cystic fibrosis patients 93, and characterized by a pilus adhesin of
structural motif similar to RrgA, would support biofilm inhibition in pneumococcal strains. Figure 2.12 shows
chemical structures of validated saccharides of varying disaccharide moieties with saturated farnesols functionalized
with tetra(ethylene glycol) compared to general surfactants comprising monododecyl ethers.

DβM inhibited

bacterial growth best in Streptococcus sanguinis SK36 (Figure 2.13A), a human pathogen causing infective
endocarditis. 94, 95 S. sanguinis is less prone to lysis than TIGR4 and expresses pilin proteins of comparable structural
elements as TIGR4. Thus, S. sanguinis was used a model organism for preliminary assessment of microbe biofilm
inhibition and dispersion. DβM has a critical micelle concentration (CMC) of about 170 μM 96, thus we explored if
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Figure 2.12 Synthetic ligands used in validation screen of pneumococcal biofilm growth inhibition and biofilm dispersion.

any observed growth inhibition is due to lysis of bacteria. S. sanguinis was grown to OD600 of 0.3 and the culture was
split in half, one treated with 100 μM DβM (determined minimal inhibitory concentration for S. sanguinis) and the
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other untreated. Culture in absence of DβM continued to grow and the culture incubated with DβM stopped
growing with no indication of lysis (Figure 2.13B) indicating DβM preserves cell viability. We also evaluated the effect
of DβM on red blood cells (RBC) to determine 50% hemolysis of RBC. Figure 2.14A shows intense red coloration of
solutions correlated to oxygen-carrying pigment hemoglobin released into the surrounding medium. Such pigment
is indicative of RBC breakdown and is quantified by taking absorbance of supernatant incubated with DβM at 541
nm. 50% hemolysis (HC50) of RBC was determined to be 227 μM from a sigmoidal curve fit (Figure 2.14B). The
inhibitory concentration of 100 μM used in our compound screen is below the obtained HC50, deeming the effective
concentration of DβM acceptable.

A

B

Figure 2.13 (A) Screen of compounds (100 μM) for inhibition of S. sanguinis growth. (B) Bacteria growth assay to assess lytic
property of DβM (culture of S. sanguinis grown to OD600 0.3 and then split in half for incubation with 100 μM DβM. OD600 of both
untreated and treated cultures with DβM was monitored for seven hours.
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Figure 2.14 Hemolysis of RBC in presence of DβM. (A) The supernatants of RBC mixed and incubated for two hours with
different concentrations of DβM were collected and diluted to a detectable amount for quantification by a UV-Vis
platereader. (B) HC50 plot of absorbance values (taken at 541 nm) for each RBC suspension with sterile PBS solution treated
with DβM.

As we shown DβM inhibits streptococcal growth, a structure-activity correlation study was done to
determine the critical components required for bacterial inhibition and biofilm dispersion. We hypothesized
saccharides with a hydrophobic tail motif are beneficial to bind pilin proteins and compared biofilm dispersive activity
between DβM and a ligand with monododecyl ethers without the sugar unit, C12EG4OH. For this assay, plates
containing pre-formed biofilm from incubated cultures were treated with either DβM or C12EG4OH to see if biofilm
could be dispersed. The bacteria were stained with crystal violet used to visualize viable bacterial cell membranes.
Crystal violet was washed with H2O and residual stain was solubilized with 95% EtOH, and biofilm formation was
quantified by measuring absorbance at 590 nm (Figure 2.15A). Media (tryptic soy broth + 0.5% yeast extract) control
and a replicate (both in gray) showed low crystal violet absorbance indicating no biofilm, closely matching low
amount of biofilm in presence of increasing DβM (S. sanguinis dispersion concentration of >60 μM). In contrast,
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C12EG4OH did not disperse pre-formed biofilm as indicated by intense crystal violet stain for biofilm remained
attached to inner surface of 96-well plate (Figure 2.15B). Our findings reveal both the aliphatic tail and maltose
moiety on ligand are important elements for bacterial inhibition and biofilm dispersion.
We next determined if a pilin protein in S. sanguinis PilA we hypothesized to be recognized by DβM imparts
biofilm inhibition and biofilm dispersion. To test the hypothesis, biofilm dispersion of ∆pilA, ∆pilB, and ∆pilC mutants
of S. sanguinis (pilA, pilB and pilC genes code for pilin proteins analogous to RrgA, RrgB, and RrgC) obtained from the
Xu lab (Virginia Commonwealth University) was assessed. DβM dispersed biofilm in S. sanguinis wildtype, ∆pilB and
∆pilC mutants, but no such dispersion is observed for S. sanguinis ∆pilA to suggest DβM is specific for PilA protein

B

A

Figure 2.15 (A) Structures of compounds used for structure-activity correlation study and plot of crystal violet absorbance at 590
nm to analyze amount of biofilm in S. sanguinis after addition of DβM or C12EG4OH. (B) Crystal violet plate of S. sanguinis treated
with various concentrations of either DβM or C12EG4OH to visualize biofilm.

but not for other pilin proteins PilB and PilC (Figure 2.16A). Figure 2.16B shows the crystal violet plate to visualize
no effect of 100 µM DβM on S. sanguinis ∆pilA, concluding that PilA protein is involved in DβM recognition.

74

A

∆
∆
∆
∆
∆
∆

B

Figure 2.16 (A) Crystal violet absorbance at 590 nm plot of biofilm in S. sanguinis and ∆pilA, ∆pilB, and
∆pilC mutants with and without DβM. (B) Crystal violet plate used to visualize biofilm: 1 – media only,
2 – wild type (WT) S. sanguinis, 3 – WT + DβM (100 µM), 4 – ∆pilA, 5 – ∆pilA + DbM (100 µM).

2.4.3 Discussion of results on DβM inhibition of S. sanguinis growth and biofilm dispersion
The above findings provide insight into pilin protein PilA to be a determining factor in DβM interaction.
Using the knowledge of inhibitory and dispersive properties of DβM, we now look into direct interaction of RrgA
protein with DβM. As both the saccharide unit and hydrophobic tail motif bind pilin protein, we propose these
regions of the ligand would bind lectin protein RrgA. The preliminary work with S. sanguinis model showed ∆pilA
does not interact with DβM and that PilA has an essential role for DβM activity. Thus, considering pilA gene is shown
to be essential for biofilm dispersion, we hypothesize the analog of PilA in S. pneumoniae TIGR4 (rrgA gene encoding
RrgA protein) is involved in biofilm dispersion. S. pneumoniae TIGR4 could be similarly characterized to see if in
presence of DβM the molecule interacts with RrgA of TIGR4 pathogenicity and to demonstrate ∆rrgA strain is not
responsive to DβM (deletion of rrgA leading to no biofilm dispersion). Preliminary steps to obtain the gene knockout
mutant and characterization of TIGR4 bacteria inhibition are explained in following segments.
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2.4.4 TIGR4 ∆rrgA strain construction and role of isolated RrgA in S. pneumoniae TIGR4 glycan recognition
TIGR4 ∆rrgA was created by a splicing overlap extension (SOE) PCR. The chimeric DNA was transformed
into TIGR4 S. pneumoniae and the gene coding for rrgA was successfully replaced with an erythromycin antibiotic
marker. The ∆rrgA strain will be used to determine if RrgA is a target of DβM and to probe how DβM disperses
biofilm formed by this mutant. Conditions to ensure TIGR4 biofilm establishment are in progress as we observed
biofilm formation for this organism is more difficult to obtain under in vitro experiments compared to S. sanguinis
SK36 model. Our preliminary results for TIGR4 wildtype bacteria growth and biofilm inhibition under anaerobic
instead of microaerophilic conditions to improve biofilm formation do show DβM inhibits TIGR4 growth optimally
using 100 µM of ligand (Figure 2.17A). To see the full spectrum of DβM inhibition, TIGR4 was supplemented with
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Figure 2.17 (A) Screen of compounds (100 μM) for inhibition of S. pneumoniae TIGR4 wildtype growth by monitoring OD600. (B)
MIC plot for TIGR4 wildtype strain. (C) Crystal violet plate of S. pneumoniae TIGR4 treated with various concentrations of DβM to
visualize biofilm inhibition.
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DβM at concentrations from 10 to 200 µM. OD600 was measured for each sample and plotted as a normalized
absorbance to determine MIC for TIGR4 (Figure 2.17B). Once OD600 was measured, bacteria in the plate containing
TIGR4 treated with DβM was discarded and remaining biofilm was stained with crystal violet to correlate amount of
bacteria growth inhibition and biofilm formation (Figure 2.17C). Even less amount of DβM (ca. <60 µM) was effective
for TIGR4 compared to S. sanguinis in bacteria growth inhibition providing information that DβM potentially targets
pneumococci through pilin interaction.
To gain a molecular depiction of RrgA interaction with DβM, a docking study was done using crystal
structure of RrgA (PDB 2ww8). Figure 2.18 shows the crystal structure of RrgA (solved by Izore é t al.) comprised of
four domains folding into U-shaped structure.64 D3 domain carries a metal ion-dependent adhesion site (MIDAS)
motif and adopts a fold resembling an integrin domain that stretches out as arms. Integrin molecules are found
across eukaryotic cell surface proteins and interact with the extracellular matrix such as collagen as confirmed by
Hilleringmann, Becke et al. who shown pneumococcal pili adhesive clusters of RrgA recognize laminin and
fibronectin.97, 98 Izore é t al. point to two insertion arms on major adhesin site D3 comprised of basic charge (from
lysine residues) to provide a binding site for negatively charged glycosaminoglycans, linear polysaccharides attached
to proteoglycans, to direct association to fibronectin and bridge interaction of a bacterium to host matrices. Thus,

Figure 2.18 RrgA is an elongated molecule comprising four domains associated semilinearly as "beads on a string." D1 (on
N-terminus) displays an IgG domain. D2 comprises residues folding from the N- terminal domain and an integrin I-like
domain is observed in gray of D3. C-terminus of RrgA comprises domain D4. Calcium ions (two) are represented as lime
spheres and one magnesium as a violet sphere. [PDB: 2ww8]

77

Figure 2.19 Docking of DβM into D3 domain of RrgA using AutoDock Vina. DβM ligand is represented as a surface molecule
in blue. Ribbon structure of RrgA is also shown with DβM as a ball and stick representation. [PDB: 2ww8]

the conserved sequence similarity of RrgA to pilus adhesins indicate distinct folds of these proteins that allow
pathogens to evade host defense mechanisms.
According to molecular modeling of saccharide binding to RrgA performed by us, we propose a different
binding mechanism not exclusive to charge interactions proposed by Izore é t al. involving a distinct binding groove
in which inhibitors could occupy. The following results suggest a structure-based inhibitor design on basis of a
binding pocket of sufficient size to accommodate ligands of various size to associate RrgA and interfere in adhesion
properties.
Notably, a MIDAS motif is located in the central region of D3 and is conserved among RrgA-like adhesins in
pathogenic species S. pneumoniae, S. agalactiae, and S. pyogenes. RrgA has a deep binding groove (Figure 2.19) in
which DβM occupies observed by molecular docking. Polar (threonine and serine) and basic (arginine and lysine)
amino acids form a cradle around DβM surrounded by hydrophobic residues (Figure 2.20A). Ser 236 from the MIDAS
domain forms a hydrogen bond (2.9 Å) with an O atom on saccharide portion of DβM. Two internal hydrogen bonds
and four additional H-bonds involving Ser, Thr, Asn and Lys in close proximity to DβM are found. The close proximity
of DβM to metal complex implies the possibility of RrgA to bind sugars in the groove along with metal atoms (in this
case a magnesium ion). Magnesium thus appears to be important for RrgA function and was incorporated in the
purification process for RrgA as metal could facilitate carbohydrate binding. Calcium ions were also introduced as
these are resolved in the crystal structure.
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The arrangement of residues in RrgA such as Arg, Asn, and flanking side chains such as Tyr, Gln and Lys are
also ideal for accommodating carbohydrates, a composition typically observed for binding trisaccharides and
branched oligosaccharides in which metals (calcium in LecB from P. aeruginosa or manganese in PfbA S. pneumoniae)
are bound.99, 100 We shown that D3 domain can accommodate larger polysaccharides (blood group H antigen
trisaccharides with a C12 alkyl chain, Figure 2.20B) in same pocket as DβM, a likely binding cavity for other modified
synthetic saccharides. Therefore, the binding site is proposed as a target to conduct structure activity correlation
study to direct systematic modification of saccharides and tail region for binding and biofilm dispersion experiments.
Given this information on spatial proximity of protein side chains distinctive to carbohydrate binding, DβM
is expected to closely match the position of the ligand provided from modeling. Individual domains of RrgA are
further connected by short linkers and are reported to have little interaction, thus, assuring proper fold and function
in the tip adhesin (D3) unit, our primary focus here. Another area of focus would be to see if multiple site binding
of a carbohydrate to pilin protein synergistically increases affinity of a ligand to RrgA as observed for PfbA, a
conserved multiligand adhesin protein that helps bacteria to colonize the host by recognizing fibronectin and blood
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proteins such as plasminogen and human serum albumin. Different constructs of RrgA either composed of individual
D3, D2, D1, or D4 fragments (or combination including D3/D2 or D1/D4) could be isolated to carry out such affinity
study, and pinpoint exact regions molecule binds. Beta helix (seen for PfbA)101 and beta propeller (seen for LecB)102
are common carbohydrate recognition motifs, thus DβM could potentially bind to a similar motif as D2 of RrgA.
Conformational dynamic processes RrgA undergoes should be considered for DβM (comprised of both a sugar unit
and a potentially flexible hydrophobic tail) to favorably secure a spot in a deep groove of the protein as opposed to
flat regions on protein surfaces as oligosaccharides could also bind shallow surfaces. ITC would thus be instrumental
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Figure 2.20 (A) DβM and residues within a 3.0Å zone from ligand atoms in the substrate cavity. MIDAS domain comprises of Asp
and Ser residues coordinating a magnesium ion (lime sphere). DβM is shown in stick highlighted in blue surface. Labels
correspond to side chain positions from selected crystal domain used for docking. (B) Docking of saccharides into RrgA. DβM is
shown in cyan stick and a trisaccharide (blood group H type antigen) with C12 attached in yellow stick bound in pocket.
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in obtaining a complete thermodynamic profile of binding free energy.
To directly measure interaction of pilin protein RrgA with DβM, RrgA protein was recombinantly expressed
to quantitatively analyze binding affinity of ligand to lectin protein. Day et al. measured before by surface plasmon
resonance (SPR) RrgA binds various saccharides.63 We compared affinity of RrgA to maltose (reported Kd of 1 µM
measured by SPR) and DβM (maltose fused to a hydrophobic tail) by ITC in order to verify the binding affinity and
determine Kd for RrgA and DβM including number of binding sites. ITC experiment attempts with protein and either
ligand however did not yield a significant heat signature, and ligand into buffer also gave a similar profile suggesting
any possible enthalpy of micelle dissipation in case of DβM is too small to influence heat of binding. To reason
possible contributors of no binding heats and see if secondary structure of protein is affected, the fold of RrgA was
assessed by circular dichroism to give a similar secondary structure content as reported by Moschioni et al.74 The
four structural domains of RrgA make interpretation of the overall fold difficult to deconvolute and since each
domain is associated through short linkers, the protein might confer a significant level of flexibility. Thus, crystallized
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Figure 2.21 (A) Overview of phenol sulfuric acid method colorimetric analysis for detection of carbohydrates. Aqueous phenol
solutions containing oligosaccharides, polysaccharides or glycoproteins produce an orange-yellow color characteristic of
phenol with pentoses and hexoses in a strongly acidic medium. Concentrated acid into phenol generates heat to completely
hydrolyze glycosidic bonds. (B) UV-vis spectra of sulfuric acid and phenol aqueous solution into different concentrations of
prepared galactose solutions. (C) Standard calibration curve fit of nmol sugar versus 490 nm for galactose.
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recombinant RrgA does not reflect the dynamic properties of the native protein and full extent of conformations the
macromolecule might undergo.

Figure 2.22 Absorption spectra of the reaction product of RrgA protein hydrolysate with 5% phenol and 95% sulfuric acid.

We considered if other sugars could occupy the ligand binding pocket and prevent access of DβM or other
carbohydrates. Carbohydrates are comprised of monosaccharide units of neutral sugars D-galactose, D-mannose,
D-glucose, and L-fucose; amino sugars D-glucosamine and D-galactosamine in a N-acetyl form. These
monosaccharides could represent less than 1% to more than 80% of the weight of a molecule and exist in varying
proportions.103 Thus, to estimate the sugar content in the protein solution, a colorimetric reaction was done to
determine approximate concentrations. For accurate analysis of monosaccharide, disaccharide and polysaccharide
components from a given sugar that is released upon acid hydrolysis, a phenol-sulfuric acid method developed by
Dubois et al. is implemented as a reliable resource (Figure 2.21A).104 Dehydration of hydrolyzed saccharides form
furfural derivatives during the reaction. Fufural is allowed to develop a colored adduct with phenol and its
concentration is detected by visible light absorption with a maximum absorbance at 490 nm. We investigated the
interaction of monosaccharides or oligosaccharides with lectin protein RrgA as any non-specific carbohydrates,
especially for microcalorimetry titration experiments, could interfere in heats of binding.
For complex oligosaccharides of different hexose units, a mixture of known monosaccharides is shown to
provide accurate calibration curves for concentration determination.105 An absorbance profile of sugar (nmol)
(Figure 2.21B) versus 490 nm differs in slope for a corresponding free monosaccharide due to differences in mass of
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free sugars. We chose a simple sugar galactose to fit a standard curve of known amount and correlate concentration
of monosaccharides to RrgA (Figure 2.21C). The absorption spectra of the reaction product of RrgA protein
hydrolysate with 5% phenol and concentrated H2SO4 is shown in Figure 2.22. Sugar content in RrgA (10 ug) was
determined to be low (2 nmol or 0.36 ug) indicating minimal specificity of simple sugars to RrgA and low likelihood
that the binding site is blocked for ligand access. Hence, conformational flexibility of protein influencing probable
binding events yet to be elucidated could be reason for a gap in correlating bioactivity observed from biofilm
inhibition assays and molecular binding studies using ITC.

2.5 Conclusions and Outlook
Designing synthetic saccharides specific to lectin protein RrgA to inhibit and disperse biofilm is an innovative
approach to treat pneumococcal infections as pili are essential components to progress disease pathogenesis. Our
identified lead molecule DβM is active against pneumococcal organisms S. sanguinis including TIGR4 biofilm
formation and is shown by us to be effective below the critical micelle concentration. Thus, interaction of DβM to
RrgA is not merely due to aggregation but foreseeable specificity to a binding pocket of sufficient depth to
accommodate saccharides. We also showed DβM is not hemolytic demonstrating DβM is not toxic to red blood cells
and could be used in humans. Synthetic saccharides could, therefore, be used with similar cytocompatibility to treat
pneumococcal infection. We also established that a major adhesin pili protein PilA found in S. sanguinis is responsive
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Figure 2.23 Scheme for pneumococcal infection treatment using combination therapy of antibiotic and synthetic saccharides.
(A) Pathogen and host cell surface recognition. (B) Biofilm formation and inflammation showing bundle of diplococci sticking to
each other (C) Elimination of virulent microbes on surface layer of biofilm and Inhibition of biofilm formation by synthetic
saccharides. Synthetic saccharides are depicted to interact with pilin protein RrgA (orange) and interfere in biofilm formation
by displacing pili (blue beads on spheres) to glycan receptors (light blue).
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to a disaccharide and hydrophobic tail composition to guide characterization of TIGR4 pilin RrgA using a structureactivity correlation-based approach. We expect RrgA will display similar affinity to such glycan structures (including
larger trisaccharide moieties of blood group H antigens) as supported by computational modeling results strongly
suggesting avidity of ligand to lectin sites. Interestingly, the trisaccharide we observed to bind RrgA using molecular
docking comprises a rhamnose unit, naturally found in P. aeruginosa organisms. We envision we could create
bacterial growth inhibitors similar to synthetic analogs of rhamnolipids (as done by Yan-Yeung Luk and coworkers)
to inhibit and reverse biofilms formed by S. pneumoniae and P. aeruginosa as these pathogens often coexist in
antibiotic-resistant biofilms.106, 107 ITC analysis for DβM binding to recombinant protein RrgA did not show binding
affinity (initially hypothesized monosaccharide sugar maltose would bind RrgA with lower affinity compared to DβM
comprised of a bulky hydrophilic sugar group and hydrophobic tail). Thus, the conformational dynamism of RrgA
needs to be considered to characterize affinity of lectin to ligands. In a broad application scope, we believe our
saccharide-based biofilm inhibitor approach could be used in combination with antibiotic erythromycin, commonly
used to treat pneumoniae against TIGR4-promoted biofilm (scheme shown in Figure 2.23). This combination therapy
would provide an alternative approach to relieve existing deficiencies in treatment methods for a number of
antibiotic-resistant pneumococci.

2.6 Experimental
Supplementary figures noted in 2.6 Experimental can be found in Appendix II.
Cloning, expression and purification of RrgA: RrgA (S. pneumoniae strain TIGR4) comprising 833 amino acids was
cloned into a C-terminal 6xHis tag expression vector pET-24a using standard recombinant DNA technique and
designed primers (RrgA clade I) described by Moschioni et al.74 The recombinant plasmid was incorporated into E.
coli BL21(DE3). Protein expression was induced by adding isopropyl-β-D-thiogalactopyranoside (0.5 mM final
concentration) to a bacterial culture in Luria Broth (1X) media supplemented with 50 ug/mL kanamycin at an OD600
of 0.5-0.6. Bacteria was grown at 25°C for 4 h to avoid inclusion body formation and then harvested by centrifugation
(4,000 x g at 4°C for 20 min). Bacterial pellet (6 g) was lysed with phenylmethylsulfonyl fluoride (PMSF) of 0.5 mM
final concentration in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol, 100 uM CaCl2, 100 uM MgCl2 and 20 mM
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imidazole. Soluble fraction was collected after centrifugation (20,000 x g at 4°C for 30 min) and applied to a metal
chelate affinity chromatography on a His-Trap HP column (GE Healthcare) connected to an AKTA purifier. Imidazole
gradient of 0-500 mM was used to elute protein at approximately 50%. Pooled fractions (>90% purity) [Figure S2.1]
containing protein were buffer exchanged into 20 mM Tris-HCl (pH 7.4), 20 mM NaCl, 5% glycerol and injected into
a 5-mL loop HiTrap Q HP column (BioRad) [Figure S2.2]. Protein was eluted with 30 column volumes of 20 to 500
mM NaCl, 5% glycerol in 20 mM Tris-HCl pH 7.4. Protein purity was determined by SDS-PAGE (10%). For final storage
of protein, the following buffers were used for ITC experiments: (1) 25 mM Tris-HCl pH 8.0, 100 mM NaCl (2) 20 mM
Hepes pH 7.5, 100 mM NaCl or (3) Phosphate-buffered saline solution 1X pH 7.5 (Cold Spring Harbor recipe). Protein
was dialyzed 14-16 h using a 7 kDa MWCO dialysis cassette (ThermoFisher Scientific) and protein concentration was
determined by measuring absorbance at 280 nm on a UV-Vis spectrophotometer (extinction coefficient is 87100 M1

cm-1) [Figure S2.3].

ESI-MS analysis of RrgA: Isolated protein appeared at a higher molecular weight band (>100 kDa) on SDS-PAGE
gels (Figure S2.4 and Figure S2.5); however, theoretical weight is approximately 93 kDa. Identity of isolated protein
was validated by electrospray ionization coupled to a mass spectrometry technique via a bottom-up approach. RrgA
(20 ug) in 100 mM Tris-HCl (pH 8.0) sample was submitted to the core facility for Proteomics and Mass Spectrometry
at Upstate Medical University. Tryptic peptides, resulting from initially digesting the protein, were analyzed by LCMS and peptide masses were surveyed against a Uniprot database for Streptococcus pneumoniae (Figure S2.6). The
data for LC-MS proteome characterization indicated peptide fragments aligned with the cell wall surface anchor
family protein of S. pneumoniae. Highest scoring peptide spectrum matches and the protein sequence alignment of
first accession match (A0A4F7IM51) with RrgA are provided (Figure S2.7).

TIGR4 ∆rrgA construction and pneumococcal transformation: To generate a chimeric fusion of TIGR4 carrying
erythromycin (selected antibiotic resistant marker to insert at rrgA locus), a gene splicing by overlap extension (SOE)
was performed, followed by transformation of S. pneumoniae TIGR4 competent cells, and selection of transformants
by polymerase chain reaction (PCR). Description of SOE procedure and materials referenced here are originally
reported by Iannelli and Pozzi.108 Linear fragments of DNA are produced to include the following three amplicons
using three pairs of oligonucleotide primers listed in Table S2.1 of Appendix II: (1) 1042 bp upstream region of rrgA
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and rrgA reverse (with a 22 bp overhang complementary to erm gene) for PCR step 1 (2) erm gene (761 bp) from a
TIGR4 psaA template for PCR step 2 (3) 1051 bp downstream region of rrgA with a 22 bp erm overhang and rrgA
reverse for PCR step 3. These three PCR fragments are amplified using a high-fidelity DNA polymerase, Phusion
(Thermo Scientific), according to manufacturer’s guidelines (SOE chimeric DNA assembly is graphically represented
in Figure S2.8). PCR conditions are described in the following reaction setups.
Reaction setup (50 μL) for PCR steps 1 and 3:
PCR (1): rrgA_F forward primer (0.5 μM), rrgAerm_R reverse primer (0.5 μM), dNTP (400 μM), TIGR4
genomic template (0.5 ng*uL-1), Phusion high fidelity buffer (1X), Phusion DNA polymerase 2U/50 μL.
PCR (3): rrgAerm_F forward primer (0.5 μM), rrgA_R reverse primer (0.5 μM), dNTP (400 μM), TIGR4
genomic template (0.5 ng*uL-1), Phusion high fidelity buffer (1X), Phusion DNA polymerase 2U/50 μL
Thermocycling conditions: initial denaturation 98°C, 30 sec; denaturation 98°C, 10 sec; annealing gradient
(30 sec): 64°C (5X), 62°C (5X), 60°C (5X), 58°C (5X), 56°C (5X), 54°C (10X); extension 72°C, 1.5 min; final
extension 72°C, 10 min.

Reaction setup (50 μL) for PCR step 2:
PCR (2): erm_J214 forward primer (0.5 μM), erm_J215 reverse primer (0.5 μM), dNTP (400 μM), TIGR4 psaA
DNA template (0.4 ng*uL-1), Phusion high fidelity buffer (1X); Phusion DNA polymerase 2U/50 μL.
Thermocycling conditions: initial denaturation 98°C, 30 sec; denaturation 98°C, 10 sec; annealing gradient
(30 sec): 66°C (5X), 64°C (5X), 62°C (5X), 58°C (5X), 54°C (5X), 50°C (10X); extension 72°C, 5 min; final
extension 72°C, 10 min.
PCR amplicons are observed by agarose gel electrophoresis (Figure S2.9) and purified using a QIAquick PCR
purification kit (QIAGEN).
Reaction setup to amplify chimeric fusion TIGR4 ∆rrgA using PCR products from steps 1, 2 and 3 as a template:
Outer primers rrgA_F and rrgA_R are used with equimolar quantities of purified PCR (1), PCR (2) and PCR(3)
as the template. The overlapping ends anneal and act as primers for extension of the complementary strand.
Reaction conditions (50 μL): 50 ng of each product, rrgA_F forward primer (0.5 μM), rrgA_R reverse primer
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(0.5 μM), dNTP (400 μM), Phusion high fidelity buffer (1X); Phusion DNA polymerase 2U/50 μL.
Thermocycling conditions: initial denaturation 98°C, 30 sec; denaturation 98°C, 10 sec; annealing gradient
(30 sec): 65°C (4X), 63°C (4X), 61°C (4X), 59°C (4X), 57°C (4X), 55°C (4X), 53°C (4X), 51°C (10X) ; extension
72°C, 5 min; final extension 72°C, 5 min.
PCR amplicon is observed by agarose gel electrophoresis (Figure S2.10) and resulting PCR fusion product (2,810 bp
of genomic TIGR4 mutant ∆rrgA) is purified using a Monarch DNA gel extraction kit.

Preparation of precompetent cells: 20 μL of a frozen TIGR4 stock culture was inoculated in 980 μL acidified ToddHewitt broth (supplemented with 0.5% yeast extract) to pH 6.5 and incubated in an anaerobic pouch (GasPak EZ,
BD) at 37°C until OD600 reached early exponential phase of 0.03. To activate competence, TIGR4 cells were induced
with 1 mM CaCl2, 1.0 mg BSA, 10 mM NaOH and 100 ng of competence stimulating peptide (pH 7.6) at 37°C in
GasPak for 15 min. For DNA internalization, purified chimeric ∆rrgA genomic DNA (500 ng total) was added to 1 mL
of activated competent cell culture and incubated at 37°C in anaerobic pouch for 90 min. 100 μL of transformed
TIGR4 was plated on a 10 ug/mL erm-supplemented BHI (Brain Heart Infusion) agar medium and incubated at 37°C
in anaerobic pouch. Within 24 h, plaques could be observed on plate.

PCR screen to validate construct design: Pair of primers rrgA_seq_F and rrgA_seq_R was used to cover the
chimeric locus (erm insert) and check borders between the erm gene and upstream and downstream flanking regions
of TIGR4 by PCR. The integrity of the erm insert was verified by a PCR screen of the purified genomic DNA isolated
from individual colonies selected from BHI plate. PCR conditions: rrgA_seq_F forward primer (0.5 μM), rrgA_seq_R
reverse primer (0.5 μM), dNTP (400 μM), ∆rrgA genomic DNA (60 ng), Phusion high fidelity buffer (1X), Phusion DNA
polymerase 2U/50 μL
Thermocycling conditions: initial denaturation 98°C, 30 sec; denaturation 98°C, 10 sec; annealing gradient
(30 sec): 64°C (4X), 62°C (4X), 60°C (4X), 58°C (4X), 56°C (4X), 54°C (10X); extension 72°C, 1.5 min; final
extension 72°C, 10 min.
PCR amplicons (linear DNA) are observed by agarose gel electrophoresis (Figure S2.11) and purified using QIAquick
PCR purification kit. DNA is submitted to Genewiz for sequence validation using rrgA_seq_F and rrgA_seq_R
primers (Table S2.2).
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Glycerol stock preparation of recombinant construct: Colony from agar plate positive for recombinant DNA
was inoculated into tryptic soy broth (TSB) supplemented with 0.5% yeast extract (YE) and 10 μg/mL erm.
Inoculum was grown in anaerobic pouch at 37°C to OD600 of 0.2. Culture was vortexed and 1 mL was transferred
into a cryogenic vial containing 400 μL of 80% glycerol. The mixture was vortexed and stored at -80°C. Two
subclones were recovered by streaking a frozen glycerol stock culture onto BHI agar plate (containing 10 ug/mL
erm). A colony was recovered and grown in TSB + 0.5% YE at 37°C to OD600 of 0.3-0.4 to make a glycerol stock as
described.

Biofilm inhibition of S. sanguinis SK36 and S. pneumoniae TIGR4:
S. sanguinis wt, ∆pilA, ∆pilB and ∆pilC biofilm inhibition: Overnight culture was made by making a 1000-fold
dilution of either S. sanguinis wt or mutant glycerol stock in TSB + 0.5% YE media and incubated under anaerobic
condition using GasPak EZ, BD pouch for 14 h. Overnight culture was diluted to OD600 of 0.01 into 20 mL of TSB +
0.5% YE and split in half: (1) untreated culture (no DβM addition) (2) culture treated with 100 μM DβM. DβM (10
mM) stock was made accordingly: 5.11 mg of DβM (Avanti) dissolved in 1.0 mL sterile H2O and syringe filtered
through a 0.22 µm syringe filter. 10 μL of DβM (10 mM) stock was added to 1.0 mL of culture to prepare (2). 200
μL of (2) was added to a 96-well plate (done in triplicate). 200 μL of (1) was added in same plate to monitor
bacteria growth inhibition. The plate was covered with an anaerobic film for 24 h in GasPak at 37°C. Bacteria
growth was monitored at OD600 on a plate reader. Media from plate was discarded and plate was washed with PBS
(2X), H2O(1X), and stained with 0.1% crystal violet (CV). CV was discarded and plate was washed with H2O until
control (media) was clear. The residual stain was solubilized with 95% EtOH. Biofilm formation was quantified by
measuring absorbance at 590 nm.
S. pneumoniae TIGR4 biofilm inhibition assay was performed according to procedure outlined for S.
sanguinis SK36.
Biofilm dispersion of S. sanguinis SK36: Overnight culture was prepared as described above. An OD600 of
1.33-1.35 was diluted to 0.01 in 20 mL of TSB + 0.5% YE and 1.0 mL aliquots of 0.01 were made. 200 μL of the
aliquoted culture was transferred into a 96-well plate and covered with an anaerobic film for 24 h in GasPak pouch
incubated at 37°C. 180 μL of overnight culture was dispensed, and the plate was washed with 200 μL of PBS and
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discarded. Upon rinsing wells containing pre-formed biofilm with PBS, 200 μL of media (TSB + 0.5% YE) was added
to control (media alone or untreated culture) wells, and 200 μL of media containing 100 μM of DβM was added to
individual wells with wt or mutant strains. Plate was incubated for an additional 24 h in GasPak at 37°C. Bacterial
growth was monitored at OD600 on a plate reader. Media from plate was discarded and plate was washed with
PBS (2X), H2O(1X), and stained with 0.1% crystal violet (CV). CV was discarded and plate was washed with H2O
until control (media) was clear. The residual stain was solubilized with 95% EtOH. Biofilm formation was quantified
by measuring absorbance at 590 nm.

Compound screen and initial bacterial growth analysis of S. sanguinis SK36 and S. pneumoniae TIGR4:
Synthetic ligands (HβM, SFβC, SFEG4OH, NβM, C12EG4OH) used in validation screen of pneumococcal biofilm
growth inhibition or biofilm dispersion were provided by the laboratory of Dr. Yan-Yeung Luk (Syracuse University,
Chemistry). Compound screen was done using mentioned procedure for S. sanguinis and S. pneumoniae biofilm
inhibition using 100 μM of ligand. Following concentrations of DβM and C12EG4OH were used for biofilm dispersion
assay in S. sanguinis: 20 μM, 40 μM, 60 μM, 80 μM, 100 μM and 150 μM.
For initial bacteria growth analysis for S. sanguinis, an overnight culture of S. sanguinis diluted to OD600
0.01 was grown to OD600 of 0.3 (took seven hours) at 37°C under anaerobic conditions. The 0.3 OD600 culture was
split in half, one treated with DβM (100 μM) and other untreated. The two cultures were incubated at 37°C and
OD600 measurements were taken every hour of each culture for a total of seven hours. Obtained OD600 data was
plotted against an hourly time course to determine lysis properties of DβM.
Bacteria inhibition was analyzed for S. pneumoniae TIGR4 with DβM at concentrations of 10 μM, 15 μM,
20 μM, 25 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM, 150 μM and 200 μM to determine
MIC. DβM was added to a TIGR4 OD600 culture of 0.01 and plated in a 96-well plate, sealed with anaerobic film,
and incubated for 24 h at 37°C. Bacteria growth was monitored at OD600 on a plate reader and readings were used
to plot a MIC curve. IC50 was determined by fitting data to equation for dose-response inhibition and plotting a
log(inhibitor) versus normalized response curve using GraphPad Prism 9.109

Hemolysis experiment: Blood from healthy sheep was obtained from Hemostat Labs. The serum was removed from
the blood by centrifugation at 1500 rpm for 5 min, and RBCs were washed three times with sterile PBS. Following
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the last wash, RBCs were resuspended in sterile PBS and 300 µL aliquots were mixed to a final volume of 1.5 mL of
various concentrations of DβM: 10 μM, 30 μM, 50 μM, 75 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM, 400 μM
and 500 μM in PBS solution. The RBC suspension (300 μL) with DβM was incubated for 2 h and centrifuged for 5 min
at 4000 rpm. Hemolytic activity was estimated using 1% Triton X-100 as a positive control and sterile PBS solution as
a negative control. Dilutions of solutions were made accordingly if intensity of absorbance exceeded readable value
by spectroscopy. The absorbance of the supernatant was recorded at 541 nm. Percent hemolysis was calculated as
(ODsample – ODnegative control)/(ODpositive control − ODnegative control) × 100%.

Phenol Sulfuric Acid method: Sample preparation: 50 μL of sugar was mixed with 150 μL of analytical grade H2SO4.
30 μL of 5% phenol was added immediately to sugar + H2SO4 mixture. The solution was boiled for 5 min at 95°C to
develop color and cooled for 5 min at room temperature. Light absorption at 490 nm was recorded on a
spectrophotometer. Reference solutions are prepared identically except carbohydrate is replaced by MilliQ H2O.
The standard calibration curve for galactose was built by relating different concentrations of carbohydrate in nmol
(x-axis) and absorbance (y-axis) to obtain a coefficient of linear regression line. A linear correlation between
galactose concentrations and light absorbance was observed.

The absorbance value of RrgA (10 μg) protein

hydrolysate falls on the standard curve corresponding to 2.04 nmol.

Isothermal titration calorimetry (ITC): ITC experiments using a MicroCal PEAQ-ITC (Malvern) were performed to
analyze the binding of RrgA with maltose (product #M5885 Sigma Aldrich) and n-Dodecyl-β-D-maltoside or DβM
(product #850520 Avanti). Purified RrgA dialyzed against buffer (either Tris-HCl pH 8.0, Hepes pH 7.5 or PBS pH 7.5
showing no significant change in heats of binding) was loaded in the sample cell (or syringe in reverse titration).
Representative thermograms using 25 mM Tris-HCl pH 8.0, 100 mM NaCl are shown as other buffer conditions did
not alter ITC results. The carbohydrate ligand (maltose) was prepared in the dialysate and titrated into the sample
cell in a series of injections (Figure S2.12). Reverse titration was performed for DβM and protein so to avoid any
detergent build-up in ITC lines (Figure S2.13 and Figure S2.14). All experiments were conducted at 25°C with stirrer
speed set constant at 700 rpm. 30 mM stock of maltose was made in buffer (dialysate) and this stock was diluted to
reach 1 mM maltose final concentration for loading into syringe. Further dilution of maltose was made in buffer to
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reach 500 μM maltose concentration for ITC study. DβM stock was prepared according to conditions set for maltose
preparation except DβM was loaded into cell for reverse titration with appropriate dilutions.

Molecular modeling of RrgA and saccharides: Docking models were established with the UCSF Chimera server
using the Autodock feature based on the crystal structure of RrgA (PDB accession no. 2ww8). Molecular graphics
were also produced using the Chimera package from the Resource of Biocomputing, Visualization, and Informatics
at the University of California, San Francisco.110
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Short antimicrobial peptides self-assemble in presence of metals
to form hydrogels
Jennifer H. Yoon, Dr. Areetha D’Souza, Dr. Olga V. Makhlynets

Portion of chapter describes work leading to following publication:
D'Souza, A.; Yoon, J. H.; Beaman, H.; Gosavi, P.; Lengyel-Zhand, Z.; Sternisha, A.; Centola, G.; Marshall,
L. R.; Wehrman, M. D.; Schultz, K. M.; Monroe, M. B.; Makhlynets, O. V., Nine-Residue Peptide SelfAssembles in the Presence of Silver to Produce a Self-Healing, Cytocompatible, Antimicrobial Hydrogel. ACS
Appl Mater Interfaces 2020, 12 (14), 17091-17099.
Yoon performed peptide synthesis, LC-MS analysis of peptides, ICP-OES analysis and silver release assay on L9 hydrogel
including rheology on D-His F11. D’Souza performed major rheology experiments and characterization of L9 (CD and
antimicrobial assay), F9, and F11 peptides. Beaman performed cytocompatibility assays. Gosavi, Lengyel-Zhand,
Sternisha, and Centola contributed to earlier characterization of L9 (peptide synthesis or inhibition of bacterial growth
assay in presence of silver). Marshall collected images of L9 peptide hydrogel using TEM.

Abstract
Chronic wounds propagate a cascade of impaired healing associated with illnesses stemming from pressure injuries
to diabetic ulcers-- a silent epidemic resulting in millions of Americans suffering from agonizing and long-term
treatment methods related to infection, disability, and amputation. Our existing inventory of antibiotics face
solubility, cytotoxicity, and overdose issues heightening the risk of pathogenic microorganisms methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa to subsist. To address an unmet clinical need for
wound dressings, self-assembling fibrillar peptides are employed for use as implant coatings, gels, and creams.
Fibrillar peptides formed into hydrogels are mechanically robust, reversible in disassembly, and tailorable for
functional behavior. The large water content in a hydrogel moreover provides physical similarity to tissues ideal for
biocompatibility and encapsulation of hydrophilic drugs. A shape-filling antimicrobial peptide-based hydrogel
formulation referred to as L9 is described. L9 is a moisture-rich short synthetic peptide ideal for skin regeneration.
L9 is envisioned to be sealed as a “just-add-water” formulation conveniently used in syringe format for use as a
topical hydrogel dressing. We show our peptide design binds silver, used extensively in wound healing application,
and releases only small amounts of this ion over time thereby overcoming silver toxicity. Silver binding is achieved
through incorporation of an unnatural amino acid, 3’-pyridyl alanine (3’PyA) into the peptide sequence. The peptide
forms a strong hydrogel and folds into a β-sheet conformation as characterized by rheology, circular dichroism, and
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transmission electron microscopy.

Finally, L9 displays antimicrobial activity against Escherichia coli and

Staphylococcus aureus and is not toxic to fibroblasts, indicating our hydrogel is suitable as an injectable, antimicrobial
wound sealant.
Furthermore, we consider the design of a hydrogel material wherein the inherent structural and functional
properties could be tuned for immediate dissolution in response to stimuli in particular pH and reduction state.
Typically, exchange of dressings during wound care can be painful requiring removal of dry gauze once saline has
evaporated from material which results in a slow and unpleasant healing process. To alleviate secondary injury in
wound care, we envision creating a hydrogel that dissolves in response to changes in redox state of metal-crosslinked
fibrils. Copper(II) is used to coordinate an unnatural amino acid 3-(4’-pyridyl)-L-alanine in a phenylalanine and
arginine rich core peptide sequence. Upon addition of ascorbic acid (vitamin C), metal is reduced to change hydrogel
stiffness inducing a reversible sol-to-gel state. We show this metal-coordinated peptide forms a strong hydrogel
with self-healing properties, resilient to shear stress, and can be easily soaked in vitamin C for ease of removal.
Furthermore, tri-amino acid (FHH) sequences were introduced into the core peptide (without pyridine transition
metal complex). FHH is fixed on ends of the N- and C- termini and the resulting peptide self-assembled into a strong
gel. Our results showcase modest modifications of our original design can lead to alternate supramolecular
structures.

3.1

Antimicrobials in wound healing

3.1.1 Introduction
Wound healing is a major priority in patient care as chronic wounds associated with skin and soft tissue
infections account for the most common burden in antimicrobial therapy for health care systems.1, 3 The declining
rate of drug discovery and rise in multidrug resistance organisms showing reduced susceptibility to antibacterial
agents challenge potency of pharmaceuticals of natural or synthetic origin.4 The shortcomings of natural compounds
in particular are poor bioavailability and formulation difficulties due to size and complexity enthusing momentum to
create synthetic analogues. Only few classes of antibiotics have entered medicine (lipopeptides, oxazolidinones and
streptogramins) specific for gram-positive bacterial infections with little progress in new treatment methods for
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gram-negative infections.5 Antimicrobial peptides (AMP) intrinsically found in insects and humans resolve issues
presented by posing broad spectral activity against both gram-negative and gram-positive bacteria extending to
fungi, viruses, and parasites. The multipotency is achieved by a mechanism in which AMP associate with the
microbial cytoplasmic membrane instead of targeting a single molecule. AMP are structurally diverse and their
affinity for negatively charged phospholipids results in disruption of membrane topology to act as disinfectants, a
defense system as powerful as a body of circulating cells (for example antibodies or lymphocytes in adaptive
immunity) to protect the host. AMP are also beneficial since they are not prone to instigate resistance mechanisms
on membrane surfaces as microbes are less likely to change their phospholipid organization, and thus resistance to
peptides are orders of magnitude lower compared to conventional antibiotics. 6, 7 Hence, AMP also referred to as
host defense peptides are considered to be promising antimicrobial and immunomodulatory agents to alleviate
infectious disease and promote wound healing.

3.1.2 Host defense peptide properties
The molecular composition of host defense peptides is classified into four subsets: alpha-helical structures
(LL-37, cecropin or magainin), beta-sheet motifs (β-defensins or protegrins), peptides with one or more
predominating amino acids including glycine, tryptophan, arginine or histidine (indolicidin), and loop peptides
(bactenecin). Humans produce two dominating classes of antimicrobial peptides cathelicidins and defensins
(elaborated more in Table 3.1; crystal structures shown in Figure 3.1) involved in inactivating microbes by directly
perturbing the outer barrier of bacteria and permitting molecules to pass through the cell wall for attack. In wound
fluids and wound tissue of healing skin, host defense peptides such as human cathelicidin LL-37 (a G-protein-coupled
receptor to attract neutrophils) impede infection by invasive skin microbes P. aeruginosa, S. aureus and
Streptococcus by becoming upregulated by epidermal keratinocytes. β-defensins are also shown to be induced by
S. aureus via epidermal growth factor receptors and demonstrate capacity to inhibit bacterial infections by
stimulating migratory immature dendritic cells and proliferate keratinocytes to promote cutaneous wound healing.8
Defensins adopt a triple-stranded β-sheet structure comprising a hairpin loop with disulfide bridges and are directly
exposed to microbial flora in the lung, kidney, and are expressed in epithelia. Histatins comprise the other major
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group of cationic, histidine-rich coil peptides found in human saliva. Histatin’s mode of action and structure are of
significant interest due to its activity domains comprising of antimicrobial and wound healing specific domains. ROS
production is another property of histatins due to their metallopeptide properties capable of coordinating redox
active metal ions, an especially interesting topic as N-terminal domains of an amino-terminal Cu2+/Ni2+ binding motif
(ATCUN) with a histidine of Histatin-5 (Figure 3.1) binds divalent metal to impart fungicidal activity.9 In sum, these
classes of peptides are defined as short, cationic and amphipathic of 10-50 amino acids with an overall positive
charge of +2 to +9. A proportion of the peptide is comprised of hydrophobic residues (30%)10 permitting the peptide
to fold into an amphiphilic structure in three dimension and contact membranes. The cationic and amphiphilic
components of antimicrobial peptides are thus essential to accumulate at polyanionic microbial surfaces comprised
of lipopolysaccharides and teichoic acids found in gram-negative and gram-positive bacteria, respectively. Once

Peptide

Sequence

Cathelicidin
LL-37

LLGDFFRKSKEKIGK
EFKRIVQRIKDFLRN
LVPRTES

Mammalian
defensin
hbD-3

Histatin 5

QKYYCRVRGGRCAVL
SCLPKEEQIGKCSTR
GRKCCRRKK

DSHAKRHHGYKRKFH
EKHHSHRGY

No. of
amino
acids

37

39

24

Conformation

Origin and activity

Linear

Only one human cathelicidin LL-37 is
characterized and derived from
proteolysis of c-terminal region of
protein CAP18. Expressed in
leukocytes (neutrophils, T cells, B
cells) and in epithelial cells of skin,
gastrointestinal, and respiratory
tracts. Stimulates wound
vascularization and reepithelialization of healing skin.

β sheet and β
hairpin loop

Broad spectrum peptide antibiotic
killing pathogenic and opportunistic
bacteria and yeast Candida albicans.
hbD-3 is produced upon contact with
bacteria and is expressed by skin
and tonsil tissues.

(adopts random coil in
hydrophilic
environment, and ! helical structure in
hydrophobic
environment)

Random coil in
aqueous solution
and !-helical
structure in nonaqueous
environment

Strong antimicrobial activity with
potent antifungal impact. Inhibits
host and bacterial enzymes involved
in periodontal disease with
metallopeptide properties. Used in
clinical trials as gel formulations and
mouth rinse.

Table 3.1 Host defense peptides and their biological roles.2
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Figure 3.1 ATCUN motif of Histatin 5 involved in ROS production and secondary structures of cathelicidin LL-37 and
mammalian defensin protein hbD-3. PDB codes: 2K6O (LL-37) and 1KJ6 (hbD-3)

inserting into the membrane, antimicrobial peptides disrupt the bilayer integrity for microbicidal activity. These
cationic peptides are thus shown to be impressive with meaningful outcome, though their potential lability to
proteases and surging costs in manufacturing do limit continued search and conception of novel peptide-based
biomolecules for topical applications.11 Physiological salt and serum conditions could also be impediments for
therapeutic peptide use as salts may inactivate defensin peptides, and LL-37 is antagonized by mono- and di-valent
cations.12, 13 Therefore, new practices designing peptides to acquire potent salt-insensitive antimicrobial properties
and resist proteolytic cleavage through alterations in peptide hydrophobicity, amphiphilicity, and backbone domains
are of consideration.

3.1.3

Building blocks of antimicrobial peptides for design of biomaterials
Amino acids are utilized for synthesis of peptides and proteins in biological systems. Natural amino acids

except glycine are chiral and exist in the L-form distinguished from each other by a side chain unit on the central
carbon atom. The amino acid sequence (written as one letter codes) influences the primary structure and depending
on the property of the side chain each amino acid is categorized as hydrophilic, hydrophobic, charged, or as
uncategorized in case for cysteine, glycine and proline (Figure 3.2).14 These latter three amino acids determine
structural modifications such as bends in peptide chains; glycine removes steric hindrance in a structure by
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introducing a better degree of flexibility than other amino acids, whereas proline due to its locked conformation
introduces structural rigidity, and cysteine offers site for chemical modification through peptide crosslinking.
Hydrophobic amino acids can be further split into two categories: (1) aliphatic residues A, I, L, M and V (2) aromatic
residues F, W and Y. Aromatic side chains are involved in β -sheet stacking and are important in stabilizing peptide
folds. Hydroxyl groups (on serine and threonine) and CONH ends (on asparagine and glutamine) are involved in
hydrogen bonding interactions categorized as hydrophilic and uncharged. Charged amino acids histidine, arginine
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Figure 3.2 Amino acid structures with one letter abbreviations comprised in peptide sequences.

and lysine are positively charged of pKa values 6.5, 10 and 12, respectively. Aspartate and glutamate are negatively
charged with both pKa values near 4.4. Such charged amino acids contribute to peptide assembly. Given the
abundant properties of amino acid building blocks, supramolecular structures can be designed with limitless
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possibilities for assembling peptide sequences and optimizing peptide properties by selective modifications.15
In principle, the sequence determines basic conformations of 𝛼-helix, β-sheet and coiled-coil character of
a peptide. β-sheet conformations in particular adopt an extended backbone arrangement through hydrogen bond
interactions between backbone amides and carbonyls to organize into fibrous structures. This motif consists of
alternating hydrophobic and hydrophilic residues to assemble into β-sheets burying a hydrophobic face and exposing
a hydrophilic face to surrounding water. β-sheet peptides can form hierarchical structures from ribbons to fibrils
based on peptide concentration and salt content.16 The arrangement of these peptides into ordered structures
through non-covalent weak interaction has become an attractive tool for generating polymers for biomedical
applications: drug delivery, tissue engineering, bioimaging, disease diagnostics.17 Comprehensively, peptide systems
are stable, affordable, quick to construct (up to 50 amino acids) by solid phase peptide synthesis to high purity and
good yield.18 Unnatural amino acids or other functional epitopes can be incorporated to enhance complexity of
structure as well as function for instance improving cell adhesion or signaling to enhance specificity without need to
append full-size proteins.19 A classic example of polymers formed by supramolecular assembly is a hydrogel (a low
molecular weight soft solid) formed from self-aggregation of small molecular components.20 Hydrogels are highly
process dependent, thus different properties from a single gelator are accessible and can be utilized to design gelforming materials for wound healing application. In the proceeding sections, various designs of peptide hydrogels
promoted by self-assembly are illustrated.

3.1.4 Self-assembly of short peptides to form hydrogels
Soft semi-solid materials referred as hydrogels formed by self-assembled polymer fibrils contain a crosslink of fibers shaped into a network amenable for immobilizing large amount of water. The mechanical strength,
hydrating properties, and biocompatibility make these biopolymers suitable for applications as an encapsulating
matrix for biologics, wound dressings, and implantable devices.21, 22 Short peptides are found to self-assemble into
hydrogel structures through amphiphilicity or self-complementarity of peptide sequences formed from (1) noncovalent hydrophobic stacking interactions from aromatic or bulky protecting moieties fluorenylmethoxycarbonyl
(Fmoc); (2) hydrogen bonding and (3) electrostatic interactions owing to their reversible nature.23, 24 Hydrogels can
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further transition from a sol-to-gel state by external stimuli (pH, temperature, or ionic conditions). A prominent
direction in the creation of novel hydrogels is integrating properties of natural protein elements as building blocks
for supramolecular structures. Amyloid fibrils are naturally occurring self-assembled structures of disease-related
origin. They serve as templates for biomaterials fabrication, and metal-binding elements or synthetic building blocks
can be incorporated into these amyloid-forming sequences. 25 Figure 3.3A illustrates the aggregation process of βamyloid peptides composed of two parts wherein the first step is a reversible nucleation of peptide fragments
sequentially adding to a growing nucleus. A second part occurs once the nucleus reaches a critical mass and leads
to formation of a large aggregate. These aggregates are stable and are determined by monitoring the turbidity of
the solution as a function of time (t). Thus, these interconnected fibrils rich in β-sheet structure could be used as a
model system to form gel nanostructures.26
Gazit et al. reported efficient self-assembly of a short peptide, the diphenylalanine aromatic core of βamyloid polypeptide, into a hydrogel in aqueous solution over a broad pH range stable across an array of
temperatures.

An amine-modified analogue Fmoc-FF (Figure 3.3B) gel could assume various geometric

morphologies in the chosen vessel and could be injectable through a syringe, an ideal property for medical
applications such as tissue engineering.27 Ulijn and coworkers investigated the self-assembly system of Fmoc-FF
wherein the viscoelastic properties of the gel were assessed by oscillatory rheology. The storage modulus (G’) which
gives the elastic response was an order of magnitude larger than the loss modulus (G”), a quantitative measure of
viscosity, characteristic of a solid-like gel forming a strong and rigid composition.28 Thota et al. reported spontaneous
self-assembly of a dipeptide leucine and α,β dehydrophenylalanine (∆Phe) located at the c-terminus into a stable
hydrogel under physiological conditions. ∆Phe is an analogue of phenylalanine comprised of a double bond at the
Cα and Cβ atoms and conformationally constrains the peptide backbone to resist enzymatic digestion. The
mechanical strength of the gel determined by the storage modulus (G’) was surveyed at increasing peptide amounts
from 0.4 wt% to 1 wt%. Cooperativity between peptide concentration and strength was observed.29
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One special feature of hydrogels utilized for functionalization is the sol-to-gel transition (Figure 3.3C)
involving monomeric peptides in which assembly is triggered by a change in solution conditions or applying external
triggers such as thermal energy, addition of salts, or altering pH and solvent.30 Hydrogels can be characterized
qualitatively by a vial-inversion observation followed by rheological measurements to assess mechanical properties
of the gel.31 Designs incorporating ionic sites of repeating hydrophilic and hydrophobic amino acids or charged
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Figure 3.3 (A) Fundamental mechanism of polymerization involves filamentous aggregates through two interrelated
Fmoc-FF
processes: (1) generation of fibril nuclei by a nucleation stage, and (2) growth of
nuclei to form long fibrils. A typical
aggregation curve is shown monitoring turbidity of solution as a function of time (t). Spontaneous gel formation scheme is
illustrated below. Monomeric peptides (gray) self-assemble to form ordered fibrils (purple). Fibrils cross-link to form a gel
matrix. Timescale of fibrillar assembly and gel formation depends on rate constants ka, k-a, kb, and k-b. (B) Fmoc-FF structure
(a diphenylalanine aromatic core of β-amyloid polypeptide). (C) Vial-inversion observation to qualitatively characterize
hydrogel formation by transition in solution (sol) state to gel state.

106

character are important in governing self-assembly of self-complementary peptides forming β-sheet structures.32
Bruce Yu and coworkers designed a pair of decapeptides of positively charged and negatively charged character with
Tryptophan (W) incorporated as a spectroscopic probe: (1) Acetyl-WKVKVKVKVK-CONH2 and (2) AcetylEWEVEVEVEV-CONH2. The alternating nonpolar and charged sequence pattern results in self-complementary of
peptides with high propensity to form β-sheets. The peptides co-assemble and due to repetitiveness of each unit,
faster assembly rate is observed to form a hydrogel with rapid recovery after shear-induced breakdown.33 Schneider
et al. designed a 20-residue β-hairpin forming structure (Figure 3.4A) introduced by a DPro-LPro linker between two
stretches of alternating lysine and valine peptide sequences. The peptide adopts a random coil conformation at low
pH and is soluble in water due to electrostatic repulsion of protonated lysine side chains. Free amines are
deprotonated once an equal volume of Gibco Dulbecco’s Modified Eagle Medium (DMEM) cell culture media at pH
7.4 containing 160 mM mono- and divalent salts are added. The resulting peptide folds into an antiparallel β-sheet
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structure and self-assembles to form a hydrogel.34 The peptide design represents a pH, temperature, and ionic
dependent

system

with

interesting

capacity

for

modification

with

unnatural

amino

acid

3-

amidoethoxyaminodiacetoxy-2-aminopropionic acid for coordinating metal (Figure 3.4B). Schneider and coworkers
modified the sequence to create a metal-triggered folding of the VDPPT β-turn peptide derivative with hydrophilic
lysine and hydrophobic isoleucine residues. The unnatural amino acid positioned on the c-terminus is negatively
charged and switches to neutral state upon chelating zinc ions. The metal-peptide interaction induces assembly of
a β-sheet fibrillar hydrogel.35 Thus, the authors demonstrate the unique adaptability of peptide design to
incorporate ionic complementarity and in particular metal-responsive features using non-natural amino acids to
initiate self-assembly of fibrils to form novel hydrogelators. As metals such as zinc are involved in wound healing
processes including cell replication, protein synthesis and inhibiting infectious microbial proliferation on wounds,36,
37

we explore the concept of metal-induced hydrogelation as a route to incorporate antimicrobial properties in our

peptide design. We characterized a silver-based fibrillar hydrogel for prospective topical administration in chronic
wound therapy.
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3.2 A short peptide self-assembles in presence of silver to produce a self-healing,
cytocompatible, and antimicrobial hydrogel

3.2.1 Introduction
A fundamental property of living tissues is their self-healing and recovery properties after damage. In
nature we see repair of biological systems at the molecular (DNA repair) and macroscopic (wound healing) levels,
and such self-healing marvels inspire intense development of self-healing hydrogels able to undergo recovery of
their shape, structure, and functionality upon physical or chemical deformation.38 Injectable hydrogels are
promising materials for biomedical applications due to their biocompatibility, ease of administration, and
resemblance to natural extracellular matrices.39 They are exceptionally useful in biomedicine as they do not require
surgical or implantation procedures as hydrogels can be pre-formed ex vivo and delivered in a minimally invasive
approach. Upon applied mechanical force through a delivery tool such as a syringe, the hydrogel undergoes shear

Figure 3.5 Hydrogel is pre-formed in a syringe format and applied to wound site (in red). Upon applied pressure gel deforms
and flows to conform into shape of skin surface (peach blocks). Polymer reforms broken crosslinks (metal-ligand interaction
is shown in above case represented by an ion in pink sphere coordinated to ligand in thick black semi-circles) and recovers
gelation upon removal of mechanical force.

stress (displayed by a drop in storage modulus) to allow gel to flow during injection. Removal of shear results in gel
recovery or restoration in elastic modulus and reformation of physical crosslinks (Figure 3.5).40, 41 This method
provides uniform distribution of the injected gel and considerable control in dynamic properties of the gel by
modulating specific interactions in the composition.

109

The earliest self-healing hydrogels were blended with cross-linking agents to achieve recovery upon damage
through a polymerization reaction; however, this strategy allows the hydrogel to be repaired only once or twice.
Often such poor control of polymer chains interlinked by permanent non-reversible bonds owe to brittleness, poor
transparency and a reduced self-healing arrangement.42 Recent strategies encompass introducing non-covalent
interactions for preparation of self-healing hydrogels capable of undergoing multiple cycles of healing.43 One
particular interaction is chelation based on two or more ligands at a central atom providing lone pair electrons to
interact with empty orbitals in a transition metal ion.

Metalloproteins and catalytic centers provide such

coordination chemistry to enforce structural integrity, and metal ions in these sites are kinetically labile to provide
reversible formation of polymer networks. Common metal ions used in metal-based supramolecular systems include
Mn, Fe, Co, Ni, Cu, Ag, and Zn in low oxidation states.44, 45 Chelating ligands conjugated to polymer backbones include
bisphosphonates, catechols, histidines, and pyridines (Figure 3.6). Bisphosphonates for instance chelate metal ions
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Figure 3.6 Bisphosphonates are utilized as anti-osteoporotic drugs due to affinity for Ca(II) ions and are used in therapeutic
application. Hyaluronan (HA)-bisphosphonate (BP) polymeric solutions lead to immediate hydrogel formation upon bridging of
ligand to calcium. HA-BP(Ag+) is useful for developing antimicrobial and moldable hydrogels in wound healing. Catechols found in
mussels (able to firmly attach to wet surfaces such as rocks and wood) inspire design of functional materials and can participate in
both coordination bonding and covalent cross-linking. Triscatechol-Fe(III) complexes shown in diagram reach Keq of 1040 and are
incorporated in mussel-inspired synthetic polymer materials used for self-healing, tissue adhesive, and elasticity purposes.
Histidine domains coordinate with metal ions such as Cu(II), Ni(II), Co(II), and Zn(II) ions of different strengths in binding constants
to create hydrogel networks. Even stronger coordination complexes are formed with pyridine-derived ligands including the parent
pyridine, 2,2’-bypyridine (bpy), and terpyridine (tpy) and metals Co(II), Co(III), Cu(II), Mn(II), and Fe(II) used in design of polymeric
networks. Co(II)-tpy on PEG shown above self-heals within 300s with >90% recovery of G’ value.1
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with different strength and affinity for calcium or silver. Hyaluronan-based silver crosslinking hydrogels undergo
shear stress and self-heal within 30 seconds after damage. The reversible coordination of this moldable hydrogel
allows for filling into irregularly shaped wounds.46 Hence, these polymers adopt different mechanical strengths
through a dynamic metal-ligand association serving as ideal healing motifs.47, 48
Coordination number and conformation of chelating center can be principally tuned so that the complex
exists in distinct linear or branched configurations. Such cross-links reform in a hydrogel upon rupture and the
hydrogel shows shear-thinning behavior, a decrease in viscosity under shear stress. One important consideration of
self-healing hydrogels is metal-ligand kinetics. Formation of self-healing hydrogels depends on the equilibrium
constant (Keq) of metal ion and ligand bond formation. Association of the metal and ligand depends on both the
ligand concentration and metal ion in solution to support a suitably contiguous network of cross-link density

metal
ion

+

Ka
Kd

ligand

Keq =

=

ka
kd

Figure 3.7 Metal-ligand coordination bonds expressed as Keq for interaction between metal and ligand motifs. Keq
is represented as a ratio of the association (ka) and dissociation (kd) kinetic constants.

(gelation point) to form a hydrogel. Furthermore, the degree of metal-ligand association depends on Keq expressed
as a ratio of the association ka (active) and disassociation kd (inactive) kinetic constants (Figure 3.7). Too low of
either metal or ligand concentration or small Keq would not be sufficient in forming a hydrogel, whereas, an
excessively big Keq for a coordination complex would be too stable. Hence, an appropriate reversible control by
external forces of active and inactive crosslinks determine the hydrogel’s mechanical properties (with an elevated
ka signifying short gelation time and rapid recovery after damage).49 We show incorporation of a non-natural amino
acid 3’-pyridyl alanine (3’PyA) binds silver in a short nine-residue peptide sequence to form a strong hydrogel that
can recover to original stiffness once applied strain is removed. Silver nitrate is commonly used as an antimicrobial
agent through a mechanism of ROS generation and interaction of negatively charged bacterial membranes.50, 51
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Silver-based antimicrobials are increasingly viewed as attractive topical applications in wound healing and burn
therapy,52, 53 however, high concentration of silver used in such development is toxic to mammalian cells.54, 55 To
minimize silver toxicity we developed an antimicrobial hydrogel that binds Ag(I) and releases only small quantities
of metal ion. The amount of silver released is sufficient for bactericidal activity and is non-toxic to fibroblast cells,
providing an initial indication that the hydrogel is applicable for wound-healing purposes.

3.2.2 Design of L9 hydrogel using a minimalist approach
Our hydrogel design was inspired by a minimalist approach pioneered by DeGrado and coworkers who
showed that a seven-residue peptide Fmoc-LKLKLKL-NH2 adopts a β-sheet secondary structure.56 Geisler and
Schneider also demonstrated peptides composed of alternating hydrophobic and hydrophilic residues produce
strong gels.57 We hypothesized introducing metal-binding residues into LKLKLKL would synergistically drive selfassembly and gelation properties. We replaced lysine with arginine as the positively charged side chain on arginine
is shown to promote antimicrobial propensity of peptide due to its affinity for negatively charged bacterial
membranes.58, 59 As arginine side chains reduce peptide self-assembly at neutral pH due to Coulombic repulsive
forces between peptide units, we incorporated pyridyl alanine (PyA) amino acids at the terminal regions of the
peptide sequence.60 PyA coordinates metal ions under near neutral pH conditions and forms complexes with a low
coordination number. We sought to create a silver-promoted gelator using a short peptide design sequence Ac-(3’PyA)LRLRLRL(3’-PyA)-CONH2 we termed L9 (Figures 3.8A and 3.8B). Addition of one equivalent of Ag(I) to L9 peptide
triggers gel formation with a storage modulus (G’) of 1014 Pa and a corresponding loss modulus of 37 Pa (Table in
Figure 3.9), whereas L9 with no metal ions forms a weaker gel (ca. 15-fold lower G’ value). The stiffness parameters
are comparable to those of biomimetic peptide hydrogels undergoing gelation at different temperature or pH.61 We
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also considered if the coordinating site in L9 framework could be altered by replacing 3’ pyridyl alanine with a ligand
N atom on a different position on the aromatic ring. 4’ pyridyl alanine metal binding ligand (Figure 3.8C) was
incorporated into the L9 sequence to understand the impact of coordinating site on hydrogel assembly. Ac-(4’PyA)LRLRLRL(4’-PyA)-CONH2 formed a weaker gel (ca. 40-fold lower G’) in either presence or absence of silver
compared to L9 (3’-PyA) + Ag(I). Furthermore, only L9 (3’-PyA) + Ag(I) promoted gel formation (Figure 3.9A) with a
distinct fibrillar morphology as demonstrated by rheology (Figure 3.9B), CD and TEM (Figure 3.10). L9 gave a CD
signature characteristic of β-sheets with a significant increase in signal magnitude in presence of Ag(I), consistent
with a more defined secondary structure. Our findings recapitulate the impact of terminal nitrogen pyridyl rings
have on metal-peptide frameworks and the significant differences in structure correlated to function based on
location of nitrogen atom as indicated for other designs.62
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Table 3.2
Sample

Conc
L9
(wt %)

Ag(I)
equiv
vs L9

NaNO3
equiv
vs L9

L9 (3’PyA)

67 ± 0.5

L9 (3’PyA)
L9 (3’PyA)

G’ (Pa)

1
1

1

L9 (4’PyA)

1014 ±
23
197 ± 28
27 ± 0.5

L9 (4’PyA)

25 ± 1

1

G” (Pa)

11
3
37
9
16
6
5 ±

±
±
±
2

5 ± 2

Figure 3.9 (A) Composition of hydrogels influences physical properties of L9: vial 1, L9 (3’PyA) 1 wt% + 1 eq Ag(I). vial 2, L9
(4’PyA) 1 wt% + 1 eq Ag(I). vial 3, L9 (3’PyA) 0.5 wt% + 0.5 eq Ag(I) + 2 eq NaNO3. (B) Evolution of the storage modulus over
& Interfaces
time for L9 peptides usingACS
1 wt%Applied
peptide atMaterials
pH 8.0. Storage
modulus (G’) and loss modulus (G”) values are provided in table
3.2 for different L9 rheology parameters. Experiments done in triplicate to ensure reproducibility.

A

B
L9 (3'-PyA)
L9 (3'-PyA) + 2.5 eq NaNO3
L9 (3'-PyA) + 0.5 eq Ag
L9 (3'-PyA) + 0.5 eq Ag
+ 2 eq NaNO3
L9 (4'-PyA)
L9 (4'-PyA) + 0.5 eq Ag
+ 2eq NaNO3

Figure 3.10 (A) Circular dichroism (CD) of L9 with 3’-PyA and 4’-PyA prepared with and without 0.5 equiv of Ag(I) and 2 equiv
of NaNO3. Final concentration of peptide is 0.5 wt%. (B) TEM image of 0.5 wt% L9 peptide in presence of 0.5 equiv of Ag(I) and
2 equiv of NaNO3.

Figure 3. Characterization of L9 peptide with silver
ions. (A) Silver release assay
114
showed that only 9 µM of silver is released into the solution over 72 hours when

Increase in storage modulus is moreover exclusively driven by silver coordination to L9 as addition of a
sodium nitrate salt alone, shown to neutralize charges and induce gelation of peptides of positively charged
character,63 to L9 does not considerably enhance gelation (only 3-fold higher G’ compared to L9 peptide shown in
Figure 3.9 table). Such conclusion is supported by poor β-sheet character for L9 in presence of only sodium nitrate
salt (Figure 3.10A). Only in presence of a silver salt composition do we see L9 adopting enhanced β-sheet folds. As
ionic strength and pH are clearly important components in triggering self-assembly and gelation,64-66 we investigated
if we could optimize silver content in L9 to consider potential silver toxicity of L9 + Ag(I).

3.2.3 Optimizing silver content in L9
To reduce potential metal toxicity from silver containing L9 hydrogel, we examined if concentration of Ag(I)
could be reduced for gel formation. Adjusting metal ion content to different concentrations relative to peptide
amount has been shown to result in an assorted fibril strength with reduction of metal loaded into the hydrogel to
be bioactive and inhibit bacterial infection.67,

68

L9 assembled into various stiffness depending on silver

concentration. Reducing Ag(I) in L9 hydrogel produced weaker gels (comparable G’ for either a 1 wt% L9 or 0.5 wt%
L9 in presence of 0.5 eq silver indicated in Figure 3.11, table 3.3), thus we looked into compensating for silver
reduction by introducing sodium nitrate as an additive to increase gelation and strength. Incorporating 0.5
equivalent Ag(I) into 0.5 wt% of L9 in presence of 2 equivalents of sodium nitrate gave a G’ of 1860 Pa (Figure
3.11A), >130-fold enhancement compared to G’ of 0.5 wt% L9 (14 Pa). Thus, sodium nitrate salt synergistically
increases gelation for L9 composed of half the original amount of Ag(I) and lesser percentage of peptide needed to
form a stiff hydrogel. These findings indicate the importance of screening charges on L9 under a different stiffness
parameter.
To determine if L9 bound to Ag(I) undergoes similar gelation at physiological conditions as pH 8 used
throughout our experiments, the storage moduli of hydrogel with silver at different pH values of 8, 7, and 6 were
collected (Figure 3.11B). In all cases, L9 and Ag(I) in presence of sodium nitrate reached the same G’ value after one
hour to indicate L9-Ag(I) can be used at physiological pH conditions. Thus, using pyridyl alanine for silver
coordination is a major benefit as the low pKa (of approximately 5)69 of this unnatural amino acid allows for operation
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at a broad pH range often found in healing wounds.70 Pyridyl alanine coordinating silver irrespective to pH
fluctuations is a unique feature and is a better ligand compared to natural amino acids, such as histidine used to
develop hydrogels,71 limited by their higher pKa.
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Table 3.3
Sample

L9 (3’PyA)

Conc L9
(wt %)

Ag(I)
equiv
vs L9

1

0.5

NaNO3
equiv vs
L9

L9 (3’PyA)

8

L9 (3’PyA)
L9 (3’PyA)
L9 (3’PyA)

pH

2.5

0.5
0.5

G’ (Pa)

G” (Pa)

435 ± 29

23 ± 5

14 ± 1

4 ± 1

63 ± 4

10 ± 2

454 ± 4

32 ± 3

1860 ± 4

45 ± 0.03

L9 (3’PyA)

0.5
0.5

2
2

7

1838 ± 10

52 ± 8

L9 (3’PyA)

0.5

2

6

1875 ± 28

28 ± 16

Figure 3.11 (A) Evolution of the storage modulus over time for L9 peptides using 0.5 wt% peptide monitored at 0.5% strain at
25 °C. (B) Storage moduli of hydrogel (0.5 wt% peptide) with silver (0.5 eq) + 2 eq NaNO3 at different pH values of 8, 7, and 6.
Table 3.3 displays storage modulus (G’) and loss modulus (G”) measured for peptides monitored for one hour. Experiments
done in triplicate to ensure reproducibility.

116

3.2.4 L9 silver release and antimicrobial action
Wound dressings containing silver are widely developed with considerable variations in structure,
composition, and silver content (either in ionic forms Ag+, Ag2+, Ag3+ or atomic Ag0 oxidizes to Ag+ based on chemical
composition of the biological media).72 Silver-based dressings ActicoatTM, Aquacel® Ag, and PolyMem® Silver are
commercially available and their cytotoxicities in a monolayer of cell culture, tissue explant, and in an excised wound
model (measuring reepithelization) were evaluated. Burd et al. provided reasons for delayed wound healing or
inhibition of wound epithelization from clinical observations of common topical silver dressing use.73 The major
shortcoming of existing silver-based dressings is their toxicity due to release of excess silver deterring optimal clinical
performance.

The critical determinants of potential cytotoxicity are the dressings affinity for moisture, silver

composition, and silver form (either metallic, bound, or ionic). PolyMem® Silver is a foam-based dressing made of a
starch copolymer locking in silver into the dressing and is extremely absorbant (releasing less silver compared to
other commercial dressings). The dressing is made of glycerin to soften non-viable tissue and a film to allow oxygen
and moisture vapor to be permeable. In addition, PolyMem® Silver allows wound exudate and slough to enter the
foam and provides a kill zone within the composition for embedded silver (Ag0) to exert antimicrobial activity against
infectious bacteria without damaging healthy cells within the wound. In contrast, ActicoatTM, a non-woven textile
delivering silver from the coated polyethylene mesh surface, was significantly cytotoxic on both keratinocytes and
fibroblasts. Only upon pretreatment of ActicoatTM (containing metallic nanocrystalline Ag0) in saline did the dressing
show a reduction in silver release and become less cytotoxic.
In another case, dressings soaked in DMEM supplemented with 10% fetal bovine serum (FBS) led to a
heightened cytotoxic effect in Aquacel® Ag (a hydrocolloid fiber) and the amount of silver (Ag+) release increased.
Serum is a complex mixture of plasma proteins, growth factors and hormones, thus the mechanism involved in
serum-promoted silver release may be due to presence of sodium and chloride ions encouraging silver dissociation.
Extraction of silver can also be observed in protein-rich medium whereby silver-protein complexes may form, which
increase silver solubility in fluid.74 Lastly, silver sulfadiazine is a popularly used wound dressing in the form of
polyester gauze with hydrocolloid Ag+ particles dispersed in a Vaseline paste. The gauze is used for burn patients but
is found to impair in vivo wound healing and delay epithelization. Silver sulfadiazine is thus becoming more obsolete
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Figure 3. Characterization of the L9 peptide with silver ions. (A) Silver release assay showed that only
72 h when the gel was prepared using L9 + 0.5 equiv of Ag(I) + 2 equiv of NaNO3 (0.5 wt % L9). Th
212 μM. Black dots correspond to silver released into media as measured at diﬀerent time points and
same hydrogel sample into media changed each day. (B) CD of L9 with 3′-PyA and 4′-PyA prepared
equiv of NaNO3. The ﬁnal concentration of the L9 peptide is 0.5 wt %. (C) TEM image of the L9 pept
2Figure
equiv
of NaNO3. of L9 peptide with silver ion. (A) Silver release assay shows 9 μM silver is released into solution
3.12 Characterization
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of NaNO3.
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of silver released into solution from these 24-hour extracts were measured by ICP-OES.

This assay more closely

models amount of silver released when hydrogel is applied and diffused into wound as silver is depleted. The highest
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DMEM at pH 7.4 to match conditions hydrogel would
experience in
wound environment.

Figure 3.13 Inhibition of bacterial growth on agar plates with E. coli (ATCC 25922) by (1) 1 wt% L9 hydrogel with one
equivalent Ag(I) and (2) L9 both added on top of culture.

We next examined if this low amount of silver is an ample amount to kill bacteria by setting up a bacterial
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(Figure 3.13).
was. added
on top of plate culture and incubated overnight at 37°C. Gram
and 2 Hydrogel
equiv ofsample
NaNO
3 (A,B) Inhibition of growth as measured for E. coli (ATCC 25922) and
negative bacteria E. coli (ATCC 25922) was inhibited by L9 in presence and absence of silver ions, showcasing peptide
alone is antimicrobial. Nonetheless, the silver-containing hydrogel inhibits bacteria of a larger area and is found to
be reduced over time as evident by brown coloration after 10 hours of incubation. To quantitatively measure E. coli
growth in contact with L9 and L9 + Ag(I) surfaces, hydrogels were prepared and covered with low-density bacteria
culture. Untreated E. coli grew normally after a 24-hour incubation, whereas L9 and L9 + Ag(I) inhibited growth
(Figure 3.12B). Most interestingly the level of growth inhibition for L9 + Ag(I) hydrogel was same as for a control
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compared to the silver salt. Transmission electron microscopy
(TEM) images of L9−Ag (Figure 3C) show the formation of
ﬁbril-like structures.
Antimicrobial Properties. Growth of Gram-negative
bacteria, E. coli (ATCC 25922), was inhibited by hydrogels
with and without silver ions; however, the area of bacterial
growth inhibition was larger in the case of a silver-containing
hydrogel (Figure 4A). Thus, silver ions serve a multipurpose
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role in driving self-assembly of peptides
into 3D hydrogels,
enhancing their stability, and conferring additional antimicrobial eﬃcacy to the resulting material. It should be noted that
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to the surface of the hy
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the cell culture media for
hydrogel sample assemb
additional 2 equiv of Na
dead assay (Figure 5B) a
(Figure 5A), demonstrat
products are not toxic t

3.2.5 L9 silver cytocompatibility and hemolysis
Finally, we evaluated L9 + Ag(I) hydrogel cytocompatibility with mouse 3T3 fibroblast cells. Fibroblasts are
critical in supporting wound healing and are involved in breaking down fibrin clots and creating collagen to provide
strength and structure.79 Thus, fibroblasts were used to measure biomaterial cytocompatibility. An indirect contact
assay was done as 3T3 cells did not attach to surface of L9 + Ag(I). Fibroblasts were incubated with an extract of
hydrogel (0.5 wt% L9 + 0.5 eq Ag(I) and 2 eq of NaNO3) soaked in DMEM for 72 hours (Figure 3.14B). The extract of
media showed no toxicity in a live-dead assay demonstrating that products released from hydrogel into solution are
not toxic to fibroblast cells. Figure 3.14 shows cells stained with two dyes Calcein acetoxymethyl (AM) and ethidium
homodimer I to check cell viability and number of live cells versus total number of cells imaged by fluorescence
microscopy. Calcein AM is a cell-permeant dye used to determine cell viability by conversion of this esterase
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by intracellular esterases. Esterases cleave the acetoxymethyl ester moiety (region of molecule protecting
carboxylic acids making dye neutral) to yield a charged compound which is membrane impermeable. Once trapped
inside cells, Calcein fluorescent dye stains live cells green. Ethidium homodimer I, a membrane impermeable nucleic
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Figure 3.14 L9-Ag(I) hydrogel extracts are cytocompatible with fibroblast cells and do not lyse RBCs. Live dead cell viability assay
Figure 5. Hydrogel
extracts do not lyse RBCs and are cytocompatible with ﬁbroblast cells. Live-dead cell viability assay of 3T3 mouse ﬁbroblast
of 3T3 mouse fibroblast with (A) media and (B) 72 h extract of media in contact with hydrogel prepared from 0.5 wt% L9 peptide
with (A) media and (B) 72 h extract of the hydrogel prepared from L9 + 0.5 equiv of Ag(I) + 2 equiv of NaNO3 (0.5 wt % peptide); (C) 9 μM
+ 0.5 equiv Ag(I) + 2 equiv NaNO3; (C) 9 μM of AgNO3 (concentration of silver released from hydrogel measured by ICP-OES); (D)
of silver released from the hydrogel as measured by ICP; (D) 423 μM AgNO3. ICP-OES);
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characterize cytocompatibility of 3T3 cells in direct attachment
compared to the silver salt. Transmission electron microscopy
to the surface of the hydrogel, but we could not achieve a
(TEM) images of L9−Ag (Figure 3C) show the formation of
120 suﬃcient interaction. Therefore, to evaluate cytotoxicity of
ﬁbril-like structures.
Antimicrobial Properties. Growth of Gram-negative
L9−Ag, we used an indirect contact assay and incubated
bacteria, E. coli (ATCC 25922), was inhibited by hydrogels
ﬁbroblasts with the extract prepared from soaking hydrogels in

acid stain, is weakly fluorescent until bound to DNA of compromised plasma membranes and emits red fluorescence.
The amount of silver released as determined by ICP-OES of 9 μM in a separate control was not toxic (Figure 3.14C),
indicating the low content of silver from hydrogel released into DMEM is cytocompatible. Conversely, high
concentration of silver (423 μM of AgNO3) used to prepare hydrogel is toxic to cells (Figure 3.14D) as indicated by
no live cell staining by Calcein.
In a separate cytotoxicity assay, neutral red dye was incorporated into 3T3 fibroblast cells treated with
hydrogel (Figure 3.15). The weakly cationic dye (net charge of zero) penetrates cellular membranes gated by a pH
gradient and concentrates in the lysosomes of viable cells. Amount of retained dye is proportional to number of
viable cells, whereas nonviable cells with a poor capacity to produce ATP and maintain a pH gradient cannot retain
neutral red.80 A positive (cytocompatible) control comprising media (DMEM, 10% FBS, 1% penicillin-streptomycin)
and a negative (cytotoxic) control consisting of 6% H2O2 with culture media were made. In another set, extracts
prepared by incubation of media with various samples for 72 hours were used to treat mouse 3T3 fibroblasts and
cytocompatibility was measured by taking the absorbance of the dye at 540 nm. Viable and dead cells were
distinguished according to capacity of lysosomes to take up neutral red dye and quantitatively analyzed using a plate
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Figure 3.15 Cytocompatibility as measured by neutral red uptake (NRU) assay. Extracts were prepared by
incubation of the media with various samples for 72 hours. Mouse 3T3 fibroblasts were treated with these extracts
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extract in contact with hydrogel prepared from 3.75 mM L9 (0.5wt%), 1.88 mM Ag (0.5
eq) and 7.5 mM NaNO3 (2 eq) in buffer (50 mM HEPES, pH 8.0). “L9” hydrogel was
prepared from L9 (0.5wt%) and 2.5 eq of NaNO3. Samples containing just variable silver
concentration (“9 µM Ag” and “423 µM Ag”) were prepared by adding AgNO3 to the
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media and these samples were incubated for 72 hours before treatment of fibroblast
cells.

reader. Our results demonstrate L9 peptide, silver binding to L9, and amount of silver released are not toxic to 3T3
fibroblasts. Moreover, the amount of silver released by L9 hydrogel does not cause red blood cell (RBC) hemolysis,
whereas total amount of Ag(I) contained in hydrogel lysed nearly 40% RBCs in a control experiment (Figure 3.14E).

3.2.6 L9 possesses self-healing properties
Another desirable feature of hydrogels is a fast response to mechanical stresses or shears as observed in
the human body through recovery of their viscoelasticity by a disassembly and reassembly process. Muscles and
cartilages undergo substantial mechanical loads, yet these soft tissues are highly elastic, tough, and recover swiftly
within a time scale of seconds under strain. However, emulating mechanical properties of tissues in the form of
synthetic biomaterials is extremely challenging. Efforts to enhance mechanical strength and toughness of hydrogels
have been made by introducing sacrificial bonds using short polymer chains or polymer networks; nonetheless, the
bulk of synthetic hydrogels is limited by a deficiency in a self-recovery mechanism.81 Examples of load-bearing
materials overcoming this issue comprise of folded proteins exhibiting mechanical stability to fold quickly upon
release of an applied force. Yi Cao and coworkers combined protein engineering and theoretical modeling to create
a framework for a protein hydrogel with tunable elasticity, toughness and self-healing capacity.82 They also
illustrated peptide-metal complexes can be designed as physical cross-linkers since metal coordination complexes
are known to display fast binding and unbinding kinetics.83 Metal binding sites were arranged in tandem and

Figure 3.16 Shear recovery of the hydrogel prepared from 0.5 wt% L9 peptide with 0.5 equiv of Ag(I) and 2 equiv of NaNO3
monitored at 0.5% strain at 25 °C.
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incorporated into a short histidine-rich peptide sequence to observe for cooperativity of ligands to bind zinc metal
ions and improve stability. As self-healing hydrogels based on metal-ligand coordination chemistry are continuing
to improve in rheological behavior and biological functionality, we observed for self-healing propensity of L9
hydrogel. To examine shear recovery of hydrogel, L9-Ag(I) was subjected to 1000% strain followed by an oscillation
time sweep experiment (0.5% strain) for one hour to assess sample recovery after deformation (Figure 3.16). L9Ag(I) undergoes shear thinning under applied strain and recovers to its original gelation once strain is removed. The
finding gives insight into the dynamic property of L9 hydrogel and the cooperativity of metal-ligand coordination and
mechanical strength of gel upon rupture. The resulting gel is therefore potentially suited in biomedical application
for use in syringe delivery into wounds as L9-Ag(I) is able to undergo a fully reversible sol-gel transition.

3.3 Copper binding peptide self-assembles to form a self-healing, stimuliresponsive hydrogel
3.3.1 Introduction
We also investigated if copper could be incorporated into a nine-residue phenylalanine and arginine rich core
sequence (referred to as F9) by coordination to an unnatural amino acid 3-(4’-pyridyl)-L-alanine (Figure 3.17). Cu(II)
reduction to Cu(I) would result in an altered coordination site and induce a change in hydrogel stiffness. Ascorbic
acid is used as a reductant and is considered beneficial as the solution could lower pH at wound site to more acidic
conditions, thereby reducing toxicity of bacteria, promoting angiogenesis and fibroblast activity.84, 85 Rheological
properties of resulting peptide hydrogel were determined. Lastly, cooperativity of di- or tri-amino acid sequences

A

Ac-(4’PyA)-F-R-F-R-F-R-F-(4’PyA)-CONH2

N

N

N

N

Cu(II)

Ac-(4’PyA)-F-R-F-R-F-R-F-(4’PyA)-CONH2

B

C

Figure 3.17 (A) Design of a copper binding peptide that assembles in presence of a metal coordinating ligand.
Peptide sequence of primary focus is shown known as F9. Cu(II) coordinates to an unnatural amino acid 3-(4’pyridyl)-L-alanine (colored in purple).
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with gelation-promoting components are prevalent in self-assembling materials with tunable properties. For
instance, supramolecular structures arise from non-covalent interaction of a diphenylalanine and aspartic acid (FFD)
tri-amino acid peptide to a short peptide gelator GHK. Copper complexation to a stoichiometric amount of each
peptide leads to gelation with a storage modulus of 1,500 Pa.86-89 We discovered a tri-amino acid sequence FHH
appended to each end of a shorter version F9 core peptide (Ac-FHH-FRFRF-HHF-CONH2) in absence of metal
promotes self-assembly and gelation.

3.3.2 Pyridine ligands of F9 peptide coordinate Cu(II) to promote gelation, self-healing and
redox-responsiveness
Pyridines with a single N atom participate in ligand metal ion-induced dipole interactions with Cu(II) cations
and N lone pair electron forming a strong interaction. Prominent σ donation upon pyridine ligation to copper and
less steric crowding around the metal center compared to other transition metal coordinates owe to high Cu(II)pyridyl binding energy.90 We observed location of N atom in pyridyl ring impacts gelation outcome and the optimal

A

B
F9 + Cu(II)
F9 + Cu(II)
+ ascorbate

Sample

Sequence

Conc (wt%)

G’(Pa)

G”(Pa)

F9

54

4.3

F9+Cu(II)
0.5 eq

4262

75.3

F9+Cu(II)
0.5 eq
+ascorbate
5 eq

24.9

10.7

F9
+ascorbate

103.5

15.1

Ac-(4’PyA)FRFRFRF(4’PyA)-CONH2

1

Table 3.4

Figure 3.18 (A) Evolution of storage modulus over time for F9 and F9 mixed with Cu(II). Storage moduli for F9 treated
with ascorbate are provided in table to compare hydrogel stiffness with F9 and F9 + Cu(II). Loss modulus (G", a
measure of viscosity or flow of material) is also noted for each sample. 1 wt% of peptide was used and 0.5 equivalent
copper sulfate to form hydrogels. (B) Ascorbic acid reduces copper bound to F9 to Cu(I) resulting in a gel-to-sol
transition.
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Figure 3.19 Shear recovery of F9 peptide 1 wt% and Cu(II) 1 eq upon 1000% strain for 30 sec, followed by an
oscillation time sweep (0.5% strain) for 2 hours. Iterations of deformation experiment (shown on same plot) were
done to observe for reformation of hydrogel after applying shear stress.

position of N for copper coordination is provided by 3-(4’-pyridyl)-L-alanine or 4’PyA ligand. Data from rheology
shows F9(4’PyA) in presence of 0.5 eq copper forms a strong hydrogel (ca. 80-fold improvement in gelation relative
to F9 with no copper) [Figure 3.18A]. F9 is moreover redox-responsive, forming a soft composition once Cu(II)
reduces to Cu(I) upon addition of reducing agent ascorbate (Figure 3.18B). Such stiffness change could be attributed
to Cu(II) adopting a different coordination (able to adopt diverse configurations from trigonal planar to tetrahedral
geometries of 2 to 6 coordination bonds) and this plasticity distorts hydrogel integrity.91 F9 also displays self-healing
properties undergoing shear thinning under applied strain followed by complete gelation recovery once strain is
removed (Figure 3.19). The self-healing properties of F9 are ideal features for potential delivery of a preset hydrogel
inside a syringe format to wound site.

3.3.3 Shorter F9 version gelation properties in presence of copper
F9 sequence was shortened to seven amino acids Ac-(4’PyA)-FRFRF-(4’PyA)-CONH2 named F7 to
see if variation in core peptide influences gelation patterns. F7 stocks were made and lyophilized before dissolving
in ice-cold sterile water to make a 2 wt% solution. An equal volume of 100 mM HEPES pH 8 was combined with 2
wt% peptide to reach 1 wt% final concentration for rheology. For a sample of 1 wt% peptide and one equivalent of
copper, an appropriate amount of a 50 mM CuSO4 (made in H2O) was mixed with peptide and an equal volume of
100 mM HEPES pH 8 buffer. For copper samples without peptide, H2O was combined with a 50 mM CuSO4 and
combined with buffer. The final buffer composition is 50 mM HEPES pH 8 in both conditions. Oscillatory time sweep
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For preparing 1 wt% peptide and one equivalent copper solution, 13.5 uL of a 50 mM CuSO4 in H2O was mixed with
For preparing 1 wt% peptide and one equivalent copper solution, 13.5 uL of a 50 mM CuSO4 in H2O was mixed with
24 uL of ice-cold sterile H2O and 37.5 uL of 100 mM HEPES pH 8.0 buffer.
24 uL of ice-cold sterile H2O and 37.5 uL of 100 mM HEPES pH 8.0 buffer.

Rheology
F7(4’P) (2 wt% or 18 mM) was made and aliquoted into 1.5 mL Eppendorf tubes. The aliquots were lyophilized and
37.5 uL of ice-cold sterile H2O was added to one sample to make a 2 wt% solution. 37.5 uL of 100 mM HEPES pH 8.0
was combined with 2 wt% peptide for rheology experiment to reach a 1 wt% final peptide. 75 uL of solution was
pipetted onto Arg2 platform. Conditions for rheology: Cone in plate was used with an oscillatory time sweep at 0.5%
strain, 6.283 rad/s, 1 hour, 25°C. Solvent trap was used to maintain moisture inside system.
For preparing 1 wt% peptide and one equivalent copper solution, 13.5 uL of a 50 mM CuSO4 in H2O was mixed with
24 uL of ice-cold sterile H2O and 37.5 uL of 100 mM HEPES pH 8.0 buffer.

Table 3.5

Sample
Sample

SequenceSequence
Sample
Sequence

ConcConc
(wt%)
(wt%)
Conc
(wt%)

F7
F7

Ac-(4’PyA)-FRFRFAc-(4’PyA)-FRFRF(4’PyA)-CONH2
Ac-(4’PyA)-FRFRF(4’PyA)-CONH2
(4’PyA)-CONH
F7 + Cu(II)
2

F7

1
1

1

G’
(Pa)
G’
G’(Pa)
(Pa)

G” (Pa) G”
G”(Pa)
(Pa)

2.439

0.06911

20210

927.5

2.439
2.439

0.06911
0.06911

1 eq

F7 + Cu(II)
20210
927.5
F7 + Cu(II)
20210
927.5
1
eq
Figure
3.20 Evolution of storage modulus over time for F7 and F7 mixed with Cu(II). Storage moduli are provided in
1 eq

table 3.5 to compare hydrogel stiffness between F7 and F7
2 + Cu(II). Loss modulus (G") is shown in red in bottom plot
overlaid with F7 + 1 Cu(II) data and values are noted for each sample. 1 wt% of peptide combined with one equivalent
copper sulfate was used to form hydrogels. JY4032, JY4033 (Further repeats are required to determine G’
2 in immediate gelation with other F7 batches and, therefore,
reproducibility as addition of copper to peptide resulted
2
limited rheology experimentation).

at 0.5% strain, 6.283 rad/s, 25°C for one hour was set. A solvent trap was used to maintain moisture inside system.
104 order of magnitude difference in G’ was observed between F7 and F7 + Cu(II) indicating potential for screening
shorter versions of peptides for copper coordination to form strong gels (rheology data in Figure 3.20). Our goal is
to characterize different wt% of F7 in presence and absence of copper to compare stiffness parameters with F9. The
amount of copper would be reduced accordingly to determine optimal amount of copper needed to create a stiff
hydrogel. Thereafter, shear recovery experiments on F7 and derivatives would be performed.
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3.3.4 Phenylalanine and dihistidine incorporation to F9 sequence
Lastly, we discovered histidine ligands, initially intended to coordinate copper as they are known to
generate stable square planar complexes and exist in binding sites of metal transporters,92 improve gelation of
phenylalanine and arginine core peptides in absence of metal. We modified the N- and C- termini of F9 to create a
shorter core sequence similar to F7 but with a tri-amino acid sequence FHH appended (Ac-FHH-FRFRF-HHFCONH2 (F11). F11 peptide (1 wt%) exhibited poor gelation in presence of one equivalent copper (low metal
complexation) with G’ of 16.6 Pa and G” of 11.3 Pa. F11 (1 wt%) peptide with no metal formed a strong gel with G’
of 63406 Pa and G” of 4040 Pa (Figure 3.21). Our proposal is to characterize pH-responsiveness of this strong
hydrogel to create a material that changes stiffness to conditions conducive for different healing stages.

Table 3.6
Sample

50 mM Hepes
pH 8.0

Sequence

Conc
(wt%)

G”(Pa)

63406

4040

16.6

11.3

13.3

10.8

Ac-FHHFRFRFHHF-CONH2
(or F11)

F11
+ 1 eq
Cu(II)
50 mM Hepes
pH 8.0

G’(Pa)

1

Ac-FdHdHFRFRFdHdHFCONH2

Figure 3.21 Evolution of storage modulus over time for F11 and F11 + 1 eq Cu(II). Storage moduli are provided in
table to compare hydrogel stiffness. 1 wt% of peptide was used to form hydrogels.

Schneider and coworkers previously showed a mixture of D and L peptides form a more rigid hydrogel
assembly from mixed enantiomerically pure peptides.93

As D-amino acid incorporated hydrogels enhance

mechanical strength and proteolytic stability, 94, 95 we designed F11 peptide derivatives with histidine replaced with
d

His to integrate such positive features into the design. Comparable G’ values were observed between dHis version
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F11 (G’ 13.3 Pa and G” 10.8 Pa) and F11 + Cu(II). Affinity of metals for a peptide where N- and C- termini of F11 were
slightly modified by fixing Phe between two dHis amino acids in a tri-amino acid sequence Ac-dHFdH-FRFRFdHFdH-CONH
2

was analyzed. Data shows weak affinity of this D-amino acid substituted peptide for various metals,

similar to data observed for original F11 sequence, but with Ag(I)-induced gelation to be most prominent (Figure

Table 3.7
metal

Peptide sequence

Conc (wt%)

G’(Pa)

0

28

0.5 eq Ag+

367

1 eq Ag+
1 eq Mn2+

Ac-dHFdH-FRFRFdHFdH-CONH
2

1

454
140

1 eq Ca2+

130

1 eq Co2+

39

1 eq Cu2+

46

1 eq Mg2+

13

Figure 3.22 Evolution of storage modulus over time for D-His substituted F11 in presence of various metals. 1 wt% of
peptide combined with either 0.5 or 1 eq metal was used to form hydrogels. JY4019
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3.22). Data portrays the inherent mechanical strength of F11 peptide with no dependence on metal addition to form
a strong hydrogel.

3.4 Conclusions and future outlook
In conclusion, a rationally designed nine-residue peptide L9 self-assembles by coordination of metal
coordinating ligands, pyridyl alanines, to silver and forms a self-supportive gel. The pyridyl ligands associate Ag(I)
with strong affinity and this ligand’s low pKa allows for operation at reduced pH values found in healing wounds.70
Gelation is specific for silver and not exclusively due to presence of salts as L9-Ag(I) forms β-sheet rich fibrils as
shown by circular dichroism and TEM. L9-Ag(I) moreover displays exceptional gel formation with a G’ value of 1860
Pa and is self-healing allowing for potential use in syringe delivery of hydrogel into any wound geometry. The peptide
hydrogel, furthermore, releases small amounts of silver in solution at concentrations sufficient to kill bacteria but
not harmful to 3T3 fibroblast cells. Other key features of our peptide design are the resulting hydrogel possessing
antimicrobial properties with positively charged residues providing additional association of gel to the microbial
membrane to enhance bactericidal activity of L9-Ag(I). Thus, L9 peptide comprised of both charged residues and
pyridyl alanines with gelation triggered by metal ions and an assembly aided by salt allows for optimal contact with
biological fluids containing high salt concentrations. For future outlook, we would like to see if L9 can be improved
for direct attachment to cell tissues by incorporating cell-binding motifs such as a tri-amino acid sequence RGD
(arginine-glycine-aspartate). RGD motif is an integrin binding motif present in ECM proteins abundant in skin and
has been used readily to enhance cell adhesion for mammalian cells.96-99 Our preliminary data on adding a sequence
extension -G-RGD to the peptide hydrogel displays similar gelation properties or stiffness as the parent sequence.
The RGD extension to C-terminal end of sequence is observed to be optimal for peptide assembly into hydrogel.
In another facet of our metal-based hydrogel design, we explored design of a copper-binding peptide
forming hydrogel able to change stiffness in response to a switch in redox state. We foresee efficient copper
coordination to unnatural amino acid pyridyl ligands would lead to hydrogel resistance to proteases, a concern for
existing biomaterial design aspects. The addition of positively charged arginine side chains and copper ions can
enhance antimicrobial properties of the hydrogels for counteracting microbe toxicity at site of wounds. Assessing
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physical and chemical properties of F9 are underway using circular dichroism and transmission electron microscopy.
We are also looking into copper toxicity with fibroblast cells and amount of copper released over time by F9 + Cu(II)
using inductively coupled plasma emission spectroscopy. In addition, we would like to see if our peptide designs can
coordinate other metals such as calcium to reduce potential toxicity contributed by transition metals. Ideally calcium,
shown to be used in multiple regeneration medicine applications particularly in wound healing,100 could be used to
induce gelation of peptide and resulting hydrogel could be examined with fibroblasts. Finally, a peptide that does
not exhibit a metal-induced gelation was identified and further studies on this strong hydrogel containing tri-amino
acid sequences FHH are in progress to see for pH-responsiveness behavior. Overall, our designed scaffolds
demonstrate redox active and self-assembling features for practical application in wound care.

3.5 Experimental
Peptide Synthesis and Purification. The peptides were synthesized by manual Fmoc solid-phase synthesis at
elevated temperature using Amide Rink (Chem-Impex) and Fmoc-protected amino acids (GL Biochem Shanghai Ltd.)
using previously reported protocols.101 Coupling of Fmoc-3-(3ʹ-pyridyl)-L-alanine or Fmoc-3- (4ʹ-pyridyl)-L-alanine
was performed at room temperature for 30 min by following a double-coupling of unnatural amino acid. Peptides
were acetylated at the N-terminus. Cleavage of the peptides from the resin and side-chain deprotection were
simultaneously achieved by treatment with a mixture of trifluoroacetic acid [TFA/H2O/ triisopropyl silane (TIS)] in a
ratio of 95:2.5:2.5 by volume for 2 h at room temperature. The crude peptides were precipitated and washed with
cold methyl-tert-butyl ether and purified on a Varian ProStar 210 preparative reverse-phase high-performance liquid
chromatography system with a C4 preparative column (Vydac), using a linear gradient of solvent A (0.1% TFA in Milli
Q water) and solvent B (90% CH3CN, 9.9% Milli Q water, and 0.1% TFA). The identities of the peptides were confirmed
using a Bruker Autoflex III Smartbeam MALDI-TOF mass spectrometer. The purity of the obtained peptides was
evaluated on an Agilent Infinity II 1260 with an analytical Zorbax Eclipse XDB-C18 column (4.6 mm × 150 mm).

L9 Peptide Stock Preparation. Pure lyophilized peptides were then dissolved in cold Milli-Q water to make 15 mM
stock solutions (2 wt% solution). The peptide solution was then centrifuged for 5 min at 6500 rpm to remove the
precipitate (typically only a small amount of insoluble material). The concentrations of the peptides were determined
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by measuring the absorbance at 267 nm on an Agilent 8453 UV−Vis spectrophotometer using ε267 = 4274 M−1 cm−1.102
The peptide stock solutions were then aliquoted into 150 or 75 μL aliquots and lyophilized. The lyophilized aliquots
were then stored at −20 °C until further use. Spectra of the L9 peptide with 3′-PyA and 4′-PyA are shown in Figure
S3.3 to illustrate the difference in PyA absorption. To measure the concentration of L9 (4′-PyA) and L9(His), we
determined extinction coefficients of these peptides. To do so, pure lyophilized L9 (4′-PyA) and L9(His) peptides (<97%
purity) were dissolved in cold Milli Q water and the solutions were then centrifuged for 5 min at 6500 rpm. The
solutions were then aliquoted into Eppendorf tubes of known weight and lyophilized. Tubes with lyophilized
peptides were weighed to determine the weight of peptide content and then the powder was dissolved in Milli Q
water to prepare 15 mM stock solutions of peptides. The extinction coefficients were determined by measuring the
absorbance at 255 nm for L9 (4′-PyA) and 214 nm for L9(His) on an Agilent 8453 UV−Vis spectrophotometer. The
extinction coefficients were determined as ε255 = 4439 M−1 cm−1 and ε214 = 7203 M−1 cm−1 for L9 (4′-PyA) and L9(His),
respectively. The peptide stock solutions were then aliquoted into 75 μL aliquots and lyophilized. The lyophilized
aliquots were stored at −20 °C until further use.

F9 Peptide Stock Preparation. Lyophilized F9 peptide was dissolved in ice-cold MilliQ water to prepare a 14 mM
stock (2 wt% w/v). Peptide solution was spin-filtered and centrifuged at 6,500 rpm for 10 min. Concentrations of
peptides were determined by measuring absorbance on an Agilent 8453 UV-Vis spectrophotometer using ɛ255= 4434
M-1 cm-1 or ε214 = 7203 M−1 cm−1 (for histidine containing sequence). The peptide stocks were aliquoted into 75 µL
aliquots and lyophilized. The lyophilized aliquots were stored at -20oC until further use.

Rheometry. Bulk rheology was utilized to measure the storage (G′) and loss (G′′) moduli of the peptide hydrogel
scaffolds. An aliquot of the powdered peptide was dissolved in ice-cold water (75 μL) to prepare a 15 mM stock and
mixed with a vortex mixer (GeneMate, BioExpress) for 10 s to provide a solution of 2 wt% L9. The peptide solution
was centrifuged (Eppendorf, Microcentrifuge 5424) for 5 min at 6000 rpm to remove bubbles. Ice-cold buffer (100
mM HEPES, pH 8) or AgNO3 in buffer (15 mM) was pipetted (75 μL) into the peptide solution (15 mM, 75 μL) and
gently pipette-mixed. Sample solutions (85 μL) were pipetted onto the rheometer (Ares G2, TA Instruments-Waters)
equipped with a solvent trap, and the moduli were measured on a cone and plate geometry with a 2° 20 mm cone
at a gap of 57 μm. Gelation was monitored by performing oscillation time sweep experiments at 25 °C with a constant
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0.5% strain and 6.283 rad/s angular velocity for 1 h to ensure complete gelation. In shear recovery tests, samples
were subjected to 1000% strain at 6.283 rad/s for 30 s, followed by an oscillation time sweep experiment (0.5%
strain) for 1 h to check the sample recovery after shear. Experiments were completed in triplicate to ensure
reproducibility. Hydrogels with lower concentration of peptide (0.5 wt% final) were prepared by mixing 7.5 mM
peptide stock (75 μL) with a buffer containing 3.75 mM AgNO3 and 15 mM NaNO3 (75 μL). To prepare hydrogels at
variable pH, peptide stock was mixed with the buffer (100 mM HEPES) adjusted to pH 7 or 6, containing AgNO3 and
NaNO3. Figure S3.1 in Appendix III includes evolution of storage modulus for hydrogels made by mixing L9(His)
peptide (1 wt%) and one equivalent of AgNO3. Evolution of storage modulus for hydrogels made by mixing L9 (3’PyA) peptide (1 wt%) and variable amount of AgNO3 (zero to one equivalent) is shown in Figure S3.2 of Appendix III.

F9 and F11 Peptide Hydrogel Rheometry. Bulk rheology was utilized to measure the storage (G′) and loss (G′′)
moduli of the peptide hydrogels. An aliquot of lyophilized peptide was dissolved in ice-cold water (75 μL) to prepare
a 14 mM stock and mixed with a vortex mixer (GeneMate, BioExpress) for 10 s to provide a solution of 2 wt% w/v of
F9. The peptide solution was centrifuged (Eppendorf, Microcentrifuge 5424) for 5 min at 6000 rpm to remove
bubbles. Ice-cold buffer (100 mM HEPES, pH 8) or CuSO4 (50 mM stock prepared in MilliQ water) in buffer was
pipetted (75 μL) into the peptide solution (14 mM, 75 μL) and gently pipette-mixed. Sample solution (75 μL) was
pipetted onto the rheometer (Ares G2, TA Instruments-Waters) equipped with a solvent trap, and the moduli were
measured on a cone and plate geometry with a 2° 20 mm cone at a gap of 57 μm. Gelation was monitored by
performing oscillation time sweep experiments at 25 °C with a constant 0.5% strain and 6.283 rad/s angular velocity
for 1 hr to ensure complete gelation. In shear recovery assays, samples were subjected to 1000% strain at 6.283
rad/s for 30 s, followed by an oscillation time sweep experiment (0.5% strain) for 2 hr to evaluate sample recovery
after shear. Experiments were completed in triplicate to ensure reproducibility. F11 and D-His analogue peptide
fractions were prepared as similar method for F9 from 2 wt% w/v (14 mM stock) divided in 75 μL aliquots and
lyophilized. F11 hydrogel was prepared by addition of ice-cold water (14 mM, 75 μL) and ice-cold buffer (100 mM
HEPES, pH 8) or ice-cold buffer with 35 mM ascorbate (75 μL). Sample solution (85 μL) was pipetted onto rheometer
plate using rheology experimental conditions mentioned for F9 analysis.
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Circular Dichroism Spectroscopy. CD spectra were acquired on a Jasco J-715 CD spectrometer collecting ten scans
(4 s averaging time) for each spectrum and using a quartz cuvette with 0.1 mm path length. The measurements were
performed on samples containing L9 peptides (3.75 mM) in a buffer (50 mM HEPES, pH 8) with and without AgNO3
(1.88 mM) or NaNO3 (7.5 mM, 2 equiv). The samples were incubated at 37 °C overnight to ensure gel formation
before measurements. Care was taken that the sample absorbance never exceeded 1.5 at all wavelengths to produce
reliable ellipticity values. Mean residue ellipticity (MRE, deg·cm2·dmol−1) values were calculated using the following
equation, where θ is the ellipticity (mdeg), l is the path length (cm), C is the peptide concentration (M), N is the
number of residues.

MRE =

+
,-×/×0×1

Transmission Electron Microscopy. Hydrogel samples containing L9 peptide (3.75 mM) in a buffer (50 mM HEPES,
pH 8), AgNO3 (1.88 mM), and NaNO3 (7.5 mM) were prepared and incubated at 37 °C overnight to ensure gel
formation. After incubation, aliquots of 10 μL were adsorbed for 2−3 min onto carbon-coated 200-mesh copper grids
(Ted Pella). Excess liquid was wicked away with filter paper, and grids were then stained with one 5 μL drop of 2%
(w/v) uranyl acetate. After drying under vacuum, samples were viewed with a JEOL-JEM 2100F field emission
electron microscope at an acceleration voltage of 200 kV. Electron micro- graphs were recorded on a Gatan OneView
4K CCD camera.

Silver Release Assay. The lyophilized peptide aliquot was dissolved in 75 μL of sterile Milli Q water to make a 7.5
mM solution (1 wt%). AgNO3 (Sigma-Aldrich) was dissolved in Milli Q water to make a 1 M stock solution and syringefiltered by passing through 0.22 μm sterile centrifugal filter. This stock was further diluted using sterile buffer (100
mM HEPES, pH 8) to make a solution containing both AgNO3 and NaNO3 (15 mM NaNO3 and 3.75 mM AgNO3). The
hydrogel samples were prepared in duplicate inside 1.5 mL microcentrifuge tubes by mixing the peptide stock (35
μL of 7.5 mM) and AgNO3 containing NaNO3 (35 μL). Samples were incubated at 37 °C overnight to ensure gel
formation. After incubation, DMEM (550 μL) was added to each tube and incubated at 37 °C without shaking. Sample
aliquots (50 μL) were removed after 1, 3, 6, 24, 48, and 72 h and diluted with 3950 μL of 1% HNO3 (TraceMetal grade,
Fisher). Samples were prepared in duplicates for each time point and aliquots were removed from different samples
to ensure no volume change of the media in interaction with the gel for different time points. The concentration of
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Ag(I) was measured using ICP−optical emission spectrometry (OES) (ICP−OES, PerkinElmer Optima 3300 DV) for each
time point. To evaluate silver release at variable pH (6, 7, and 8), we prepared hydrogels as described above but
using buffer adjusted to different pH values. After the formation of the hydrogel, DMEM with variable pH (6, 7, and
8) was added to the samples and sample aliquots were taken at 24 h to measure silver in the solution. To measure
how silver is released by the same sample into fresh media, we prepared the hydrogel as described above (0.5 wt%
L9, 0.5 equiv of Ag(I), and 2 equiv of NaNO3). After overnight incubation at 37 °C, DMEM was added (550 μL) and the
tubes were incubated at 37 °C without shaking. After 24 h of incubation, the media was removed and replaced with
550 μL fresh DMEM. Aliquots of the media (50 μL) were removed, diluted with 3950 μL of 1% HNO3 (TraceMetal
grade, Fisher), and stored for further analysis. In the following 3 days, we replaced media every 24 h and prepared
a sample of incubated media for ICP analysis. The concentration of Ag(I) was measured using ICP−OES.

Inhibition of Bacterial Growth Assay. AgNO3 (Sigma-Aldrich) was dissolved in Milli Q water to make a 1 M stock
solution. Milli Q water, buffer (100 mM HEPES pH 8), and 1 M AgNO3 solution were sterilized by filtering through
0.22 μm sterile centrifugal filters. In order to prevent the precipitation of silver, we used nitric acid (TraceMetal
grade, Fisher) to adjust the pH of the buffer instead of commonly used HCl acid. The lyophilized peptide aliquot was
dissolved in 150 μL of sterile Milli Q water to make 7.5 mM solution of L9. A solution of 3.75 mM AgNO3 and 15 mM
NaNO3 was made in a buffer (100 mM HEPES, pH 8.0). The hydrogel sample containing Ag was prepared by mixing
the peptide stock solution (100 μL of 7.5 mM) and AgNO3 and NaNO3 solution in buffer (100 μL). The hydrogel sample
without Ag was prepared by adding buffer instead of AgNO3 solution. Control samples without the peptide were
prepared by adding water instead of peptide solution to the buffer containing AgNO3 and buffer without AgNO3. All
samples were prepared in a 48-well plate in triplicate. The plate was covered with a Breathe-Easy permeable
membrane and incubated at 37 °C overnight to ensure gel formation. The culture of E. coli (ATCC 25922) was started
by mixing overnight culture (100 μL) in LB (5 mL) and the resulting culture was grown at 37 °C, shaking at 150 rpm
for about 3 h until OD600 = 0.3. The culture of S. aureus (ATCC 25923) was prepared by mixing overnight culture (100
μL) in tryptic soy broth (5 mL) and the culture was grown at 37 °C, shaking at 150 rpm for about 3 h until OD600 = 0.3.
The cultures were then diluted to OD600 = 0.001 with sterile media and this diluted culture was added to each well
(300 μL). The plate was then covered with a new membrane and placed in a shaker at 37 °C for 24 h (150 rpm). Next
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day, 200 μL of the culture was carefully removed from the top and transferred to a 96-well plate to measure OD600
using a plate reader.

Bacterial Growth Assay on LB/Agar Plates. The hydrogel and the control samples were prepared in 1 mL centrifuge
tubes as described above. The hydrogel was allowed to form by incubating the samples at 37 °C for 3 h. The culture
of E. coli (ATCC 25922) was started as described above. The bacterial culture of OD600 = 0.3−0.4 was diluted fivefold
with LB (Luria-Bertani medium) and this diluted culture was plated on the agar plate (200 μL). The hydrogel samples
(25 μL) and the control samples (10 μL) were added on top of the freshly plated culture and the plate was incubated
at 37 °C overnight.

Cytocompatibility Assay. Cytocompatibility was examined using NRU and live/dead assays. The lyophilized peptide
was dissolved in 150 μL of sterile Milli Q water to prepare a 7.5 mM peptide stock. AgNO3 (Sigma-Aldrich) was
dissolved in Milli Q water to make a 1 M stock solution and syringe-filtered by passing through 0.22 μm sterile
centrifugal filter. The hydrogel sample (0.5 wt%) containing silver was prepared by mixing the peptide stock (35 μL
of 7.5 mM) and AgNO3 containing NaNO3 (35 μL of 3.75 mM AgNO3 and 15 mM NaNO3) in buffer (100 mM HEPES,
pH 8). The final hydrogel contained 3.75 mM L9, 1.88 mM AgNO3, and 7.5 mM NaNO3. Hydrogel samples were
incubated overnight at room temperature. Samples were also prepared to evaluate toxicity of various Ag(I)
concentrations. These samples were prepared by adding water instead of the peptide stock. All samples were
prepared in triplicate and incubated at 37 °C overnight. After incubation, 550 μL of DMEM was added to each tube,
and the samples were incubated for 72 h at 37 °C without shaking. The sample with silver released by the hydrogel
(as measured by ICP) contained 9 μM silver nitrate. Mouse embryonic fibroblast cells (3T3, ATCC) were cultured and
maintained in DMEM with 10% FBS and 1% penicillin/streptomycin at 37 °C in a 5% CO2 humidified atmosphere.
Approximately 12−24 h before testing, cells were seeded into 96-well plates at concentrations of 1 × 104 and 1.6 ×
103 cells/well for the NRU and live/dead assays, respectively. Immediately prior to testing, culture media was
removed and extracts (200 μL) were added to wells (n = 3) for each tested group. Positive (cytocompatible) controls
received no treatment and negative (cytotoxic) controls received 50 μL of 30% H2O2. The 96-well plates were placed
into an incubator at 37 °C in 5% CO2 for 3 h. After treatment, extract media was removed and cells were washed
with 1× phosphate-buffered saline (PBS) (200 μL) and then NRU dye (200 μL, 1:99) in media (DMEM, 10% FBS, 1%
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penicillin-streptomycin) was added to the treated cells. The plate was placed back into the incubator for 2 h. Then,
the stain was removed and cells were washed with 1× PBS (200 μL). The solubilizing solution (150 μL) was added to
each well and the absorbance at 540 nm was measured using a plate reader. Percent cytocompatibility was
calculated as (Absextract − Absnegative control)/ (Abspositive control − Absnegative control) × 100 for an average of 3 runs.
For the live/dead assay, cell extracts were removed and calcein AM (50 μL of 2 μM solution) with ethidium
homodimer-1 (2 μM) was placed onto each well and incubated for 30 min. Cells were imaged on a Leica DMI 4000B
microscope using blue and green light to create overlaid images that were analyzed using ImageJ. Three images were
taken in random locations of each well. Cell viability was calculated as the number of live cells divided by the total
number of cells in each image. Each tested extract was then averaged (n = 9) for cytocompatibility.

Hemolysis. Lyophilized peptide aliquots (3 mg) were dissolved in ice-cold Milli Q water (150 μL) to prepare a stock
of 15 mM L9. A solution containing 7.5 mM AgNO3 and 30 mM NaNO3 was prepared in the buffer (100 mM HEPES,
pH 8.0). The hydrogel sample (1 wt%) containing silver was prepared by mixing peptide stock solution (35 μL of 15
mM) and AgNO3 and NaNO3 (35 μL containing 7.5 mM Ag(I) and 30 mM NaNO3) in 1.5 mL tubes in duplicates. The
“460 μM Ag” sample was prepared by mixing water (35 μL) and AgNO3 (35 μL of 7.5 mM). These samples were
incubated at 37 °C overnight, and then, DMEM (500 μL) was added to each tube. The samples were further incubated
for 72 h at 37 °C and 150 rpm. After media was added, the “14 μM Ag” sample contained 14 μM and “460 μM Ag”
contained 460 μM silver nitrate, respectively. For hydrogel samples containing 1 wt% L9 and 1 equiv of Ag, we found
by ICP that 14 μM Ag is released into the solution. Blood from healthy sheep was obtained from Hemostat Labs. The
serum was removed from the blood by centrifugation at 1500 rpm for 5 min, and RBCs were washed three times
with sterile PBS. Following the last wash, the RBCs were resuspended in sterile PBS (100 μL in 10 mL of PBS--1% (v/v)
cell suspension). The RBC suspension (50 μL) was then mixed with 72 h extracts (150 μL) and incubated for 3 h at
37 °C and 150 rpm. Hemolytic activity was estimated using 0.2% Triton X-100 as a positive control and DMEM as a
negative control. After incubation for 3 h, the samples were centrifuged for 2 min at 4000 rpm. The absorbance of
the supernatant was recorded at 415 nm. Percent hemolysis was calculated as (ODsample −ODnegative control) /(ODpositive
control −ODnegative control)

x 100%.

136

3.6 References
1.
Shi, L.; Ding, P.; Wang, Y.; Zhang, Y.; Ossipov, D.; Hilborn, J., Self-Healing Polymeric Hydrogel Formed by
Metal-Ligand Coordination Assembly: Design, Fabrication, and Biomedical Applications. Macromol Rapid Commun
2019, 40 (7), e1800837.
2.
De Smet, K.; Contreras, R., Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol
Lett 2005, 27 (18), 1337-47.
3.
Khan, A.; Miller, W. R.; Arias, C. A., Mechanisms of antimicrobial resistance among hospital-associated
pathogens. Expert Review of Anti-Infective Therapy 2018, 16 (4), 269-287.
4.
Van Damme, P. A.; Hartman, E. H., Rapidly progressive soft tissue infections. Lancet Infect Dis 2006, 6 (2),
65; author reply 66-7.
5.
Marr, A. K.; Gooderham, W. J.; Hancock, R. E. W., Antibacterial peptides for therapeutic use: obstacles and
realistic outlook. Current Opinion in Pharmacology 2006, 6 (5), 468-472.
6.
Nizet, V., Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol
2006, 8 (1), 11-26.
7.
Zasloff, M., Antimicrobial peptides in health and disease. N Engl J Med 2002, 347 (15), 1199-200.
8.
Niyonsaba, F.; Ushio, H.; Nakano, N.; Ng, W.; Sayama, K.; Hashimoto, K.; Nagaoka, I.; Okumura, K.;
Ogawa, H., Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation
and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007, 127 (3), 594-604.
9.
Melino, S.; Gallo, M.; Trotta, E.; Mondello, F.; Paci, M.; Petruzzelli, R., Metal-binding and nuclease activity
of an antimicrobial peptide analogue of the salivary histatin 5. Biochemistry 2006, 45 (51), 15373-83.
10.
Hancock, R. E.; Lehrer, R., Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998, 16 (2), 828.
11.
Hancock, R. E.; Sahl, H.-G., Antimicrobial and host-defense peptides as new anti-infective therapeutic
strategies. Nature biotechnology 2006, 24 (12), 1551-1557.
12.
Bowdish, D. M.; Davidson, D. J.; Lau, Y. E.; Lee, K.; Scott, M. G.; Hancock, R. E., Impact of LL-37 on antiinfective immunity. J Leukoc Biol 2005, 77 (4), 451-9.
13.
Goldman, M. J.; Anderson, G. M.; Stolzenberg, E. D.; Kari, U. P.; Zasloff, M.; Wilson, J. M., Human βdefensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88 (4), 553-560.
14.
Ulijn, R. V.; Smith, A. M., Designing peptide based nanomaterials. Chem Soc Rev 2008, 37 (4), 664-75.
15.
Kumar, M.; Ing, N. L.; Narang, V.; Wijerathne, N. K.; Hochbaum, A. I.; Ulijn, R. V., Amino-acid-encoded
biocatalytic self-assembly enables the formation of transient conducting nanostructures. Nat Chem 2018, 10 (7),
696-703.
16.
Singh, N.; Kumar, M.; Miravet, J. F.; Ulijn, R. V.; Escuder, B., Peptide-Based Molecular Hydrogels as
Supramolecular Protein Mimics. Chemistry 2017, 23 (5), 981-993.
17.
Li, J.; Xing, R.; Bai, S.; Yan, X., Recent advances of self-assembling peptide-based hydrogels for biomedical
applications. Soft Matter 2019, 15 (8), 1704-1715.
18.
Palomo, J. M., Solid-phase peptide synthesis: an overview focused on the preparation of biologically
relevant peptides. Rsc Advances 2014, 4 (62), 32658-32672.
19.
Hosoyama, K.; Lazurko, C.; Munoz, M.; McTiernan, C. D.; Alarcon, E. I., Peptide-Based Functional
Biomaterials for Soft-Tissue Repair. Front Bioeng Biotechnol 2019, 7, 205.
20.
Draper, E. R.; Adams, D. J., Controlling the Assembly and Properties of Low-Molecular-Weight Hydrogelators.
Langmuir 2019, 35 (20), 6506-6521.
21.
Norton, L. W.; Tegnell, E.; Toporek, S. S.; Reichert, W. M., In vitro characterization of vascular endothelial
growth factor and dexamethasone releasing hydrogels for implantable probe coatings. Biomaterials 2005, 26 (16),
3285-97.
22.
Blatchley, M. R.; Gerecht, S., Acellular implantable and injectable hydrogels for vascular regeneration.
Biomed Mater 2015, 10 (3), 034001.
23.
Orbach, R.; Mironi-Harpaz, I.; Adler-Abramovich, L.; Mossou, E.; Mitchell, E. P.; Forsyth, V. T.; Gazit, E.;
Seliktar, D., The rheological and structural properties of Fmoc-peptide-based hydrogels: the effect of aromatic
molecular architecture on self-assembly and physical characteristics. Langmuir 2012, 28 (4), 2015-22.

137

24.
Orbach, R.; Adler-Abramovich, L.; Zigerson, S.; Mironi-Harpaz, I.; Seliktar, D.; Gazit, E., Self-assembled
Fmoc-peptides as a platform for the formation of nanostructures and hydrogels. Biomacromolecules 2009, 10 (9),
2646-51.
25.
Gazit, E., The “correctly folded” state of proteins: is it a metastable state? Angewandte Chemie International
Edition 2002, 41 (2), 257-259.
26.
Ozbas, B.; Rajagopal, K.; Schneider, J. P.; Pochan, D. J., Semiflexible chain networks formed via selfassembly of beta-hairpin molecules. Phys Rev Lett 2004, 93 (26 Pt 1), 268106.
27.
Mahler, A.; Reches, M.; Rechter, M.; Cohen, S.; Gazit, E., Rigid, self-assembled hydrogel composed of a
modified aromatic dipeptide. Advanced Materials 2006, 18 (11), 1365-1370.
28.
Smith, A. M.; Williams, R. J.; Tang, C.; Coppo, P.; Collins, R. F.; Turner, M. L.; Saiani, A.; Ulijn, R. V., Fmocdiphenylalanine self assembles to a hydrogel via a novel architecture based on π–π interlocked β-sheets. Advanced
materials 2008, 20 (1), 37-41.
29.
Thota, C. K.; Yadav, N.; Chauhan, V. S., "A novel highly stable and injectable hydrogel based on a
conformationally restricted ultrashort peptide". Sci Rep 2016, 6, 31167.
30.
Fichman, G.; Gazit, E., Self-assembly of short peptides to form hydrogels: Design of building blocks, physical
properties and technological applications. Acta biomaterialia 2014, 10 (4), 1671-1682.
31.
Gulrez, S. K.; Al-Assaf, S.; Phillips, G. O., Hydrogels: methods of preparation, characterisation and
applications. Progress in molecular and environmental bioengineering-from analysis and modeling to technology
applications 2011, 117-150.
32.
Yokoi, H.; Kinoshita, T.; Zhang, S., Dynamic reassembly of peptide RADA16 nanofiber scaffold. Proc Natl
Acad Sci U S A 2005, 102 (24), 8414-9.
33.
Ramachandran, S.; Tseng, Y.; Yu, Y. B., Repeated rapid shear-responsiveness of peptide hydrogels with
tunable shear modulus. Biomacromolecules 2005, 6 (3), 1316-21.
34.
Schneider, J. P.; Pochan, D. J.; Ozbas, B.; Rajagopal, K.; Pakstis, L.; Kretsinger, J., Responsive hydrogels
from the intramolecular folding and self-assembly of a designed peptide. J Am Chem Soc 2002, 124 (50), 15030-7.
35.
Micklitsch, C. M.; Knerr, P. J.; Branco, M. C.; Nagarkar, R.; Pochan, D. J.; Schneider, J. P., Zinc-triggered
hydrogelation of a self-assembling beta-hairpin peptide. Angew Chem Int Ed Engl 2011, 50 (7), 1577-9.
36.
Tenaud, I.; Leroy, S.; Chebassier, N.; Dreno, B., Zinc, copper and manganese enhanced keratinocyte
migration through a functional modulation of keratinocyte integrins. Exp Dermatol 2000, 9 (6), 407-16.
37.
Beyersmann, D.; Haase, H., Functions of zinc in signaling, proliferation and differentiation of mammalian
cells. Biometals 2001, 14 (3-4), 331-41.
38.
Hager, M. D.; Greil, P.; Leyens, C.; van der Zwaag, S.; Schubert, U. S., Self-healing materials. Adv Mater
2010, 22 (47), 5424-30.
39.
Yu, L.; Ding, J., Injectable hydrogels as unique biomedical materials. Chem Soc Rev 2008, 37 (8), 1473-81.
40.
Haines-Butterick, L.; Rajagopal, K.; Branco, M.; Salick, D.; Rughani, R.; Pilarz, M.; Lamm, M. S.; Pochan,
D. J.; Schneider, J. P., Controlling hydrogelation kinetics by peptide design for three-dimensional encapsulation and
injectable delivery of cells. Proc Natl Acad Sci U S A 2007, 104 (19), 7791-6.
41.
Guvendiren, M.; Lu, H. D.; Burdick, J. A., Shear-thinning hydrogels for biomedical applications. Soft matter
2012, 8 (2), 260-272.
42.
Peppas, N. A.; Huang, Y.; Torres-Lugo, M.; Ward, J. H.; Zhang, J., Physicochemical foundations and
structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng 2000, 2, 9-29.
43.
Taylor, D. L.; In Het Panhuis, M., Self-Healing Hydrogels. Adv Mater 2016, 28 (41), 9060-9093.
44.
Heller, M.; Schubert, U. S., Optically active supramolecular poly (l-lactide) s end-capped with terpyridine.
Macromolecular Rapid Communications 2001, 22 (16), 1358-1363.
45.
Constable, E., The coordination chemistry of 2, 2′: 6′, 2 ″-terpyridine and higher oligopyridines. Advances in
Inorganic Chemistry 1986, 30, 69-121.
46.
Shi, L.; Zhao, Y.; Xie, Q.; Fan, C.; Hilborn, J.; Dai, J.; Ossipov, D. A., Moldable Hyaluronan Hydrogel Enabled
by Dynamic Metal-Bisphosphonate Coordination Chemistry for Wound Healing. Adv Healthc Mater 2018, 7 (5).
47.
Mozhdehi, D.; Ayala, S.; Cromwell, O. R.; Guan, Z., Self-healing multiphase polymers via dynamic metalligand interactions. J Am Chem Soc 2014, 136 (46), 16128-31.
48.
Li, C. H.; Wang, C.; Keplinger, C.; Zuo, J. L.; Jin, L.; Sun, Y.; Zheng, P.; Cao, Y.; Lissel, F.; Linder, C.; You,
X. Z.; Bao, Z., A highly stretchable autonomous self-healing elastomer. Nat Chem 2016, 8 (6), 618-24.

138

49.
Appel, E. A.; del Barrio, J.; Loh, X. J.; Scherman, O. A., Supramolecular polymeric hydrogels. Chem Soc Rev
2012, 41 (18), 6195-214.
50.
Marambio-Jones, C.; Hoek, E. M. V., A review of the antibacterial effects of silver nanomaterials and
potential implications for human health and the environment. Journal of Nanoparticle Research 2010, 12 (5), 15311551.
51.
Eckhardt, S.; Brunetto, P. S.; Gagnon, J.; Priebe, M.; Giese, B.; Fromm, K. M., Nanobio silver: its interactions
with peptides and bacteria, and its uses in medicine. Chem Rev 2013, 113 (7), 4708-54.
52.
Monafo, W. W.; Freedman, B., Topical therapy for burns. Surg Clin North Am 1987, 67 (1), 133-45.
53.
Modak, S. M.; Fox, C. L., Jr., Sulfadiazine silver-resistant Pseudomonas in Burns. New topical agents. Arch
Surg 1981, 116 (7), 854-7.
54.
Miura, N.; Shinohara, Y., Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells.
Biochem Biophys Res Commun 2009, 390 (3), 733-7.
55.
Hidalgo, E.; Bartolomé, R.; Barroso, C.; Moreno, A.; Domínguez, C., Silver nitrate: antimicrobial activity
related to cytotoxicity in cultured human fibroblasts. Skin Pharmacol Appl Skin Physiol 1998, 11 (3), 140-51.
56.
DeGrado, W.; Lear, J., Induction of peptide conformation at apolar water interfaces. 1. A study with model
peptides of defined hydrophobic periodicity. Journal of the American Chemical Society 1985, 107 (25), 7684-7689.
57.
Geisler, I. M.; Schneider, J. P., Evolution-based design of an injectable hydrogel. Advanced Functional
Materials 2012, 22 (3), 529-537.
58.
Veiga, A. S.; Sinthuvanich, C.; Gaspar, D.; Franquelim, H. G.; Castanho, M. A.; Schneider, J. P., Argininerich self-assembling peptides as potent antibacterial gels. Biomaterials 2012, 33 (35), 8907-8916.
59.
de Leeuw, E.; Rajabi, M.; Zou, G.; Pazgier, M.; Lu, W., Selective arginines are important for the antibacterial
activity and host cell interaction of human alpha-defensin 5. FEBS Lett 2009, 583 (15), 2507-12.
60.
Sawada, T.; Matsumoto, A.; Fujita, M., Coordination-driven folding and assembly of a short peptide into a
protein-like two-nanometer-sized channel. Angewandte Chemie 2014, 126 (28), 7356-7360.
61.
Ozbas, B.; Kretsinger, J.; Rajagopal, K.; Schneider, J. P.; Pochan, D. J., Salt-triggered peptide folding and
consequent self-assembly into hydrogels with tunable modulus. Macromolecules 2004, 37 (19), 7331-7337.
62.
Misra, R.; Saseendran, A.; Dey, S.; Gopi, H. N., Metal-Helix Frameworks from Short Hybrid Peptide
Foldamers. Angewandte Chemie 2019, 131 (8), 2273-2277.
63.
Caplan, M. R.; Moore, P. N.; Zhang, S.; Kamm, R. D.; Lauffenburger, D. A., Self-assembly of a beta-sheet
protein governed by relief of electrostatic repulsion relative to van der Waals attraction. Biomacromolecules 2000,
1 (4), 627-31.
64.
Wang, C.; Stewart, R. J.; Kopecek, J., Hybrid hydrogels assembled from synthetic polymers and coiled-coil
protein domains. Nature 1999, 397 (6718), 417-20.
65.
Petka, W. A.; Harden, J. L.; McGrath, K. P.; Wirtz, D.; Tirrell, D. A., Reversible Hydrogels from SelfAssembling Artificial Proteins. Science 1998, 281 (5375), 389-392.
66.
McMillan, R. A.; Conticello, V. P., Synthesis and Characterization of Elastin-Mimetic Protein Gels Derived
from a Well-Defined Polypeptide Precursor. Macromolecules 2000, 33 (13), 4809-4821.
67.
Xu, C.; Cai, Y.; Ren, C.; Gao, J.; Hao, J., Zinc-triggered hydrogelation of self-assembled small molecules to
inhibit bacterial growth. Sci Rep 2015, 5, 7753.
68.
Hu, Y.; Xu, W.; Li, G.; Xu, L.; Song, A.; Hao, J., Self-Assembled Peptide Nanofibers Encapsulated with
Superfine Silver Nanoparticles via Ag⁺ Coordination. Langmuir 2015, 31 (31), 8599-605.
69.
Ohr, K.; Gilmartin, B. P.; Williams, M. E., Pyridine-substituted oligopeptides as scaffolds for the assembly of
multimetallic complexes: variation of chain length. Inorg Chem 2005, 44 (22), 7876-85.
70.
Schneider, L. A.; Korber, A.; Grabbe, S.; Dissemond, J., Influence of pH on wound-healing: a new perspective
for wound-therapy? Archives of dermatological research 2007, 298 (9), 413-420.
71.
Guo, Y.; Wang, S.; Du, H.; Chen, X.; Fei, H., Silver ion-histidine interplay switches peptide hydrogel from
antiparallel to parallel β-Assembly and enables controlled antibacterial activity. Biomacromolecules 2018, 20 (1),
558-565.
72.
McShan, D.; Ray, P. C.; Yu, H., Molecular toxicity mechanism of nanosilver. J Food Drug Anal 2014, 22 (1),
116-127.

139

73.
Burd, A.; Kwok, C. H.; Hung, S. C.; Chan, H. S.; Gu, H.; Lam, W. K.; Huang, L., A comparative study of the
cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen
2007, 15 (1), 94-104.
74.
Loza, K.; Sengstock, C.; Chernousova, S.; Köller, M.; Epple, M., The predominant species of ionic silver in
biological media is colloidally dispersed nanoparticulate silver chloride. RSC advances 2014, 4 (67), 35290-35297.
75.
Nešporová, K.; Pavlík, V.; Šafránková, B.; Vágnerová, H.; Odráška, P.; Žídek, O.; Císařová, N.; Skoroplyas,
S.; Kubala, L.; Velebný, V., Effects of wound dressings containing silver on skin and immune cells. Scientific reports
2020, 10 (1), 1-14.
76.
Poon, V. K.; Burd, A., In vitro cytotoxity of silver: implication for clinical wound care. Burns 2004, 30 (2), 140147.
77.
McCauley, R. L.; Linares, H. A.; Pelligrini, V.; Herndon, D. N.; Robson, M. C.; Heggers, J. P., In vitro toxicity
of topical antimicrobial agents to human fibroblasts. Journal of Surgical Research 1989, 46 (3), 267-274.
78.
McCauley, R. L.; Li, Y.-Y.; Poole, B.; Evans, M. J.; Robson, M. C.; Heggers, J. P.; Herndon, D. N., Differential
inhibition of human basal keratinocyte growth to silver sulfadiazine and mafenide acetate. Journal of Surgical
Research 1992, 52 (3), 276-285.
79.
Bainbridge, P., Wound healing and the role of fibroblasts. J Wound Care 2013, 22 (8), 407-8, 410-12.
80.
Repetto, G.; del Peso, A.; Zurita, J. L., Neutral red uptake assay for the estimation of cell viability/cytotoxicity.
Nat Protoc 2008, 3 (7), 1125-31.
81.
Gong, J. P.; Katsuyama, Y.; Kurokawa, T.; Osada, Y., Double-network hydrogels with extremely high
mechanical strength. Advanced materials 2003, 15 (14), 1155-1158.
82.
Wu, J.; Li, P.; Dong, C.; Jiang, H.; Bin, X.; Gao, X.; Qin, M.; Wang, W.; Bin, C.; Cao, Y., Rationally designed
synthetic protein hydrogels with predictable mechanical properties. Nat Commun 2018, 9 (1), 620.
83.
Sun, W.; Xue, B.; Fan, Q.; Tao, R.; Wang, C.; Wang, X.; Li, Y.; Qin, M.; Wang, W.; Chen, B.; Cao, Y.,
Molecular engineering of metal coordination interactions for strong, tough, and fast-recovery hydrogels. Sci Adv
2020, 6 (16), eaaz9531.
84.
Gethin, G., The significance of surface pH in chronic wounds. Wounds uk 2007, 3 (3), 52.
85.
Kuo, S. H.; Shen, C. J.; Shen, C. F.; Cheng, C. M., Role of pH Value in Clinically Relevant Diagnosis. Diagnostics
(Basel) 2020, 10 (2).
86.
Erdogan, H.; Babur, E.; Yilmaz, M.; Candas, E.; Gordesel, M.; Dede, Y.; Oren, E. E.; Demirel, G. B.; Ozturk,
M. K.; Yavuz, M. S.; Demirel, G., Morphological Versatility in the Self-Assembly of Val-Ala and Ala-Val Dipeptides.
Langmuir 2015, 31 (26), 7337-45.
87.
Frederix, P. W.; Scott, G. G.; Abul-Haija, Y. M.; Kalafatovic, D.; Pappas, C. G.; Javid, N.; Hunt, N. T.; Ulijn,
R. V.; Tuttle, T., Exploring the sequence space for (tri-)peptide self-assembly to design and discover new hydrogels.
Nat Chem 2015, 7 (1), 30-7.
88.
Marchesan, S.; Easton, C. D.; Kushkaki, F.; Waddington, L.; Hartley, P. G., Tripeptide self-assembled
hydrogels: unexpected twists of chirality. Chem Commun (Camb) 2012, 48 (16), 2195-7.
89.
Marchesan, S.; Waddington, L.; Easton, C. D.; Winkler, D. A.; Goodall, L.; Forsythe, J.; Hartley, P. G.,
Unzipping the role of chirality in nanoscale self-assembly of tripeptide hydrogels. Nanoscale 2012, 4 (21), 6752-60.
90.
Pal, S., Pyridine: A useful ligand in transition metal complexes. In Pyridine, BoD–Books on Demand: 2018; p
57.
91.
Chaboy, J.; Díaz-Moreno, S.; Díaz-Moreno, I.; Miguel, A.; Díaz-Quintana, A., How the local geometry of the
Cu-binding site determines the thermal stability of blue copper proteins. Chemistry & biology 2011, 18 (1), 25-31.
92.
Mena, S.; Mirats, A.; Caballero, A. B.; Guirado, G.; Barrios, L. A.; Teat, S. J.; Rodriguez-Santiago, L.;
Sodupe, M.; Gamez, P., Drastic Effect of the Peptide Sequence on the Copper-Binding Properties of Tripeptides and
the Electrochemical Behaviour of Their Copper (II) Complexes. Chemistry–A European Journal 2018, 24 (20), 51535162.
93.
Nagy-Smith, K.; Beltramo, P. J.; Moore, E.; Tycko, R.; Furst, E. M.; Schneider, J. P., Molecular, Local, and
Network-Level Basis for the Enhanced Stiffness of Hydrogel Networks Formed from Coassembled Racemic Peptides:
Predictions from Pauling and Corey. ACS Cent Sci 2017, 3 (6), 586-597.
94.
Basu, K.; Baral, A.; Basak, S.; Dehsorkhi, A.; Nanda, J.; Bhunia, D.; Ghosh, S.; Castelletto, V.; Hamley, I.
W.; Banerjee, A., Peptide based hydrogels for cancer drug release: modulation of stiffness, drug release and

140

proteolytic stability of hydrogels by incorporating d-amino acid residue(s). Chem Commun (Camb) 2016, 52 (28),
5045-8.
95.
Tomasson, D. A.; Ghosh, D.; Krzisnik, Z.; Fasolin, L. H.; Vicente, A. A.; Martin, A. D.; Thordarson, P.;
Damodaran, K. K., Enhanced Mechanical and Thermal Strength in Mixed-Enantiomers-Based Supramolecular Gel.
Langmuir 2018, 34 (43), 12957-12967.
96.
Zhou, M.; Ulijn, R. V.; Gough, J. E., Extracellular matrix formation in self-assembled minimalistic bioactive
hydrogels based on aromatic peptide amphiphiles. J Tissue Eng 2014, 5, 2041731414531593.
97.
Ruoslahti, E., RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12, 697-715.
98.
Hersel, U.; Dahmen, C.; Kessler, H., RGD modified polymers: biomaterials for stimulated cell adhesion and
beyond. Biomaterials 2003, 24 (24), 4385-415.
99.
Bellis, S. L., Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 2011,
32 (18), 4205-10.
100.
Sun, J.; Tan, H., Alginate-Based Biomaterials for Regenerative Medicine Applications. Materials (Basel) 2013,
6 (4), 1285-1309.
101.
Lengyel, Z.; Rufo, C. M.; Korendovych, I. V., Preparation and Screening of Catalytic Amyloid Assemblies.
Methods Mol Biol 2018, 1777, 261-270.
102.
Griffith, R. K.; Harwood, H. J., The Synthesis of Polymers and Copolymers of β-(3-Pyridyl)-DL-alanine1a, b.
The Journal of Organic Chemistry 1964, 29 (9), 2658-2662.

141

4

Kemp Eliminases of the AlleyCat Family promote leflunomide ring
opening by precise positioning of substrate to a catalytic base
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experiments on KE07 designs and tKSI D38N. Lengyel performed NMR pH titration on AlleyCat0. Volkov performed 3D NMR
experiments. Rempillo completed docking studies.

Abstract
A minimalist design approach to redesign natural proteins for conversion of benzisoxazoles to cyanophenoxides in a
mechanism referred to as Kemp elimination was established by Korendovych, DeGrado and coworkers. Korendovych
et al. demonstrated a Ca(II)-dependent protein Calmodulin could be remodeled by slight modifications to the
hydrophobic pocket to accept a small molecule. A computational repacking algorithm was implemented to identify a
single position for an active glutamate incorporation and to determine a low-energy side chain rotamer for ligand to
interact with a docked Kemp substrate. The resulting protein catalyst AlleyCat, a C-terminal portion of CaM acting as
an allosterically controlled eliminase, productively formed a Michaelis complex with Kemp. Subsequent evolution of
full-length versions of the scaffold improved their catalytic efficiency for Kemp elimination. We show Kemp Eliminases
of the AlleyCat family are useful models for generating catalysts of practically important chemical transformations. Cterminal domains of AlleyCat family were created and screened for activity in conversion of leflunomide, an
immunosuppressor prodrug, to its active form teriflunomide nearly four orders of magnitude in rate enhancement
with a catalytic proficiency seven orders of magnitude without any optimization of the binding cavity. Such notable
activity is attributed to a precisely positioned catalytic glutamate with a high pKa in close proximity to substrate.
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4.1

Kemp elimination and features of artificial catalysts for base-promoted
deprotonation of 5-nitrobenzisoxazole

4.1.1 Introduction
Kemp elimination is an extensively documented reaction (Figure 4.1) involving a one-step mechanism of
proton transfer coupled to a N-O bond cleavage used to benchmark reactivities of aprotic dipolar solvents, catalytic
antibodies, and computationally designed enzymes.2, 3 Typically, artificial enzymes promote proton abstraction with
modest turnover numbers with kcat of < 1 s-1.4 The KE59 series of enzymes cleave 5-nitrobenzisoxazoles with kcat of
9.5 s-1 and kcat/KM of 60,000 M-1s-1, orders of magnitude below the limit of diffusion of 3-glycerolphosphate synthases
forming TIM barrels, scaffolds representing KE59 active site structures.5 To meet the challenges in accurately
modeling active site interactions, a computational enzyme design approach was undertaken by sampling candidate
backbones and composing a transition state geometry optimal for protein-substrate complex interaction. Active site
side chains were then built and examined for different degrees of rotameric freedom over multiple iterations of
directed evolution to obtain the most ideal reaction motif. Despite the computed structure being in line with the
experimental one, the efficiency only led to three orders of magnitude improvement over the uncatalyzed reaction.6,
7

Baker and coworkers’ enormous collection of disjointed active sites leads us to conceive of a simpler design scheme

combining physico-chemical intuition and an appropriately selected starting scaffold. An appropriate scaffold would
serve as a platform for dissecting speed and selectivity of de novo enzymes for an intended chemical transformation.8

Kemp elimination
catalytic base
B

O2N

H
O

B
proton
abstraction

N

H
O2N

N
O

5-nitrobenzisoxazole

ring opening

O2N

C

N

OH

2-cyano-4-nitrophenol

Figure 4.1 Kemp Elimination. A catalytic base abstracts a proton from the heterocyclic ring of 5-nitrobenzisoxazole
leading to isoxazole ring cleavage and formation of an acidic 2-cyano-4-nitrophenol product.
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Blomberg et al. used an in silico design HG3 for optimization based on Nature’s evolutionary strategy
involving mutagenesis techniques error-prone PCR and DNA shuffling to cover an entire gene sequence and identify
‘hot spots’ from each round of selection for Kemp Elimination.4 A small focused library of constructs was built with
only a single mutation fixed in each round of evolution and, in turn, accumulating only beneficial mutations to
optimize the catalyst. Their model system resulted in an artificial enzyme HG3.17, evolved after seventeen rounds
of mutagenesis and screening, accelerating Kemp elimination 108-fold over the uncatalyzed reaction (kcat/kuncat). An
active site carboxylate side chain aspartate with a pKa of 6.0 was identified to promote such noteworthy efficiency.
Aspartate is 109 -fold more effective than a simple carboxylate base such as acetate in aqueous solution for proton
abstraction. Catalytic improvement is attributed to improvement in catalytic turnover and not substrate affinity,
and HG3.17 outperforms other Kemp Eliminases by nearly two orders of magnitude. Hilvert and coworkers do,
however, recognize HG3.17 catalytic efficiency is still orders of magnitude (three to four) below the diffusion limit
of 108-109 M-1s-1 of a small molecule to protein. Thus, creating highly preorganized active sites is challenging as the
protein scaffold is considerably dynamic and not a rigid body, deeming transition-state tuning as done by Baker and
coworkers limiting the search space for conformational states to a fixed backbone assumption. Hence, a search
space capturing precise positioning of a catalytic amino acid in a broad scope of backbone conformations would be
fruitful in selecting an initial scaffold for optimization. Shortcomings and successes in de novo enzyme design
undoubtably motivate and open opportunities to create catalyst designs from different perspectives.
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4.1.2 Allosterically controlled catalyst confers Kemp Elimination by a single amino acid
modification
Minimalist design promoted by Korendovych et al. is the simplest approach to introducing new reactivity in
a desired scaffold. The minimal requirement for observing activity is a hydrophobic cavity of a given scaffold with
appropriate positioning of a glutamate to increase side chain pKa. Calmodulin (CaM) was selected as a suitable
scaffold as the binding pocket is lined with apolar residues to form a hydrophobic site for accepting small molecules
(Figure 4.2). The apolar region does not intrinsically bind small molecules for any catalytic function, allowing one to
perform in-depth characterization of substrate binding and optimization for a particular chemical transformation.
Furthermore, CaM is allosterically regulated by calcium binding at a distinct site from the hydrophobic pocket.9 A
computational repacking algorithm was utilized to identify a single position appropriate for positioning a low-energy
Glu or Asp rotamer to interact with a docked Kemp substrate (Figure 4.3). A single active site side chain was
predicted to be sufficient for substrate interaction without altering other sidechains. The initial design AlleyCat,
abbreviated for Allosterically Controlled Catalyst, gave modest activity kcat/KM of 6 M-1s-1. Other scanned regions in
the pocket introducing either Glu or Asp as a catalytic base led to inactivity.10 AlleyCat was improved via directed
evolution reaching a turnover number of 3.2 s-1 and enzymatic efficiency of 1280 M-1s-1 in seven rounds.11 The
allosteric nature of AlleyCat provides ease of screening the protein’s calcium-modulated catalytic function to convert
a colorless substrate into a yellow-colored 2-cyano-phenol product.

Figure 4.2 Precise positioning of a single catalytic residue in a deep hydrophobic pocket of c-terminal Calmodulin protein
promotes Kemp binding and substrate turnover.1
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Step 1. Identify key residues

Step 2. Identify positions capable of
supporting an active base

Step 4. Accomodate
transition state

Step 3. Ensure productive
binding capacity in design model
for Michaelis complex formation

Figure 4.3 Scheme of minimalist design approach for designing an allosterically controlled catalyst AlleyCat for
Kemp Elimination.

As minimalist computational approaches generate proteins with inherently low specificity for the intended
substrate, they are predicted to be more promiscuous as compared to other mentioned computational designs.
Libraries of Kemp Eliminases are abundant and serve as model systems for protein design methodology for
mechanistic interpretation of ring opening in isoxazoles. We were curious to see if AlleyCat family of proteins could
serve as platforms for evolution of other acid-base chemical reactivities.
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4.2

Designed Kemp Eliminases catalyze ring opening of Leflunomide by
employing an acid-base mechanism

4.2.1 Kemp Eliminase design as a model system to characterize Leflunomide conversion
Leflunomide is an isoxazole-containing molecule used as an immunomodulatory prodrug to treat
rheumatoid arthritis. The prodrug is completely metabolized following oral administration to its pharmacologically
active metabolite teriflunomide.12 The mechanism of action of this molecule has not been fully determined with
probable mode of activity to inhibit autoimmune T cell proliferation and binding of teriflunomide to a hydrophobic
tunnel leading to active site of pyrimidine ribonucleotide uridine monophosphate to impart antiproliferative
action.13 We were interested in determining if the mechanism of ring opening of this prodrug could proceed via
proton abstraction mechanism through a base-catalyzed reaction due to structural similarity to Kemp (Figure 4.4).
Designed Kemp Eliminases have not been established to perform other reactions apart from ring opening of
benzisoxazole substrates. However, we saw potential of Kemp designs, with overall lower specificity for a selected
substrate, to bind Leflunomide due to minimal computational perturbation of the active site.
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Figure 4.4 Proposed acid-base mechanism in isoxazole ring opening of Leflunomide to Teriflunomide.

Compared to benzisoxazole ring of Kemp with a strong electron withdrawing substituent on the ring,
Leflunomide is a less activated molecule and proton abstraction by a base is more rigorous as the corresponding
kuncat extrapolated from HEPES-catalyzed reaction is an order of magnitude lower compared to that for nitrobenzisoxazoles (Figure S4.1, Appendix IV). We characterized designed Kemp Eliminases evolved for generic proton
abstraction for ring opening of Leflunomide for which no mechanistic description of a base-promoted reaction has
been elucidated. We selected two sets of Kemp Eliminases, AlleyCat and seven derivatives AlleyCat1 through
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AlleyCat7 obtained by directed evolution,11 and another set of KE07 series of thermostable imidazole-3glycerophosphate synthases designed by a theozyme approach: KE07 R7 1/3H and KE07 R7 10/11G.14, 15 A recently
described ketosteroid isomerase KSI D38N shown to display significant activity for Kemp Elimination was also
included for Leflunomide conversion assays.16

4.2.2 UV-Vis assay for Leflunomide ring opening by monitoring formation of teriflunomide
We established a UV-Vis assay for monitoring the production of teriflunomide at 300 nm. The conversion of
leflunomide proceeds without formation of any side products (Figure S4.2, Appendix IV). Leflunomide ring opening
promoted by all designs was spectroscopically assayed in 96-well plates. KE07 series, which has been shown to
promote diverse chemical reactivity from Kemp Elimination to ester hydrolysis and retroaldolase activity through
computational optimization,17, 18 did not show activity for Leflunomide ring opening. No clear trend in catalytic
efficiency for leflunomide ring opening was observed for AlleyCat proteins, as expected since they were not evolved
for reactions other than Kemp Elimination, but these did perform catalysis to some degree (Table 4.1; Figures S4.3S4.11, Appendix IV). AlleyCat2, comprising of a catalytic Glu92 base and two additional mutations H107I and M144R,
and AlleyCat4 (I85L, F92E, H107I, L112R, M144R) displayed the most prominent catalytic efficiencies among the
directed evolution rounds of proteins. The secondary structure of AlleyCat2 with the most significant kcat/KM showed
typical 𝛼-helicity for Calmodulin scaffold and mutations did not disrupt overall fold (Figure S4.12, Appendix IV).
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Leflunomide ring-opening by AlleyCat2 (sky blue, black) and AlleyCat2 E92Q (lavender).
conditions: 25 μM enzyme, 100
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Glu92 to a Gln(Q) residue. No activity was observed for E92Q mutant of AlleyCat2 establishing Glu92 as an integral
Caselle et al.

ligand for catalysis (Figure 4.5).
Table 1.
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Catalytic efficiency of various designed proteins in conversion of leflunomide to teriflunomide. Condi
(unless stated otherwise): 25 mM HEPES pH 7.4, 10 mM CaCl2, 100 mM NaCl.
kcat × 10−3 /min−1

Protein

[b]

KM /µM

kcat/KM /M−1 min−1

---

---

2.14 ± 0.12

AlleyCat1

5.45 ± 0.61

263.8 ± 55

20.64 ± 4.86

AlleyCat2

15.63 ± 0.62

236.8 ± 18

66.02 ± 5.73

46.46 ± 3.9

553.8 ± 65

83.89 ± 12.10

AlleyCat2 E92Q

---

---

No activity

AlleyCat3

12.22 ± 0.93

731.1 ± 74

16.71 ± 2.12

AlleyCat4

12.56 ± 0.45

308.3 ± 19

40.74 ± 2.89

AlleyCat5

6.88 ± 1.24

462.0 ± 125

14.88 ± 4.84

[b]

---

---

6.75 ± 0.31

[b]

---

---

7.35 ± 0.52

KE07

---

---

No activity

KE07 R7 1/3 H

---

---

No activity

---

---

0.32 ± 0.04

---

---

No activity

AlleyCat

[a]

AlleyCat2
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AlleyCat6
AlleyCat7

[b]

KE07 R7 10/11G
KSI D38N

[a]
in 25 mM TAPS pH 9.0, 10 mM CaCl2, 100 mM NaCl.
[b]

individual kcat and KM values could not be determined.
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Table 4.1 Catalytic efficiency of various designed proteins in conversion of leflunomide to teriflunomide. Conditions
(unless stated otherwise): 25 mM HEPES pH 7.4, 10 mM CaCl2, 100 mM NaCl.
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4.2.3 Implementing NMR spectroscopy to determine active site glutamate residue pKa
pKa of the active site glutamate in the AlleyCat family of proteins has been reported before to be effectively
elevated when side chain carboxylate is deeply buried in the CaM hydrophobic pocket.11 The apparent pKa of Glu92
catalytic base was determined to be 7.06 ± 0.02 from a pH activity profile of AlleyCat2 in leflunomide ring opening
(Figure 4.6). The pKa closely matches that of the construct for Kemp Elimination (6.73 ± 0.03).11 As the apparent pKa
is a product of multiple coupled equilibria of active base deprotonation and substrate deprotonation, providing little
understanding of pKa contributed by other carboxylates in the active site, we implemented protein NMR
spectroscopy as a tool to directly measure the pKa of active residue Glu92. Other than the direct pKa determination
reported by Hiebler et al. for a catalytic residue in a de novo designed esterase,19 no other cases implementing NMR
as a spectroscopic tool for pKa determination of de novo designed catalysts has been performed. 2D CBCG(CO)
spectrum for all positions of side chain CO resonances was collected at pH 7.0. Cα, Cβ and Cγ assignments for
residues were obtained, however, Cγ carbon of Glu92 did not appear in AlleyCat2 spectrum (Figure 4.7A). Therefore,
we used AlleyCat (pKa of 6.9 ± 0.1 from pH activity profile for Kemp Elimination) with a known NMR solution structure
and similar effective pKa as AlleyCat2 as our model system to correlate pH dependence on enzymatic rate and pKa of
active site base. Cγ carbon of Glu92 signal in 2D CBCG(CO) spectrum of AlleyCat was clearly resolved and allowed
for direct determination
of Glu92 pKa upon titrating AlleyCat with known amount of acid to alter pH of buffered
Figure S13. Chemical (guanidinium hydrochloride, GdnCl) denaturation profile of AlleyCat2.
Conditions: 4 mM HEPES pH 7.4; 30 mM NaCl, 2 mM CaCl2; 25 µM protein in presence of various

solution. We observed
for changes
in chemical
of Cδ
for all glutamates
aspartates (Figure 4.7B
concentrations
of guanidinium
chloride shifts
(0 – 6 M).
Theresonances
chemical denaturation
data were fitand
to equation
5.

Figure 4.6 pH activity profile of AlleyCat2. Conditions: Buffer (25 mM) containing 100 mM NaCl, 10 mM CaCl2
Figure S14. pH activity profile of AlleyCat2. Conditions: Buffer (25 mM) containing 100 mM NaCl, 10
using citrate
(pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and 8.5) and TAPS (pH 9.0).
mM CaCl2 using citrate (pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and
Protein8.5)
(25and
μM)
and (pH
substrate
(0.15 (25
mM).
of substrate
the data (0.15
to equation
provided
4.4 section
TAPS
9.0). Protein
µM)Fit
and
mM). Fit3of
the data in
to Experimental
equation 3 gives
gives pKa
0.02.
pKa =
= 7.06
7.06 ±± 0.02.
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and Figure S4.14, Appendix IV). pKa of 5.10 was observed for Glu92 (Figure 4.7C; filled black circle), not drastically
different from side chain carboxylates facing outside the hydrophobic pocket, indicating Glu92 may exist in two
different conformational states. One conformation of Glu92 facing the hydrophobic core and another orientation
of side chain accessible to bulk aqueous solution are feasible (Scheme 4.1). To substantiate this hypothesis, we
introduced a Kemp analogue 5-nitrobenzotriazole to best represent the transition state of substrate interaction with
active site ligand in AlleyCat. The titration curve (Figure 4.7C, open black circle) is consistent with a two-state model
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Figure 4.7 pKa of the catalytic
side chain measured by NMR. A) 2D CBCG(CO) spectrum of AlleyCat (pink) and AlleyCat2
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Scheme 2.

A two-state model describing deprotonation behaviour of catalytic Glu92 in AlleyCat.

Scheme 4.1 A two-state model describing deprotonation behavior of catalytic Glu92 in AlleyCat.
Author Manuscript

whereby two observed pKa values correspond to two conformations of Glu92 (5.14± 0.05 and 7.71 ± 0.04). 5.14±
0.05 is identical to pKa value observed in absence of substrate and 7.71 ± 0.04 is representative of a side chain Glu92
with a strong basicity once bound to substrate. Other glutamate and aspartate pKa values were not impacted by 5nitrobenzotriazole binding. In summary, we independently validated the pKa of the active site residue of AlleyCat
Author Manuscript

and established that the pH activity profile does not precisely represent the pKa of the active residue.

4.2.4 Computational docking of Leflunomide into NMR structure of AlleyCat
. Author manuscript;
available in owing
PMC 2020 March
To further understandChemCatChem
contributing
factors
to06.elevated activity of AlleyCat2 for Leflunomide

conversion compared to the evolved Kemp Eliminases, we performed computational docking of Leflunomide into
the NMR solution structure of AlleyCat. Our goal was to assess if reshaping of the substrate binding pocket over
multiple rounds of evolution could explain differences in reactivity. Side chain rotamer sampling using algorithms
from Rosetta docking tools were done, allowing backbone C𝛼 atoms to move up to 0.3 Å. 4000 docking poses were
generated and ranked according to overall Rosetta score and Rosetta score for the docking interface energy. The
twenty lowest scoring models were identified and the most probable representation of the active site ligand Glu92
in the substrate binding pocket was chosen based on a previously established approach by DeLuca et al.20, 21 Catalytic
base Glu92 in AlleyCat has an average distance of 8.3 Å from the acidic carbon on Leflunomide, too far for proton
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abstraction (Figure 4.8A). Such large distance is observed for KE07 wherein the substrate associates with protein,
but not in a productive conformation (Figure S4.17, Appendix IV).
Caselle et al.
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Docking
of leflunomide
and AlleyCat2.
(A) Ligand
docking into
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Figure 4.8 Docking of leflunomide
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The same docking procedure was performed on AlleyCat2, and unlike other models, O(Glu92)H(C5)(leflunomide) distance decreased to 2.5 Å and allows for favorable positioning of side chain carboxylate for
proton abstraction (Figure 4.8B). Binding of Leflunomide to AlleyCat2 is nearly 2.4 REU more favorable than that to
Author Manuscript

AlleyCat and the role of M144R mutation in AlleyCat4, the second most active for Leflunomide ring opening, was
observed by docking (Figure S4.18). M144R mutation leads to a ten-fold increase in kcat/KM on AlleyCat scaffold and
leads to large changes in chemical shift of AlleyCat2 backbone resonances in presence of Leflunomide (Figure S4.16,
Appendix IV). Docking of Leflunomide to AlleyCat4 shows close proximity of the catalytic Glu92 to H(C5)(leflunomide)
ChemCatChem. Author manuscript; available in PMC 2020 March 06.

similar to AlleyCat2 ligand and substrate orientation. In contrast, AlleyCat was essentially unaffected in presence of
Leflunomide (Figure S4.16, Appendix IV). The docking studies are consistent with an increase in activity of AlleyCat2
due to conformational selection of a beneficial substrate binding mode. Moreover, protein reshaping is an important
determinant in accommodating potential substrates not originally evolved for in Kemp eliminase designs.
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4.3

Conclusions
Computationally designed catalysts by minimalist approach offer binding modes for new chemical

reactivities leading to isolation of a catalyst from the AlleyCat family of Kemp Eliminases with a notable rate
enhancement kcat/kuncat of roughly 8000 and catalytic proficiency kcat/KM of 3 x 107 M-1. These rate parameters are
considerable as these catalysts were not evolved for Leflunomide conversion, and AlleyCat2 is the first catalyst of
Leflunomide ring opening proceeding through an acid-base mechanism. Hence, protein designs using minimalist
approach allows characterization and screening of relatively small libraries of de novo catalysts. We were able to
accurately determine pKa values of active site residues that simple fits to pH active rate profiles do not provide. Lastly,
straight forward computational docking assessment revealed AlleyCat2 activity stems from not only elevated pKa of
the catalytic base once bound to substrate, but also precise positioning of the active residue in the hydrophobic
pocket of the construct.

4.4

Experimental

Materials. Reagents and buffers were purchased from BioBasic, Inc. and Santa Cruz Biotechnology, Inc. DNA
oligonucleotides were purchased from Integrated DNA Technologies (IDT). Enzymes for cloning and E. coli BL21(DE3)
pLysS and NEB5α cells were purchased from Promega and New England Biolabs. TEV protease was expressed and
purified according to the literature procedure.22 SUMO protease was expressed and purified according to the
literature procedure.23 5-methyl-N-[4-(trifluoromethyl)phenyl-1,2-oxazole-4-carboxamide] (leflunomide) was
synthesized according to literature procedure.12 pMCSG49 and pEXP5-NT/TOPO expression vectors were obtained
from DNASU and Invitrogen, respectively. Champion pET SUMO (small ubiquitin like modifying protein) vector was
obtained from Invitrogen.

Cloning. C-terminal calmodulin variants with exception of AlleyCat2 E92Q variant were cloned into pMCSG49
expression vector using ligation independent cloning24 and into Champion pET SUMO vector. The vector pMCSG49
contains an N-terminal His6-tag and a Tobacco etch virus (TEV) protease recognition site (ENLYFQ/S). pET SUMO
contains an N-terminal His6-tag, followed by SUMO tag and a protease cleavage site which allows easy removal of
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His6-tagged SUMO. AlleyCat2 E92Q variant was cloned into pEXP5-NT/TOPO vector containing an N-terminal His6tag. Cloning procedures were completed using manufacturer’s protocols. Expressing AlleyCat as a fusion to SUMO
tag increases overall yield of the protein.25 In addition, SUMO protease has improved cleavage efficiency as
compared to TEV protease. Sequences of the AlleyCat proteins are reported in Table S4.2.

Protein Expression and Purification. The vectors containing the genes of interest were transformed into E. coli
BL21(DE3) pLysS cells and expressed using IPTG (isopropyl β-D-1-thiogalactopyranoside) induction in Luria-Bertani
(LB) medium. A fresh transformant was grown in 50 mL of LB medium supplemented with 100 μg/mL of ampicillin
and 37 μg/mL chloramphenicol overnight at 37°C. The next morning 20 mL of overnight culture was diluted to 1 L of
LB and incubated at 37°C with orbital shaking at 220 rpm until OD600 reached 0.6 – 0.7. Protein expression was then
induced by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and culture was further allowed to
grow at 18°C overnight. The cells were collected by centrifugation at 4,000 g and 4°C for 20 min. The cells were lysed
by sonication in buffer containing 25 mM TRIS (pH 8.0), 20 mM imidazole, 10 mM CaCl2, and 300 mM

NaCl on ice with 0.5 mM protease inhibitor (phenylmethylsulfonyl fluoride, PMSF). The crude lysates were then
centrifuged at 20,000 g and 4°C for 30 min to remove the cell debris, and the supernatant was applied onto a NiNTA column (Clontech). The protein sample was eluted with buffer containing 25 mM TRIS (pH 8.0), 250 mM
imidazole, 10 mM CaCl2, 300 mM NaCl. The protein was then buffer- exchanged into a buffer for tag cleavage (50
mM TRIS pH 8.0, 75 mM NaCl in case for TEV cleavage, and 50 mM TRIS pH 8.0, 150 mM NaCl for SUMO cleavage)
by applying the purified sample onto a Bio-Rad 10 DG desalting column. To cleave the tag using TEV protease, EDTA
(0.5 mM) and DTT (1 mM) were added to the protein followed by addition of the TEV protease as described in
published procedure.26 TEV protease was added to a final (OD280 protein)/(OD280 TEV potease) ratio of 10/1. The
solution was sterilized using a 0.22 μm syringe filter (BioExcell catalog # 41311122) and incubated overnight at 34°C.
After the digest, DTT and EDTA were removed with a desalting column and the obtained solution was loaded on a
Ni-NTA column. The pure digested protein was collected in the flow through fractions. To cleave the tag using SUMO
protease, EDTA (0.5 mM) and DTT (1 mM) were added to the protein followed by addition of SUMO protease to
(OD280 protein)/(OD280 SUMO potease) ratio of 100/1. The solution was sterilized using a 0.22 μm filter and incubated
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for 3 hours at 30°C. After the digest, DTT and EDTA were removed with a desalting column and the protein was
collected in the flow through after Ni-NTA column.

KE07 designed protein purification was performed according to reported procedure.14 In the case for tKSI D38N
mutant, published protocol27 was followed with an additional dialysis step to remove detergent. The protein was
dialyzed using a cassette of 10 MWCO (Slide-A-Lyzer® Dialysis kit from Thermo Scientific) in a buffer containing 40
mM potassium phosphate pH 7.5.

The purity (> 95%) of the final samples was checked using SDS-PAGE (Figure S4.15). Concentration of the proteins
was calculated using the following extinction coefficients (ExPASy): 2,980 M-1cm-1 (AlleyCat-AlleyCat7; AlleyCat2
E92Q), 18,450 M-1cm-1 (KE07 designs), and 4,470 M-1cm-1 (tKSI D38N).

Kinetic Assays. Kinetic measurements were done at 22°C on a BioTek Eon3 plate reader monitoring absorbance of
the product at 300 nm using 96-well plates (UV transparent, Corning #3635). The reported results were obtained by
averaging at least three independent measurements. For a typical Michaelis-Menten experiment each sample (200
μL) contained leflunomide (100 to 300 μM), acetonitrile (2.5%), and protein (25-50 μM). To initiate the reaction,
protein (150 μL) in buffer (25 mM HEPES pH 7.4, 10 mM CaCl2, 100 mM NaCl) was dispensed into wells and then
leflunomide (50 μL) in buffer with 10% acetonitrile was added. Kemp eliminase activity of KE07, KE07 R7 1/3H, and
KE07 10/11G was measured in 25 mM HEPES pH 7.25, 100 mM NaCl buffer as was previously reported for these
designs, and for tKSI D38N protein 40 mM potassium phosphate pH 7.5 was used.14, 16, 27

For determining the product extinction coefficient, teriflunomide powder purchased from Selleck Chemicals
(product number S4169) was used. Teriflunomide stocks in 25 mM buffers (citrate at pH 5.0/5.5; MES at pH 6.0/6.5;
HEPES at pH 7.0/7.5; TRIS at pH 8.0/8.5; and TAPS at pH 9.0/9.5) were prepared in presence of 10 mM CaCl2 and
100 mM NaCl. First, a stock of teriflunomide (90 mM) was prepared by dissolving teriflunomide powder (50 mg) in
acetonitrile (2 mL) and this stock was further diluted to 1.5 mM using acetonitrile. Next, buffer (195 μL) and
teriflunomide (5 μL of 1.5 mM stock) were combined to make a solution containing 37.5 μM teriflunomide and 2.5 %
acetonitrile. Absorbance of these solutions at 300 nm was used to calculate teriflunomide extinction coefficient at
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pH profile study was performed in the following buffers (25 mM) containing 10 mM CaCl2, and 100 mM NaCl: citrate
(pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and 8.5) and TAPS (pH 9.0). Protein (25 μM) and
substrate (0.15 mM) concentrations remained constant in all reactions. The pKa of the active residue was
determined by fitting the pH dependence data either to a single pKa model:
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100 mM NaCl: citrate (pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and 8.5)
and TAPS (pH 9.0). Protein (25 µM) and substrate (0.15 mM) concentrations remained constant in all
reactions. The pKa of the active residue was determined by fitting the pH dependence data either to a
single pKa model:
(,- )/012134256 $ (,-)65/012134256 ×8)(/9:/;4)

() =

8 $ 8)(/9:/;4 )

,

(3)
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pH profile study was performed in the following buffers (25 mM) containing 10 mM CaCl2, and

x, which corresponds to the mole fraction of the corresponding states.

100 mM NaCl: citrate (pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and 8.5)

where the parameters are described as specified above, with an addition of the population coefficient x, which
and TAPSCalcium
(pH 9.0). Protein
(25 µM) andstudies
substrate (0.15
concentrations
constant inEon3
all
dependence
weremM)
done
at 22°Cremained
on a BioTek

platereader monitoring

reactions. The pKa of the active residue was determined by fitting the pH dependence data either to a

corresponds
to the
molenm.
fraction
of the corresponding
states. protein (50 µM), leflunomide (0.3 mM) in buffer (25
absorbance
at 300
Samples
(200 µL) contained
single pKa model:

(/9:/;
4)
(, )
)65/012134256
$ (,-7.4,
mM
HEPES
pH
100 ×8)
mM
NaCl)
with calcium (10 mM CaCl2) or no calcium.
Samples without calcium
( = - /012134256
,
(3)

)

8 $ 8)(/9:/;4 )

Calcium
dependence
studies
were
done
at 22°C on adventitious
a BioTek Eon3 metal
platereader
monitoring absorbance at 300 nm.
also contained
EDTA
(50
µM)
to eliminate
binding.
where () is the observed initial rate at a particular pH value, the <=> is the apparent <=> value of the

Samples (200 μL) contained
protein( (50
μM), leflunomide (0.3 mM) in buffer (25 mM HEPES pH 7.4, 100 mM NaCl)
( )
)
active
residue, the () ?@ABAC>BDE
and spectra
() ED?@ABAC>BDE
are the initialon
rates
for the proteins
fully
CD spectroscopy.
The CD
was obtained
a Jasco
J-715with
CDthe
spectrometer
using

a step scan

protonated
and(10
fullymM
deprotonated
respectively.
with
calcium
CaCl ) orstates,
no calcium.
Samples

without
calcium
also
EDTA
(50 μM)
to eliminate
averaging mode over2three runs using a quartz
cuvette
with
a contained
1 mm path
length.
Samples
contained

where
the parameters
are
as mM
specified
above, with
addition
of theCaCl
population
coefficient
protein
(25
µM)
in described
buffer (4
HEPES
pHan7.4,
2 mM
30 mM NaCl) and the sample
2 and
adventitious
metal
binding.
x, which corresponds to the mole fraction of the corresponding states.

absorbance never exceeded 1.5 at all wavelengths in order to assure reliable MRE values. The
Calcium dependence studies were done at 22°C on a BioTek Eon3 platereader monitoring

chemical
denaturation
experiments
were
byspectrometer
monitoringusing
ellipticity
proteins
222 nm in
CD
spectroscopy.
CD spectra
on aconducted
Jasco
J-715
CD
a (25
step of
scan
averagingatmode
absorbance
at 300 The
nm. Samples
(200was
µL) obtained
contained protein
(50 µM),
leflunomide
(0.3 mM) in buffer
presence
of7.4,
various
ofmM
guanidinium
chloride
(0-6without
M). The
chemical
mM
HEPES pH
100 mM concentrations
NaCl) with calcium (10
CaCl2) or no calcium.
Samples
calcium

denaturation data

over three runs using a quartz cuvette with a 1 mm path length. Samples contained protein (25 μM) in buffer (4 mM
also
contained
EDTA
(50 µM) tobelow.
eliminate adventitious metal binding.
were
fit to the
equation

HEPES
pH 7.4, 2 mM
and 30
mM
NaCl) on
and
the sample
absorbance
never
1.5 at all wavelengths in
CD spectroscopy.
TheCaCl
CD 2spectra
was
obtained
a Jasco
J-715 CD
spectrometer
usingexceeded
a step scan
ΔGcuvette
−m [ D] with a 1 mm path length. Samples contained
averaging mode over three runs using a quartz

−
order to assure
reliable
MRE+ yvalues.
The
chemical
denaturation experiments were conducted by monitoring
RT
+ (MRE
protein (25MRE
µM) inf buffer
(4 mM
HEPES
pH 7.4, 2 mM CaCl2 and 30 mM NaCl) and the sample
u
u [D])e

MRE =

ΔG −m[ D]

absorbance
never exceeded
1.5
all wavelengths in order to assure reliable MRE values. The
−
ellipticity
of proteins
at 222 nm
inat
RTpresence of various concentrations of guanidinium chloride (0-6 M). The chemical

(4)

1+ e

chemical denaturation experiments were conducted by monitoring ellipticity of proteins at 222 nm in

where MRE
is were
observed
mean
residue
ellipticity;
MREu are
mean residue
ellipticity representing
f, chemical
denaturation
data
fit to the
equation
below.
presence
of various
concentrations
of
guanidinium
chloride
(0-6 MRE
M). The
denaturation
data
were
fit to the equation
below.
the folded
and unfolded

states of the protein, respectively; [D] is the concentration of denaturant; ΔG is

the free energy of unfolding
ΔG −mof
[ D] the protein, yu is a slope for the unfolded state.
−
MRE =

MRE f + (MREu + yu [D])e

RT

(4)

ΔG −m[ D]
−
RT

Expression and
labelled protein. The plasmid containing AlleyCat gene
1+ e purification of isotopically
(4)
where MRE is observed mean residue ellipticity; MREf, MREu are mean residue ellipticity representing

in pEXP5-NT/TOPO vector was transformed into E. coli BL21 (DE3) pLysS cells and grown overnight

where
MREand
is unfolded
observed
mean
residue
ellipticity;
MRE[D]
MRE
are mean residue
ellipticity
f, is
the folded
states
of the
protein,
respectively;
theuconcentration
of denaturant;
ΔG isrepresenting the folded
the free energy of unfolding of the protein, yu is a slope for the unfolded state.

and unfolded states of the protein, respectively; [D] is the concentration of denaturant; ΔG is the free energy of
Expression and purification of isotopically labelled protein. The plasmid containing AlleyCat gene

unfolding
of the protein,
slope for the
state.
u is atransformed
in pEXP5-NT/TOPO
vectorywas
into unfolded
E. coli BL21
(DE3) pLysS cells and grown overnight

158

Expression and purification of isotopically labelled protein. The plasmid containing AlleyCat gene in pEXP5NT/TOPO vector was transformed into E. coli BL21 (DE3) pLysS cells and grown overnight at 37oC on agar plate
containing ampicillin. The next day a single colony was inoculated into LB medium (50 mL) supplemented with
ampicillin (100 μg/mL) and chloramphenicol (34 μg/mL) and was grown overnight at 37oC. Overnight culture (20 mL)
was used to inoculate 1.5X LB (1 L) containing ampicillin and chloramphenicol and the culture was incubated at 37oC
until OD600 reached 0.8. The cells were harvested by centrifugation at 4,000 g for 20 min at room temperature and
washed with unlabelled M9 minimal medium (30 mL). The cell pellet was then resuspended in M9 minimal medium
(1 L) containing 15NH4Cl (1 g) as a nitrogen source and 13C-labeled glucose (2 g) as a carbon source. The culture was
incubated at 37oC for 3 hours to allow for recovery of growth. Protein expression was induced by addition of
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and the culture was further
incubated at 37oC for 2.5 hours. Cells were harvested by centrifugation (typical yield was 2 g of paste per liter of
culture), pellets were flash frozen in liquid nitrogen and kept at -80oC until needed.

The cells were resuspended in buffer containing 25 mM TRIS pH 8.0, 20 mM imidazole, 10 mM CaCl2 and 300 mM
NaCl with 0.5 mM PMSF added. The cells were lysed by sonication on ice (20 s pulse, 20 s rest) for 10 min. The lysate
was centrifuged at 20,000 g for 30 min at 4oC to remove cell debris and the supernatant was applied onto a Ni-NTA
column (2 mL). The column was washed with resuspension buffer (50 mL) and protein was eluted with buffer
containing 25 mM TRIS pH 8.0, 250 mM imidazole, 10 mM CaCl2 and 300 mM NaCl. To remove the polyhistidine tag,
the protein was subjected to TEV digestion. The protein buffer was changed to TEV digestion buffer (50 mM TRIS pH
8.0, 75 mM NaCl) using a BioRad 10 DG desalting column, and then DTT and EDTA were added to a final concentration
of 1 and 0.5 mM, respectively. TEV protease was added to the protein to (OD280 protein)/(OD280 TEV potease) ratio
of 10/1. The solution was mixed, sterilized using a 0.22 μm filter, and incubated overnight at 34°C. Then the protein
was buffer exchanged into NMR buffer (10 mM citrate, 10 mM MES, 10 mM HEPES, 10 mM Tricine, 10 mM CaCl2 and
50 mM NaCl, pH 7.3). TEV protease and undigested protein were removed by applying the solution onto a Ni-NTA
column. The flow through was collected, and fractions containing the protein were concentrated, flash frozen in
liquid nitrogen, and kept at -80oC until use for NMR experiments.
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3D NMR experiments. All NMR experiments were performed at 25°C on 800 MHz Bruker AVANCE III HD, with a
Triple Resonance Inverse (TCI) Detection CryoProbe. Spectra were processed using TopSpin (Bruker), NMRPipe28 and
analyzed using CCPN.29 Backbone resonance assignments were obtained from a series of 3D BEST HNCACB,
HN(CO)CACB, HNCA, HN(CO)CA, HNCO, and HN(CA)CO spectra, followed by assignment of the HA, HB and methyl
groups from 2D [1H,13C] HSQC, 3D HBHA(CO)NH, and 3D H(C)CH-TOCSY experiments. Side-chain NH2 resonances of
Asn and Gln residues and the NH indole group of Trp were assigned from a 15N-edited 3D NOESY-HSQC spectrum
(τmix = 120 ms). Partial assignments of the aromatic side-chains were obtained from 2D [1H,13C] CT- HSQC(aro), 2D
13
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and NH
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D2O (10 % final concentration), DSS (0.05 %) and NaN3 (0.01 %). Sample with the inhibitor also contained 5 equiv (2.5

NMR pH titration experiments. A protein sample (1.1 mL, 0.5 mM) in NMR titration buffer at pH 7.3
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to the following equation [12]:
Δobs(pH) =

F/012134256 $ F65/012134256 ∗ 8)(/9:/;4)
8$8)(/9:/;4)

(5)
(5)

where dprotonated and ddeprotonated are the chemical shifts for the protonated and deprotonated side chain
carboxylate carbons. Where a second titration event was observed, the data set was fit to two-site

where 𝛿 protonated and 𝛿 deprotonated are the chemical shifts for the protonated and deprotonated side chain

model with pKa1 and pKa2:

carboxylate carbons. Where a second titration event was observed, the data set was fit to two-site model with pKa1
F
and
a2:K /012134256
Δ pK=
AIJ

$ F65/012134256 ×8)(/9:/;4L)
8 $ 8)(/9:/;4L )

+ (1 − K)
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(6)

where the parameters are described as specified above, with an addition of the population coefficient
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x, which corresponds to the mole fraction of the corresponding states.

8$8)

4

where dprotonated and ddeprotonated are the chemical shifts for the protonated and deprotonated side chain
carboxylate carbons. Where a second titration event was observed, the data set was fit to two-site
model with pKa1 and pKa2:

ΔAIJ = K

F/012134256 $ F65/012134256 ×8)(/9:/;4L)
8 $ 8)(/9:/;4L )

+ (1 − K)

F/012134256 $ F65/012134256 ×8)(/9:/;4P)
8 $ 8)(/9:/;4P )

(6)
(6)

where the parameters are described as specified above, with an addition of the population coefficient

where the parameters are described as specified above, with an addition of the population coefficient x, which

x, which corresponds to the mole fraction of the corresponding states.

corresponds to the mole fraction of the corresponding states.

Docking studies. State 2 of the AlleyCat structure (PDB 2KZ2) was selected as the best model for
AlleyCat.
To obtain
AlleyCat2
structure,
andwas
M144R
mutations
AlleyCat
Docking
studies.
State 2 of
the AlleyCat
structure H107I
(PDB 2KZ2)
selected
as the bestwere
modelintroduced
for AlleyCat.on
To the
obtain
construct using fixbb application. Both protein models were “cleaned” and “repacked” to make them

AlleyCat2 structure, H107I and M144R mutations were introduced on the AlleyCat construct using fixbb application.

suitable for Rosetta ligand docking. Leflunomide conformers were created using Frog2 and processed

Both
models were “cleaned”
“repacked”
make
them suitable
for Rosetta
ligand docking.
withprotein
molfile_to_params
tool toand
generate
a to
file
readable
by Rosetta.
Coordinates
ofLeflunomide
the ligand were

altered before
concatenating
it with
protein
to molfile_to_params
prevent clashes between
atoms.
Ligand
docking
conformers
were created
using Frog2
and the
processed
with
tool to generate
a file
readable
by was
Rosetta. Coordinates of the ligand were altered before concatenating it with the protein to prevent clashes between
atoms. Ligand docking was performed using RosettaScripts and XML-like language script that specifies the
parameters. We manually selected a starting point located in the center of the presumed hydrophobic binding site.
From the starting xyz coordinates, the ligand is randomly sampled several times in centroid mode within a 13.0 Å
radius sphere, followed by pose refinement before calculating the score. The 20 poses were virtually evaluated based
on the lowest total_score (< -200.0 REU) and lowest interface_delta_X (< - 9.0 REU) from a sample of 4000 decoys.
The most probable model of the complex was selected by clustering similar ligand positions using Calibur21. Using
tools in the Rosetta software suite, we compared docked ligand predictions of the complexes to determine the
effects of the mutated residues on its activity. The catalytic Glu92 faces the hydrophobic core which alters the
residue’s pKa.11 State 2 of the NMR solution structure of AlleyCat (PDB code: 2KZ2) showed the lowest energy score
among other states after repacking and showed the side chain of Glu92 residing in the binding site. Our generated
AlleyCat2 model revealed that Arg144 is facing the hydrophobic pocket. We set the search space for ligand sampling
with a sphere of 13.0 Å radius from the starting point, which spans the entire binding pocket and residues that may
be interacting with the ligand based on calculated chemical shift perturbations.
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Kemp eliminase properties of Myoglobin and nature of Myoglobin peroxidase
activity in response to invasive microbial components
Jennifer H. Yoon and Dr. Olga V. Makhlynets

Sagar Bhattacharya performed SOE PCR for H64 mutagenesis of Myoglobin and Christos Costeas worked on H64V Mb cloning
into pET-28a(+)

Abstract
Reetz

and

coworkers

demonstrated

Cytochrome

P450

monooxygenase catalyzes conversion of Kemp substrate (5nitrobenzisoxazole) through a redox mechanism by coordination
of heme-Fe(II) and substrate N atom to cleave isoxazole-based
pharmaceuticals. Rationally chosen point mutations led to notable
increase in activity, and their investigations gave insight into the
role of human P450s in conversion of the immunomodulatory drug
leflunomide to its metabolically active form teriflunomide.
Introducing Kemp substrate into metalloenzymes of essential role
in metabolism of xenobiotics and their evolvability within a completely divergent active site reactivity raises the
potential of evolving proteins to accept molecules of non-natural origin. Existing tools to screen active designs are
increasingly exhausted with limited understanding of the intricate correlation between protein structure design and
function. We envisioned [13C,15N] -Heteronuclear Spin Quantum Correlation Nuclear Magnetic Resonance (HSQCNMR) could guide our understanding of the optimization process in Myoglobin (Mb), a heme-dependent protein to
incorporate Kemp eliminase function.

Thus, we propose an NMR-guided approach would demonstrate the

evolvability and reactive diversity of a molecular design by examining chemical shifts in the protein backbone once a
molecule binds productively to initiate catalysis. Identified amino acids from NMR analysis could be pursued for indepth screening for optimization using directed evolution methods. H64V Mb mutant protein was expressed, and
NMR analysis was conducted on this variant to gain spectroscopic insight on the substrate and protein binding
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interaction important for catalysis to proceed. An NMR-based evolution methodology thus would facilitate creation
of robust enzyme scaffolds using Kemp elimination as a convenient spectroscopic benchmark to advance the evolution
process by monitoring formation of a yellow 2-cyano-4-nitrophenol product.

In the second part of this chapter, peroxidase
properties of Myoglobin are dissected to
underscore a possible defense mechanism
Mb potentiates in response to proteases and
pathogen-associated

molecular

patterns,

specifically lipopolysaccharides (LPS), as an
antimicrobial strategy.
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Auto-oxidation of

myoglobin as observed for vertebrate respiratory proteins like hemoglobin could be harnessed to generate cytotoxic
radicals or toxins to facilitate microbicidal action. Fungal Proteinase K from Tritirachium album Limber, a serine
protease exhibiting broad cleavage specificity, Subtilisin A from Bacillus licheniformis, and Trypsin from porcine
pancreas were each incubated with native sperm whale myoglobin before addition of LPS. LPS is found naturally in
Gram-negative bacteria to trigger human innate immune response. Hence, LPS-promoted peroxidation of myoglobin
could reveal associated immunological triggers heme proteins encounter and how free radicals generated in the
catalytic cycle could facilitate bacterial clearance. Peroxidase activity was monitored for myoglobin treated with both
protease and LPS or individually in different sequential order to understand the contribution of bacterial components,
often involved in microbe virulence, in peroxidase activation. 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonate) (ABTS)
was used as the peroxidase substrate to react with H2O2 and ferrylmyoglobin to produce a radical cation. A bluegreen product ABTS•+ is quantifiable by measuring absorption of peroxidase mixture at 734 nm.
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5.1

Redox-mediated Kemp elimination

5.1.1 Introduction
Manfred Reetz and coworkers identified a catalyst for Kemp elimination (Figure 5.1A) that employs a
mechanism beyond a traditional acid-base mediated deprotonation of Kemp substrate.1

Cytochrome P450

monooxygenase from Bacillus megaterium (P450-BM3) was isolated and rationally designed mutants followed a
redox process (Figure 5.1B) in which Fe(II) is oxidized to Fe(III) by electron donation to 5-nitrobenzisoxazole (Kemp).
Kemp O-N bond is broken, followed by a proton transfer and formation of Kemp elimination product 2-cyano-4nitrophenol. Heme enzymes are important in metabolism of therapeutic drugs and in breakdown of isoxazole-based
pharmaceuticals. Leflunomide, an anti-inflammatory agent, was reported to undergo redox chemistry to form the
physiologically active metabolite teriflunomide (2-cyano-3-oxo-N-[(4-trifluormethyl)phenyl]butyramide). Kemp and
leflunomide bear similar isoxazole ring structures and either molecule could undergo acid-base chemistry, yet Reetz
and coworkers show Cytochrome P450 enzyme can accept substrates of non-natural origin of no known or undefined
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Figure 5.1 Kemp eliminase mechanisms: (A) Base-mediated E2 elimination (B) Redox-mediated process.
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chemical pathways. Therefore, biological systems can perform a diverse range of transformations not initially
intended for and reveal mechanistic insight into biocatalytic processes for Kemp elimination and in metabolism of
immunomodulatory therapeutic drug leflunomide and other potential pharmaceuticals of similar chemical
composition.
As Kemp elimination is shown to be a benchmark for redox-based chemistry, we looked into evolving
Myoglobin protein using combination of site-directed mutagenesis and NMR to incorporate Kemp eliminase
properties. We predicted site-selective alteration of ligands in vicinity of heme cofactor in Myoglobin could lead to
diversification of substrate binding cavity correlated to changes in chemical shifts from HSQC-NMR to guide the
evolution process. Given the abundant knowledge on heme dioxygen binding properties and capacity to permit
coordinating exogenous molecules, Myoglobin was chosen as a favorable scaffold for directed evolution application
and to dissect catalytic promiscuity. Moreover, the small size and availability of structure and purification methods
allow spectroscopic analysis of the protein to distinguish catalytic features. Preliminary work on Myoglobin
expression, purification, and characterization by UV-Vis spectrophotometry including assessing conditions for Kemp
eliminase assays are described.

5.1.2 Globins of hemochrome family
Hemoglobin and Myoglobin comprise Nature’s essential oxygen carriers in red blood cells and oxygen
storage compartments of muscle tissues, respectively. Hemoglobins assemble into a heterotetramer binding O2
cooperatively under saturating conditions in lungs.2 Oxyhemoglobin is transported through the bloodstream to
areas of low O2 content and is delivered to myoglobin. Myoglobin is a compact, globular protein and the first protein
structure determined to high resolution by X-ray crystallography,3 representing a model system to examine
structure-function correlation (Figure 5.2A). The amphipathic pocket of myoglobin stabilizes the iron protoporphyrin
ring as iron(II) heme or iron(III) hemin. Iron atom coordinates to histidine (His93) at a proximal site and to four
pyrrole nitrogens. In absence of a proximal ligand, the equilibrium constant for binding common ligands such as CO
to ferrous or Fe(II) deoxy state of myoglobin reduces several hundred-fold. Autooxidation also proceeds rapidly in
absence of a proximal base. Thus, the proximal histidine is important in influencing reactivity of heme iron and
modification of this ligand site allows the study of enzymatic activities of heme proteins. Importantly, heme proteins
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must be slow to autoxidize to the ferric state in order to release and bind oxygen at appropriate kinetic and
thermodynamic rates.4
Other ligands apart from the pentacoordinate geometry are the distal pocket amino acids including Phe,

Leu 29
His 64
Val 68

Phe 43

O2

iron
His 93

Figure 5.2 (A) Cartoon diagram of sperm whale Myoglobin with eight 𝛼-helices bound to heme (gray stick) with O2 (red sphere)
occupying distal face of protoporphyrin ring. (B) Proximal and distal pocket amino acids below or above plane of heme (in
blue ball and stick representation) constitute Myoglobin coordination geometry. [PDB code: 1mbn]

Val, Leu, and His above the plane of the macrocycle which are conserved across species (Figure 5.2B). His64 sterically
hinders binding of CO5 and causes iron and CO bonding configuration to deviate from linear and perpendicular
orientation to heme. Such distortion of the complex is due to possible steric interactions with His64.6 His64 can also
stabilize Fe-O-O complex through hydrogen bonding and O2 binding to heme and is enhanced in more polar
conditions. Therefore, the role of specific amino acids to impose steric hindrance, regulate polarity and form
hydrogen bonds in myoglobin are fundamental properties of myoglobin function.

5.1.3 Distal pocket polarity in heme and modifications for catalysis
Iron must be fully reduced to catalyze transformation of biomolecules. Replacement of distal histidine
with either Leu or Val results in an apolar heme pocket and loss of water molecules to Fe(III). Under complete
reducing conditions of deoxymyoglobin, Fe(III)-H2O bond is broken, yet water network is maintained to His in native
state.7 Gly, Ala, or Gln substituents at distal site result in small changes in Soret absorption spectrum and can
compensate for loss of His imidazole by creating a hydrogen bonding network to iron bound water in metmyoglobin.
Gly mutation moreover reduces oxygen affinity. Recombinant versions of Myoglobin with different ligand binding
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preferences by modification at the distal pocket by Fasan and coworkers led to engineering of Myoglobin toward
cyclopropanation of aryl-substituted olefins with ethyl diazoacetate.8, 9 Native sperm whale myoglobin mutated at
distal His64 to Gly, Ala, or Val and Val68 to Gly, Ala, or Phe exhibited significant differences in diastereo-and
enantioselectivity compared to wild-type protein.

H64V and V68A double mutant variant of myoglobin

synergistically improved performance of the biocatalyst with Ala68 mutation driving improvement in
stereoinduction and Val64 mutation improving activity. Another construct H64G and V68A double mutant afforded
a cyclopropanated product with high stereoselectivity. Thus, these constructs generated by site-directed
mutagenesis of distal amino acids served as promising biocatalysts for asymmetric cyclopropanation of
difluoromethylated alkenes.10

His64

Leu29
HN

N

Distal
Val68

O
O
Fe(II)

heme

N

Proximal

NH

His93

His to Gly
mutation

Figure 5.3 Surface representation of myoglobin showing hydrophobic cleft. Mutation on distal face (in cyan) such
as a glycine substitution at position His64 on myoglobin creates space to accommodate a desired organic substrate
(lime saturated spot is a proximal His often modified for tuning redox potential). [PDB: 1mbn]
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To determine the redox chemistry of myoglobin for Kemp eliminase activity, we sought mutations distal to
iron replacing His64 with either Gly or Val which would modify the substrate pocket size for effective Kemp binding
(Figure 5.3). UV-Visible optical absorbance spectrophotometry was implemented to collect spectra of ferrous- or
ferri-protoporphyrin forms of myoglobin and evaluate iron oxidation states upon modification of ligands axial to
heme.

5.2

Expression and kinetic characterization of Myoglobin for Kemp
elimination

5.2.1 Plasmid construction and UV-Vis optical absorbance spectra of Myoglobin
Myoglobin (Mb) wildtype (gene encoding for sperm whale myoglobin) in pET22b(+)11 vector from Novagen
was generously donated by Professor Rudi Fasan’s laboratory at the University of Rochester. The gene was cloned
into pEXP5-NT/TOPO with an N-terminal His6-tag, an expression vector previously used in our laboratory with
established expression and purification methods. The plasmid was introduced into E. coli BL21(DE3) cells, and
expression levels including purification methods were established. Myoglobin was purified through nickel-NTA resin
using an imidazole gradient. Imidazole concentrations as low as 100 mM eluted protein from affinity column (Figure
5.4A), and UV-Vis spectrum of Mb (>95% purity) showed a characteristic Soret band near 408 nm corresponding to
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Figure 5.4 (A) 15% SDS-PAGE of Myoglobin wild type protein eluate collection from a nickel-NTA chromatography
purification using an imidazole gradient. (1) Precision Plus Protein™ Unstained Protein Standard (2)-(7) 20, 50, 100, 150,
200, and 250 mM imidazole eluates. (B) Dithionite reduced O2(II)Mb and met(III)Mb without dithionite treatment
overlaid spectra. Three equivalents of dithionite fully reduce protein to heme (ferrous) Mb.

171

met(III)Mb or Fe3+ oxidation state (Figure 5.4B in red). As Mb is oxidized and must be reduced to Fe(II)-Mb for kinetic
evaluation, met(III)Mb was treated with sodium dithionite (a reducing agent) under anaerobic atmosphere using a
MBRAUN glove box workstation. The Soret band shifts to 418 nm with appearance of additional peaks in visible
region (near 543 nm and 581 nm) to form O2(II)Mb upon addition of three equivalents of sodium dithionite. Protocol
to reduce Mb by dithionite was therefore established and assessment on kinetics of redox-mediated Kemp
elimination by Myoglobin was performed.

5.2.2

Kemp eliminase activity of Myoglobin and structure evaluation by HSQC-NMR
Myoglobin (Mb) wildtype displayed catalytic activity for Kemp elimination with a kcat/KM of 22.8 M-1*s-1.

Figure 5.5A shows development of a yellow 2-cyano-4-nitrophenol product monitored at 380 nm. We established
Myoglobin catalyzes Kemp elimination with quantifiable enzymatic performance from a fit to kinetic rate plot (Figure
5.5B) providing a reference point for comparison with mutant versions of Mb. Hence, Myoglobin serves as a suitable
scaffold for potential optimization. Structural characterization of Mb was next evaluated on a Bruker 800 NMR for
HSQC analysis.

15

N-labeled Mb was expressed and was stable for characterization as shown by the recorded 1H,15N

HSQC spectra (Figure 5.6). To advance knowledge on Mb catalytic activity associated with pocket reshaping,
mutations were introduced at His64 (to Val or Gly) by site directed mutagenesis and splicing by overlap extension
(SOE) PCR in the heme coordination sphere. H64V was of primary interest as this mutation is positioned above the
oxygen coordination site and directly impacts coordination of an incoming molecule by dismantling O2 binding. Thus,
apolar side chain substitutions of distal amino acids could be beneficial in Kemp affinity by better packing and
positioning of Kemp substrate, but such notion remains to be explained by more extensive structural and
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spectroscopic characterization.

A

B

Figure 5.5 Kemp eliminase activity by Myoglobin visualized on a BioTek Eon3 plate reader at 22°C. (A) 120 μM to 720 μM
of Kemp substrate was used to monitor formation of a yellow 2-cyano-4-nitrophenol product at 380 nm (evolution of
product in colored bubbles, top plot). The colored product is observed in a 96-well plate once reaction is complete (bottom
image). (B) Linear fit to processed data correlating rate of activity to Kemp substrate concentration.

Figure 5.6 1H and 15N spectrum of 15N-labeled Myoglobin on a Bruker 800 NMR (SUNY-ESF facility). Promising spatial
separation of peaks is observed for in-depth characterization of amino acids influencing Mb substrate binding and
catalysis in Kemp elimination.
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5.2.3

Structure evaluation of H64V Myoglobin by HSQC-NMR
Once collecting NMR spectra of Mb wildtype, we looked into improving the quality of spectral data by

removing His6-tag on Mb; however, TEV (tobacco etch virus) digest did not cleave tag efficiently. We reasoned Mb
could be purified without a TEV protease site as twelve histidines exist intrinsically on the globular protein and could
in theory bind nickel resin on column (Figure 5.7). Thus for Mb mutants, histidine tag near a TEV protease site was
eliminated by cloning H64V Mb into a pET-28a(+) vector at restriction sites XhoI and NcoI. H64V Mb was purified
and the isotopically labeled version was isolated. HSQC spectra of H64V heme Mb, a His6-tag containing pEXP5NT/TOPO construct and H64V heme Mb in pET-28a(+) without His6-tag showed quality of spectra permits an
improved peak assignment capacity (Figure 5.8). Backbone chemical shifts of 15N-labeled H64V Mb protein was also
compared between reduced and oxidized forms (Figure 5.9). Fe(III)-aqua H64V Mb is paramagnetic and is poorly
resolved compared to ferrous H64V Myoglobin obtained by reducing protein with three equivalents of sodium
dithionite. Confirming ferrous H64V Mb is stable and backbone structure can be assessed by NMR, we incorporated
a Kemp analog 1,2,3-triazole nitro-benzisoxazole, referred to as inhibitor as the molecule does not break down and
closely models the transition state binding mode of ligand and protein, to observe for changes in spectra. Addition
of inhibitor to ferrous H64V Mb shifts some of the peaks to suggest interaction of protein and molecule (Figure 5.10).

180∘

Figure 5.7 Two views of Myoglobin rotated 180° to show twelve exposed histidine ligands existing on the loops
and edges of the helices. [PDB: 1mbn]
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Figure 5.8 HSQC-NMR spectra of H64V heme Mb purified with His6-tag (pink) and without His6-tag (green).

Figure 5.9 UV-Vis spectra collected prior to NMR analysis of H64V met(III)Mb (before reduction) and H64V O2(II)Mb (in
presence of three equivalents of dithionite). HSQC-NMR spectra is shown comparing backbone chemical shifts of 15Nlabeled iron-bound H64V Mb protein in reduced and oxidized forms (green and blue, respectively). Fe(III)-aqua H64V Mb
is paramagnetic and has a poorly resolved spectrum (blue).
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Kemp

Inhibitor

Figure 5.10 Addition of Kemp analog (inhibitor) to Fe(II)-H64V Mb (pink) shifts some of the peaks, indicating
substrate is interacting with backbone residues (in blue). 1,2,3-triazole nitro-benzisoxazole (inhibitor) molecule is
shown in stick colored by element (C in grey, O in red, and N in blue).

5.3

Conclusions
Sperm whale myoglobin was characterized for formation of a yellow 2-cyano-4-nitrophenol product

providing an initial rate for improvement in catalytic activity for directed evolution application. A variant His64Val
Mb cloned into a pET-28a(+) vector was isolated and a Mb protein expression protocol was established to prepare
[13C, 15N]-labeled Mb without the need for a TEV protease cleavage site on protein typically required for His6-tag
removal purification procedures. HSQC-NMR of H64V ferrous Mb furthermore indicates substrate interaction with
protein. The stability of construct allows robust analysis and characterization of this mutant including other axial
ligands to be determined for evolving Mb for Kemp elimination. Our future goal is to assign peaks we observe from
HSQC-NMR upon titrating Kemp analogue into protein solution. 2D- and 3D-NMR peak assignments of our protein
designs would enable identification of specific residues interacting with the bound substrate molecule. Equipped
with such knowledge, we can proceed with re-engineering the protein at those specific substrate interaction sites
to evolve myoglobin for Kemp eliminase activity.
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5.4

Reactive oxygen species (ROS) utilized by respiratory proteins as an
immunosurveillance tactic

5.4.1

ROS-mediated antimicrobial response as a host defense mechanism
Pathogenic microbes developed mechanisms to invade host systems and evade their immune defenses by

secreting virulence factors.12, 13 Conversely, the host immune system utilizes countermeasures to safeguard itself
from invasive microbes by releasing antimicrobial peptides or toxic reactive oxygen species (ROS).14,

15

ROS-

associated defense mechanism is the most potent defense response to pathogen-associated molecular patterns
(PAMPs) intrinsic to microbes. Furthermore, ROS production is controlled by presence of microbial virulence
markers during infection, thus understanding the role of ROS in mediating antibacterial action is important in
challenging microbial intruders from gaining entry and colonizing the host.

Ding and coworkers found

methemoglobin (metHb), auto-oxidized hemoglobin in ferric form, gains peroxidase activity for production of
superoxide ions (O2•-).16 Superoxide derivatives such as hydroxyl radicals potentiate microbicidal action against the
intruding microbe through localized surge of cytotoxic free radicals (quinone in invertebrates and superoxide in
vertebrates) into the bacterial vicinity. Microbial virulence factors primarily extracellular proteases were found to
trigger peroxidase activity of metHb further enhanced by presence of PAMPs. Therefore, the host utilizes a nonself-recognition antimicrobial strategy converting respiratory proteins into ROS producers when in direct contact
with microbial proteases to ultimately eliminate the foreign microbe.

metHb
Lyse

metHb
activated
intermediate

Peroxidase
activity
conformational
change

Proteases
PAMPs
metHb

metHb + PAMP

Peroxidase
activity

Figure 5.11 Synergistic activation of metHb by microbial proteases and PAMPs. Microbial proteases first lyse metHb by
proteolysis to a partially activated intermediate, then PAMPs bind the partially activated intermediate to produce a fully
active peroxidase. Conversely, PAMPs first interact with metHb to occupy Hb sites and induce a different conformational
state to form an inactive complex subsequently cleaved by microbial proteases to create a peroxidase with only marginal
activity.
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Figure 5.12 (A) Proposed mechanism for formation of compound I in peroxidases and oxidation of substrate by
compound I intermediate. (B) Scheme for reaction of ferric myoglobin with hydrogen peroxide.

Myoglobin is also reactive in presence of hydrogen peroxide (H2O2) to form ferryl species with reaction of
met(III)Mb with H2O2 generating an initially cationic ferryl Mb radical (compound I) [Figure 5.12A]. H2O2 is reduced
to water with formation of Mb•-(IV)=O, and protonation of this species generates a Mb(III) radical that oxidizes
exogenous substrates, and in turn met(III)Mb is regenerated.4 Subtilisin A and proteinase K were shown to increase
superoxide production in metHb and LPS further elevated O2•- in a dose-dependent trend. Moreover, Phosphatidyl
lipids POPC and POPE, common to both host and microbe, did not increase O2•- to affirm LPS is specific to metHb.
LPS causes a conformational change in hemoglobin as indicated on SDS-PAGE showing unique bands arising for
metHb incubated with Subtilisin A and LPS. Such conformational changes could possibly contribute to increase in
peroxidase activity. Furthermore, LPS action is most notable (producing tenfold more superoxide ions) when
subsequently added to hemoglobin pretreated with proteases. We were curious to see if myoglobin displays similar
antimicrobial properties as metHb and if peroxidase activity is influenced by LPS when incubated with proteases.
Another experiment to try was to digest Mb to render the protein in a specific conformation and then add LPS to
see if LPS occupies sites which could amplify rate of H2O2 consumption and oxidize substrate. The substrate we
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selected for characterizing Mb peroxidase properties was 2,2′-azino-bis(3-ethylbenzothiaziline-6-sulfonate (ABTS).
The product is spectrophotometrically measurable by a UV-Vis spectrophotometer at wavelength of 734 nm. To
also see if proteases (Subtilisin A from Gram-positive bacteria, proteinase K from fungal source, and porcine trypsin)
induce similar cleavage patterns in myoglobin as observed for human metHb incubated with proteases and LPS
(representative PAMP compound), a proteolytic profile of Mb was obtained by SDS-PAGE.

5.4.2

O2 consumption by Fe(II)Mb in presence and absence of LPS
Myoglobin in pET-22b(+) vector (from Novagen), a generous gift from the Fasan lab (University of

Rochester), was expressed and purified on a nickel-NTA affinity column by imidazole gradient elution. Mb was
reduced to heme Mb with three equivalents of dithionite forming Fe(II) protoporphyrin as identified on UV-Vis
spectrum in Figure 5.13. Peaks in visible range corresponding to Fe(II)Mb is expanded as an inset in the UV-Vis
spectrum. Once confirming protein is fully reduced, an oxygenated solution containing 10 µM of Fe(II)Mb in absence
or presence of LPS (one equivalent) was prepared in a sealed anaerobic cuvette. The purpose for preparing this
solution was to determine if LPS had any influence on rate of Mb autooxidation. Fe(II)Mb is stable within the time
frame of assessing Mb oxidation with small decay to Fe(III) species as peaks in visible region and Soret band did not
diminish (Figure 5.14A). In addition, LPS does not affect rate of oxidation for Mb and does not appear to interfere

75
50
37

25
20
15

10

Figure 5.13 Purification of Myoglobin (wildtype). Lanes: (1) Biorad Precision Plus unstained protein ladder (2) Mb lysate (3)
supernatant collected from nickel-NTA affinity column (4) 25 mM Tris pH 8.0 wash (5) 20 mM imidazole eluate (6) 50 mM
imidazole eluate (7) 100 mM imidazole eluate (8) 150 mM imidazole eluate (9) 200 mM imidazole eluate (10) 250 mM imidazole
eluate (11) Myoglobin protein in 20 mM HEPES pH 7.0 storage buffer.
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A

B

C

Figure 5.14 (A) UV-Vis spectra of Fe(II)Mb (10 µM) in oxygenated buffer 20 mM HEPES pH 7.0 collected at 0 min and after 30
min of incubation. (B) UV-Vis spectrum of 10 equivalents of LPS. (C) UV-Vis spectra of Fe(II)Mb (10 µM) with one equivalent of
LPS in oxygenated buffer 20 mM HEPES pH 7.0 collected at 0 min and after 40 min of incubation.

in spectral acquisition for autooxidation and peroxidase assays (barely any absorption either in 581 nm at which
Fe(II)Mb decay is monitored or at 734 nm for detection of ABTS•+ product using 10 eq of LPS in relation to 10 µM of
Mb) [Figure 5.14B]. A kinetic trace for autooxidation was collected for Fe(II)Mb treated with LPS and combined with
buffer bubbled with O2. LPS does not substantially impact Fe(II)Mb decay >50 min of incubation (Figure 5.15) and,
therefore, does not appear to be involved in transformation of Fe(II)Mb species to ferric and ferryl intermediates for
generating free radicals.
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Figure 5.15 Autooxidation of 10 µM Fe(II)Mb in oxygenated buffer 20 mM HEPES pH 7.0 in absence or presence of
one equivalent LPS. JY2178, JY2179

5.4.3

Oxidation of ABTS by Myoglobin and LPS
To determine if LPS influences the oxidation profile of ABTS conversion to a blue-green radical product

ABTS•+, a time course reaction was established containing 0.5 µM myoglobin (serving as catalyst for reducing H2O2),
1 mM H2O2 to oxidize Mb to ferric Mb, and 1 mM ABTS as the peroxidase substrate to monitor oxidation of ABTS
upon decomposition of H2O2. Catalysis of ABTS oxidation propagated by myoglobin was first assessed and bluegreen radical was observed at 734 nm on a UV-Vis spectrophotometer (Figure 5.16). Once conditions for monitoring
ABTS catalysis was established, 0.5 µM myoglobin mixed with 10 eq LPS was combined with 1 mM H2O2 and 1 mM
ABTS to monitor reaction progress. Similar to PAMP binding to metHb, LPS partially inactivates myoglobin for
peroxidase activity as noted by deviation in product formation at roughly 600 seconds. LPS content was increased
two-fold to see for any prominent difference in LPS-induced ABTS oxidation pattern. A similar pattern is observed
whereby myoglobin devoid of LPS or Mb in presence of LPS oxidizes ABTS at a comparable rate at early stage of H2O2
consumption before a deflection in Abs734.
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Figure 5.16 Oxidation of ABTS by H2O2 catalyzed by Myoglobin. Time course reaction mixture consisted of Myoglobin (0.5
µM), H2O2 (1 mM), ABTS (1mM) in 20 mM HEPES pH 7.0 buffer. Spectra were taken at 40 s interval for 1760 s. Product
formation of ABTS•+ was observed by an absorbance increase at 734 nm. JY2181
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Figure 5.17 (A) Oxidation of ABTS by H2O2 catalyzed by Myoglobin and LPS. Time course reaction mixture consisted of
Myoglobin (0.5 µM), H2O2 (1 mM), ABTS (1 mM) in 20 mM HEPES pH 7.0 buffer in absence or presence of 10 eq LPS.
Spectra were taken at 40 s interval for 1760 s. (B) Time course assay of ABTS oxidation using same conditions as (A) but

for LPS incorporated mixture, 20 eq LPS was added. Product formation of ABTS•+ was observed by an absorbance increase
at 734 nm. (C) Fe(II)Mb autooxidation plot. Myoglobin (10 µM) was mixed with either 5 eq or 20 eq of LPS. Plot shows
LPS does not affect rate of Mb oxidation. JY2183, JY2185
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5.4.4 Peroxidase profile of myoglobin incubated with proteases and LPS
ROS production by metHb is elevated in response to microbial proteases. Accordingly, host respiratory
proteins form a strong antimicrobial defense by directly exploiting the invading microbe’s virulence factors. To
determine if oxidative properties of Myoglobin are raised in response to proteolytic cleavage with any observable
patterns in function once LPS is incorporated, peroxidase activity of Myoglobin treated with Subtilisin A, Proteinase
K, or Trypsin was characterized. ABTS oxidation was used as a model reaction to No distinguishable cleavage
patterns were observed by SDS-PAGE for one-hour cleavage aliquots of myoglobin except for trypsin digests showing
intact protein with partial degradation (lanes 11 and 12 of Figure 5.18). Myoglobin treated with LPS or any of the
mentioned proteases individually shared a similar activity profile for oxidation of ABTS; whereas, proteolytically
digested myoglobin incubated with LPS showed no peroxidase activity. Furthermore, only marginal activity is
observed in a solution of digested myoglobin for which LPS was left out of the cleavage mixture and added soon
before collecting kinetic data (named as LPS additive mixture) in Figure 5.19.
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(8) Myoglobin (10 ug), 1 hr
(9) Myoglobin (10 ug), Subtilisin A (10 ug), 1 hr
(10) Myoglobin (10 ug), Proteinase K (10 ug), 1 hr
(11) Myoglobin (10 ug), Trypsin (10 ug), 1 hr
(12) Myoglobin (10 ug), Trypsin (10 ug), 1 hr
(13) Myoglobin (10 ug), Subtilisin A (10 ug), 1 hr
(14) Precision Plus Biorad Unstained ladder, 1 hr

Blank: 50 mM HEPES pH 7.5, 75 mM NaCl, 2.5 mM CaCl2
Figure 5.18 Proteolytic digestion of Myoglobin. 10 µL of digestion sample loaded into 15% Tris-glycine gel. Expected
molecular weights of Mb and proteases (1) Myoglobin: approximately 18 kDa; (2) Subtilisin: 27.6 kDa; (3) Proteinase K: 28.9
kDa; (4) Trypsin: 23.3 kDa.
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Figure 5.19 Oxidation of ABTS by Myoglobin (0.5 µM) treated (A) individually with 10 eq LPS, 10 µg Subtilisin A, 10 µg
Proteinase K, or 10 µg Trypsin. (B) 0.5 µM Mb digest mixture containing both LPS and 10 µg Subtilisin A for one set,
and another set containing same amount of Subtilisin A followed by addition of 10 eq LPS before start of kinetic run.
(C) same condition as B but using Proteinase K. (D) same condition as B but using Trypsin. All reaction mixtures
consisted of H2O2 (1 mM), ABTS (1 mM) in 20 mM HEPES pH 7.0 buffer. Spectra were taken at 40 s interval for 1760 s.
Product formation of ABTS•+ was observed by an absorbance increase at 734 nm.
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5.5

Conclusions
In conclusion, the influence of LPS on peroxidase activity of myoglobin was evaluated to see if Mb is

activated in response to compounds such as pathogen-associated molecular patterns (PAMPs) typically regarded to
be pseudoperoxidase triggers in humans. metHb was found to adopt antimicrobial properties by producing ROS in
response to direct contact with LPS or microbial proteases.16 Myoglobin being regarded as essential O2 storage
proteins and undergoing similar oxidative mechanisms as hemoglobin, we considered Mb may rapidly oxidize
peroxidase substrates. Mb was observed to be affected by LPS and showed reduced activity in kinetic progress plots.
Proteases, however, had no distinct influence on Mb catalytic properties and showed comparable rates of ABTS
oxidation. Addition of LPS in different sequential order furthermore did not follow metHb oxidative patterns
wherein LPS added to Mb digest solution only slightly increased rate of ABTS radical cation formation before activity
diminished. Thus, myoglobin is not considered to be the ideal peroxidase model in the present case as Mb slowly
reacts with H2O2 to afford ferryl Mb paired with a transient protein radical. Compound I (ferryl cation radical) may
alternatively decay rapidly and/or due to poor basicity of distal histidine H2O2 may not be effectively deprotonated
for efficient formation of compound I.

5.6

Experimental

Chemicals and Reagents. Reagents and buffers were purchased from BioBasic, Inc. and Santa Cruz Biotechnology,
Inc. DNA oligonucleotides were purchased from Integrated DNA Technologies (IDT). Enzymes for cloning and E. coli
BL21(DE3) pLysS and NEB5α cells were purchased from Promega and New England Biolabs. 5-nitrobenzisoxazole
was prepared according to the literature procedure.17 pET-28a(+) and pEXP5-NT/TOPO expression vectors were
obtained from DNASU and Invitrogen, respectively. Site-directed mutagenesis was performed using IDT primers and
Phusion DNA polymerase (Thermo) following the manufacturer’s standard protocol. Sodium dithionite was
purchased from Sigma-Aldrich Laborchemikalien. ABTS diammonium salt ultra-pure grade was purchased from
AMRESCO. Lyophilized lipopolysaccharide (E. coli O26:B6), Subtilisin A from Bacillus licheniformis, Proteinase K from
Tritirachium album, and Trypsin (porcine pancreas) were purchased from Sigma.
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Cloning and Mutagenesis. Myoglobin was cloned into pEXP5-NT/TOPO vector containing an N-terminal His6-tag. For
the design of Myoglobin mutant genes H64V and H64G variants, a two-step SOE (Splicing by Overlap Extension) PCR
protocol was implemented using GoTaq polymerase.18 In this protocol, the first PCR step generates two fragments
comprising the mutation at the desired position. Annealing temperature is chosen based on the melting
temperatures of the primers used. Generally, an annealing temperature at 60°C for 30 s is used for the first PCR.
Initial denaturation is used at 95°C for 2 mins. For each cycle (30X total), 30 s denaturation at the same temperature
is used following a Taq polymerase protocol. Extension is performed at 72°C for 45 s.

Once

the

mutant

fragments are designed, these act as templates for the second PCR, where the fragments are combined in one PCR
tube. Annealing is performed for 30 s via a 1°C incremental temperature change using a step-gradient from 58°C to
63°C. Conditions for annealing and extension remain the same as from the first PCR step. Purified PCR products are
directly used for cloning into pET-28a(+) vector following a standard protocol. The cloning mixture is transformed
into commercial NEB 5α (TOP10). Colony screening is done with at least ten colonies to find positive hits. Colony PCR
gives bands with two different sizes (roughly either 600 bp or 1000 bp). Since, the expected size of the mutant genes
is about 600 bp, all clones with 600 bp are identified and submitted for plasmid extraction using mini-prep kit. Sanger
sequencing (Genscript, Inc.) confirmed sequences of the mutated genes (Appendix V, Figure S5.1).
Protein Expression and Purification. Myoglobin wildtype in pET-22b vector (ampR) or in pEXP5-NT/TOPO (ampR),
and H64V Mb in pET-28a(+) (kanR) were transformed into E. coli BL21 (DE3) cells. For culture growth, 100 mg*L-1
ampicillin was supplemented into the media, or in the case for H64V Mb in pET-28a(+), 50 mg*L-1 kanamycin was
supplemented. A single transformant colony was inoculated into 20 mL 1X LB medium and grown overnight at 37°C,
200 rpm. The following day, the seed culture was diluted into 1 L of TB, terrific broth media (recipe from Cold Spring
Harbor protocols), and grown at 37°C, 200 rpm until OD600 = 0.6. Before induction, the culture was cooled down to
room temperature on ice and supplemented with δ-aminolevulinic acid (0.3 mM) as a heme precursor. The culture
was then induced using IPTG (0.25 mM). Upon induction, the culture was incubated at 25°C, 150 rpm for 16-18 h.
Cultures were harvested at 4000 rpm, 4°C, 20 min. Cell paste was stored at -80°C until further use for purification.
Typical yield of wet cell paste was 2 g per 1 L of culture. For every 1 g of cell paste obtained, 5 mL of buffer containing
25 mM Tris pH 8.0 with 0.5 mM phenylmethylsulfonyl fluoride (PMSF) was added for pellet resuspension. Cells were
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disrupted by sonication (20 s on, 20 s off for 10 min). Crude cell lysate was centrifuged at 20,000 g for 30 min and
the lysate was loaded onto Ni-NTA column (2 ml, Clontech) pre-equilibrated with resuspension buffer (25 mM Tris
pH 8.0). Resin was washed with 50 mL of buffer and protein was collected with 25 mM Tris pH 8.0 using a gradient
elution from 20 mM to 250 mM of imidazole. Fractions containing protein were combined and exchanged into a
desalting column (BioRad, Econo-Pac 10G) using 20 mM HEPES pH 7.0 (storage buffer). Myoglobin concentration
was determined using a reported extinction coefficient of 157 mM-1cm-1 at 410 nm.19
Kemp Assay. Kinetic measurements were done at 22°C on a BioTek Eon3 plate reader monitoring absorbance of the
product at 380 nm using 96-well plates (UV transparent, Corning #3635) in 200 μL reaction volumes at 22 °C. In a
typical experiment 150 μL of substrate (0.12 - 0.72 mM in 20 mM HEPES pH 7.0) was added to 50 μL of buffered (10
μM) protein solution. 5- nitrobenzisoxazole was used from a 0.1 M stock in acetonitrile (the acetonitrile percentage
was 2% in all reaction mixtures). The extinction coefficient of 15,800 M-1cm-1 was used to determine the product
concentration. kcat/KM values were obtained by fitting the linear portion of the Michaelis-Menten plot to
v0 = (kcat/KM)[E]0[S]0 equation.
Autooxidation of myoglobin. Reduced myoglobin (250 µL of 40 µM) was transferred into a sealed anaerobic quartz
cuvette. Before addition of 750 µL of oxygenated buffer, a diode array UV-Vis kinetic sweep was setup following
absorbance at 581 nm. Oxygenated buffer was prepared by bubbling O2 through a falcon tube containing 20 mM
HEPES pH 7.0 on ice. For Mb solution containing LPS, a 5 mg/mL stock of LPS (E.coli O26:B6) was prepared by

dissolving lyophilized powder in buffer and taking appropriate amount to reach proper equivalents of LPS in final
mixture.
Oxidation of 2,2 ′ -azino-bis(3-ethylbenzo-thiazoline-6-sulphonic acid) (ABTS). Spectroscopic change for one
electron oxidation of ABTS by Myoglobin in presence of H2O2 in 20 mM HEPES pH 7.0 was followed by UV-Vis
spectrophotometry on a BioTek Eon3 plate reader. The reaction mixture contained 1 mM ABTS, 1 mM H2O2, and 0.5
µM Mb. The rate of ABTS cation radical formation by myoglobin was monitored at 734 nm (ε734 = 1.5×104 M−1 cm−1).20
Proteolytic digestion of Myoglobin. Myoglobin and protease mixtures were prepared by combining 105 µL of 5.6
µM Myoglobin and 10 µL of a 1 mg/mL protease. The final digest mixture contained approximately 5 µM of protein
and was kept for incubation at 37°C for one hour. 20 µL of this digest mixture was used for ABTS oxidation assay in
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a 200 µL reaction volume in a 96-well plate. All reactions containing either Subtilisin A, Proteinase K, or Trypsin with
Mb were setup in triplicate.
Reduced myoglobin preparation and dithionite standardization21. Sodium dithionite was standardized using a
solution of potassium ferricyanide spectroscopically studied at an optical density of 420 nm (absorption coefficient
of 1,020 M-1cm-1) using a 1 cm pathlength sealed quartz cuvette on a diode array UV-Vis spectrophotometer. Detailed
media components and demonstration of obtaining dithionite equivalents required to fully reduce protein sample
are outlined in reference 17. Briefly, degassed pure protein was brought into glovebox (MBRAUN) and three
equivalents of standardized dithionite were introduced to protein sample. For standardizing dithionite, 20-30 mg of
solid dithionite was brought into glovebox. 1 mL of degassed milliQ water was added to dithionite. In parallel,
potassium ferricyanide solution was prepared in same way. Dithionite stock was diluted 10-fold in milliQ water.
Two solutions were prepared: (1) 990 µL milliQ water + 10 µL potassium ferricyanide (2) 980 µL milliQ water + 10 µL
potassium ferricyanide + 10 µL of 10-fold diluted dithionite stock. Absorbances of both solutions were measured at
420 nm and resulting values were used to calculate concentration of dithionite solution.
15

N isotope labeled Myoglobin protein for NMR analysis and NMR spectroscopy sample preparation. A plasmid

encoding a gene with the desired protein sequence was transformed into E. coli BL21(DE3) cells. The next day, fresh
transformant was grown in 50 mL Luria Bertani (LB) medium overnight at 37°C in the presence of 100 µg/mL
ampicillin or in the case for pET28-a(+) H64V Mb, 50 mg*L-1 kanamycin. The next morning 10 mL of the overnight
culture were diluted with 1 L of TB media containing antibiotic and incubated at 37°C until OD600 reached 0.8. The
cells were then gently pelleted by a 30 min centrifugation at 4,000 g, washed with 30 mL of unlabeled M9 minimal
medium, and pelleted again. The cell pellet was resuspended in 1 L of M9 minimal medium solution (prewarmed to
25°C) containing 15NH4Cl (1 g/L) as nitrogen source and D-glucose (6 g/L) as carbon source and antibiotic. The culture
was incubated at 37°C for 3 hours to allow for recovery of growth and clearance of unlabeled metabolites. Protein
expression was induced by addition of IPTG to a final concentration of 0.5 mM. After a 20-hour incubation at 25°C,
the cells were harvested by centrifugation (4,000 g for 30 min). The final NMR samples of 15N-labeled proteins were
prepared at concentrations 120 μM with and without inhibitor in storage buffer containing 10% D2O. All experiments
were conducted at 30°C on a Bruker 800 MHz spectrometer equipped with cryogenic probes.
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H2O2 disproportionation by a novel Mycobacterium tuberculosis catalase
Jennifer H. Yoon and Dr. Olga V. Makhlynets

Section 6.1.5 Chanh Do and Sagar Bhattacharya isolated catalase from inclusion bodies

Abstract
Catalases are important antioxidant metalloenzymes converting H2O2 to dioxygen and water and are split into two
families of catalases (1) those containing heme cofactors ubiquitous in aerobic organisms and (2) nonheme
dimanganese catalases found in a broad assortment of microorganisms in microaerophilic habitats.

Lactic acid

bacteria Lactobacillus plantarum and thermophiles Thermus thermophilis assemble into four-helix bundles with a
dinuclear manganese site cycling through reduced and oxidized forms during turnover. Dimanganase catalases are
generally considered rare and found exclusively among prokaryotic life. Discovery of a novel catalase Rv2633c from
Mycobacterium tuberculosis able to disproportionate toxic oxygen metabolites was reported by Victor Davidson and
coworkers. Rv2633c contains a diiron site and exhibits prominent catalase activity with kcat of 1475 s-1 consistent with
a potent enzyme against oxidative stress. Our proposal was to isolate Rv2633c and see if this metalloprotein could
bind manganese as an alternative defense mechanism as the metallocentre displays similar coordinating ligands found
in nonheme catalases. Identifying Rv2633c as both a diiron and dimanganese responsive catalase could expand the
spectrum of Mn-dependent enzymes involved in virulence for therapeutic inhibition.
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6.1

Catalases of diverse structures and properties

6.1.1 Introduction
H2O2 is featured in a multitude of oxidative processes continuously processed enzymatically through either
a catalytic or peroxidatic mechanism. Ancestral bacteria evolved heme and nonheme enzymes for catalytic
dismutation of H2O2 among which catalases became dominant detoxifying enzymes of these species.1 Catalases or
hydroperoxidases are ubiquitous in converting H2O2 to water and oxygen. The overall reaction is deceptively simple
but is compartmentalized into different stages based on type of catalase involved. More than 300 catalase
sequences are available and are divided among monofunctional heme-containing catalases, bifunctional catalaseperoxidases, and a smaller number of nonheme or manganese-containing catalases. Among these catalases, various
forms take shape in the catalytic pockets to influence their interaction with reactive oxygen species. Moreover, they
provide a variety of catalytic efficiencies despite their sharing similar sequences.2 Heme-containing catalases utilize
a common two-part mechanism for H2O2 degradation. In the first step, H2O2 oxidizes heme to an oxyferryl species
(one oxidation equivalent is removed from iron, and one electron from the porphyrin ring) to generate a porphyrin
cation radical known as compound I (Equation 6.1). A second H2O2 molecule reduces Compound I to regenerate the
resting state, H2O and O2 (Equation 6.2).

Catalase [porphyrin-Fe(III)] + H2O2 à Compound I [porphyrin•+-Fe(IV)=O] + H2O

(Equation 6.1)

Compound I [porphyrin•+-Fe(IV)=O] + H2O2 à Catalase [porphyrin-Fe(III)] + H2O + O2

(Equation 6.2)

The core of these heme catalases features an active site deeply buried in a beta-barrel structure accessible via two
to three channels.

Catalase-peroxidases adopt a different sequence and overall structure compared to

monofunctional catalases, but both contain heme which describes them sharing the first two stages of H2O2
decomposition followed by a peroxidatic step. Catalase-peroxidases thus utilize an organic electron donor for
reducing Compound I to the resting state involving two one-electron transfers (Equation 6.3). The predominant
form of the enzyme is a dimer of subunits of twenty 𝛼-helical units joined by a linker. The heme active site is more
deeply buried than peroxidases but is accessible through a funnel-shaped channel to approach heme laterally rather
than perpendicularly as observed for monofunctional catalases.
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Compound I [porphyrin•+-Fe(IV)=O] + 2AH2 à Catalase [porphyrin-Fe(III)] + 2AH• + H2O

(Equation 6.3)

Lastly, nonheme or manganese comprising catalases referred to as pseudocatalases (as they do not contain heme)
reveal a catalytic center of a dimanganese site within a four-helix bundle motif of an overall homohexameric
structure. The dimanganese center is composed of a matrix of glutamate and histidine residues directly coordinating
Mn atoms. A central channel leads to the active center which is reactive based on the oxidation state of the
dimanganese cluster equally stable in either the MnII-MnII or MnIII-MnIII states, resulting in a catalase as a mixture of
these two states. Therefore, a H2O2 molecule can act as either an oxidant or reductant depending on the resting
state of the dimanganese cluster encountered. The general reaction schemes are outlined in equations 6.4 and 6.5.

H2O2 + MnII-MnII + 2H+ à 2H2O + MnIII-MnIII

(Equation 6.4)

H2O2 + MnIII-MnIII à O2 + MnII-MnII + 2H+

(Equation 6.5)

The main differences in the reaction mechanism for dimanganese catalases are the absence of a reactive
intermediate to be reduced, and instead presence of an electron donation step to dimanganese cluster for
generating O2. In addition, 2H2O molecules are produced in one step unlike heme catalases wherein one H2O is
produced in separate reactions. Collectively, catalases provide intriguing mechanistic insights into catalysis with
unusually diverse modifications in structure and active site composition to react with reactive oxygen species.
One notable enzyme is KatG found in Mycobacterium tuberculosis (MtKatG) and is essential to this
organism as this is the only characterized catalase-active enzyme carrier by M. tuberculosis and activates a frontline antitubercular agent isoniazid. KatG shares no structural homology to monofunctional catalases and is
classified as a member of plant peroxidases, hence deeming KatG a heme-dependent bifunctional catalaseperoxidase. An increasing proportion of isoniazid-resistant M. tuberculosis strains arose to produce an altered KatG
inefficient in activating the drug, thereby rendering available antitubercular agents impotent.3 As KatG is the only
identified M. tuberculosis enzyme with appreciable catalase function, the search for catalases involved in regulating
H2O2 for therapeutic target would be valuable in directing M. tuberculosis pathogenesis. Victor Davidson and
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coworkers reported a gene Rv2633c in M. tuberculosis with significant sequence similarity to those of pathogenic
strains of mycobacteria, suggesting its relevance in mycobacteria virulence. Rv2633c was expressed and purified
in E. coli and found to contain two iron atoms. This protein exhibited catalase activity (kcat of 1475 s-1 and KM of 10
mM). consistent with a role in defense against oxidative stress generated during host immune responses to M.
tuberculosis macrophage infection. As catalases also comprise a comparatively small family of other nonheme
enzymes with manganese instead of iron occupying the active site,4 we proposed to investigate if Rv2633c could
bind Mn(II) and if resulting metalloprotein could function as a catalase. Cloning of Rv2633c into a pET-28a(+) vector
for expression and purification including catalase activity are described.

6.1.2 A novel gene in Mycobacterium tuberculosis
Rv2633c in Mycobacterium tuberculosis H37Rv (Mtb) is rapidly up-regulated during infection upon
phagocytosis of bacterium by macrophages.5, 6 Rv2633c protein is also found to be critical during in vivo infection
and can inactivate host-derived antimicrobial mechanisms by adapting to phagosomal acidification and reactive
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Figure 6.1 (A) Diiron binding site of Rv2633c with a HHE cation binding motif. (B) Active site of native Mn(III,III) Lactobacillus
plantarum manganese catalase. [PDB code: 1JKU]
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oxygen species.7 However, little is known about the protein’s physiological function despite its role in Mtb
pathogenicity. Therefore, elucidating their role in defense against oxidative stress would be important in creating
therapeutics targeting new Mtb enzymes directing inhibitory strategies against host antimicrobials.
Rv2633c sequence comprises an HHE cation-binding domain common in hemerythrin proteins.
Hemerythrins do not contain heme and instead uses a di-iron center to bind oxygen.8 HHE domains are found within
four 𝛼-helical bundles providing a pocket for O2 binding to a bridging di-iron site. The two irons are coordinated
through carboxylate side chains of Glu and Asp, and five His residues (Figure 6.1A). Ma et al. recombinantly
expressed Rv2633c protein and showed the protein to be exclusive to mycobacteria based on phylogenetic analysis
and performs as a catalase forming O2 once reacting with H2O2. Therefore, Rv2633c appears to potentially serve as
a protective role against oxidants, yet further in-depth structure analysis of this protein is needed to determine how
H2O2 instead of O2 binds (O2 is typically bound to other di-iron hemerythins). We considered the dimetal binding
sites of Rv2633c could bind manganese as the active coordination sites of dimanganese catalases bridge metals
through a similar carboxylate residue and are surrounded by a constellation of two histidines and mono- or bidentate
coordinated glutamate ligands (Figure 6.1B). Distinguishing a binuclear manganese complex in Rv2633c could thus
reveal a diversity of microbial life to accept metals other than iron for antioxidant defense.

6.1.3 Cloning, expression and purification of Mtb Catalase
Rv2633c gene (or catalase gene referred to hereafter) was ordered from BioBasic and cloned into a pET28a(+) expression vector containing an N-terminal 6xHis-tag. Primers were designed to incorporate NdeI and XhoI
restriction enzyme recognition sites. The gene (500 bp) digested at these two sites was amplified and size of product
was confirmed on agarose gel. pET-28a(+) vector was also digested with same enzymes and resulting vector product
near 5 kb was identified (Figure 6.2A). Rv2633c gene and pET-28a(+) ligation product was transformed into E. coli
commercial NEB5𝛼 cells. Colonies from transformant were isolated and used to prepare a GoTaq green master mix
containing T7 primer and a primer annealing to reverse end of Rv2633c gene. PCR products were run on an agarose
gel and two bright bands (Figure 6.2B) corresponding to expected product size near 600 bp were miniprepped for
DNA sequencing. Sequencing confirmed Rv2633c incorporation into pET-28a(+) [Reference: JY10731_CAT(4)].
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Figure 6.2 (A) Rv2633c gene amplified using forward and reverse primers with NdeI and XhoI sites, respectively.
Product band is about 500 bp (left gel). O’RangeRuler 200 bp DNA ladder was loaded as a reference marker. Gel on
right showing a single bright band is of digested vector (near 5 kb) with NdeI and XhoI. New England BioLabs Mass
DNA Ladder is shown alongside sample. (B) Colony screen of ligation mixture transformed into E. coli commercial
NEB5α cells. Bright bands near 600 bp were chosen for miniprep and sequenced to confirm identity of DNA product.
JY1067, JY1068

Catalase gene encodes Rv2633c of 186 amino acids with a molecular weight of 21003.80 Da and an extinction
coefficient of 12950 M-1cm-1. Catalase plasmid was used for Rv2633c protein expression in Luria Broth media
supplemented with FeSO4*7H2O to determine reproducibility of catalase activity reported by Davidson and
coworkers. Catalase protein was purified on a Ni-NTA HiTrap column using an AKTA FPLC system with 50 mM TrisHCl pH 7.5 (0 to 500 mM imidazole gradient). Aliquots from collected fractions were loaded into a 15% acrylamide
gel and sample corresponding to a molecular size of 20 kD was saved for further purification through a Q sepharose
column using a salt gradient (Figure 6.3). A UV-Vis absorbance spectrum of purified protein is shown in Figure 6.4A,
and this sample was used for enzymatic assays to observe for catalase activity of Rv2633c.
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Figure 6.3 (A) 15% SDS-PAGE gel of Rv2633c eluates from Ni-NTA HiTrap column on an AKTA purification
system. Rv2633c near 20 kD size (last lane) was isolated for further purification. (B) Rv2633c after buffer
exchange and applied through a Q-Sepharose column into 50 mM KH2PO4 pH 7.5 for gradient elution
from 0 to 500 mM NaCl. JY1083, JY1105, JY1111

6.1.4 Catalase assay to determine enzymatic property of Rv2633c
Catalase activity of Rv2633c was determined by observing for any formation of O2 bubbles upon addition
of H2O2 to protein solution. H2O2 consumption was monitored by a continuous assay directly measuring amount of
H2O2 at absorbance of 240 nm over a 300 s time course (Figure 6.4B). To closely match conditions for catalase assay
reported by Davidson et al., low concentration of catalase was used (0.58 µM final concentration) to monitor
enzymatic decomposition of H2O2. In published literature, 1 nM was used to avoid any interference of bubbles during
the spectrophotometric catalase assay. Concentration of H2O2 was kept below 30 mM as any amount higher gave

Figure 6.4 (A) UV-Vis absorbance spectrum of Rv2633c. (B) H2O2 decomposition of Rv2633c catalase protein reconstituted
with 10 eq of iron and incubated for 20 min before mixing 10 µL of this reconstitution mixture with 20 µL of 1 M H2O2
(final concentration 20 mM), and 970 µL of 50 mM KH2PO4 pH 7.5 buffer. Reaction was monitored by observing for
decrease in absorbance at 240 nm which corresponds to concentration of H2O2.
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an absorbance that exceeds 1.3. Rv2633c was first reconstituted in iron by incubating 200 µL of 58 µM protein with
10 eq of diammonium iron(II) sulfate (10 µL of 12 mM stock). The mixture was incubated for 20 min and the reaction
mixture was made in a quartz cuvette by addition of 970 µL of 50 mM KH2PO4 pH 7.5 buffer, 20 µL of 1 M H2O2 (20
mM final concentration), and 10 µL iron(II)-catalase mixture. The cuvette containing all components was parafilmed
and inverted couple times to fully mix solution and inserted into a diode array UV-Vis compartment to monitor
reaction. A decline in absorbance at 240 nm should be observed over time which corresponds to decomposition of
H2O2 or decrease in H2O2 concentration. In our experiment, we did not observe a significant rate enhancement and
catalytic efficiency did not match kcat/KM value reported for Rv2633c (orders of magnitude lower for any suitable
comparison).

6.1.5 Isolating Rv2633c from inclusion bodies and determining metal content by ICP-OES
In optimization conditions to improve purity and isolation of Catalase protein, Rv2633c was found to be
expressed in inclusion bodies. To isolate protein from inclusion bodies, bacteria expressing the protein were
suspended in 25 mM Tris pH 8, 6 M Guanidinium Hydrochloride (GuHCl) kept on ice with protease inhibitor
(phenylmethylsulfonylfluoride of 0.5 mM final concentration). Bacteria was lysed and crude cell lysate was applied
onto a Ni-NTA column pre-equilibrated with 25 mM Tris pH 8 buffer, followed by several column volume washes
with same buffer. The refolding process of protein consisted of washing the column with decreasing concentration
of GuHCl (6M to 0M) in buffer. Rv2633c was then collected by gradient elution with 50 to 250 mM imidazole. Pure
protein was exchanged into 25 mM HEPES pH 7.5 storage buffer using a desalting column. The final purity of catalase
protein was determined by a 10% SDS-PAGE gel (Figure 6.5).
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Figure 6.5 SDS-PAGE gel (10%) of Rv2633c catalase. (1) Precision Plus Unstained protein ladder, (2) before
IPTG induction, (3) after IPTG induction, (4) lysate (soluble fraction), (5) inclusion bodies, (6) pellet after
GuHCl treatment and (7) pure protein.

Once apo protein was isolated from inclusion bodies, Rv2633c was incubated with either ammonium iron sulfate
(2.5 eq) or manganese chloride (10 eq) for three hours at 4°C. The metal-incubated protein solutions were applied
individually into a desalting column and protein eluate was collected in 25 mM HEPES pH 7.5 buffer to remove
unbound metal. The Fe(II)- and Mn(II) loaded protein samples were each diluted to 3 mL in 1% HNO3 (final
concentration of 20 µM) for ICP-OES analysis. Standards containing 0-0.2 ppm of Fe, Mn and Zn were used to identify
concentation of of any of these metals in protein analyte. ICP-OES analysis showed 40 µM of iron in Fe(II)-catalase
solution with less than 1% of Mn and 2.5% of Zn of total protein. Mn(II)-catalase solution contained 0.87 µM Fe,
0.23 µM Mn, and 1.71 µM Zn. These results show catalase binds iron in a 1:2 ratio (iron therefore fills the dimetal
site); whereas, Mn(II) is not observed to bind Rv2633c (about 1% Mn in total protein solution). ICP-OES in summary
reveals Rv2633c is a poor Mn(II) binder and that the protein prefers Fe(II). The protein with confirmed amount of
iron content was subjected to catalase assay, yet no activity was observed (no H2O2 decomposition).

6.2

Conclusions
Rv2633c reported to be an extremely efficient catalase in decomposition of H2O2 only showed small if any

catalase activity in our hands. We further investigated the metal preference of the protein using ICP-OES with iron
being the preferred metal and no interaction with manganese. ICP-OES result for Rv2633c iron content matches
that of Davidson and coworkers findings for an approximately 2:1 metal to protein binding ratio. They also analyzed
their native purified protein (not reconstituted with metal) for Cu, Mn, Ni, and Zn which showed no significant
amounts of other metals. Further analysis on the physical properties of Rv2633c would need to be performed by
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size exclusion chromatography to see if protein exists as a homodimer. Their predicted molecular mass from
Rv2633c sequence with a hexahistidine tag is 19,064 Da and migrates on SDS-PAGE as a single band. Analytical
size-exclusion chromatography shows protein to migrate at an apparent mass approximately double the expected
mass underscoring important structural components influencing reactivity. Furthermore, iron affinity for our
construct could reveal how tightly metal is bound to the dimetal site. ITC could be implemented to determine the
metal affinity and see if there is metal association pattern that could explain for differences in enzymatic properties
observed for this catalase.

6.3

Experimental

Expression and purification of Rv2633c. Rv2633c gene was ordered from BioBasic and was cloned into a pET-28a(+)
kanR vector containing an N-terminal hexa-histidine tag. Primers were designed with recognition sites for (1) NdeI
and (2) XhoI bolded in black: Forward primer (1) TTATCATATGGTGAACGCGTATGATGTGCTGAAACGCCATCATAC and
Reverse primer (2) TTATCTCGAGCTAAATCGCTTTCAGCAGATCCGCTTTGCC for restriction enzyme digest. An insert
with NdeI and XhoI recognition sites was PCR amplified using Phusion polymerase. Both insert and vector were
then treated with restriction enzymes and the digested DNA fragments were purified using QIAquick PCR
purification kit. The ligation product of vector and insert was transformed into commercial NEB5𝛼 cells and this
transformant was plated on agar supplemented with 50 µg/mL kanamycin. A colony screen of plaques from the
transformant mixture was done using GoTaq Green master mix to identify colonies containing Rv2633c to PCR
amplify the gene using T7 and reverse primer used for the initial PCR to isolate gene. Products on agarose gel
showing an expected DNA insert size of 600 bp were selected for miniprep and sequencing. Rv2633c in pET-28a(+)
[JY10731 catalase #4 (60 ng/µL)] was transformed into BL21(DE3) competent cells for protein expression in E.coli.
A starter culture for growth of catalase in a 250 mL baffled glass flask was prepared and a single colony was
inoculated into 100 mL 1X Luria Broth (LB) supplemented with 50 µg/mL kanamycin. 20 mL of overnight culture
was diluted in 1 L of 1X LB supplemented with FeSO4*7H2O (440 mg/L). Culture was grown to OD600 of 0.6 at 37°C
and induced with IPTG to a final concentration of 0.4 mM. The culture was incubated in an orbital shaker set to
150 rpm at 18°C for 18 h and was then harvested at 4000 g , 4°C, 20 min.
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For subsequent expression procedures to obtain apo protein for ICP-OES analysis for metals, an overnight culture
of 10 mL was diluted in 1 L of 1X LB containing antibiotic and incubated at 37°C to an OD600 of 0.8. The culture was
cooled down to room temperature on ice and induced with IPTG to a final concentration of 1 mM. Culture was
grown at 30°C for 3 h. Bacteria were harvested by centrifugation and yield of wet cell paste was 3 g for 1 L of
culture. Protein expressed in inclusion bodies were resuspended in 25 mM Tris pH 8 buffer (5 mL for 1 g cell paste)
containing 6 M Guanidinium Hydrochloride (GuHCl) and protease inhibitor phenylmethylsulfonyl fluoride (PMSF,
0.5 mM final concentration). Bacterial resuspension was lysed by sonication on ice for 10 min (20 s pulse on, 20 s
pulse off). Crude cell lysate was centrifuged at 20,000 g, 4°C, 30 min and the lysate was loaded onto a Ni-NTA
column (2 mL, Clontech) pre-equilibrated with resuspension buffer. Column was washed with 50 mL of buffer and
the protein was gradually refolded by washing column with decreasing concentration of GuHCl in buffer from 6 M
to 0 M GuHCl. Protein eluate was collected in 25 mM Tris pH 8 using an imidazole gradient elution from 50 mM to
250 mM. Fractions containing protein were identified by Bradford assay and concentrated to 3 mL using a 5 kDa
MWCO spin filter for exchange into 25 mM HEPES pH 7.5 storage buffer using a desalting column (BioRad). Protein
concentration was determined by measuring absorbance at 280 nm using an ExPASy calculated extinction
coefficient of 12950 M-1cm-1. Purity of final protein (molecular weight of 21003.80 Da) was determined on SDSPAGE.
ICP analysis. Apo protein purified from inclusion bodies were incubated with either (NH4)2Fe(SO4)2 (2.5 eq) or
MnCl2 (10 eq) for 3 h at 4°C. Solutions were diluted to a final concentration of 20 μM in 3 mL using storage buffer
(25 mM HEPES pH 7.5) containing 1% HNO3. Zn, Mn, and Fe were measured using ICP-OES (Perkin Elmer Optima
3300 DV) to determine elemental concentration. Standard calibration curve for ICP-OES using 0-0.2 ppm of Zn, Mn,
and Fe was collected before analyte detection.
Catalase assay. Rv2633c was reconstituted in iron by mixing 200 µL of 58 µM protein and 10 eq of iron (10 µL of
12 mM diammonium iron(II) sulfate). Rv2633c was fixed to a concentration of 0.58 µM (final concentration) to
react with 20 mM H2O2. The reaction was initiated by addition of 10 µL of Fe(II)catalase (58 µM) to 970 µL of 50
mM KH2PO4 pH 7.5 buffer and 20 µL of 1 M H2O2. Reaction was monitored by observing for decrease in absorbance
at 240 nm corresponding to concentration of H2O2 (𝜖240 = 43.6 M-1cm-1).
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Overall Conclusions

De novo designed metalloproteins exhibiting a diverse range of catalytic functions from radical anion
sequestration in small helical bundles to base-promoted cleavage of isoxazole rings in allosterically regulated
proteins are delineated in this thesis. Our findings showcase the breadth of chemical reactivity incorporated in
simple model constructs by introducing minimal, rationally designed modifications to the substrate active site
(notably just a single amino acid modification) complemented by beneficial mutations in the interior of the protein
pocket or a channel leading to a metallosite. We build on our basic understanding of model proteins to create useful
protein catalysts and reinforce protein NMR as a powerful tool to interpret structural details of proteins which
provide insight with atomic precision essential elements in a given catalytic mechanism.
Furthermore, the microbicidal action of short self-assembling peptides forming hydrogels is elaborated and
their self-healing property is ideal for convenient storage and delivery in wound care application. A similar minimalist
approach is undertaken in our hydrogel design to incorporate elements that enforce peptide assembly to trigger
gelation in presence of silver and impart antimicrobial action. The coordination geometries of natural and unnatural
amino acids to metal spheres are considered in order to achieve efficient assembly patterns. Unique molecular
patterns are also featured in defense mechanisms of human pathogens, and respiratory proteins especially heme
proteins are associated with producing toxic radicals for microbicidal action against such invasive microorganisms.
Although Myoglobin was not identified as a ROS producer in presence of microbial virulence factors, we identified
sugars comprised of alkyl chains are beneficial in blocking adherence of microbes involved in invasive biofilm
formation. Molecular modeling reveals a binding pocket in a pneumococcal protein of sufficient size to accept sugars
of various composition, serving as a potential site to direct ligands to obstruct colonization of microbial proteins to
human mucosa associated with chronic respiratory disease.
In essence, protein and peptide design strategies to create not only new materials important for patient
care of chronic wounds but also probe contributing factors (specific coordination geometry of ligands in active sites,
degree of hydration of substrate access channel, or contacts of molecules to sites on protein domains) influencing
function are identified. We envision our constructs can be repurposed using computational set of tools or directed
evolution to enhance features for an intended application such as creating robust metallohydrolases for
bioremediation application or antimicrobial agents.
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Appendix I

DFsc
3His-G2DFsc
UFsc
4G-UFsc

MDELRELLKAEQQAIKIYKEVLKKAKEGDEQELARLIQEIVKAEKQAVKVYKEAAEKARNPEKRQVIDKILED
MDELRELLKAEQQGIKILKEVLKKAKEGDEQELARLNQEIVKAEKQGVKVYKEAAEKARNPEKRQVIDKILED
MDELRELLKAEQQAIKIYKEVLKKAKEGDEQELARLIQEIVKAEKQAVKVYKEAAEKARNPEKRQVIDKILED
MDELRELLKGEQQGIKIYKEVLKKAKEGDEQELARLIQEIVKGEKQGVKVYKEAAEKARNPEKRQVIDKILED
*********.***.****************************.***.**************************

DFsc
3His-G2DFsc
UFsc
4G-UFsc
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EEKHIEWLKAASKQGNAEQFASLVQQILQDHQRHVEEIEKKN
EEKHIEWLKAASKQGNAEQFASLVQQILQDHQRHVEEIEKKN
******************************.***********

Figure S1.1 Sequence alignment of DF proteins used in this work. DFsc and 3His-G2DFsc differ
by six mutations: A14G, Y18L,
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Figure S1.2 Circular
dichroism of DF and UFsc proteins. Overlay of (A) apo DF proteins, (B) apo DFsc and zinc-bound DFsc, (C)
Figure S6. Circular dichroism of DF proteins. Overlay of (A) apo DF proteins, (B) apo DFsc and
apo UFsc and zinc-bound
and
zinc-bound
4G-UFsc.
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HEPES (pH 7.6). Final concentration of Zn(II) was 200 µM.
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Figure S2. Oxidation of DTBC by dioxygen in presence of metal-free DF proteins. UV-Vis

Figure S1.3 Oxidation of DTBC by dioxygen in presence of metal-free DF proteins. UV-Vis spectra of reaction mixtures
spectra of reaction mixtures containing (A) apo DFsc, (B) apo UFsc, (C) apo 4G-UFsc, and (D) 3,5-dicontaining (A) apo DFsc, (B) apo UFsc, (C) apo 4G-UFsc, and (D) 3,5-di- tert-butyl catechol (DTBC) alone. Experimental
tert-butyl catechol (DTBC) alone. Experimental Conditions: 50 μM protein, 500 μM DTBC substrate,
Conditions: 50 μM
protein, 500 μM DTBC substrate, and O2-saturated
buffer (25 mM HEPES, 100 mM NaCl, pH 7.6). Spectra
and O2-saturated buffer (25 mM HEPES, 100
mM NaCl, pH 7.6). Spectra were taken immediately
were taken immediately
after
addition
of
oxygenated
buffer
(orange),
after
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2 (cyan),
12 (blue),
after addition of oxygenated buffer (orange), after 1 (green),
2 (cyan),
12 (blue),
24 (violet),
and24
48(violet), and
48 hours (pink).hours
Absorption
band with band
maximum
at ~400 nm
corresponds
to quinone
productproduct
(the only
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(pink). Absorption
with maximum
at ~400
nm corresponds
to quinone
(the
only formed in
reaction D). species formed in reaction D).
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B

Figure S1.4 Titration of SQ• ̄ and ITS mixture with sodium dithionite. The radical was generated by mixing DFsc (50 μM),
Ni(II) (100 μM), DTBC (500 μM), and O2 in 50 mM HEPES (pH 7). After overnight incubation, the mixture was degassed,
brought into anaerobic glove box, and ITS was added to a final concentration of 35 μM. This solution was titrated with
dithionite and spectra were recorded after 30 min of equilibration (A). UV-Vis spectrum of 35 μM potassium
indigotetrasulfonate (ITS) in water (B).
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Figure S17. HSQC spectrum of DFsc protein. Experimental conditions: 800 µM protein in 25 mM
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Figure S1.9 DTBC binds to DFsc at pH 6. HSQC spectra of DFsc protein (black, 800 μM protein) and DFsc with two
Figure S19. DTBC binds to DFsc at pH 6. HSQC spectra of DFsc protein (black, 800 µM protein)
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Figure S1.10 Heatmap showing how much backbone signals shift in the presence of DTBC. DFsc protein (400 μM)
was titrated with DTBC up to two equivalents. Changes in chemical shift Δδbinding were mapped onto DFsc
Figure S20. Heatmap showing how much backbone signals shift in the presence of DTBC.
structure (PDB 2HZ8): red corresponds to maximum shift and blue to minimum shift.

DFsc protein (400 µM) was titrated with DTBC up to two equivalents. Changes in chemical shift
Δδbinding were mapped onto DFsc structure (PDB 2HZ8): red corresponds to maximum shift and blue
to minimum shift.
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Figure S20. Heatmap showing how much backbone signals shift in the presence of DTBC.
DFsc protein (400 µM) was titrated with DTBC up to two equivalents. Changes in chemical shift
Δδbinding were mapped onto DFsc structure (PDB 2HZ8): red corresponds to maximum shift and blue
to minimum shift.

Figure S1.11 Chemical shift analysis of [13C,15N] DFsc with
DTBC. Chemical shift perturbations of DFsc Val48 (filled circles),
Figure S21. Chemical shift analysis of [13C,15N] DFsc with DTBC. Chemical shift perturbations of
Lys52 (open circles), Glu30 (filled squares), Gln102 (open squares), and Lys114 (filled triangles) backbone amide resonances,
DFsc Val48 (filled circles), Lys52 (open circles), Glu30 (filled squares), Gln102 (open squares), and
fitted simultaneously to a binding model with the shared KD. The solid lines show the best fit with KD = 52 ± 18 μM, where
Lys114 (filled triangles) backbone amide resonances, fitted simultaneously to a binding model with the
the error is the fitting uncertainty. The titration was performed with 0.4 mM DFsc in 25 MES, 100 mM NaCl (pH 6) at 300 K.
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C

shared KD. The solid lines show the best fit with KD = 52 ± 18 µM, where the error is the fitting
uncertainty. The titration was performed with 0.4 mM DFsc in 25 MES, 100 mM NaCl (pH 6) at 300 K.
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Figure S22. Model of protein-DTBC interaction generated using Rosetta. (A) DFsc, (B) DFsc
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Figure S9. ITC analysis of DFsc metal binding. Baseline- and offset-corrected data for the titration

Figure S1.13 ITC analysis
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Figure S7. ITC analysis of UFsc metal binding. Baseline- and offset-corrected data for the titration
of (A) 106
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with
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of 0.4 μL during data
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between
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180
s),
(C)
220
μM
UFsc
with
4
mM
CoCl
(1
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between injections was 210 s) at 25˚C in 25 mM HEPES, 100 mM NaCl (pH 7.6) buffer with stirring
rpm. (B, D, F, H) Binding isotherms resulting from the integration of A, C, E, G, respectively. For analysis the first point was ignored,
speed of 750 rpm. (B, D, F, H) Binding isotherms resulting from the integration of A, C, E, G,
and the data A-H were fit with the one set of sites model. Data from titration G-H were analyzed using a competitive model where
respectively. For analysis the first point was ignored, and the data A-H were fit with the one set of
thermodynamic parameters for Zn(II)-TETA binding were determined by ITC: number of binding sites – 0.777 ± 0.005, Kd – 0.173
sites model. Data from titration G-H were analyzed using a competitive model where thermodynamic
± 0.065 μM, ΔH – 3.57 ± 0.06 kcal/mol. Thermodynamic parameters derived from the fitting are summarized in Table S2.
parameters for Zn(II)-TETA binding were determined by ITC: number of binding sites – 0.777 ± 0.005,
Kd – 0.173 ± 0.065 μM, ΔH – 3.57 ± 0.06 kcal/mol. Thermodynamic parameters derived from the fitting
are summarized in Table S1.
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μL during
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Number of binding sites

0.763 ± 0.004

0.836 ± 0.077

0.959 ± 0.005

0.817 ± 0.000

Kd, nM

220 ± 37

67 ± 4

9,250 ± 520

0.030 ± 0.004

ΔH, kcal/mol

-7.61 ± 0.08

-9.21 ± 0.02

-2.57 ± 0.02

-12.0 ± 0.1

Table S3. Thermodynamic parameters for DFsc metal binding obtained using isothermal titration
calorimetry.
Thermodynamic parameters

Nickel (II)

Cobalt (II)

Manganese (II)

Zinc (II)

Number of
binding sites

First binding event

0.834 ± 0.112

1.06 ± 0.02

0.853 ± 0.034

0.955 ± 0.027

Second binding
event

1.31 ± 0.11

0.604 ± 0.014

0.724 ± 0.033

0.988 ± 0.026

Kd, nM

First binding event

10,400 ± 1,400

56 ± 3

228 ± 37

109 ± 34

Second binding
event

2,090 ± 230

133 ± 10

197 ± 37

213 ± 14

First binding event

6.64 ± 0.37

4.89 ± 0.18

3.96 ± 1.91

1.86 ± 0.46

Second binding

4.62 ± 0.18

9.22 ±0.36

5.48 ± 2.28

3.18 ± 0.44

ΔH, kcal/mol

Table S1. Thermodynamic
parameters for UFsc metal binding obtained using isothermal titration
event
calorimetry.
Table S1 Thermodynamic parameters for DFsc metal binding obtained using isothermal titration calorimetry.
Table
S1. Thermodynamic
for UFsc metal
obtained
using
titration
Thermodynamic
parametersparameters
Nickel (II)
Cobaltbinding
(II)
Manganese
(II) isothermal
Zinc (II)
calorimetry.
Number of binding sites
Thermodynamic
parameters
K
d, nM

0.632 ± 0.003
112Nickel
± 28.0 (II)

0.617 ± 0.005
269Cobalt
± 116 (II)

0.755 ± 0.005
Manganese
(II)
173
± 56.0

0.993 ± 0.003
Zinc
(II)
0.076
± 0.013

Number
of binding sites
ΔH,
kcal/mol

0.632± ±0.04
0.003
4.12

0.617± ±0.02
0.005
1.46

0.755± ±0.03
0.005
2.39

0.993±±0.05
0.003
-1.85

Kd, nM

112 ± 28.0

269 ± 116

173 ± 56.0

0.076 ± 0.013

ΔH, kcal/mol

4.12 ± 0.04

1.46 ± 0.02

2.39 ± 0.03

-1.85 ± 0.05

Table S2. Thermodynamic parameters for 4G-UFsc metal binding obtained using isothermal titration
Table S2 Thermodynamic parameters for UFsc metal binding obtained using isothermal titration calorimetry.
calorimetry.
Table S2. Thermodynamic parameters for 4G-UFsc metal binding obtained using isothermal titration
Thermodynamic parameters
Nickel (II)
Cobalt (II)
Manganese (II)
Zinc (II)
calorimetry.
Number of binding sites

0.763 ± 0.004

0.959 ± 0.005

0.817 ± 0.000

Thermodynamic parameters
Kd, nM
Number of binding sites
ΔH, kcal/mol

Nickel (II)
Cobalt (II)
220 ± 37
67 ± 4
0.763 ± 0.004 0.836 ± 0.077
-7.61 ± 0.08
-9.21 ± 0.02

0.836 ± 0.077

Manganese (II)
9,250 ± 520
0.959 ± 0.005
-2.57 ± 0.02

Zinc (II)
0.030 ± 0.004
0.817 ± 0.000
-12.0 ± 0.1

Kd, nM

220 ± 37

9,250 ± 520

0.030 ± 0.004

67 ± 4

Table
S3kcal/mol
Thermodynamic parameters for-7.61
4G-UFsc
metal-9.21
binding
obtained using
isothermal
titration
ΔH,
± 0.08
± 0.02
-2.57 ±
0.02
-12.0 ± calorimetry.
0.1
Table S3. Thermodynamic parameters for DFsc metal binding obtained using isothermal titration
calorimetry.
Table S3. Thermodynamic parameters for DFsc metal binding obtained using isothermal titration
Thermodynamic parameters
Nickel (II)
Cobalt (II)
Manganese (II)
Zinc (II)
calorimetry.
Number of
First binding event
Thermodynamic
parameters
binding
sites
Second binding
event
Number of
First binding event
binding
sites
K
First binding event
d, nM
Second binding
event binding
Second
event
Kd, nM
First binding event
ΔH, kcal/mol
First binding event
Second binding
event
Second binding
ΔH, kcal/mol
First binding event
event
Second binding
event

0.834 ± 0.112
Nickel (II)

1.06 ± 0.02
Cobalt (II)

0.853 ± 0.034
0.955 ± 0.027
Manganese (II)
Zinc (II)

1.31 ± 0.11
0.834 ± 0.112
10,400 ± 1,400
1.31 ± 0.11
2,090 ± 230
10,400 ± 1,400
6.64 ± 0.37
2,090 ± 230

0.604 ± 0.014
1.06 ± 0.02
56 ± 3
0.604 ± 0.014
133 ± 10
56 ± 3
4.89 ± 0.18
133 ± 10

0.724 ± 0.033
0.853 ± 0.034
228 ± 37
0.724 ± 0.033
197 ± 37
228 ± 37
3.96 ± 1.91
197 ± 37

0.988 ± 0.026
0.955 ± 0.027
109 ± 34
0.988 ± 0.026
213 ± 14
109 ± 34
1.86 ± 0.46
213 ± 14

4.62 ± 0.18
6.64 ± 0.37

9.22 ±0.36
4.89 ± 0.18

5.48 ± 2.28
3.96 ± 1.91

3.18 ± 0.44
1.86 ± 0.46

4.62 ± 0.18

9.22 ±0.36

5.48 ± 2.28

3.18 ± 0.44
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Appendix II

Figure S2.1 Chromatogram of protein peak elution from a metal chelate affinity His-Trap HP column connected
to an AKTA system. Peak corresponds to 250 mM imidazole in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% glycerol,
100 uM CaCl2 and 100 uM MgCl2. A linear gradient of 0-500 mM imidazole was used.

Figure S2.2 Chromatogram of protein elution peak from a HiTrap Q HP column (BioRad) using a gradient run of
20 to 500 mM NaCl, 5% glycerol in 20 mM Tris-HCl pH 7.4.
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Figure S2.3 UV-Vis spectrum of RrgA (diluted 20-fold) from a concentrated stock. 280 nm absorbance
was recorded to accurately determine the concentration of protein stock for use in ITC experiments.

250
150
100
75
50
37
25
20
15
10

Figure S2.4 SDS-PAGE (10%) of purified RrgA protein (fractions collected from His-Trap HP column).
250 kDa
150
100
75
50
37
25
20

Figure S2.5 SDS-PAGE (10%) of RrgA pooled from HiTrap Q HP column.
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LCMS

Database search

Protein
theoretical

Yoon 10

intensity

peptides

m/z

Highest scoring peptide spectrum matches:
(1) Cell wall surface anchor family protein Streptococcus pneumoniae (Accession: A0A4F7IM51)
#PSMs 1888
(2) Ancillary pilus subunit Streptococcus pneumoniae=rrgA (Accession: A7KT94)
#PSMs 1557
(3) Ancillary pilus subunit Streptococcus pneumoniae=rrgA (Accession: A7KT66)
#PSMs 376
Rough no. of amino acids 886
MW: 98.8 Da
Identified

peptide spectra matches for RrgA

>tr|A0A4F7IM51|A0A4F7IM51_STREE Cell wall surface anchor family
protein OS=Streptococcus pneumoniae OX=1313 GN=SAMEA2796719_00964
PE=4
SV=1MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSPAIGKVVIKETGEGGALLGDAVFELKN
NTDGTTVSQRTEAQTGEAIFSNIKPGTYTLTEAQPPVGYKPSTKQWTVEVEKNGRTTVQGEQVENREE
ALSDQYPQTGTYPDVQTPYQIIKVDGSEKNGQHKALNPNPYERVIPEGTLSKRIYQVNNLDDNQYGIE
LTVSGKTVYEQKDKSVPLDVVILLDNSNSMSNIRNKNARRAERAGEATRSLIDKITSDSENRVALVTY
ASTIFDGTEFTVEKGVADKNGKRLNDSLFWNYDQTSFTTNTKDYSYLKLTNDKNDIVELKNKVPTEAE
DHDGNRLMYQFGATFTQKALMKADEILTQQARQNSQKVIFHITDGVPTMSYPINFNHATFAPSYQNQL
NAFFSKSPNKDGILLSDFITQATSGEHTIVRGDGQSYQMFTDKTVYEKGAPAAFPVKPEKYSEMKAAG
YAVIGDPINGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYYNGNIAPDGYDVFTVGIGINGDPGT
DEATATSFMQSISSKPENYTNVTDTTKILEQLNRYFHTIVTEKKSIENGTITDPMGELIDLQLGTDGR
FDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNAKVLYDTTEKRIRVTGLYLGTDEKVTLTYNVRLN
DEFVSNKFYDTNGRTTLHPKEVEQNTVRDFPIPKIRDVRKYPEITISKEKKLGDIEFIKVNKNDKKPL
RGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYRLFENSEPAGYKPVQNKPIV
AFQIVNGEVRDVTSIVPQDIPAGYEFTNDKHYITNEPIPPKREYPRTGGIGMLPFYLIGCMMMGGVLL
YTRKHP

>tr|A7KT94|A7KT94_STREE Ancillary pilus subunit OS=Streptococcus
pneumoniae OX=1313 GN=rrgA PE=4 SV=1
MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSPAIGKVVIKETGEGGALLGDAVF
ELKNNTDGTTVSQRTEAQTGEAIFSNIKPGTYTLTEAQPPVGYKPSTKQWTVEVEKNGWT
TVQGEQVENREEALSDQYPQTGTYPDVQTPYQIIKVDGSEKNGQHKALNPNPYERVIPEG
TLSKRIYQVNNLDDNQYGIELTVSGKTVYERKDKSVPLDVVILLDNSNSMSNIRNKNARR
AERAGEATRSLIDKITSDPENRVALVTYASTIFDGTEFTVEKGVADKNGKRLNDSLFWNY
DQTSFTTNTKDYSYLKLTNDKNDIVELKNKVLTEAEDHDGNRLMYQFGATFTQKALMKAD
EILTQQARQNSQKVIFHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGILLS
DFITQATSGEHTIVRGDGQSYQMFTDKTVYEKGAPAAFPVKPEKYSEMKAAGYAVIGDPI
NGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYYNGNIAPDGYDVFTVGIGINGDPGT
DEATATSFMQSISSKPENYTNVTDTTKILEQLNRYFHTIVTEKKSIENGTITDPMGELID
LQLGTDGRFDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNAKVLYDTTEKRIRVTGLY
LGTDEKVTLTYNVRLNDEFVSNKFYDTNGRTTLHPKEVEQNTVRDFPIPKIRDVRKYPEI
TISKEKKLGDIEFIKVNKNDKKPLRDAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDG
KLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPAGYEFTN
DKHYITNEPIPPKREYPRTGGIGMLPFYLIGCMMMGGVLLYTRKHP

A0A4F7IM51
RrgA

MKKVRKIFQKAVAGLCCISQLTAFSSIVAL
------------------------------

A0A4F7IM51
RrgA

ELKNNTDGTTVSQRTEAQTGEAIFSNIKPG
ELKNNTDGTTVSQRTEAQTGEAIFSNIKPG
******************************

A0A4F7IM51
RrgA

TVQGEQVENREEALSDQYPQTGTYPDVQTP
TVQGEQVENREEALSDQYPQTGTYPDVQTP
******************************

A0A4F7IM51
RrgA

TLSKRIYQVNNLDDNQYGIELTVSGKTVYE
TLSKRIYQVNNLDDNQYGIELTVSGKTVYE
******************************

A0A4F7IM51
RrgA

AERAGEATRSLIDKITSDSENRVALVTYAS
AERAGEATRSLIDKITSDSENRVALVTYAS
******************************

A0A4F7IM51
RrgA

DQTSFTTNTKDYSYLKLTNDKNDIVELKNK
DQTSFTTNTKDYSYLKLTNDKNDIVELKNK
******************************

A0A4F7IM51
RrgA

EILTQQARQNSQKVIFHITDGVPTMSYPIN
EILTQQARQNSQKVIFHITDGVPTMSYPIN
******************************

A0A4F7IM51
RrgA

DFITQATSGEHTIVRGDGQSYQMFTDKTVY
DFITQATSGEHTIVRGDGQSYQMFTDKTVY
******************************

A0A4F7IM51
RrgA

NGGYIWLNWRESILAYPFNSNTAKITNHGD
NGGYIWLNWRESILAYPFNSNTAKITNHGD
******************************

A0A4F7IM51
RrgA

DEATATSFMQSISSKPENYTNVTDTTKILE
DEATATSFMQSISSKPENYTNVTDTTKILE
******************************

A0A4F7IM51
RrgA

LQLGTDGRFDPADYTLTANDGSRLENGQAV
LQLGTDGRFDPADYTLTANDGSRLENGQAV
******************************

A0A4F7IM51
RrgA

LGTDEKVTLTYNVRLNDEFVSNKFYDTNGR
LGTDEKVTLTYNVRLNDEFVSNKFYDTNGR
******************************

A0A4F7IM51
RrgA

TISKEKKLGDIEFIKVNKNDKKPLRGAVFS
TISKEKKLGDIEFIKVNKNDKKPLRGAVFS
******************************

A0A4F7IM51
RrgA

KLTFKNLSDGKYRLFENSEPAGYKPVQNKP
KLTFKNLSDGKYRLFENSEPAGYKPVQNKP
******************************

A0A4F7IM51
RrgA

DKHYITNEPIPPKREYPRTGGIGMLPFYLI
DKHYITNEPIPPKRELEHHHHHH------*************** :

Figure
S2.6 LC-MS
proteome characterization
for cell
anchoring
protein.
Tryptic
peptide
masses
surveyed
Figure 13. LC-MS
proteome
characterization
for cell anchoring
pilin
protein.pilin
Tryptic
peptide
masses
surveyed
against
theagainst
Uniprot database
the Uniprot
database
for Streptococcus
pneumoniae
aligned
bestfamily
with the
cell wall
anchor
family
protein
for Streptococcus
pneumoniae
aligned
best with the cell
wall surface
anchor
protein
and surface
the ancillary
pilus
subunit
of S.and
pneumoniae.
the ancillary pilus subunit of S. pneumoniae (top three scoring peptide spectrum matches are ranked above the
alignment).
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RrgA

r family
6719_00964

GALLGDAVFELKN
TTVQGEQVENREE
QVNNLDDNQYGIE
TSDSENRVALVTY
IVELKNKVPTEAE
NHATFAPSYQNQL
VKPEKYSEMKAAG
FTVGIGINGDPGT
GELIDLQLGTDGR
DEKVTLTYNVRLN
EFIKVNKNDKKPL
PAGYKPVQNKPIV
YLIGCMMMGGVLL

ptococcus

GDAVF
KNGWT
VIPEG
KNARR
LFWNY
LMKAD
GILLS
IGDPI
GDPGT
GELID
VTGLY
KYPEI
TGEDG
YEFTN

A0A4F7IM51
RrgA

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSPAIGKVVIKETGEGGALLGDAVF 60
------------------------------METPETSPAIGKVVIKETGEGGALLGDAVF 30
*****************************

A0A4F7IM51
RrgA

ELKNNTDGTTVSQRTEAQTGEAIFSNIKPGTYTLTEAQPPVGYKPSTKQWTVEVEKNGRT 120
ELKNNTDGTTVSQRTEAQTGEAIFSNIKPGTYTLTEAQPPVGYKPSTKQWTVEVEKNGRT 90
************************************************************

A0A4F7IM51
RrgA

TVQGEQVENREEALSDQYPQTGTYPDVQTPYQIIKVDGSEKNGQHKALNPNPYERVIPEG 180
TVQGEQVENREEALSDQYPQTGTYPDVQTPYQIIKVDGSEKNGQHKALNPNPYERVIPEG 150
************************************************************

A0A4F7IM51
RrgA

TLSKRIYQVNNLDDNQYGIELTVSGKTVYEQKDKSVPLDVVILLDNSNSMSNIRNKNARR 240
TLSKRIYQVNNLDDNQYGIELTVSGKTVYEQKDKSVPLDVVILLDNSNSMSNIRNKNARR 210
************************************************************

A0A4F7IM51
RrgA

AERAGEATRSLIDKITSDSENRVALVTYASTIFDGTEFTVEKGVADKNGKRLNDSLFWNY 300
AERAGEATRSLIDKITSDSENRVALVTYASTIFDGTEFTVEKGVADKNGKRLNDSLFWNY 270
************************************************************

A0A4F7IM51
RrgA

DQTSFTTNTKDYSYLKLTNDKNDIVELKNKVPTEAEDHDGNRLMYQFGATFTQKALMKAD 360
DQTSFTTNTKDYSYLKLTNDKNDIVELKNKVPTEAEDHDGNRLMYQFGATFTQKALMKAD 330
************************************************************

A0A4F7IM51
RrgA

EILTQQARQNSQKVIFHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGILLS 420
EILTQQARQNSQKVIFHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGILLS 390
************************************************************

A0A4F7IM51
RrgA

DFITQATSGEHTIVRGDGQSYQMFTDKTVYEKGAPAAFPVKPEKYSEMKAAGYAVIGDPI 480
DFITQATSGEHTIVRGDGQSYQMFTDKTVYEKGAPAAFPVKPEKYSEMKAAGYAVIGDPI 450
************************************************************

A0A4F7IM51
RrgA

NGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYYNGNIAPDGYDVFTVGIGINGDPGT 540
NGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYYNGNIAPDGYDVFTVGIGINGDPGT 510
************************************************************

A0A4F7IM51
RrgA

DEATATSFMQSISSKPENYTNVTDTTKILEQLNRYFHTIVTEKKSIENGTITDPMGELID 600
DEATATSFMQSISSKPENYTNVTDTTKILEQLNRYFHTIVTEKKSIENGTITDPMGELID 570
************************************************************

A0A4F7IM51
RrgA

LQLGTDGRFDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNAKVLYDTTEKRIRVTGLY 660
LQLGTDGRFDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNAKVLYDTTEKRIRVTGLY 630
************************************************************

A0A4F7IM51
RrgA

LGTDEKVTLTYNVRLNDEFVSNKFYDTNGRTTLHPKEVEQNTVRDFPIPKIRDVRKYPEI 720
LGTDEKVTLTYNVRLNDEFVSNKFYDTNGRTTLHPKEVEQNTVRDFPIPKIRDVRKYPEI 690
************************************************************

A0A4F7IM51
RrgA

TISKEKKLGDIEFIKVNKNDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDG 780
TISKEKKLGDIEFIKVNKNDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDG 750
************************************************************

A0A4F7IM51
RrgA

KLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPAGYEFTN 840
KLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPAGYEFTN 810
************************************************************

A0A4F7IM51
RrgA

DKHYITNEPIPPKREYPRTGGIGMLPFYLIGCMMMGGVLLYTRKHP
DKHYITNEPIPPKRELEHHHHHH----------------------*************** :

886
833

Figure
S2.7
highest scoring peptide spectrum match (accession #A0A4F7IM51) aligned against RrgA in Clustal Omega.
Figure
14.The
The highest scoring peptide spectrum match (accession #A0A4F7IM51) aligned against RrgA in Clustal Omega.
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Figure S2.8 SOE based generation of ∆rrgA. Complementary PCR primers are used to produce two DNA fragments
(SOE_piece 1 and SOE_piece 3) from TIGR4 genome with overlapping ends to an erm insert (amplified out from a separate
TIGR4 psaA plasmid). These fragments are used as template in subsequent PCR in which overlapping ends anneal to erm
using outer end primers rrgA_F and rrgA_R to generate the mutagenic deletion.

Oligonucleotide primers

Sequence (5' to 3')

rrgA_F

GTGTGACCCAATCCATACTTCCATC

rrgA_R
rrgAerm_F

GCATAATCACCTGCTTCAAGTGCAAC
CGGGAGGAAATAATTCTATGAGAGTGT
AGAAATGATAATATCTATG

rrgAerm_R

TTGTTCATGTAATCACTCCTTCTATTCA
TAGAACAAGTTAATCCTTC

erm_J214
erm_J215

GAAGGAGTGATTACATGAACAA
CTCATAGAATTATTTCCTCCCG

Table S2.1 SOE primers for three separate amplifications to obtain erythromycin
(erm) fragment and PCR products of heterologous erm overhangs flanking TIGR4
chromosome for downstream fusion PCR.
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Oligonucleotide primers

Sequence (5' to 3')

rrgA_seq_F

GCACTTTTATACGCTTTTGCTACG

rrgA_seq_R

GCAATGTAATGAATTACACATGAC

Table S2.2 SOE validation sequence primers: expected amplicon size of 1093 bp.

3.0 kb
2.0
1.5
1.0

1.0 kb

0.5

0.5 kb

Figure 15. ITC study of RrgA and maltose. Maltose in buffer (in red) and maltose titrated into RrgA (in black) raw

thermograms shown. Final concentrations at end of titration of ligand and protein amount to a 1:1 ratio. 25 mM
Tris-HCl, 100 mM NaCl (pH 8.0) was used as buffer.

Figure S2.9 (left) PCR products from PCR steps 1 and 3 (SOE_piece_1 and SOE_piece 3). (right) PCR product from
PCR step 2 (erm).

3.0 kb
2.0
1.5
1.0
0.5

Figure S2.10 PCR product of SOE fusion of all three pieces (bright band near 3kb). PCR fusion product (expected
2,810 bp) was purified using a Monarch DNA gel extraction kit.
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1.0 kb

TIGR4 ∆rrgA

Spectrum

2.001
178.32

260/280
mg/L

Figure S2.11 PCR screen to validate construct design: Pair of primers rrgA_seq_F and rrgA_seq_R were used to
cover the chimeric locus (erm insert) and check borders between erm gene and upstream and downstream
flanking regions of TIGR4 by PCR. The integrity of the erm insert was verified by submitting purified linear DNA
isolated from an individual colony selected from BHI plate for sequencing. Peaks corresponding to nucleobases
of erm locus were resolved.
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A

B

C

Figure S2.12 ITC study of RrgA and maltose. Raw thermograms shown of (A) 1.0 mM maltose in syringe
titrated into buffer inside cell (B) 500 μM of maltose titrated into 50 μM RrgA inside cell (C) 1.0 mM maltose
titrated into 184 μM RrgA inside cell. Final concentrations at end of titration of ligand and protein amount to
a 1:1 ratio. Composition of buffer: 25 mM Tris-HCl pH 8.0, 100 mM NaCl.
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Figure S2.13 Thermogram of DβM (inside cell) and buffer in syringe (25 mM Tris-HCl pH 8.0, 100 mM NaCl)
shows low heats of dilution indicating no contribution of heats from solvent in reverse titration experiment.

Figure S2.14 ITC study of RrgA and DβM. 230 μM RrgA titrated into DβM (final ratio 1:1). Composition of
buffer: 25 mM Tris-HCl pH 8.0, 100 mM NaCl.
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Appendix III
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Figure S1. Evolution of storage modulus for hydrogels made by mixing L9(His) peptide

Figure S3.1 Evolution of storage modulus for hydrogels made by mixing L9(His) peptide (1 wt%) and one equivalent
(1wt%) and 1 eq of AgNO3.
of AgNO3.
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Figure S2. Evolution of storage modulus for hydrogels made by mixing L9 (3’-PyA)

Figure S3.2 Evolution of storage modulus for hydrogels made by mixing L9 (3’-PyA) peptide (1 wt%) and variable
peptide (1wt %) and variable amount of AgNO3 (0-1 eq).
amount of AgNO3 (zero to one equivalent).
1.0
L9 (3'-PyA)
L9 (4'-PyA)

Absorbance (a.u.)
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0.6

2
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300
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350

Figure
S3.3
peptides
with 3’-PyA
and
4’-PyA in water.
Figure
S4.UV-vis
UV-vis spectra
spectra ofof
L9L9
peptides
with 3’-PyA
and 4’-PyA
in water.
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Appendix IV
Table S1. pKa values of glutamate residues and chemical shifts of the carboxylate carbons (protonated
and deprotonated) in the presence and also in the absence of inhibitor.
Chemical shift of the carbon
in the protonated side
carboxylate

pKa

Chemical shift of the carbon in
the deprotonated side
carboxylate

Without
inhibitor

With inhibitor

Without
inhibitor

With
inhibitor

Without
inhibitor

With inhibitor

E82

3.8 ± 0.3

4.2 ± 0.3

178.1 ± 1.4

179.4 ± 1.2

183.7 ± 0.03

183.7 ± 0.05

E83

4.6 ± 0.05

4.7 ± 0.1

179.7 ± 0.2

180.6 ± 0.3

183.9 ± 0.02

183.7 ± 0.006

E84

4.8 ± 0.07

4.8 ± 0.06

179.98 ± 0.3

179.6 ± 0.3

184.0 ± 0.05

183.7 ± 0.007

E87

4.5 ± 0.1

4.2 ± 0.3

179.8 ± 0.3

178.03 ± 1.7

183.9 ± 0.03

183.8 ± 0.01

E92

5.1 ± 0.05

177.6 ± 0.1

177.2 ± 0.09

181.4 ± 0.04

181.6 ± 0.03

E114

5.1 ± 0.05

5.1 ± 0.04

178.9 ± 0.2

178.7 ± 0.1

182.9 ± 0.05

182. 8 ± 0.01

E119

4.6 ± 0.1

4.1 ± 0.2

180.1 ± 0.3

178.4 ± 1.3

184.0 ± 0.03

184.3 ± 0.007

E120

4.6 ± 0.1

4.7 ± 0.1

179.6 ± 0.3

179.6 ± 0.4

183. 4 ± 0.04

183.3 ± 0.007

E123

5.1 ± 0.1

5.5 ± 0.05

180.4 ± 0.3

181.1 ± 0.1

184.0 ± 0.09

183.8 ± 0.01

E127

–

5.5 ± 0.07

–

180.5 ± 0.2

–

183.9 ± 0.02

E139

5.1 ± 0.1

4.5 ± 0.2

179.9 ± 0.3

178.7 ± 0.9

184.0 ± 0.1

183.8 ± 0.009

pKa1 = 5.1 ± 0.04
pKa2 = 7.7 ± 0.04

Table S4.1. pKa values of glutamate residues and chemical shifts of the carboxylate carbons (protonated and deprotonated) in
the presence and also in the absence of inhibitor
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Table S2. Sequences of the AlleyCat proteins (affinity purification tag removed).
Proteins

Sequences

AlleyCat

Mutations
(relative to
C-terminal CaM)
F92E

AlleyCat1

F92E, M144R

SMKDTDSEEE IREAFRVEDK DGNGYISAAE
LRHVMTNLGE KLTDEEVDEM IREADIDGDG
QVNYEEFVQR MTAK*

AlleyCat2

F92E, H107I,
M144R

SMKDTDSEEE IREAFRVEDK DGNGYISAAE
LRIVMTNLGE KLTDEEVDEM IREADIDGDG
QVNYEEFVQR MTAK*

AlleyCat3

F92E, H107I,
L112R, M144R

SMKDTDSEEE IREAFRVEDK DGNGYISAAE
LRIVMTNRGE KLTDEEVDEM IREADIDGDG
QVNYEEFVQR MTAK*

AlleyCat4

185L, F92E,
H107I, L112R,
M144R

SMKDTDSEEE LREAFRVEDK DGNGYISAAE
LRIVMTNRGE KLTDEEVDEM IREADIDGDG
QVNYEEFVQR MTAK*

AlleyCat5

I85L, F92E,
H107I, L112R,
A128T, M144R

SMKDTDSEEE LREAFRVEDK DGNGYISAAE
LRIVMTNRGE KLTDEEVDEM IRETDIDGDG
QVNYEEFVQR MTAK*

AlleyCat6

I85L, F92E,
H107I, L112R,
M124L, A128T,
M144R
I85L, A88Q, F92E,
H107I, L112R,
M124L, A128T,
M144R

SMKDTDSEEE LREAFRVEDK DGNGYISAAE
LRIVMTNRGE KLTDEEVDEL IRETDIDGDG
QVNYEEFVQR MTAK*

AlleyCat7

SMKDTDSEEE IREAFRVEDK DGNGYISAAE
LRHVMTNLGE KLTDEEVDEM IREADIDGDG
QVNYEEFVQM MTAK*

SMKDTDSEEE LREQFRVEDK DGNGYISAAE
LRIVMTNRGE KLTDEEVDEL IRETDIDGDG
QVNYEEFVQR MTAK*

Table S4.2. Sequences of the AlleyCat proteins (affinity purification tag removed)
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Figure S1. Nonenzymatic leflunomide conversion (0.2 mM) at X mM concentrations of HEPES pH 7.4
(X = 10, 25, 50, 75, 100) on left plot. Determination of the kuncat for base-promoted leflunomide ringFigure opening
S4.1 Nonenzymatic
Nonenzymatic
leflunomide
conversion
(0.2
mM)
at
mMbuffer
concentrations
of HEPES
pHplot.
7.4
(X
= 10, 25,pH
50,7.4
by extrapolation
of HEPES–catalyzed
reaction
to Xzero
on right
Figure
S1.
leflunomide
conversion
(0.2
mM)
at X concentration
mM concentrations
of The
HEPES
-6 the-1kuncat for base-promoted leflunomide ring- opening by extrapolation of
75, 100)
on leftkplot.
Determination of
obtained
uncat value is 1.96 x 10 min .
(X = 10, 25, 50, 75, 100) on left plot. Determination of the k
for base-promoted leflunomide ring-

HEPES–catalyzed reaction to zero buffer concentration on right plot. Theuncat
obtained kuncat value is 1.96 x 10-6 min-1.

opening by extrapolation of HEPES–catalyzed reaction to zero buffer concentration on right plot. The
obtained kuncat value is 1.96 x 10-6 min-1.

Figure S4.2 A representative HPLC chromatogram ( 𝜆 = 254 nm) showing elution times for the substrate and product.
Figure S2. A representative HPLC chromatogram ( l = 254 nm) showing elution times for the substrate
and product.

Figure S2. A representative HPLC chromatogram ( l = 254 nm) showing elution times for the substrate
and product.

Figure S4.3 Teriflunomide
formation
catalyzed
by AlleyCat.
Conditions:
2525mM
7.4;100
100mM
mM NaCl, 10 mM
Figure S3. Teriflunomide
formation
catalyzed
by AlleyCat.
Conditions:
mM HEPES
HEPES pH
pH 7.4;
CaCl2; 0.1 – 0.3
mM
substrate
25 μM
AlleyCat. 25 μM AlleyCat.
NaCl,
10 final
mM CaCl
0.3 mM final substrate
concentration;
2; 0.1 – concentration;
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Figure S3. Teriflunomide formation catalyzed by AlleyCat. Conditions: 25 mM HEPES pH 7.4; 100 mM
NaCl, 10 mM CaCl2; 0.1 – 0.3 mM final substrate concentration; 25 μM AlleyCat.

Figure S4.4 Teriflunomide
formation catalyzed
AlleyCat1.
25 mM HEPES
pH HEPES
7.4; 100pH
mM
NaCl,
Figure S4. Teriflunomide
formationby
catalyzed
by Conditions:
AlleyCat1. Conditions:
25 mM
7.4;
100 10 mM CaCl2; 0.1
– 0.3 mM finalmM
substrate
μMmM
AlleyCat1.
NaCl, 10concentration;
mM CaCl2; 0.150
– 0.3
final substrate concentration; 50 μM AlleyCat1.

Figure S5. Teriflunomide formation catalyzed by AlleyCat2. Conditions: 25 mM HEPES pH 7.4; 100

Figure S4.5 Teriflunomide
catalyzed
AlleyCat2.
25 mM
pHHEPES
7.4; 100
mM NaCl,
10
mM CaCl
– 0.3by
mM
final substrate
concentration;
25 HEPES
μM
Figure
S5.formation
Teriflunomide
formation
catalyzed
byConditions:
AlleyCat2.
Conditions:
25AlleyCat2.
mM
pHmM
7.4; NaCl,
100 10 mM CaCl2; 0.1
2; 0.1
– 0.3 mM final substrate
concentration;
25 –μM
mM NaCl,
10 mM CaCl2; 0.1
0.3AlleyCat2.
mM final substrate concentration; 25 μM AlleyCat2.

Figure S6. Teriflunomide formation catalyzed by AlleyCat2. Conditions: 25 mM TAPS pH 9.0; 100 mM

Figure S4.6 Teriflunomide
formation
catalyzed
AlleyCat2.
Conditions:
2525mM
TAPS pH 9.0; 100 mM NaCl, 10 mM CaCl2; 0.1 –
NaCl, 10
CaCl2; 0.1
–formation
0.3 mMbyfinal
substrate
concentration;
μM AlleyCat2.
Figure
S6.mM
Teriflunomide
catalyzed
by AlleyCat2.
Conditions:
25 mM TAPS pH 9.0; 100 mM
0.3 mM final substrate concentration; 25 μM AlleyCat2.
NaCl, 10 mM CaCl2; 0.1 – 0.3 mM final substrate concentration; 25 μM AlleyCat2.
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Figure S4.7 Teriflunomide
formation
catalyzed
by
AlleyCat3.
Conditions:
25 mM HEPES
pH
7.4; 100
NaCl,
Figure
Teriflunomide
formation
catalyzed
AlleyCat3.Conditions:
Conditions:
mM
HEPES
pHmM
7.4;100
100 10 mM CaCl2; 0.1
Figure
S7.S7.
Teriflunomide
formation
catalyzed
byby
AlleyCat3.
2525mM
HEPES
pH
7.4;
mM
NaCl,
10
mM
CaCl
0.3 AlleyCat3.
mM final substrate concentration; 50 μM AlleyCat3.
– 0.3 mM finalmM
substrate
50–μM
2; 0.1
NaCl,
10concentration;
mM
CaCl
2; 0.1 – 0.3 mM final substrate concentration; 50 μM AlleyCat3.

Figure S4.8 Teriflunomide formation catalyzed by AlleyCat4. Conditions: 25 mM HEPES pH 7.4; 100 mM NaCl, 10 mM CaCl2; 0.1
Figure S8. Teriflunomide formation catalyzed by AlleyCat4. Conditions: 25 mM HEPES pH 7.4; 100
– 0.3 mM finalFigure
substrate
concentration;
25 μM AlleyCat4.
S8. Teriflunomide
by AlleyCat4.
Conditions:
25 mM
HEPES pH 7.4; 100
mM NaCl,
10 mM CaCl ;formation
0.1 – 0.3 catalyzed
mM final substrate
concentration;
25 μM
AlleyCat4.
2

mM NaCl, 10 mM CaCl2; 0.1 – 0.3 mM final substrate concentration; 25 μM AlleyCat4.

Figure S4.9 Teriflunomide
formation catalyzed
bycatalyzed
AlleyCat5.
25 mM HEPES
pH 7.4;
100pH
mM
NaCl,
Figure S9. Teriflunomide
formation
byConditions:
AlleyCat5. Conditions:
25 mM
HEPES
7.4;
10010 mM CaCl2; 0.1
– 0.3 mM finalmM
substrate
concentration;
AlleyCat5.
NaCl, 10
mM CaCl2; 0.150– uM
0.3 mM
final substrate concentration; 50 uM AlleyCat5.
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Figure S9. Teriflunomide formation catalyzed by AlleyCat5. Conditions: 25 mM HEPES pH 7.4; 100
mM NaCl, 10 mM CaCl2; 0.1 – 0.3 mM final substrate concentration; 50 uM AlleyCat5.

Figure S4.10 Teriflunomide formation catalyzed by AlleyCat6. Conditions: 25 mM HEPES pH 7.4; 100 mM NaCl, 10 mM CaCl2; 0.1
Figure S10. Teriflunomide formation catalyzed by AlleyCat6. Conditions: 25 mM HEPES pH 7.4; 100
– 0.3 mM final substrate
50–μM
mM NaCl,concentration;
10 mM CaCl2; 0.1
0.3 AlleyCat6.
mM final substrate concentration; 50 μM AlleyCat6.

Figure S4.11 Teriflunomide formation catalyzed by AlleyCat7. Conditions: 25 mM HEPES pH 7.4; 100 mM NaCl, 10 mM CaCl2; 0.1
Figure S11. Teriflunomide formation catalyzed by AlleyCat7. Conditions: 25 mM HEPES pH 7.4; 100
– 0.3 mM final substrate
concentration; 50 μM AlleyCat7.
mM NaCl, 10 mM CaCl ; 0.1 – 0.3 mM final substrate concentration; 50 μM AlleyCat7.
2
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Figure S12. Circular dichroism spectrum of AlleyCat2. Conditions: 4 mM HEPES pH 7.4; 30 mM NaCl,
2 mM CaCl2; 25 μM protein.

Figure S11. Teriflunomide formation catalyzed by AlleyCat7. Conditions: 25 mM HEPES pH 7.4; 100
mM NaCl, 10 mM CaCl2; 0.1 – 0.3 mM final substrate concentration; 50 μM AlleyCat7.

Figure S4.12 Circular dichroism
spectrum of AlleyCat2. Conditions : 4 mM HEPES pH 7.4; 30 mM NaCl, 2 mM CaCl2; 25 μM protein.
Figure S12. Circular dichroism spectrum of AlleyCat2. Conditions: 4 mM HEPES pH 7.4; 30 mM NaCl,
2 mM CaCl2; 25 μM protein.

Figure S4.13 Chemical (guanidinium hydrochloride, GdnCl) denaturation profile of AlleyCat2. Conditions: 4 mM HEPES pH 7.4; 30
Figure S13. Chemical (guanidinium hydrochloride, GdnCl) denaturation profile of AlleyCat2.
mM NaCl, 2 mMConditions:
CaCl2; 25 μM
protein in presence of various concentrations of guanidinium chloride (0 – 6 M). The chemical
4 mM HEPES pH 7.4; 30 mM NaCl, 2 mM CaCl2; 25 µM protein in presence of various
denaturation data
were fit to equation
5.
concentrations
of guanidinium
chloride (0 – 6 M). The chemical denaturation data were fit to equation
5.

Figure S14. pH activity profile of AlleyCat2. Conditions:
229 Buffer (25 mM) containing 100 mM NaCl, 10
mM CaCl2 using citrate (pH 5.0), MES (pH 6.0 and 6.5), HEPES (pH 7.0 and 7.5), TRIS (pH 8.0 and
8.5) and TAPS (pH 9.0). Protein (25 µM) and substrate (0.15 mM). Fit of the data to equation 3 gives
pKa = 7.06 ± 0.02.

Figure S15. Dependence of chemical shift of Cd resonances in E82, E83, E84, E87, E114, E119, E120,

Figure S4.14 Dependence of chemical shift of C𝛿 resonances in E82, E83, E84, E87, E114, E119, E120, E123 and E139 in AlleyCat
E123 and E139 in AlleyCat (0.5 mM) in the absence and also in the presence of 5-nitrobenzotriazole
(0.5 mM) in the absence and also in the presence of 5-nitrobenzotriazole (2.5 mM). Titration was done in buffer containing 10
Titration
was
in buffer10containing
mM
10 mM
MES, 10 mM HEPES,
10 spectra
mM
mM citrate, 10 mM (2.5
MES,mM).
10 mM
HEPES,
10 done
mM Tricine,
mM CaCl210
and
50citrate,
mM NaCl.
Two-dimensional
CBCG(CO)
were
collected at 298 K inTricine,
H2O on10
a Bruker
800
MHz
NMR
instrument.
mM CaCl2 and 50 mM NaCl. Two-dimensional CBCG(CO) spectra were collected at 298 K
in H2O on a Bruker 800 MHz NMR instrument.

Figure S16. 15% SDS-PAGE gel of proteins used in this study with His6 tag removed; (left to right):

Figure S4.15 15% SDS-PAGE
gelAlleyCat2,
of proteins
used inAlleyCat4,
this study
with His6
tag removed;
(left
to right): AlleyCat1, AlleyCat2, AlleyCat3,
AlleyCat1,
AlleyCat3,
AlleyCat5,
AlleyCat6,
AlleyCat7,
AlleyCat.
AlleyCat4, AlleyCat5, AlleyCat6, AlleyCat7, AlleyCat.
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Figure S4.16
HSQC
spectra
AlleyCat0
(top) and (top)
AlleyCat2
(bottom) in
the absence
(blue) and
in the
Figure
S17.
HSQCofspectra
of AlleyCat0
and AlleyCat2
(bottom)
in the absence
(blue)
andpresence
in the (red) of
leflunomide.
Conditions:
Protein
- 200 μM,
leflunomide
- 200- μM,
20 mM
HEPES pH- 200
6.9, 10
CaCl2,
100 mM.
presence
(red) of
leflunomide.
Conditions:
Protein
200 µM,
leflunomide
µM,mM
20 mM
HEPES
pH The peak
corresponding
to
the
backbone
amide
resonance
of
residue
144
is
marked
in
both
cases.
6.9, 10 mM CaCl2, 100 mM. The peak corresponding to the backbone amide resonance of residue
144 is marked in both cases.
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Figure S18. Docking of leflunomide into KE07 (round 7-2) [PDB: 6CT3]. Distance of O(Glu101)Figure S4.17H(C5)(leflunomide)
Docking of leflunomide
into KE07
(round
7-2)site.
[PDB: 6CT3]. Distance of O(Glu101)- H(C5)(leflunomide) is shown in
is shown
in the
active
the active site.
Figure S18. Docking of leflunomide into KE07 (round 7-2) [PDB: 6CT3]. Distance of O(Glu101)H(C5)(leflunomide) is shown in the active site.

Figure S19. Docking of leflunomide into AlleyCat4 [PDB: 2KZ2]. Distance of O(Glu92)H(C5)(leflunomide) is depicted from two different views of the same structure.
Figure S19. Docking of leflunomide into AlleyCat4 [PDB: 2KZ2]. Distance of O(Glu92)Figure S4.18H(C5)(leflunomide)
Docking of leflunomide
into AlleyCat4
[PDB:
2KZ2]. Distance
O(Glu92)H(C5)(leflunomide) is depicted from two
is depicted
from two
different
views ofofthe
same structure.
different views of the same structure.

Figure S20. Active site composition of Ac2. Glu92 (red) is surrounded by hydrophobic residues (green)

thesite
pocket.
Figure S4.19lining
Active
composition of Ac2. Glu92 (red) is surrounded by hydrophobic residues (green) lining the pocket.

232

Appendix V

Table S5.1 SOE PCR primers for design of His64 mutants
H64V Mb
forward
H64V Mb
reverse
H64G Mb
forward
H64G Mb
reverse

GAAGACCTGAAAAAAGTGGGTGTTACCGTT
(Tm: 60.7°C)
AACGGTAACACCCACTTTTTTCAGGTCTTC
(Tm: 60.7°C)
GAAGACCTGAAAAAAGGGGGTGTTACCGTT
(Tm: 62.1°C)
AACGGTAACACCCCCTTTTTTCAGGTCTTC
(Tm: 62.1°C)

Table S5.2 Primers designed and used for cloning H64V Mb
into pET-28a(+) between xhoI and ncoI restriction sites.

pET-28a(+)Mb
(ncoI) forward

TTATCCATGGTTCTGTCTGAAGGT
GAATGGCAGCTGGTTC
(Tm: 66.3°C)

pET-28a(+)Mb
(xhoI) reverse

TTATCTCGAGTTAACCCTGGTAAC
CCAGTTCTTTGTATTTAGCAGCG
(Tm: 65.9°C)

Table S5.3 Original Myoglobin template used to design plasmid
for His64Val Mb into pET-28a(+). Histidine-enriched tag
(GSGHHHHHH portion) was removed with designed primers
(shown in Table S5.2).
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1: 200bp ladder
2: SOE_F & H64G_R
3: SOE_R & H64G_F
4: SOE_F & H64V_R
5: SOE_R & H64V_F
Conditions:
Initial Denat.:
95°C, 2mins
Denaturation: 95°C,
30s
Annealing: 60°C, 30s
Extension: 72°C, 45s
30 cycles

1: 200bp ladder
(2)(3): H64G
(4)(5): H64V
Conditions:
Initial Denat.: 95°C,
2mins
Denaturation: 95°C, 10s
Annealing: 63°C, 30s
62°C, 30s
61°C, 30s
60°C, 30s
59°C, 30s
58°C, 30s
Extension: 72°C, 60s
5X each, last 10X cycles

Colony Screen Results for
Myoglobin H64G
1: 200bp ladder
(2)-(9): H64G colonies
Conditions:
Initial Denat.: 95°C,
2mins
Denaturation: 95°C, 10s
Annealing: 63°C, 30s
62°C, 30s
61°C, 30s
60°C, 30s
59°C, 30s
58°C, 30s
Extension: 72°C, 60s
5X each, last 10X cycles

- - - - - - - - - - - - - - - - - Colony Screen Results for Myoglobin
H64V
1: 200bp ladder
(2)-(9): H64V colonies
Conditions:
Initial Denat.: 95°C, 2mins
Denaturation: 95°C, 10s
Annealing: 63°C, 30s
62°C, 30s
61°C, 30s
60°C, 30s
59°C, 30s
58°C, 30s
Extension: 72°C, 60s
5X each, last 10X cycles

Figure S5.1 SOE Conditions, PCR and colony screen results for Myoglobin H64 mutants.
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1: 200bp ladder
2: pET-28a(+)Mb H64V
3: pET-28a(+)Mb H64V
Conditions:
Initial Denat: 95 C, 2mins
Denaturation: 95 C, 30s
Gradient annealing: 65 C (2X),
63 C (2X), 61 C (2X), 59 C (2X),
57 C (2X), 55 C (25X)
Extension: 72 C, 1.40 min

Colony Screen Results for pET-28a(+)Mb
H64V
1: 200bp ladder
2-12: H64V colonies
Conditions:
Initial Denat.: 95 C, 2mins
Denaturation: 95 C, 10s
Annealing: 63 C, 30s
62 C, 30s
61 C, 30s
60 C, 30s
59 C, 30s
58 C, 30s
Extension: 72 C, 60s
5X each, last 10X cycles

Figure S5.2 Gradient PCR parameters and colony screen results for His64V mutant in pET-28a(+).
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